

PROTAC

PROTACs or Proteolysis Targeting Chimeric Molecules are heterobifunctional nanomolecules that theoretically target any protein for ubiquitination and degradation. In terms of the structure, PROTACs consist of one moiety which is recognized by the E3 ligase. This moiety is then chemically and covalently linked to a small molecule or a protein that recognizes the target protein. The trimeric complex formation leads to the transfer of ubiquitins to the target protein.

By removing target proteins directly rather than merely blocking them, PROTACs can provide multiple advantages over small molecule inhibitors, which can require high systemic exposure to achieve sufficient inhibition, often resulting in toxic side effects and eventual drug resistance. PROTAC molecules possess good tissue distribution and the ability to target intracellular proteins, thus can be directly applied to cells or injected into animals without the use of vectors.

Targeted protein degradation using the PROTAC technology is emerging as a novel therapeutic method to address diseases, such as cancer, driven by the aberrant expression of a disease-causing protein. In addition to the use of PROTACs for the treatment of human disease, these molecules provide a chemical genetic approach to “knock down” proteins to study their function. Currently, there are several small molecule inhibitors that have been found to show good biological activity by specifically targeting BET, estrogen receptor (ER), androgen receptor, etc.

LYTAC, AUTAC and ATTEC are PROTAC degraders specifically targeting membrane proteins via lysosomal pathway. SNIPER and molecular glue are special PROTACs, while SNIPER consists of ligand for RING E3 ligase family and molecular glue comprises a short or almost no linker.

References:

- [1] Sakamoto KM. *Pediatr Res.* 2010 May;67(5):505-8.
- [2] Neklesa TK, et al. *Pharmacol Ther.* 2017 Jun;174:138-144.
- [3] Ding Y. *Trends Pharmacol Sci.* 2020, 41(7):464-474.
- [4] Schreiber S L. *Cell*, 2021, 184(1):3-9.

Target List in PROTAC

• ATTECs	3
• AUTACs	5
• E3 Ligase Ligand-Linker Conjugates	7
• Ligands for E3 Ligase	37
• Ligands for Target Protein for PROTAC	48
• LYTACs	56
• Molecular Glues	58
• PROTAC Linkers	61
• PROTAC-Linker Conjugates for PAC	342
• PROTACs	344
• PROTACs	367
• SNIPERS	368
• Target Protein Ligand-Linker Conjugates	372



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

ATTECs

Autophagosome-tethering compounds


Autophagosome-tethering compound (ATTEC) degrades target proteins via lysosomal pathway rather than common proteasome pathway. ATTEC degrades target proteins by molecular glue mechanism, and its molecular weight is smaller than AUTAC. ATTEC shortens the distance between LC3 receptor and target protein and then the target protein was phagocytosed and transferred into lysosomal for degradation.

ATTECs

LC3-mHTT-IN-AN1

Cat. No.: HY-130258

LC3-mHTT-IN-AN1 (Compound AN1) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins.



Purity: 97.14%


Clinical Data: No Development Reported

Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LC3-mHTT-IN-AN2

Cat. No.: HY-130259

LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins.



Purity: 96.07%

Clinical Data: No Development Reported

Size: 10 mM × 1 mL, 50 mg, 100 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

AUTACs

Autophagy-targeting chimeras


Autophagy-targeting chimera (AUTAC) degrades target proteins via lysosomal pathway rather than common proteasome pathway. One end of AUTAC is target protein ligand, the other end is a site of K63 ubiquitin modification, and the two parts are connected by linker. AUTAC induces recognition of LC3 receptors of autophagosomes by K63-linked polyubiquitination and then the Target-AUTAC complex was phagocytosed and transferred into lysosomal for degradation.

AUTACs

AUTAC1

Cat. No.: HY-134183

AUTAC1 is a **MetAP2**-targeting autophagy-mediated degrader (**AUTAC**). AUTACs contain a degradation tag and a warhead to provide target specificity. AUTAC1 contains an FBnG (p-Fluorobenzyl Guanine) and a Fumagillol moiety. Fumagillol binds covalently to MetAP2.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AUTAC2

Cat. No.: HY-134184

AUTAC2 is a **FKBP12**-targeting autophagy-mediated degrader (**AUTAC**). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AUTAC4

Cat. No.: HY-134640

AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (**AUTAC**). AUTAC4 downregulates cytosolic proteins and promotes targeted mitochondrial turnover via **mitophagy**.




Purity: 99.12%
Clinical Data: No Development Reported
Size: 5 mg

Halo PROTAC 1

Cat. No.: HY-129652

Halo PROTAC 1 is a conjugate of ligands for E3 and 22-atom-length linker. The connector of linker is Halogen group.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

E3 Ligase Ligand-Linker Conjugates

E3 Ligase Ligand-Linker Conjugate, which is one part of Proteolysis Targeting Chimeric Molecules (PROTACs), incorporates a ligand for the E3 ubiquitin ligase and a linker. After linked to the ligand for target protein (such as JQ1 for BRD4 protein, Molibresib for BET protein), those conjugates can be used for constituting PROTACs that target protein for ubiquitination and degradation. Currently, several PROTACs have been found to show good biological activity by specifically targeting BET, estrogen receptor (ER), androgen receptor, etc. MedChemExpress (MCE) offers a wide range of high quality E3 Ligase Ligand-Linker Conjugates including von Hippel-Lindau (VHL) ligands, MDM2 ligands, Cereblon (CRBN) ligands and cIAP1 ligands conjugating with different linkers (PEGs, Alkyl-Chain, Alkyl/ether, etc.). It's convenient and time-saving for designing and synthesizing a wide variety of novel PROTACs (ARV-825, dBET1, MT-802, etc.), which can expand the application of PROTACs in the treatment of cancer, autoimmunity, inflammation and other diseases.

E3 Ligase Ligand-Linker Conjugates Chemicals

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl (VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11)

Cat. No.: HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.




Purity: 99.89%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-amido-C5-acid

Cat. No.: HY-130798

(S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).




Purity: 97.84%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH

(VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH)

Cat. No.: HY-131168

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH (VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH) is a E3 ligase ligand-linker conjugate that contains on one end a VHL ligand.




Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C1-Br

Cat. No.: HY-138862

(S,R,S)-AHPC-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C1-NH2

Cat. No.: HY-138861

(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C1-NH2 hydrochloride

Cat. No.: HY-138861A

(S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C10-NH2

(VH032-C10-NH2)

Cat. No.: HY-129941

(S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C10-NH2 dihydrochloride

(VH032-C10-NH2 dihydrochloride)

Cat. No.: HY-129941A

(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C2-NH2

Cat. No.: HY-136163A

(S,R,S)-AHPC-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C2-NH2 dihydrochloride

Cat. No.: HY-136163

(S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 25 mg

(S,R,S)-AHPC-C2-PEG4-N3**(VH032-C2-PEG4-N3)****Cat. No.:** HY-130654


(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C3-NH2**(VH032-C3-NH2)****Cat. No.:** HY-130711


(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C3-NH2 hydrochloride**(VH032-C3-NH2 hydrochloride)****Cat. No.:** HY-130711B


(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(S,R,S)-AHPC-C3-NH2 TFA**(VH032-C3-NH2 TFA)****Cat. No.:** HY-130711A


(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2**(VH032-C4-NH2)****Cat. No.:** HY-114176A


(S,R,S)-AHPC-C4-NH2 is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2 dihydrochloride**(VH032-C4-NH2 dihydrochloride)****Cat. No.:** HY-114176B


(S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2 hydrochloride (VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; ...)**Cat. No.:** HY-114176


(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: 95.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-C5-COOH**(VH032-C5-COOH)****Cat. No.:** HY-136055


(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized **E3 ligase ligand-linker conjugate**, contains the VH032 VHL-based ligand and a linker to form PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C5-NH2**(VH032-C5-NH2)****Cat. No.:** HY-136187


(S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERR α) PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2**(VH032-C6-NH2)****Cat. No.:** HY-136006B

(S,R,S)-AHPC-C6-NH2 (VH032-C6-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: 96.64%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

(S,R,S)-AHPC-C6-NH2 dihydrochloride
(VH032-C6-NH2 dihydrochloride)

Cat. No.: HY-136006

(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2 hydrochloride
(VH032-C6-NH2 hydrochloride)

Cat. No.: HY-136006A

(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl; VHL
Ligand-Linker Conjugates 12; ...)

Cat. No.: HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group.




Purity: 95.46%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-C7-amine
(VH032-C7-amine)

Cat. No.: HY-136186

(S,R,S)-AHPC-C7-amine (VH032-C7-amine) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERR α) PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C8-NH2
(VH032-C8-NH2)

Cat. No.: HY-133487B

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.




Purity: 95.07%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-C8-NH2 dihydrochloride
(VH032-C8-NH2 dihydrochloride)

Cat. No.: HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C8-NH2 hydrochloride
(VH032-C8-NH2 hydrochloride)

Cat. No.: HY-133487A

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-CO-C9-acid
(VH032-NH-CO-C9-acid)

Cat. No.: HY-139345

(S,R,S)-AHPC-CO-C9-acid is an E3 ligase ligand-linker conjugate that can be connected to the ligand for protein to form PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-Me-C10-Br

Cat. No.: HY-130642

(S,R,S)-AHPC-Me-C10-Br is a synthesized **E3 ligase ligand-linker conjugate**. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-Me-C10-NH2

Cat. No.: HY-130847

(S,R,S)-AHPC-Me-C10-NH2 is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).




Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-Me-C5-COOH

Cat. No.: HY-130849

(S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).




Purity: 96.19%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Me-C7 ester

Cat. No.: HY-130640

(S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-X_L PROTAC degraders.




Purity: 95.49%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2

Cat. No.: HY-131387

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736).




Purity: 95.06%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

(S,R,S)-AHPC-Me-decanedioic acid

Cat. No.: HY-132938

(S,R,S)-AHPC-Me-decanedioic acid is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc

(VH032-O-Ph-PEG1-NH-Boc)

Cat. No.: HY-130638

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized E3 ligase ligand-linker conjugate which is used for the EED-targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-O-Ph-PEG1-NH2

(VH032-O-Ph-PEG1-NH2)

Cat. No.: HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614).




Purity: 96.97%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

(S,R,S)-AHPC-PEG1-N3 (VH032-PEG1-N3; VHL Ligand-Linker

Conjugates 9; E3 ligase Ligand-Linker Conjugates 3)

Cat. No.: HY-103600

(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.




Purity: 98.41%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG1-NH2

(VH032-PEG1-NH2)

Cat. No.: HY-136008

(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-PEG1-NH2 dihydrochloride

(VH032-PEG1-NH2 dihydrochloride)

Cat. No.: HY-136008A

(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-PEG1-NH2 dihydrochloride can be used to design PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-PEG1-OTs (VH032-PEG1-OTs; VHL Ligand-Linker

Conjugates 2; E3 ligase Ligand-Linker Conjugates 51)

Cat. No.: HY-125846


(S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10) Cat. No.: HY-103607


(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-N3 (VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13) Cat. No.: HY-103599


(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2; VHL Ligand-Linker Conjugates 3; ...) Cat. No.: HY-103603A


(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) Cat. No.: HY-103603B


(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride; ...) Cat. No.: HY-103603


(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: 96.08%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-N3 (VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12) Cat. No.: HY-103598


(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-NH2 (VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; ...) Cat. No.: HY-103602A


(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-NH2 hydrochloride (VH032-PEG3-NH2 hydrochloride; ...) Cat. No.: HY-103602


(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG3-propionic acid Cat. No.: HY-136165


(S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.












Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











(S,R,S)-AHPC-PEG4-N3 (VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4) Cat. No.: HY-103601

(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g











<p>(S,R,S)-AHPC-PEG4-NH2 (VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4; ...)</p> <p>Cat. No.: HY-103604A</p>	<p>(S,R,S)-AHPC-PEG4-NH2 hydrochloride (VH032-PEG4-NH2 hydrochloride; ...)</p> <p>Cat. No.: HY-103604</p>
<p>(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.51% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.44% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g</p>
<p>(S,R,S)-AHPC-PEG5-Boc</p> <p>Cat. No.: HY-131959</p>	<p>(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 58)</p> <p>Cat. No.: HY-130271</p>
<p>(S,R,S)-AHPC-PEG5-Boc is a E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for Cdc20 degrader CP5V.</p>  <p>Purity: 95.29% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 95.01% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg</p>
<p>(S,R,S)-AHPC-PEG6-C4-Cl (VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9)</p> <p>Cat. No.: HY-103606</p>	<p>(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride (VH032 phenol-alkylC6-amine dihydrochloride)</p> <p>Cat. No.: HY-136183</p>
<p>(S,R,S)-AHPC-PEG6-C4-Cl is a conjugate of ligands for E3 and 25-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG6-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker.</p>  <p>Purity: 98.07% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and an alkyl linker used for PROTAC degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride (VH032-phenol-C4-NH2 dihydrochloride)</p> <p>Cat. No.: HY-136184</p>	<p>2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br</p> <p>Cat. No.: HY-132939</p>
<p>(S,R,S)-AHPC-phenol-C4-NH2 (VH032-phenol-C4-NH2) dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is a E3 ligase ligand-linker conjugate for PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>A 410099.1 amide-PEG2-amine-Boc</p> <p>Cat. No.: HY-136273</p>	<p>A 410099.1 amide-PEG3-amine-Boc</p> <p>Cat. No.: HY-136272</p>
<p>A 410099.1 amide-PEG2-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG2-amine-Boc can conjugates with target protein ligands.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG3-amine-Boc can conjugates with target protein ligands.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>A 410099.1, amine-Boc</p> <p style="text-align: right;">Cat. No.: HY-136269A</p>	<p>A 410099.1, amine-Boc hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-136269</p>
<p>A 410099.1, amine-Boc is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>A 410099.1, amine-Boc hydrochloride is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).</p>  <p>Purity: 95.03% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57)</p> <p style="text-align: right;">Cat. No.: HY-130270</p>	<p>Boc-A 410099.1 amide-alkylC4-amine</p> <p style="text-align: right;">Cat. No.: HY-136274</p>
<p>AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57) incorporates an IAP ligand for the E3 ubiquitin ligase, and a SNIPER linker. AhR Ligand-Linker Conjugates 1 can be used to design SNIPER.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-A 410099.1 amide-alkylC4-amine is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-alkylC4 linker with terminal amine. Boc-A 410099.1 amide-alkylC4-amine can conjugates with target protein ligands.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>cIAP1 Ligand-Linker Conjugates 1 (E3 ligase Ligand-Linker Conjugates 41)</p> <p style="text-align: right;">Cat. No.: HY-128820</p>	<p>cIAP1 Ligand-Linker Conjugates 10 (E3 ligase Ligand-Linker Conjugates 47)</p> <p style="text-align: right;">Cat. No.: HY-128826</p>
<p>cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 10 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 10 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 11 (E3 ligase Ligand-Linker Conjugates 33)</p> <p style="text-align: right;">Cat. No.: HY-128812</p>	<p>cIAP1 Ligand-Linker Conjugates 11 Hydrochloride (E3 ligase Ligand-Linker Conjugates 33 Hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-128812A</p>
<p>cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 12 (E3 ligase Ligand-Linker Conjugates 38)</p> <p style="text-align: right;">Cat. No.: HY-128817</p>	<p>cIAP1 Ligand-Linker Conjugates 13 (E3 ligase Ligand-Linker Conjugates 43)</p> <p style="text-align: right;">Cat. No.: HY-128822</p>
<p>cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 13 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 13 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>











<p>cIAP1 Ligand-Linker Conjugates 14 (E3 ligase Ligand-Linker Conjugates 36)</p>	<p>cIAP1 Ligand-Linker Conjugates 15 (E3 ligase Ligand-Linker Conjugates 34)</p>
<p>cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 15 hydrochloride (E3 ligase Ligand-Linker Conjugates 34 hydrochloride)</p>	<p>cIAP1 Ligand-Linker Conjugates 16</p>
<p>cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 16 is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>cIAP1 Ligand-Linker Conjugates 2 (E3 ligase Ligand-Linker Conjugates 37)</p>	<p>cIAP1 Ligand-Linker Conjugates 2 Hydrochloride (E3 ligase Ligand-Linker Conjugates 37 Hydrochloride)</p>
<p>cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 2 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 Hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 3 (E3 ligase Ligand-Linker Conjugates 40)</p>	<p>cIAP1 Ligand-Linker Conjugates 4 (E3 ligase Ligand-Linker Conjugates 42)</p>
<p>cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 4 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 4 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 5 (E3 ligase Ligand-Linker Conjugates 39)</p>	<p>cIAP1 Ligand-Linker Conjugates 6 hydrochloride (E3 ligase Ligand-Linker Conjugates 35 hydrochloride)</p>
<p>cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 6 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 6 hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>

<p>cIAP1 Ligand-Linker Conjugates 7 (E3 ligase Ligand-Linker Conjugates 44)</p>	<p>cIAP1 Ligand-Linker Conjugates 8 (E3 ligase Ligand-Linker Conjugates 46)</p>
<p>cIAP1 Ligand-Linker Conjugates 7 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 7 can be used to design SNIPERs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 8 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 8 can be used to design SNIPERs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 9 (E3 ligase Ligand-Linker Conjugates 45)</p>	<p>EN219-O-C4-NH2 TFA</p>
<p>cIAP1 Ligand-Linker Conjugates 9 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 9 can be used to design SNIPERs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>EN219-O-C4-NH2 TFA incorporates an E3 ubiquitin ligase ligand, and a PROTAC linker. EN219-O-C4-NH2 TFA can be used to design PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Glutarimide-Isoindolinone-NH-PEG2-COOH</p>	<p>Glutarimide-Isoindolinone-NH-PEG3-COOH</p>
<p>Glutarimide-Isoindolinone-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.51% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Glutarimide-Isoindolinone-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.12% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Glutarimide-Isoindolinone-NH-PEG4-COOH</p>	<p>Lenalidomide-acetylene-C5-COOH (Cereblon ligand-linker Conjugate)</p>
<p>Glutarimide-Isoindolinone-NH-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.52% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-acetylene-C5-COOH can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 98.32% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg</p>
<p>Lenalidomide-C4-NH2 hydrochloride (Cereblon ligand 1 hydrochloride; ...)</p>	<p>Lenalidomide-C5-amido-Boc</p>
<p>Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein.</p> <p>Purity: 98.85% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>Lenalidomide-C5-amido-Boc is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-amido-Boc can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 95.10% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>

<p>Lenalidomide-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-122725B</p>	<p>Lenalidomide-C5-NH2 TFA</p> <p>Cat. No.: HY-122725A</p>
<p>Lenalidomide-C5-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs, such as MDM2 PROTAC degrader.</p> <p>Purity: 98.45%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs, such as MDM2 PROTAC degrader.</p> <p>Purity: 98.94%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg</p>
<p>Lenalidomide-PEG1-azide</p> <p>Cat. No.: HY-133139</p>	<p>Lenalidomide-PEG3-iodine</p> <p>Cat. No.: HY-130982</p>
<p>Lenalidomide-PEG1-azide is a E3 ligase ligand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-PEG3-iodine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a 3-unit PEG linker. Lenalidomide-PEG3-iodine can be used in the synthesis of a series of PROTACs, such as SJF620 (HY-133137).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg</p>
<p>Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride</p> <p>Cat. No.: HY-130682</p>	<p>Lenalidomide-propargyl-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-130683</p>
<p>Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).</p> <p>Purity: 99.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>N-Boc-SBP-0636457-O-C3-COOH</p> <p>Cat. No.: HY-131190</p>	<p>N-Descyclopropanecarbaldehyde Olaparib</p> <p>Cat. No.: HY-75706</p>
<p>N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based ligand for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4.</p> <p>Purity: 99.27%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 250 mg</p>
<p>NJH-2-030</p> <p>Cat. No.: HY-143348</p>	<p>Nutlin-C1-amido-PEG4-C2-N3 (MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48)</p> <p>Cat. No.: HY-128832</p>
<p>NJH-2-030 can be used as a covalent recruiter for FEM1B in targeted protein degradation applications.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 g, 2 g</p>

<p>Pom-8PEG</p> <p style="text-align: right;">Cat. No.: HY-132288</p>	<p>Pomalidomide 4'-alkylC5-acid</p> <p style="text-align: right;">Cat. No.: HY-130737</p>
<p>Pom-8PEG, an E3 ligase ligand-linker conjugate, incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and an 8-unit PEG linker. Pom-8PEG can be used in the synthesis of PROTAC, such as IDO1 PROTAC degrader.</p>  <p>Purity: 95.09% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Pomalidomide 4'-alkylC5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.</p>  <p>Purity: 98.78% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Pomalidomide 4'-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-132208</p>	<p>Pomalidomide 4'-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-130652</p>
<p>Pomalidomide 4'-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.24% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>
<p>Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H)</p> <p style="text-align: right;">Cat. No.: HY-131647</p>	<p>Pomalidomide-amido-C1-Br</p> <p style="text-align: right;">Cat. No.: HY-130617</p>
<p>Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 5-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 95.02% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 50 mg, 100 mg</p>
<p>Pomalidomide-amido-C3-COOH</p> <p style="text-align: right;">Cat. No.: HY-131185</p>	<p>Pomalidomide-amido-C3-piperazine-N-Boc</p> <p style="text-align: right;">Cat. No.: HY-131186</p>
<p>Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.22% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-amido-C4-amido-C6-NH-Boc (Cereblon Ligand-Linker Conjugates 21; E3 Ligase Ligand-Linker Conjugates 54)</p> <p style="text-align: right;">Cat. No.: HY-125884</p>	<p>Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc (Cereblon Ligand-Linker Conjugates 20; ...)</p> <p style="text-align: right;">Cat. No.: HY-125883</p>
<p>Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55) Cat. No.: HY-130521</p>	<p>Pomalidomide-amino-PEG3-NH2 Cat. No.: HY-133817A</p>
<p>Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-amino-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-amino-PEG3-NH2 hydrochloride Cat. No.: HY-133817</p>	<p>Pomalidomide-amino-PEG4-NH2 Cat. No.: HY-138859</p>
<p>Pomalidomide-amino-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>Pomalidomide-amino-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Pomalidomide-amino-PEG4-NH2 hydrochloride Cat. No.: HY-138859A</p>	<p>Pomalidomide-amino-PEG5-NH2 Cat. No.: HY-133816A</p>
<p>Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.27% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Pomalidomide-amino-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-amino-PEG5-NH2 hydrochloride Cat. No.: HY-133816</p>	<p>Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH (Cereblon Ligand-Linker Conjugates 14; ...) Cat. No.: HY-128848</p>
<p>Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 95.02% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Pomalidomide-C2-NH2 (Cereblon Ligand-Linker Conjugates 15) Cat. No.: HY-128846</p>	<p>Pomalidomide-C2-NH2 hydrochloride (Cereblon Ligand-Linker Conjugates 15 hydrochloride) Cat. No.: HY-128846A</p>
<p>Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 96.10% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>

<p>Pomalidomide-C3-NH2</p> <p>Cat. No.: HY-131888A</p> <p>Pomalidomide-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Pomalidomide-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-131888</p> <p>Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-C4-NH2</p> <p>Cat. No.: HY-138845</p> <p>Pomalidomide-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Pomalidomide-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-138845A</p> <p>Pomalidomide-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-C7-COOH</p> <p>Cat. No.: HY-133799</p> <p>Pomalidomide-C7-COOH is a synthesized E3 ligase cereblon ligand-linker conjugate. Pomalidomide-C7-COOH is an intermediate for the synthesis of PROTAC BCL-XL degraders.</p> <p>Purity: 98.04% Clinical Data: No Development Reported Size: 25 mg, 100 mg, 500 mg</p> 	<p>Pomalidomide-PEG1-azide</p> <p>Cat. No.: HY-133138</p> <p>Pomalidomide-PEG1-azide is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-PEG1-C2-COOH</p> <p>Cat. No.: HY-137531</p> <p>Pomalidomide-PEG1-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology.</p> <p>Purity: 99.88% Clinical Data: No Development Reported Size: 25 mg</p> 	<p>Pomalidomide-PEG1-C2-N3 (Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50)</p> <p>Cat. No.: HY-125843</p> <p>Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10.</p> <p>Purity: 99.65% Clinical Data: No Development Reported Size: 25 mg</p> 
<p>Pomalidomide-PEG2-azide</p> <p>Cat. No.: HY-137537</p> <p>Pomalidomide-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 95.01% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 500 mg</p> 	<p>Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid)</p> <p>Cat. No.: HY-131872</p> <p>Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 99.87% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p> 

<p>Pomalidomide-PEG2-Tos</p> <p>Cat. No.: HY-130295</p>	<p>Pomalidomide-PEG3-azide</p> <p>Cat. No.: HY-137538</p>
<p>Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugates, composed of a cereblon ligand and two-unit PEG linker.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 98.44% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 500 mg</p>
<p>Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30)</p> <p>Cat. No.: HY-128716</p>	<p>Pomalidomide-PEG3-C2-NH2 hydrochloride (Cereblon Ligand-Linker Conjugates 5 hydrochloride; ...)</p> <p>Cat. No.: HY-128716B</p>
<p>Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 5 TFA; ...)</p> <p>Cat. No.: HY-128716A</p>	<p>Pomalidomide-PEG4-azide</p> <p>Cat. No.: HY-141015</p>
<p>Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Pomalidomide-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 96.05% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Pomalidomide-PEG4-C-COOH (Cereblon Ligand -Linker Conjugates 1; E3 Ligase Ligand-Linker Conjugates 1)</p> <p>Cat. No.: HY-21930</p>	<p>Pomalidomide-PEG4-C2-NH2 (Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22)</p> <p>Cat. No.: HY-112599</p>
<p>Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.10% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 95.11% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>
<p>Pomalidomide-PEG4-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-112599B</p>	<p>Pomalidomide-PEG4-Ph-NH2 (Cereblon Ligand-Linker Conjugates 9; E3 Ligase Ligand-Linker Conjugates 2)</p> <p>Cat. No.: HY-41549</p>
<p>Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>









<p>Pomalidomide-PEG6-butyl iodide</p> <p>Cat. No.: HY-136156</p>	<p>Pomalidomide-PEG6-NH2 hydrochloride</p> <p>Cat. No.: HY-136161</p>
<p>Pomalidomide-PEG6-butyl iodide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide 4'-ether-alkylC2-amine</p> <p>Cat. No.: HY-136162A</p>	<p>Thalidomide 4'-ether-alkylC2-amine hydrochloride</p> <p>Cat. No.: HY-136162</p>
<p>Thalidomide 4'-ether-alkylC2-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride</p> <p>Cat. No.: HY-136160</p>	<p>Thalidomide-4-O-C10-COOH</p> <p>Cat. No.: HY-132858</p>
<p>Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride can be used to design the PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-4-O-C10-COOH is a E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.86% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-5-PEG3-NH2</p> <p>Cat. No.: HY-138786</p>	<p>Thalidomide-5-PEG4-NH2</p> <p>Cat. No.: HY-138785</p>
<p>Thalidomide-5-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-5-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-amido-PEG2-NH2</p> <p>Cat. No.: HY-138858</p>	<p>Thalidomide-amido-PEG2-NH2 hydrochloride</p> <p>Cat. No.: HY-138858A</p>
<p>Thalidomide-amido-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-amido-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thalidomide-C2-amido-C2-COOH</p> <p>Cat. No.: HY-130713</p>	<p>Thalidomide-NH-amido-C2-NH2</p> <p>Cat. No.: HY-138849</p>
<p>Thalidomide-C2-amido-C2-COOH incorporates a CRBN ligand for the E3 ubiquitin ligase, and a linker. Thalidomide-C2-amido-C2-COOH can be used to design PROTAC CDK2/9 Degradar-1 (HY-130709).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-138849A</p>	<p>Thalidomide-NH-amido-C3-NH2</p> <p>Cat. No.: HY-138850</p>
<p>Thalidomide-NH-amido-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-138850A</p>	<p>Thalidomide-NH-amido-C4-NH2</p> <p>Cat. No.: HY-134984</p>
<p>Thalidomide-NH-amido-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-134984A</p>	<p>Thalidomide-NH-amido-C5-NH2</p> <p>Cat. No.: HY-138851</p>
<p>Thalidomide-NH-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-138851A</p>	<p>Thalidomide-NH-amido-C6-NH2</p> <p>Cat. No.: HY-138852</p>
<p>Thalidomide-NH-amido-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>Thalidomide-NH-amido-C6-NH2 hydrochloride Cat. No.: HY-138852A</p>	<p>Thalidomide-NH-amido-C8-NH2 Cat. No.: HY-138853</p>
<p>Thalidomide-NH-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C8-NH2 hydrochloride Cat. No.: HY-138853A</p>	<p>Thalidomide-NH-amido-PEG1-C2-NH2 Cat. No.: HY-138854</p>
<p>Thalidomide-NH-amido-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-PEG1-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride Cat. No.: HY-138854A</p>	<p>Thalidomide-NH-amido-PEG2-C2-NH2 Cat. No.: HY-138855</p>
<p>Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride Cat. No.: HY-138855A</p>	<p>Thalidomide-NH-amido-PEG3-C2-NH2 Cat. No.: HY-138856</p>
<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride Cat. No.: HY-138856A</p>	<p>Thalidomide-NH-amido-PEG4-C2-NH2 Cat. No.: HY-138857</p>
<p>Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-138857A</p>	<p>Thalidomide-NH-C10-COOH</p> <p>Cat. No.: HY-130716</p>
<p>Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-C2-PEG3-OH</p> <p>Cat. No.: HY-131308</p>	<p>Thalidomide-NH-C4-NH-Boc</p> <p>Cat. No.: HY-130639</p>
<p>Thalidomide-NH-C2-PEG3-OH is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.64% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-NH-C4-NH2 TFA</p> <p>Cat. No.: HY-130814</p>	<p>Thalidomide-NH-C5-NH2</p> <p>Cat. No.: HY-134986</p>
<p>Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-136237</p>	<p>Thalidomide-NH-C6-NH-Boc</p> <p>Cat. No.: HY-130854</p>
<p>Thalidomide-NH-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis.</p>  <p>Purity: 96.11% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Thalidomide-NH-C6-NH2</p> <p>Cat. No.: HY-129704</p>	<p>Thalidomide-NH-C6-NH2 hydrochloride</p> <p>Cat. No.: HY-129704B</p>
<p>Thalidomide-NH-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Thalidomide-NH-C6-NH2 TFA</p> <p>Cat. No.: HY-129704A</p>	<p>Thalidomide-NH-C8-NH2</p> <p>Cat. No.: HY-138846</p>
<p>Thalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.82% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg</p>	<p>Thalidomide-NH-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-C8-NH2 hydrochloride</p> <p>Cat. No.: HY-138846A</p>	<p>Thalidomide-NH-PEG1-NH2</p> <p>Cat. No.: HY-134985</p>
<p>Thalidomide-NH-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-PEG1-NH2 hydrochloride</p> <p>Cat. No.: HY-131867</p>	<p>Thalidomide-NH-PEG2-C2-NH-Boc</p> <p>Cat. No.: HY-130853</p>
<p>Thalidomide-NH-PEG1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis.</p>  <p>Purity: 98.17% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Thalidomide-NH-PEG2-COOH</p> <p>Cat. No.: HY-138772</p>	<p>Thalidomide-NH-PEG3-COOH</p> <p>Cat. No.: HY-138771</p>
<p>Thalidomide-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.74% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Thalidomide-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.33% Clinical Data: No Development Reported Size: 50 mg</p>
<p>Thalidomide-NH-PEG3-propionic acid</p> <p>Cat. No.: HY-136166</p>	<p>Thalidomide-NH-PEG4-COOH</p> <p>Cat. No.: HY-134591</p>
<p>Thalidomide-NH-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.72% Clinical Data: No Development Reported Size: 25 mg, 100 mg</p>	<p>Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.</p>  <p>Purity: 98.55% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>

<p>Thalidomide-NH-PEG4-Ms</p> <p style="text-align: right;">Cat. No.: HY-131998</p>	<p>Thalidomide-NH-PEG7</p> <p style="text-align: right;">Cat. No.: HY-130648</p>
<p>Thalidomide-NH-PEG4-Ms is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-PEG8-Ts</p> <p style="text-align: right;">Cat. No.: HY-131912</p>	<p>Thalidomide-O-amide-C5-NH2</p> <p style="text-align: right;">Cat. No.: HY-141423</p>
<p>Thalidomide-NH-PEG8-Ts is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 8-unit PEG linker used in PROTAC technology, such as IDO1 PROTAC degrader (HY-131911).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amide-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Thalidomide-O-amide-C5-NH2 TFA</p> <p style="text-align: right;">Cat. No.: HY-141423A</p>	<p>Thalidomide-O-amido-C3-COOH (Cereblon Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 15)</p> <p style="text-align: right;">Cat. No.: HY-103612</p>
<p>Thalidomide-O-amide-C5-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.49% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>
<p>Thalidomide-O-amido-C3-NH2 (Cereblon Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 52)</p> <p style="text-align: right;">Cat. No.: HY-115560</p>	<p>Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA; ...)</p> <p style="text-align: right;">Cat. No.: HY-115560A</p>
<p>Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.18% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p>
<p>Thalidomide-O-amido-C3-PEG3-C1-NH2</p> <p style="text-align: right;">Cat. No.: HY-131646</p>	<p>Thalidomide-O-amido-C4-N3 (Cereblon Ligand-Linker Conjugates 4; E3 ligase Ligand-Linker Conjugates 18)</p> <p style="text-align: right;">Cat. No.: HY-103615</p>
<p>Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.48% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.63% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 2 g</p>

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6; E3 Ligase Ligand-Linker Conjugates 19)

Cat. No.: HY-107438

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C4-NH2 hydrochloride

Cat. No.: HY-107438A

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: 98.11%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA; ...)

Cat. No.: HY-103613

Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 99.74%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11; E3 Ligase Ligand-Linker Conjugates 25)

Cat. No.: HY-112618

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C6-NH2 hydrochloride

Cat. No.: HY-112618B

Thalidomide-O-amido-C6-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA; ...)

Cat. No.: HY-112618A

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: 99.82%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20)

Cat. No.: HY-107439

Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C8-NH2 hydrochloride

Cat. No.: HY-107439A

Thalidomide-O-amido-C8-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand-Linker Conjugates 2 TFA; ...)

Cat. No.: HY-103614

Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand-Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 99.11%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc

Cat. No.: HY-145177

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>Thalidomide-O-amido-PEG-C2-NH2</p> <p>Cat. No.: HY-122694</p>	<p>Thalidomide-O-amido-PEG-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-122694A</p>
<p>Thalidomide-O-amido-PEG-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-amido-PEG-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.54%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 (Cereblon Ligand-Linker Conjugates 12; ...)</p> <p>Cat. No.: HY-112600</p>	<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 12 TFA; ...)</p> <p>Cat. No.: HY-112600A</p>
<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.28%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 (Cereblon Ligand-Linker Conjugates 10; E3 Ligase Ligand-Linker Conjugates 24)</p> <p>Cat. No.: HY-112617</p>	<p>Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-112617B</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulator for the treatment of cancer.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, can be an immunomodulator for the treatment of cancer.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 10 TFA; ...)</p> <p>Cat. No.: HY-112617A</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3 ; E3 Ligase Ligand-Linker Conjugates 14)</p> <p>Cat. No.: HY-107440</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.52%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-107440A</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 TFA; ...)</p> <p>Cat. No.: HY-103611</p>
<p>Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 98.29%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 100 mg</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.55%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>

Thalidomide-O-amido-PEG4-C2-NH2

Cat. No.: HY-122710

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride

Cat. No.: HY-122710A

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C10-NH2

Cat. No.: HY-130963

Thalidomide-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C11-acid

Cat. No.: HY-138860

Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C2-acid

Cat. No.: HY-131880

Thalidomide-O-C2-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 95.76%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Thalidomide-O-C3-acid

Cat. No.: HY-131876

Thalidomide-O-C3-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

Thalidomide-O-C3-NH2

Cat. No.: HY-138847

Thalidomide-O-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C3-NH2 hydrochloride

Cat. No.: HY-138847A

Thalidomide-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C4-COOH

Cat. No.: HY-130950

Thalidomide-O-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Thalidomide-O-C4-NH2

Cat. No.: HY-130948

Thalidomide-O-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>Thalidomide-O-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-130948B</p>	<p>Thalidomide-O-C5-acid</p> <p>Cat. No.: HY-131889</p>
<p>Thalidomide-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 96.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-O-C5-NH2</p> <p>Cat. No.: HY-138848</p>	<p>Thalidomide-O-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-138848A</p>
<p>Thalidomide-O-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-COOH</p> <p>Cat. No.: HY-130951</p>	<p>Thalidomide-O-C6-NH2</p> <p>Cat. No.: HY-135250</p>
<p>Thalidomide-O-C6-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-NH2 hydrochloride</p> <p>Cat. No.: HY-135250B</p>	<p>Thalidomide-O-C6-NH2 TFA</p> <p>Cat. No.: HY-135250A</p>
<p>Thalidomide-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12^{F36V} and BET.</p> <p>Purity: 98.53%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p>	<p>Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12^{F36V} and BET.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-NHBoc</p> <p>Cat. No.: HY-141887</p>	<p>Thalidomide-O-C7-acid</p> <p>Cat. No.: HY-131874</p>
<p>Thalidomide-O-C6-NHBoc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>Thalidomide-O-C7-NH2</p> <p>Cat. No.: HY-130949</p>	<p>Thalidomide-O-C8-NH2</p> <p>Cat. No.: HY-133485</p>
<p>Thalidomide-O-C7-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C8-NH2 hydrochloride</p> <p>Cat. No.: HY-133485B</p>	<p>Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32)</p> <p>Cat. No.: HY-126458</p>
<p>Thalidomide-O-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 97.57% Clinical Data: No Development Reported Size: 25 mg, 100 mg</p>
<p>Thalidomide-O-PEG4-amine</p> <p>Cat. No.: HY-141010</p>	<p>Thalidomide-O-PEG4-amine hydrochloride</p> <p>Cat. No.: HY-141010A</p>
<p>Thalidomide-O-PEG4-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-PEG4-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-PEG4-amine TFA</p> <p>Cat. No.: HY-141010B</p>	<p>Thalidomide-O-PEG4-azide</p> <p>Cat. No.: HY-140844</p>
<p>Thalidomide-O-PEG4-amine TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Thalidomide-O-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-PEG4-Boc</p> <p>Cat. No.: HY-141014</p>	<p>Thalidomide-O-PEG4-NHS ester</p> <p>Cat. No.: HY-141012</p>
<p>Thalidomide-O-PEG4-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.23% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>

<p>Thalidomide-PEG2-C2-NH2 (Thalidomide-NH-PEG2-C2-NH2)</p>	<p>Thalidomide-PEG2-C2-NH2 hydrochloride (Thalidomide-NH-PEG2-C2-NH2 hydrochloride)</p>
<p>Thalidomide-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-PEG2-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-PEG2-C2-NH2 TFA (Thalidomide-NH-PEG2-C2-NH2 TFA)</p>	<p>Thalidomide-PEG2-NH2</p>
<p>Thalidomide-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 98.85% Clinical Data: No Development Reported Size: 25 mg, 100 mg</p>	<p>Thalidomide-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Thalidomide-PEG3-COOH</p>	<p>Thalidomide-PEG3-NH2</p>
<p>Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.05% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Thalidomide-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-PEG4-COOH</p>	<p>Thalidomide-PEG4-NH2 hydrochloride</p>
<p>Thalidomide-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 95.08% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-PEG4-Propargyl</p>	<p>Thalidomide-PEG5-COOH</p>
<p>Thalidomide-PEG4-Propargyl is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.09% Clinical Data: No Development Reported Size: 100 mg</p>

<p>Thalidomide-PEG5-NH2</p> <p>Cat. No.: HY-138784</p>	<p>Thalidomide-Piperazine 5-fluoride</p> <p>Cat. No.: HY-134983</p>
<p>Thalidomide-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-Piperazine 5-fluoride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-piperazine-Boc</p> <p>Cat. No.: HY-134982</p>	<p>Thalidomide-Piperazine-PEG1-COOH</p> <p>Cat. No.: HY-138782</p>
<p>Thalidomide-piperazine-Boc is an intermediate that can be used in the synthesis of B-cell lymphoma 6 protein (BCL6) PROTAC.</p> <p>Purity: 99.75%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg</p>	<p>Thalidomide-Piperazine-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.79%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-Piperazine-PEG1-NH2</p> <p>Cat. No.: HY-138789</p>	<p>Thalidomide-Piperazine-PEG1-NH2 diTFA</p> <p>Cat. No.: HY-138789A</p>
<p>Thalidomide-Piperazine-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-Piperazine-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.84%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-Piperazine-PEG2-COOH</p> <p>Cat. No.: HY-138781</p>	<p>Thalidomide-Piperazine-PEG2-NH2</p> <p>Cat. No.: HY-138788</p>
<p>Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.96%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>	<p>Thalidomide-Piperazine-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-Piperazine-PEG2-NH2 diTFA</p> <p>Cat. No.: HY-138788A</p>	<p>Thalidomide-Piperazine-PEG3-COOH</p> <p>Cat. No.: HY-138780</p>
<p>Thalidomide-Piperazine-PEG2-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.76%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Piperazine-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.66%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>


<p>Thalidomide-Piperazine-PEG3-NH2</p> <p>Cat. No.: HY-138787</p>	<p>Thalidomide-Piperazine-Piperidine</p> <p>Cat. No.: HY-138783</p>
<p>Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Piperazine-Piperidine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-Piperazine-Piperidine hydrochloride</p> <p>Cat. No.: HY-138783A</p>	<p>Thalidomide-Propargyne-PEG1-COOH</p> <p>Cat. No.: HY-138778</p>
<p>Thalidomide-Piperazine-Piperidine hydrochloride is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-Piperazine-Piperidine hydrochloride incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Propargyne-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.45%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>
<p>Thalidomide-Propargyne-PEG2-COOH</p> <p>Cat. No.: HY-138777</p>	<p>Thalidomide-Propargyne-PEG3-COOH</p> <p>Cat. No.: HY-138776</p>
<p>Thalidomide-Propargyne-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.07%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>	<p>Thalidomide-Propargyne-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.01%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg</p>
<p>VH032-PEG3-acetylene</p> <p>Cat. No.: HY-128767</p>	<p>VH032-PEG5-C6-Cl (HaloPROTAC 2)</p> <p>Cat. No.: HY-112495</p>
<p>VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.</p>  <p>Purity: 96.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>VH032-PEG5-C6-Cl (HaloPROTAC 2) is a conjugate of ligands for E3 and 21-atom-length linker. The connector of linker is Halogen group. VH032-PEG5-C6-Cl incorporates the VH032 based VHL ligand and 5-unit PEG linker.</p>  <p>Purity: 99.76%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p>
<p>VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 29)</p> <p>Cat. No.: HY-111824</p>	<p>VH285-PEG4-C4-Cl (HaloPROTAC 3)</p> <p>Cat. No.: HY-111997</p>
<p>VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>VH285-PEG4-C4-Cl (HaloPROTAC 3) is a conjugate of ligands for E3 and 16-atom-length linker. The connector of linker is Halogen group. VH285-PEG4-C4-Cl incorporates the VH285 based VHL ligand and an alkyl/ether-based linker.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

VHL Ligand-Linker Conjugates 15

(E3 Ligase Ligand-Linker Conjugates 56)

Cat. No.: HY-125906

VHL Ligand-Linker Conjugates 15 incorporates an VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 15 can be used to design PROTACs.



Purity: >98%


Clinical Data: No Development Reported

Size: 1 mg, 5 mg

VHL Ligand-Linker Conjugates 17

Cat. No.: HY-133046

VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader.



Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Ligands for E3 Ligase

E3 ligase-recruiting Moiety

A PROTAC (Proteolysis Targeting Chimeric Molecule) is a protein degrader comprised of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand for target protein (target binder). The association between an E3 ligase and a target protein induced by a PROTAC will lead to the transfer of ubiquitin and degradation of the targeted protein.

E3 ligases catalyze the transfer of ubiquitin to targeted proteins and determine the specificity of the proteins. There are hundreds of E3 ligases in cells, but only a limited number of them are successfully used in reported PROTACs, such as VHL (von Hippel-Lindau disease tumor suppressor protein), CRBN (Cereblon), MDM2 (the mouse double minute 2 homologue) and IAP (inhibitor of apoptosis).

Ligands for E3 Ligase Inhibitors, Modulators & Chemicals


<p>(4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2; E3 ligase Ligand 15)</p> <p>(4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>(R)-Pomalidomide-pyrrolidine</p> <p>(R)-Pomalidomide-pyrrolidine, a CRBN ligand, can be connected to the ligand for protein by a linker to form PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>(S,R,S)-AHPC (VH032-NH2; VHL ligand 1)</p> <p>(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p>Purity: 98.92% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>(S,R,S)-AHPC hydrochloride (VH032-NH2 hydrochloride; VHL ligand 1 hydrochloride)</p> <p>(S,R,S)-AHPC hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p>Purity: 99.54% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g, 5 g</p>
<p>(S,R,S)-AHPC TFA (VH032-NH2 TFA; VHL ligand 1 TFA)</p> <p>(S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>(S,R,S)-AHPC-Boc (VH032-Boc)</p> <p>(S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.</p> <p>Purity: 95.15% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>(S,R,S)-AHPC-Me (VHL ligand 2; E3 ligase Ligand 1A)</p> <p>(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Lindau (VHL) E3 ligase-based BET PROTAC degrader.</p> <p>Purity: 98.70% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride)</p> <p>(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p> <p>Purity: 98.39% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g</p>
<p>(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride; E3 ligase Ligand 1)</p> <p>(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p> <p>Purity: 98.58% Clinical Data: No Development Reported Size: 500 mg, 2 g</p>	<p>(S,R,S)-AHPC-propargyl (VH032-propargyl; VHL ligand 7)</p> <p>(S,R,S)-AHPC-propargyl (VH032-propargyl) is a VHL ligand which is used in "click reaction" for PROTACs.</p> <p>Purity: 98.12% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg</p>

<p>(S,S,S)-AHPC hydrochloride (S,S,S)-VH032-NH2 hydrochloride)</p> <p>(S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.</p> <p>Purity: 99.90% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>ALV2</p> <p>ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC_{50} of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable T_{reg} cell phenotype in the inflammatory tumor microenvironment.</p> <p>Purity: 98.07% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>AR antagonist 1</p> <p>AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BC-1215</p> <p>BC-1215 is an inhibitor of F-box protein 3 (FBXO3), a ubiquitin E3 ligase component, IC_{50}=0.9 μg/mL for IL-1β release). BC-1215 decreases Fbxo3-Fbxl2 interaction and prevents SCF^{Fbxo3} catalyzed Fbxl2 ubiquitination.</p> <p>Purity: 99.93% Clinical Data: Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Bestatin-amido-Me (PROTAC IAP binding moiety 1)</p> <p>Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CC-17369 (7-Hydroxy pomalidomide; Pomalidomide metabolite M16)</p> <p>CC-17369 (7-Hydroxy pomalidomide) is a metabolite of Pomalidomide. CC-17369 is the Pomalidomide -based cereblon (CRBN) ligand used in the recruitment of CRBN protein. CC-17369 can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CC-885</p> <p>CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity.</p> <p>Purity: 99.23% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Cereblon inhibitor 1</p> <p>Cereblon inhibitor 1, an isoindoline derivative, is a cereblon E3 ubiquitin ligase modulating drug. Cereblon inhibitor 1 has the potential for cancer research.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CFT7455</p> <p>CFT7455 is an orally active zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3) degrader. CFT7455 is an anti-cancer agent that binds with high affinity to the cereblon E3 ligase (K_d of 0.9 nM) (WO2022032132A1; Compound 1).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>cIAP1 ligand 1 (E3 ligase Ligand 12)</p> <p>cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.</p> <p>Purity: 98.51% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg, 250 mg</p>

cIAP1 ligand 2 (E3 ligase Ligand 11)

Cat. No.: HY-128809

cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

cIAP1 ligand 4

Cat. No.: HY-139656

cIAP1 ligand 4 is a ligand for E3 ligase that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRBN modulator-1

Cat. No.: HY-138040

CRBN modulator-1, a Thalidomide analog and a CRBN modulator extracted from WO2020006262A1, compound 10, has an IC_{50} of 3.5 μ M and a K_i of 0.98 μ M.




Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E3 ligase Ligand 10

Cat. No.: HY-128807

E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

E3 ligase Ligand 13

Cat. No.: HY-128810

E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

E3 ligase Ligand 14

Cat. No.: HY-128811

E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

E3 ligase Ligand 18

Cat. No.: HY-129653

E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 21

Cat. No.: HY-144980

E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 22

Cat. No.: HY-144983

E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











E3 ligase Ligand 23

Cat. No.: HY-144985

E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.























Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











<p>E3 ligase Ligand 8</p> <p style="text-align: right;">Cat. No.: HY-43961</p> <p>E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.</p>  <p>Purity: 99.32% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g</p>	<p>E3 ligase Ligand 9</p> <p style="text-align: right;">Cat. No.: HY-128806</p> <p>E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>Eragidomide (CC-90009)</p> <p style="text-align: right;">Cat. No.: HY-130800</p> <p>Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4^{CRBN} to selectively target GSPT1 for ubiquitination and proteasomal degradation.</p>  <p>Purity: 99.65% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Iberdomide (CC-220)</p> <p style="text-align: right;">Cat. No.: HY-101291</p> <p>Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC₅₀ of ~150nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.</p>  <p>Purity: 98.84% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>KB02-COOH</p> <p style="text-align: right;">Cat. No.: HY-131385</p> <p>KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610).</p>  <p>Purity: 98.88% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>LCL-PEG3-N3</p> <p style="text-align: right;">Cat. No.: HY-139999</p> <p>LCL-PEG3-N3 is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>LCL-PEG3-N3 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-139999A</p> <p>LCL-PEG3-N3 (hydrochloride) is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Lenalidomide (CC-5013)</p> <p style="text-align: right;">Cat. No.: HY-A0003</p> <p>Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p>  <p>Purity: 99.91% Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g</p>
<p>Lenalidomide hemihydrate (CC-5013 hemihydrate)</p> <p style="text-align: right;">Cat. No.: HY-A0003B</p> <p>Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator.</p>  <p>Purity: 99.95% Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>Lenalidomide hydrochloride (CC-5013 hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-A0003A</p> <p>Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.</p>  <p>Purity: >98% Clinical Data: Launched Size: 1 mg, 5 mg</p>

<p>Lenalidomide-4-aminomethyl</p> <p>Cat. No.: HY-138882</p>	<p>Lenalidomide-4-aminomethyl hydrochloride</p> <p>Cat. No.: HY-138882A</p>
<p>Lenalidomide-4-aminomethyl is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-4-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Lenalidomide-4-OH</p> <p>Cat. No.: HY-W076696</p>	<p>Lenalidomide-5-aminomethyl</p> <p>Cat. No.: HY-W077589A</p>
<p>Lenalidomide-4-OH is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-OH can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 98.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg</p>	<p>Lenalidomide-5-aminomethyl is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-aminomethyl can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Lenalidomide-5-aminomethyl hydrochloride</p> <p>Cat. No.: HY-W077589</p>	<p>Lenalidomide-5-Br</p> <p>Cat. No.: HY-W072954</p>
<p>Lenalidomide-5-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 98.12%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>	<p>Lenalidomide-5-Br is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-Br can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 98.97%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg</p>
<p>Lenalidomide-6-F</p> <p>Cat. No.: HY-138881</p>	<p>Lenalidomide-Br</p> <p>Cat. No.: HY-43722</p>
<p>Lenalidomide-6-F is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-6-F can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.</p> <p>Purity: 99.86%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg, 500 mg</p>
<p>Lenalidomide-d5 (CC-5013-d5)</p> <p>Cat. No.: HY-A00035</p>	<p>Lenalidomide-I</p> <p>Cat. No.: HY-131318</p>
<p>Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-I (Compound 72), an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, is used in the recruitment of CRBN protein.</p> <p>Purity: 98.82%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg</p>

<p>Lenalidomide-OH</p> <p>Cat. No.: HY-133144</p>	<p>MV-1-NH-Me (PROTAC IAP binding moiety 2)</p> <p>Cat. No.: HY-111853</p>
<p>Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137).</p> <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>N-Boc-SBP-0636457-OH</p> <p>Cat. No.: HY-131189</p>	<p>Nutlin carboxylic acid (MDM2 ligand 1; E3 ligase Ligand 16)</p> <p>Cat. No.: HY-128837</p>
<p>N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid (MDM2 ligand 1) can be connected to the ligand for protein by a linker to form PROTACs.</p> <p>Purity: 98.29%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>NV03</p> <p>Cat. No.: HY-125292</p>	<p>Pomalidomide (CC-4047)</p> <p>Cat. No.: HY-10984</p>
<p>NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a K_d of 2.4 μM. NV03 has anticancer activity.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: 99.96%</p> <p>Clinical Data: Launched</p> <p>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p>
<p>Pomalidomide-5-O-CH3</p> <p>Cat. No.: HY-139541</p>	<p>Pomalidomide-5-OH (5-Hydroxy pomalidomide; CC-17368)</p> <p>Cat. No.: HY-123324</p>
<p>Pomalidomide-5-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Pomalidomide-5-OH (5-hydroxy pomalidomide) is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Pomalidomide-6-O-CH3</p> <p>Cat. No.: HY-139542</p>	<p>Pomalidomide-6-OH</p> <p>Cat. No.: HY-139540</p>
<p>Pomalidomide-6-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Pomalidomide-6-OH is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-OH can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>Pomalidomide-C5-Dovitinib</p> <p>Cat. No.: HY-139996</p>	<p>Pomalidomide-d3 (CC-4047-d3)</p> <p>Cat. No.: HY-10984S1</p>
<p>Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-d3 (CC-4047-d3) is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-d5 (CC-4047-d5)</p> <p>Cat. No.: HY-10984S</p>	<p>Pomalidomide-PEG4-COOH</p> <p>Cat. No.: HY-133699</p>
<p>Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-PEG4-COOH is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG4-COOH contains the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology (extracted from patent WO2017184995A1).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>TD-106</p> <p>Cat. No.: HY-114406</p>	<p>Thalidomide 4-fluoride (Cereblon ligand 4; E3 ligase Ligand 4)</p> <p>Cat. No.: HY-41547</p>
<p>TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation.</p>  <p>Purity: 99.17% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966).</p>  <p>Purity: 99.54% Clinical Data: No Development Reported Size: 10 mg, 50 mg, 100 mg, 500 mg</p>
<p>Thalidomide 5-fluoride</p> <p>Cat. No.: HY-W087383</p>	<p>Thalidomide D4</p> <p>Cat. No.: HY-14658S</p>
<p>Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.</p>  <p>Purity: 99.85% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.</p>  <p>Purity: 98.03% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-4-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-13954S</p>	<p>Thalidomide-4-OH (Cereblon ligand 2; E3 ligase Ligand 2)</p> <p>Cat. No.: HY-103596</p>
<p>Thalidomide-4-C3-NH2 hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-C3-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-4-OH (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 99.88% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>


<p>Thalidomide-5,6-Cl</p> <p>Cat. No.: HY-139547</p>	<p>Thalidomide-5,6-F</p> <p>Cat. No.: HY-W093272</p>
<p>Thalidomide-5,6-Cl is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5,6-Cl can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-5,6-F is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5,6-F can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 500 mg</p>
<p>Thalidomide-5-CH2-NH2 hydrochloride</p> <p>Cat. No.: HY-W129872</p>	<p>Thalidomide-5-COOH</p> <p>Cat. No.: HY-139539</p>
<p>Thalidomide-5-CH2-NH2 (hydrochloride) is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-CH2-NH2 (hydrochloride) can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-5-COOH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-COOH can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-5-methyl</p> <p>Cat. No.: HY-139548</p>	<p>Thalidomide-5-NH2-CH2-COOH</p> <p>Cat. No.: HY-46531</p>
<p>Thalidomide-5-methyl is the Thalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase.</p>  <p>Purity: 96.03% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-5-OH</p> <p>Cat. No.: HY-23095</p>	<p>Thalidomide-5-PEG2-Cl</p> <p>Cat. No.: HY-139543</p>
<p>Thalidomide-5-OH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 98.07% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg</p>	<p>Thalidomide-5-PEG2-Cl is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-PEG2-Cl can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-5-propargyne-NH2 hydrochloride</p> <p>Cat. No.: HY-139546</p>	<p>Thalidomide-5-propoxyethanamine</p> <p>Cat. No.: HY-139544</p>
<p>Thalidomide-5-propargyne-NH2 hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-propargyne-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-5-propoxyethanamine is the Thalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thalidomide-benzo</p> <p>Cat. No.: HY-139549</p>	<p>Thalidomide-NH-CH₂-COOH</p> <p>Cat. No.: HY-131717</p>
<p>Thalidomide-benzo hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-benzo can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-CH₂-COOH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-NH-CH₂-COOH can be connected to the ligand for protein by a linker to form PROTACs, such as THAL-SNS-032 (HY-123937).</p>  <p>Purity: 98.20%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p>
<p>Thalidomide-O-C8-Boc</p> <p>Cat. No.: HY-131159</p>	<p>Thalidomide-O-C8-COOH</p> <p>Cat. No.: HY-130952</p>
<p>Thalidomide-O-C8-Boc is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-Boc can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 95.12%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 250 mg, 500 mg</p>	<p>Thalidomide-O-C8-COOH is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 95.30%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg</p>
<p>Thalidomide-O-COOH (Cereblon ligand 3; E3 ligase Ligand 3)</p> <p>Cat. No.: HY-103597</p>	<p>Thalidomide-propargyl</p> <p>Cat. No.: HY-126457</p>
<p>Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 99.73%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.</p>  <p>Purity: 99.97%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg</p>
<p>VH-298</p> <p>Cat. No.: HY-100947</p>	<p>VH032</p> <p>Cat. No.: HY-120217</p>
<p>VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a K_d value of 80 to 90 nM, used in PROTAC technology.</p>  <p>Purity: 99.83%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL/HIF-1α interaction inhibitor with a K_d of 185 nM. VH032 can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p>Purity: 99.52%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>
<p>VH032 thiol (VHL ligand 6)</p> <p>Cat. No.: HY-111823</p>	<p>VH032-cyclopropane-F (VHL ligand 3; E3 ligase Ligand 19)</p> <p>Cat. No.: HY-125905</p>
<p>VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.</p>  <p>Purity: 95.91%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4.</p>  <p>Purity: 99.39%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 250 mg</p>

VH032-OH

Cat. No.: HY-136164

VH032-OH is the VH032-based VHL ligand. VH032-OH can be connected to the ligand for protein by a linker to form PROTACs.




Purity: 97.82%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

VHL Ligand 8

Cat. No.: HY-133045

VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader.




Purity: 98.12%
Clinical Data: No Development Reported
Size: 100 mg

VL285

Cat. No.: HY-111663

VL285 is a potent VHL ligand with an IC_{50} of 0.34 μ M.




Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

β -Naphthoflavone-CH2-Br

(β -NF-CH2-Br)

Cat. No.: HY-130842

β -Naphthoflavone-CH2-Br (β -NF-CH2-Br) is an arylhydrocarbon receptor (AhR) ligand. β -Naphthoflavone-CH2-Br can be used to synthesize the PROTAC β -NF-JQ1 (HY-130256).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β -Naphthoflavone-CH2-OH

(β -NF-CH2-OH)

Cat. No.: HY-130269

β -Naphthoflavone-CH2-OH (β -NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β -Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins











Ligands for Target Protein for PROTAC

Target Protein-binding Moiety











The PROTAC molecule consists of a target protein ligand and an E3 ubiquitin ligase ligand, with a linker binds them together. The ligand for target protein will lead to attachment of a PROTAC to the proteins of interest for ubiquitin and subsequent degradation.

Target proteins are usually proteins whose overexpression or accumulation may play important roles in the progress of diseases. Numbers of PROTACs have been developed to degrade kinases (such as MEK, KRAS, CDK and Bcr/Abl), transcription factors (such as p53, STAT, RAR, ER and AR), epigenetic tools (such as HDAC and BET bromodomain) and E3 ligase themselves (such as MDM2).

Ligands for Target Protein for PROTAC Inhibitors & Chemicals


<p>(+)-JQ-1 (JQ1)</p> <p>Cat. No.: HY-13030</p> <p>(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC_{50}s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy.</p> <p>Purity: 99.90% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>A-1210477-piperazinyl (PROTAC Mcl1-binding moiety 1)</p> <p>Cat. No.: HY-125908</p> <p>A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Abemaciclib metabolite M18 (LSN3106729)</p> <p>Cat. No.: HY-126534</p> <p>Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Abemaciclib metabolite M18 hydrochloride (LSN3106729 hydrochloride)</p> <p>Cat. No.: HY-126534A</p> <p>Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.</p> <p>Purity: 99.01% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Abemaciclib metabolite M18-d8 (LSN3106729-d8)</p> <p>Cat. No.: HY-126534S</p> <p>Abemaciclib metabolite M18-d8 (LSN3106729-d8) is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>ABM-14</p> <p>Cat. No.: HY-131388</p> <p>ABM-14 is a ligand for targeting androgen receptor (AR) for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Androgen receptor antagonist 1</p> <p>Cat. No.: HY-130992</p> <p>Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC_{50} of 59 nM.</p> <p>Purity: 99.39% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Androstanolone acetate (Dihydrotestosterone acetate)</p> <p>Cat. No.: HY-111847</p> <p>Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs.</p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p> 
<p>AP1867-2-(carboxymethoxy) (PROTAC FKBP12-binding moiety 2)</p> <p>Cat. No.: HY-114420</p> <p>AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12^{F36V}-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules.</p> <p>Purity: 96.44% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>AP1867-3-(aminoethoxy)</p> <p>Cat. No.: HY-129363</p> <p>AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p> <p>Purity: 99.10% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 

<p>Apcin-A</p> <p style="text-align: right;">Cat. No.: HY-130841</p>	<p>ATRA-hydroxyimino (CRABP-II ligand 1)</p> <p style="text-align: right;">Cat. No.: HY-111839</p>
<p>Apcin-A, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V (HY-130257).</p> <p>Purity: ≥95.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>BET-IN-6</p> <p style="text-align: right;">Cat. No.: HY-130813</p>	<p>BI-4464</p> <p style="text-align: right;">Cat. No.: HY-124625</p>
<p>BET-IN-6 is a potent and high affinity BRD2/BRD4 inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the synthesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC₅₀ of 17 nM. A PTK2 ligand for PROTAC.</p> <p>Purity: 99.27%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>BMS-1166-N-piperidine-COOH</p> <p style="text-align: right;">Cat. No.: HY-131187</p>	<p>CBP/p300 ligand 2</p> <p style="text-align: right;">Cat. No.: HY-138539</p>
<p>BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.</p> <p>Purity: 98.17%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>CCR7 Ligand 1 (CCR7-Cmp2105)</p> <p style="text-align: right;">Cat. No.: HY-133073</p>	<p>CDK9-IN-10</p> <p style="text-align: right;">Cat. No.: HY-130850</p>
<p>CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a K_d of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligand, suppresses arrestin binding in response to activation by CCL19 with an IC₅₀ of 7.3 μM.</p> <p>Purity: 99.64%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg</p>	<p>CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>CDK9-IN-11</p> <p style="text-align: right;">Cat. No.: HY-130852</p>	<p>Ch55-O-C3-NH2 (RAR ligand 1)</p> <p style="text-align: right;">Cat. No.: HY-111843</p>
<p>CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Ch55-O-C3-NH2 (RAR ligand 1) is a Ch 55-based ligand, which targets RAR. Ch55-O-C3-NH2 (RAR ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>Dasatinib carbaldehyde (BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4) Cat. No.: HY-111857</p> <p>Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4) Cat. No.: HY-44103</p> <p>Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Desmorpholinyl Navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) Cat. No.: HY-131232</p> <p>Desmorpholinyl Navitoclax-NH-Me is a Bcl-xL inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).</p>  <p>Purity: 99.43% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Dimethyl-F-OICR-9429-COOH Cat. No.: HY-141799</p> <p>Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DUPA Cat. No.: HY-111606</p> <p>DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>EED226-COOH Cat. No.: HY-130979</p> <p>EED226-COOH is an EED226-derived ligand for target protein EED ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2.</p>  <p>Purity: 99.68% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Estrone-N-O-C1-amido (ERα ligand 1) Cat. No.: HY-111845</p> <p>Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FN-1501-propionic acid Cat. No.: HY-130981</p> <p>FN-1501-propionic acid is a CDK2/9 ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>GNF5-amido-Me (PROTAC ABL binding moiety 2) Cat. No.: HY-111852</p> <p>GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HG-7-85-01-Decyclopropane (PROTAC ABL binding moiety 3) Cat. No.: HY-111855</p> <p>HG-7-85-01-Decyclopropane, the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

I-BET762 carboxylic acid (Molibresib carboxylic acid;
GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2) Cat. No.: HY-107443


I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a **BRD4** inhibitor with a pIC_{50} of 5.1.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Ibrutinib
(PCI-32765) Cat. No.: HY-10997


Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Imatinib carbaldehyde (CGP-57148B carbaldehyde; STI571
carbaldehyde; PROTAC ABL binding moiety 1) Cat. No.: HY-111849


Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ipatasertib-NH2
(GDC-0068-NH2; RG7440-NH2) Cat. No.: HY-130988


Ipatasertib-NH2 (GDC-0068-NH2; RG7440-NH2) is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ipatasertib-NH2 dihydrochloride
(GDC-0068-NH2 dihydrochloride; RG7440-NH2 dihydrochloride) Cat. No.: HY-130988A


Ipatasertib-NH2 dihydrochloride is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAK683-CH2CH2COOH
(GDC-0068-CH2CH2COOH) Cat. No.: HY-130815


MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-Deshydroxyethyl Dasatinib
(N-Deshydroxyethyl BMS-354825) Cat. No.: HY-107447


N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

N-Deshydroxyethyl Dasatinib-d8
(N-Deshydroxyethyl BMS-354825-d8) Cat. No.: HY-107447S


N-Deshydroxyethyl Dasatinib-d8 is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

N-piperidine Ibrutinib hydrochloride
(Compound 1) Cat. No.: HY-130983


N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC_{50} s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively.











Purity: 95.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navitoclax-piperazine
(ABT-263-piperazine) Cat. No.: HY-44432

Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg


<p>OICR-9429-N-C2-NH2</p> <p>Cat. No.: HY-141798</p> <p>OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Palbociclib-propargyl (PROTAC CDK6 ligand 1)</p> <p>Cat. No.: HY-130296</p> <p>Palbociclib-propargyl is a ligand for target protein CDK6 for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC_{50} of 2.1 nM for CDK6.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p> 
<p>PD0325901-O-C2-dioxolane</p> <p>Cat. No.: HY-131295</p> <p>PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.</p> <p>Purity: 98.76% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Piperidine-GNE-049-N-Boc</p> <p>Cat. No.: HY-134592</p> <p>Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.</p> <p>Purity: 98.82% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>PROTAC Bcl-xL ligand-1</p> <p>Cat. No.: HY-139304</p> <p>PROTAC Bcl-xL ligand-1 is a ligand for Bcl-xL that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>PROTAC BET-binding moiety 1</p> <p>Cat. No.: HY-107451</p> <p>PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.</p> <p>Purity: 82.01% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p> 
<p>PROTAC BET-binding moiety 2</p> <p>Cat. No.: HY-43723</p> <p>PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain.</p> <p>Purity: 99.30% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p> 	<p>PROTAC BRD4 Degrader-7</p> <p>Cat. No.: HY-136857</p> <p>PROTAC BRD4 Degrader-7 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC_{50}s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC BRD4 ligand-1</p> <p>Cat. No.: HY-129939</p> <p>PROTAC BRD4 ligand-1 is a potent BET inhibitor and a ligand for target BRD4 protein for PROTAC GNE-987 (HY-129937A).</p> <p>Purity: 99.50% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>PROTAC BRD4 ligand-2</p> <p>Cat. No.: HY-132942</p> <p>PROTAC BRD4 ligand-2 is a ligand for target BRD4 protein for PROTAC CFT-2718.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 

<p>PROTAC BRD4-binding moiety 1</p> <p style="text-align: right;">Cat. No.: HY-107442</p>	<p>PROTAC BRD9-binding moiety 1</p> <p style="text-align: right;">Cat. No.: HY-107445</p>
<p>PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC BRD9-binding moiety 1 is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC BRD9-binding moiety 1 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-107445A</p>	<p>PROTAC CDK9 ligand-1</p> <p style="text-align: right;">Cat. No.: HY-115729</p>
<p>PROTAC BRD9-binding moiety 1 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p> <p>Purity: 98.20%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>PROTAC CDK9 ligand-1 is a CDK9 ligand that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC Her3-binding moiety 1</p> <p style="text-align: right;">Cat. No.: HY-107444</p>	<p>PROTAC IRAK4 ligand-1</p> <p style="text-align: right;">Cat. No.: HY-129967</p>
<p>PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966).</p> <p>Purity: 99.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>PROTAC PTK6 ligand-1</p> <p style="text-align: right;">Cat. No.: HY-139660</p>	<p>Quizartinib</p> <p style="text-align: right;">(AC220) Cat. No.: HY-13001</p>
<p>PROTAC PTK6 ligand-1 is an intermediate for BTK kinase inhibitor preparation. PROTAC PTK6 ligand-1 can be used in the synthesis of ARD-61 (HY-139659).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC_{50}s of 4.2 and 1.1 nM, respectively.</p> <p>Purity: 99.01%</p> <p>Clinical Data: Launched</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p>
<p>SI-109</p> <p style="text-align: right;">Cat. No.: HY-129603</p>	<p>SirReal1-O-propargyl</p> <p style="text-align: right;">(PROTAC Sirt2-binding moiety 1) Cat. No.: HY-107453</p>
<p>SI-109 is a potent STAT3 SH2 domain inhibitor ($K_i=9$ nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 ($IC_{50}=3$ μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36.</p> <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p>	<p>SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC_{50} of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

SLF

Cat. No.: HY-114872

SLF is a synthetic ligand for **FK506-binding protein (FKBP)** with an affinity of 3.1 μ M for FKBP51 and an IC_{50} of 2.6 μ M for FKBP12. SLF can be used in the synthesis of PROTAC.




Purity: 98.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SLF TFA

Cat. No.: HY-114872A

SLF TFA is a synthetic ligand for **FK506-binding protein (FKBP)** with an affinity of 3.1 μ M for FKBP51 and an IC_{50} of 2.6 μ M for FKBP12. SLF TFA can be used in the synthesis of PROTAC.




Purity: 95.04%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SLF-amido-C2-COOH
 (PROTAC FKBP12-binding moiety 1)

Cat. No.: HY-107452

SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs.




Purity: 98.82%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

SMARCA-BD ligand 1 for Protac

Cat. No.: HY-44012

SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMARCA-BD ligand 1 for Protac dihydrochloride

Cat. No.: HY-44012A

SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.




Purity: 98.56%
Clinical Data:
Size: 5 mg, 10 mg, 50 mg, 100 mg

TFC 007

Cat. No.: HY-110167

TFC-007, a selective hematopoietic prostaglandin D synthase (**H-PGDS**) inhibitor, show high inhibitory activity against H-PGDS enzyme (IC_{50} value of 83 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

LYTACs

Lysosome-targeting chimeras

Lysosome targeting chimera (LYTAC) degrades target proteins via lysosomal pathway rather than common proteasome pathway. LYTAC degrades target proteins by binding to asialoglycoprotein receptor on lysosomal through its asialoglycoprotein receptor ligand. Another side of LYTAC is usually an antibody so it can bind to target protein for degradation.

LYTACs

D-MoDE-A (1)

Cat. No.: HY-142881

D-MoDE-A (1) is a bifunctional small molecule that mediates the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M-MoDE-A (2)

Cat. No.: HY-142885

M-MoDE-A (2) is a bifunctional small molecule that mediates the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

tri-GalNAc-COOH

Cat. No.: HY-139482

tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research.




Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

tri-GalNAc-COOH (acetylation)

Cat. No.: HY-145013

tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg













www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Molecular Glues

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. Molecular glues are a class of small molecule compounds that can induce or stabilize the interaction between proteins. If one of the protein is ubiquitin ligase, molecular glue can cause another protein to undergo ubiquitin modification and degradation through the proteasome pathway, which is similar to PROTAC. However, these molecules are classified as ligand for E3 ligase as functional molecules in subsequent classification. Older drugs, thalidomide, lenalidomide, and pomalidomide, together with CC-90009 and CC-92480 reported later all belong to this category.

Molecular Glues

<p>(S)-Thalidomide (S)-(-)-Thalidomide)</p> <p>Cat. No.: HY-14658A</p> <p>(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>ALV2</p> <p>Cat. No.: HY-137206</p> <p>ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC_{50} of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable T_{reg} cell phenotype in the inflammatory tumor microenvironment.</p> <p>Purity: 98.07% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Eragidomide (CC-90009)</p> <p>Cat. No.: HY-130800</p> <p>Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4^{CRBN} to selectively target GSPT1 for ubiquitination and proteasomal degradation.</p> <p>Purity: 99.65% Clinical Data: Phase 2 Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>FPFT-2216</p> <p>Cat. No.: HY-145319</p> <p>FPFT-2216, a "molecular glue" compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>HQ461</p> <p>Cat. No.: HY-144981</p> <p>HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.</p> <p>Purity: 98.07% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Lenalidomide (CC-5013)</p> <p>Cat. No.: HY-A0003</p> <p>Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p> <p>Purity: 99.91% Clinical Data: Launched Size: 10 mM \times 1 mL, 100 mg, 500 mg, 1 g</p> 
<p>Lenalidomide hemihydrate (CC-5013 hemihydrate)</p> <p>Cat. No.: HY-A0003B</p> <p>Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator.</p> <p>Purity: 99.95% Clinical Data: Launched Size: 10 mM \times 1 mL, 100 mg, 500 mg</p> <p>0.5 H₂O</p> 	<p>Lenalidomide hydrochloride (CC-5013 hydrochloride)</p> <p>Cat. No.: HY-A0003A</p> <p>Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.</p> <p>Purity: >98% Clinical Data: Launched Size: 1 mg, 5 mg</p> <p>H-Cl</p> 
<p>Lenalidomide-d5 (CC-5013-d5)</p> <p>Cat. No.: HY-A0003S</p> <p>Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Mezigidomide (CC-92480)</p> <p>Cat. No.: HY-129395</p> <p>Mezigidomide (CC-92480), a cereblon E3 ubiquitin ligase modulating drug (CELMoD), acts as a molecular glue. Mezigidomide shows high affinity to cereblon, resulting in potent antimyeloma activity.</p> <p>Purity: 98.09% Clinical Data: Phase 2 Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>Pomalidomide (CC-4047)</p>	<p>Pomalidomide-d3 (CC-4047-d3)</p>
<p>Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: 99.96%</p> <p>Clinical Data: Launched</p> <p>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p>	<p>Pomalidomide-d3 (CC-4047-d3) is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Pomalidomide-d5 (CC-4047-d5)</p>	<p>Thalidomide D4</p>
<p>Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.</p> <p>Purity: 98.03%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>TMX-4100</p>	<p>TMX-4113</p>
<p>TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC_{50} values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma.</p> <p>Purity: 98.42%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>TMX-4116</p>	
<p>TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC_{50}s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

PROTAC Linkers

PROTACs (Proteolysis Targeting Chimeric Molecules) are heterobifunctional protein degraders and promising targeted therapeutics candidates for cancer. The PROTAC linker connects two functional motifs of a PROTAC, a target protein binder and an E3 ligase recruiter.

The linker plays an important role in a PROTAC. The features of the linker (type, length, attachment position) can affect the formation of ligase:PROTAC:target ternary complex, resulting in influencing the efficient ubiquitination of the target protein and its ultimate degradation. The optimal lengths of the PROTAC linkers are reported varying from 12-carbon to over 20-carbon, and the commonly used linkers in the development of PROTACs are PEGs, Alkyl-Chain and Alkyl/ether.


PROTAC Linkers Chemicals

(+)-Biotin-ONP

((+)-Biotin 4-nitrophenyl ester)

Cat. No.: HY-130888

(+)-Biotin-ONP is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(+)-Biotin-PEG10-OH

((+)-Biotin-PEG10-alcohol)

Cat. No.: HY-130889

(+)-Biotin-PEG10-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(+)-Biotin-PEG12-OH

Cat. No.: HY-130890

(+)-Biotin-PEG12-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(+)-Biotin-PEG2-hydrazide

Cat. No.: HY-130892

(+)-Biotin-PEG2-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(+)-Biotin-PEG6-hydrazide

Cat. No.: HY-130891

(+)-Biotin-PEG6-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(+)-Biotin-SLC

Cat. No.: HY-130887

(+)-Biotin-SLC is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(10-Bromodecyl)phosphonic acid

Cat. No.: HY-140330

(10-Bromodecyl)phosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

(2-Pyridyldithio)-PEG2-Boc

Cat. No.: HY-141361

(2-Pyridyldithio)-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(2-Pyridyldithio)-PEG4-alcohol

Cat. No.: HY-141359

(2-Pyridyldithio)-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











(2-Pyridyldithio)-PEG4-propargyl











Cat. No.: HY-141360

(2-Pyridyldithio)-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.























Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg






<p>(4-Oxo-4H-quinazolin-3-yl)-acetic acid</p> <p>Cat. No.: HY-W030545</p>	<p>(5,6)TAMRA-PEG3-Azide-PEG3-Desthiobiotin</p> <p>Cat. No.: HY-140948</p>
<p>(4-Oxo-4H-quinazolin-3-yl)-acetic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>(5,6)TAMRA-PEG3-Azide-PEG3-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>(E)-TCO-PEG4-NHS ester</p> <p>Cat. No.: HY-141167A</p>	<p>(R)-Azetidine-2-carboxylic acid</p> <p>Cat. No.: HY-W017755</p>
<p>(E)-TCO-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>(R)-Azetidine-2-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). (R)-Azetidine-2-carboxylic acid is also a alkyl chain-based PROTAC linker that can be.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>(R)-TCO-OH</p> <p>Cat. No.: HY-141186A</p>	<p>(S)-TCO-PEG3-amine</p> <p>Cat. No.: HY-141178A</p>
<p>(R)-TCO-OH is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>(S)-TCO-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>(S)-TCO-PEG4-acid</p> <p>Cat. No.: HY-141159A</p>	<p>(S,R,S)-AHPC-PEG2-acid</p> <p>Cat. No.: HY-141016</p>
<p>(S)-TCO-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>(S,R,S)-AHPC-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>(±)15-HETE</p> <p>Cat. No.: HY-113336B</p>	<p>1,1,1-Trifluoroethyl-PEG2-azide</p> <p>Cat. No.: HY-140845</p>
<p>(±)15-HETE is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: ≥99.0% Clinical Data: No Development Reported Size: 25 µg (312.04 µM * 250 µL in Ethanol)</p>	<p>1,1,1-Trifluoroethyl-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>1,1,1-Trifluoroethyl-PEG2-propargyl</p> <p>Cat. No.: HY-140886</p> <p>1,1,1-Trifluoroethyl-PEG2-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>1,1,1-Trifluoroethyl-PEG4-alcohol</p> <p>Cat. No.: HY-141247</p> <p>1,1,1-Trifluoroethyl-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>1,1,1-Trifluoroethyl-PEG4-amine</p> <p>Cat. No.: HY-140243</p> <p>1,1,1-Trifluoroethyl-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>1,1,1-Trifluoroethyl-PEG4-aminoxy</p> <p>Cat. No.: HY-140445</p> <p>1,1,1-Trifluoroethyl-PEG4-aminoxy is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>1,1,1-Trifluoroethyl-PEG4-azide</p> <p>Cat. No.: HY-130543</p> <p>1,1,1-Trifluoroethyl-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>1,1,1-Trifluoroethyl-PEG4-propargyl</p> <p>Cat. No.: HY-140887</p> <p>1,1,1-Trifluoroethyl-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>1,1,1-Trifluoroethyl-PEG4-Tos</p> <p>Cat. No.: HY-140379</p> <p>1,1,1-Trifluoroethyl-PEG4-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>1,2-Bis(2-iodoethoxy)ethane</p> <p>Cat. No.: HY-133143</p> <p>1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker. 1,2-Bis(2-iodoethoxy)ethane can be used in the synthesis of MT802 (HY-122562) and SJF620 (HY-133137). MT-802 and SJF620 are potent PROTAC BTK degraders with DC_{50}s of 1 nM and 7.9 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>1,3-bis(carboxyethoxy)-2,2-bis(carboxyethoxy)propane</p> <p>Cat. No.: HY-140527</p> <p>1,3-bis(carboxyethoxy)-2,2-bis(carboxyethoxy)propane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>1,3-Bis-aminoxy propane</p> <p>Cat. No.: HY-116924</p> <p>1,3-Bis-aminoxy propane is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>1,3-Dibromo-5,5-dimethylhydantoin</p> <p>Cat. No.: HY-Y0786</p>	<p>1,7-Bis-Boc-1,4,7-triazaheptane</p> <p>Cat. No.: HY-W017829</p>
<p>1,3-Dibromo-5,5-dimethylhydantoin is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg</p>	<p>1,7-Bis-Boc-1,4,7-triazaheptane is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: ≥97.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg</p>
<p>1-(Isopropylthio)-2,3,4,6-tetra-o-Ac-beta-D-glucosylpyranose</p> <p>Cat. No.: HY-141139</p>	<p>1-(t-Boc-Aminoxy)-3-aminoxy-propane</p> <p>Cat. No.: HY-140405</p>
<p>1-(Isopropylthio)-2,3,4,6-tetra-o-Ac-beta-D-glucosylpyranose is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data:</p> <p>Size: 1 mg, 5 mg</p>	<p>1-(t-Boc-Aminoxy)-3-aminoxy-propane is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data:</p> <p>Size: 1 mg, 5 mg</p>
<p>1-Boc-azetidine-3-carboxylic acid</p> <p>Cat. No.: HY-40141</p>	<p>1-Boc-azetidine-3-yl-methanol</p> <p>Cat. No.: HY-40152</p>
<p>1-Boc-azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^{*/sup}.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 1 g</p>	<p>1-Boc-azetidine-3-yl-methanol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-yl-methanol is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^{*/sup}.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 1 g</p>
<p>1-Bromo-6-chlorohexane</p> <p>Cat. No.: HY-W009787</p>	<p>1-Cbz-3-Hydroxyazetidine</p> <p>Cat. No.: HY-77475</p>
<p>1-Bromo-6-chlorohexane is a PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>1-Cbz-3-Hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Cbz-3-Hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 g, 5 g</p>
<p>1-Cbz-azetidine-3-carboxylic acid</p> <p>Cat. No.: HY-W004868</p>	<p>1-Isothiocyanato-PEG3-azide</p> <p>Cat. No.: HY-140843</p>
<p>1-Cbz-azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Cbz-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^{*/sup}.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg</p>	<p>1-Isothiocyanato-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data:</p> <p>Size: 1 mg, 5 mg</p>

<p>1-Isothiocyanato-PEG4-alcohol</p> <p>Cat. No.: HY-141246</p>	<p>1-N-Boc-3-hydroxyazetidine</p> <p>Cat. No.: HY-40142</p>
<p>1-Isothiocyanato-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>1-N-Boc-3-hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-N-Boc-3-hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 1 g</p>
<p>11-Aminoundecanoic acid</p> <p>Cat. No.: HY-W014831</p>	<p>11-Maleimidoundecanoic acid</p> <p>Cat. No.: HY-130908</p>
<p>11-Aminoundecanoic acid is an alkyl chain based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>11-Maleimidoundecanoic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>2,2-Oxybis(ethylamine)</p> <p>Cat. No.: HY-140208</p>	<p>2,3,4,6-Tetra-o-acetyl-alpha-galactosylpyranosyl bromide</p> <p>Cat. No.: HY-141137</p>
<p>2,2-Oxybis(ethylamine) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 250 mg, 500 mg</p>	<p>2,3,4,6-Tetra-o-acetyl-alpha-galactosylpyranosyl bromide is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>2-((Azido-PEG8-carbamoyl)methoxy)acetic acid</p> <p>Cat. No.: HY-140459</p>	<p>2-(2-(6-chlorohexyloxy)ethoxy)ethanamine hydrochloride</p> <p>Cat. No.: HY-W096093</p>
<p>2-((Azido-PEG8-carbamoyl)methoxy)acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 500 mg, 1 g</p>	<p>2-(2-(6-chlorohexyloxy)ethoxy)ethanamine (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>2-(Azido-PEG2-amido)-1,3-propanediol</p> <p>Cat. No.: HY-141248</p>	<p>2-(Azido-PEG3-amido)-1,3-bis(carboxylethoxy)propane</p> <p>Cat. No.: HY-140522</p>
<p>2-(Azido-PEG2-amido)-1,3-propanediol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>2-Azido-PEG3-amido-1,3-bis(carboxylethoxy)propane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>2-(Azido-PEG3-amido)-1,3-bis(NHS ester)</p> <p>Cat. No.: HY-140865</p>	<p>2-(Benzyloxy)ethanol</p> <p>Cat. No.: HY-W007853</p>
<p>2-(Azido-PEG3-amido)-1,3-bis(NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>2-(Benzyloxy)ethanol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.32% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>2-(Biotin-amido)-1,3-bis-(C1-PEG1-acid)</p> <p>Cat. No.: HY-125392</p>	<p>2-Amino-1,3-bis(carboxylethoxy)propane</p> <p>Cat. No.: HY-23212</p>
<p>2-(Biotin-amido)-13-bis(carboxylethoxy)propane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>2-Amino-13-bis(carboxylethoxy)propane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>2-Bromo-2,2-dimethyl-acetamido-PEG3-acid</p> <p>Cat. No.: HY-141384</p>	<p>2-Phthalimidehydroxy-acetic acid</p> <p>Cat. No.: HY-133425</p>
<p>2-Bromo-22-dimethyl-acetamido-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>20-(tert-Butoxy)-20-oxoicosanoic acid</p> <p>Cat. No.: HY-W034597</p>	<p>22-(tert-Butoxy)-22-oxodocosanoic acid</p> <p>Cat. No.: HY-W046348</p>
<p>20-(tert-Butoxy)-20-oxoicosanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 20-(tert-Butoxy)-20-oxoicosanoic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs <su.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>22-(tert-Butoxy)-22-oxodocosanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 22-(tert-Butoxy)-22-oxodocosanoic acid is also a alkyl chain-based PROTAC linker that can be used in t.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>3,4-Dibromo-Mal-PEG2-amine</p> <p>Cat. No.: HY-141004</p>	<p>3,4-Dibromo-Mal-PEG2-amine TFA</p> <p>Cat. No.: HY-141004A</p>
<p>3,4-Dibromo-Mal-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>3,4-Dibromo-Mal-PEG2-amine TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>











<p>3,4-Dibromo-Mal-PEG2-N-Boc</p> <p>Cat. No.: HY-141005</p>	<p>3,4-Dibromo-Mal-PEG4-Boc</p> <p>Cat. No.: HY-141006</p>
<p>3,4-Dibromo-Mal-PEG2-N-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>3,4-Dibromo-Mal-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>3,4-Dibromo-Mal-PEG8-acid</p> <p>Cat. No.: HY-141003</p>	<p>3,4-Dibromo-Mal-PEG8-Boc</p> <p>Cat. No.: HY-141007</p>
<p>3,4-Dibromo-Mal-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>3,4-Dibromo-Mal-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>3,6,9-Trioxaundecanedioic Acid</p> <p>Cat. No.: HY-W067705</p>	<p>3,6-Dioxaoctanedioic acid</p> <p>Cat. No.: HY-W004945</p>
<p>369-Trioxaundecanedioic Acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 500 mg</p>	<p>36-Dioxaoctanedioic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg</p>
<p>3-(2-Pyridyldithio)propanoic Acid</p> <p>Cat. No.: HY-130157</p>	<p>3-Aminophenol-PEG4-methyl</p> <p>Cat. No.: HY-134742</p>
<p>3-(2-Pyridyldithio)propanoic Acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.36% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>3-Aminophenol-PEG4-methyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>3-Maleimidopropionic acid</p> <p>Cat. No.: HY-42145</p>	<p>3-Mercaptopropionic acid NHS ester</p> <p>Cat. No.: HY-136159</p>
<p>3-Maleimidopropionic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.27% Clinical Data: No Development Reported Size: 500 mg</p>	<p>3-Mercaptopropionyl-N-hydroxysuccinimide ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 500 mg</p>











<p>4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol</p> <p>Cat. No.: HY-141274</p>	<p>4-(N-Boc-amino)-1,6-heptanedioic acid</p> <p>Cat. No.: HY-140534</p>
<p>4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 250 mg, 500 mg</p>	<p>4-(N-Boc-amino)-1,6-heptanedioic acid is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>4-Boc-amino-2,2-dimethylbutyric acid</p> <p>Cat. No.: HY-W090446</p>	<p>4-Bromobutylphosphonic acid</p> <p>Cat. No.: HY-140328</p>
<p>4-Boc-amino-2,2-dimethylbutyric acid is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>4-Bromobutylphosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>4-Maleimidobutyric acid</p> <p>Cat. No.: HY-W037355</p>	<p>5-(Biotinamido)pentylamine</p> <p>Cat. No.: HY-W076543</p>
<p>4-Maleimidobutyric acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg</p>	<p>5-Biotinamidopentylamine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.40% Clinical Data: No Development Reported Size: 100 mg</p>
<p>5-(Biotinamido)pentylazide</p> <p>Cat. No.: HY-134695</p>	<p>5-endo-BCN-pentanoic acid</p> <p>Cat. No.: HY-140350</p>
<p>5-Biotinamidopentylazide is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>5-endo-BCN-pentanoic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>5-Ethynyl-2'-deoxyuridine</p> <p>Cat. No.: HY-118411</p>	<p>5-[Boc(methyl)amino]pentanal</p> <p>Cat. No.: HY-138520</p>
<p>5-Ethynyl-2'-deoxyuridine (EdU), a thymidine analogue, is incorporated into cellular DNA during DNA replication and the subsequent reaction of EdU with a fluorescent azide in a "Click" reaction.</p>  <p>Purity: 99.77% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg, 500 mg</p>	<p>5-[Boc(methyl)amino]pentanal is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>6-Bromohexylphosphonic acid</p> <p>Cat. No.: HY-140329</p>	<p>6-Maleimidocaproic acid sulfo-NHS</p> <p>Cat. No.: HY-136158</p>
<p>6-Bromohexylphosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>6-Maleimidocaproic acid sulfo-NHS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>6-Maleimidocaproic acid-PFP ester</p> <p>Cat. No.: HY-140990</p>	<p>6-Maleimidocaproic acid</p> <p>Cat. No.: HY-77959</p>
<p>6-Maleimidocaproic acid-PFP ester is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>6-Maleimidocaproic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>7-O-(Amino-PEG4)-paclitaxel</p> <p>Cat. No.: HY-141147</p>	<p>7-O-(Cbz-N-amido-PEG4)-paclitaxel</p> <p>Cat. No.: HY-141148</p>
<p>7-O-(Amino-PEG4)-paclitaxel is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.61% Clinical Data: No Development Reported Size: 25 mg</p>	<p>7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>7-Octynoic acid</p> <p>Cat. No.: HY-69220</p>	<p>9-Decyn-1-ol</p> <p>Cat. No.: HY-130985</p>
<p>7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ac4GalNAI</p> <p>Cat. No.: HY-140343</p>	<p>Ac4GalNAz</p> <p>Cat. No.: HY-141128</p>
<p>Ac4GalNAI is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ac4GalNAz is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Ac4GlcNAk</p> <p style="text-align: right;">Cat. No.: HY-141136</p> <p>Ac4GlcNAk is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acetamido-PEG2-Br</p> <p style="text-align: right;">Cat. No.: HY-134701</p> <p>Acetamido-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acetamido-PEG3-Br</p> <p style="text-align: right;">Cat. No.: HY-134706</p> <p>Acetamido-PEG3-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-C1-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140483</p> <p>Acid-C1-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-C2-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140011</p> <p>Acid-C2-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-C2-PEG4-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130436</p> <p>Acid-C2-PEG4-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acid-PEG1-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140479</p> <p>Acid-PEG1-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG10-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-143836</p> <p>Acid-PEG10-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acid-PEG12-CHO</p> <p style="text-align: right;">Cat. No.: HY-134703</p> <p>Acid-PEG12-CHO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-PEG12-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-143837</p> <p>Acid-PEG12-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Acid-PEG13-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141097</p>	<p>Acid-PEG14-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-143838</p>
<p>Acid-PEG13-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG14-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acid-PEG2-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140480</p>	<p>Acid-PEG2-ethyl propionate</p> <p style="text-align: right;">Cat. No.: HY-W096144</p>
<p>Acid-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Acid-PEG2-ethyl propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acid-PEG25-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141098</p>	<p>Acid-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130549</p>
<p>Acid-PEG25-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-PEG3-C2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs for the degradation of EGFR and inhibition of mTOR.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acid-PEG3-mono-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140484</p>	<p>Acid-PEG3-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140511</p>
<p>Acid-PEG3-mono-methyl ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-PEG3-SSPy</p> <p style="text-align: right;">Cat. No.: HY-132090</p>	<p>Acid-PEG4-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-23167</p>
<p>Acid-PEG3-SSPy is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-PEG4-C2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs for the inhibition of mTOR.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>








<p>Acid-PEG4-mono-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-W039197</p>	<p>Acid-PEG4-S-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140589</p>
<p>Acid-PEG4-mono-methyl ester is a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-PEG4-S-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-PEG4-S-S-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140114</p>	<p>Acid-PEG5-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140481</p>
<p>Acid-PEG4-S-S-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG5-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-PEG5-mono-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140485</p>	<p>Acid-PEG5-TEMPO</p> <p style="text-align: right;">Cat. No.: HY-140512</p>
<p>Acid-PEG5-mono-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG5-TEMPO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-PEG6-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140482</p>	<p>Acid-PEG6-mono-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140486</p>
<p>Acid-PEG6-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG6-mono-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Acid-PEG7-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-W190816</p>	<p>Acid-PEG8-S-S-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-W096114</p>
<p>Acid-PEG7-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acid-PEG8-S-S-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Acid-PEG9-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141096</p> <p>Acid-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Acid-PEG9-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-143835</p> <p>Acid-PEG9-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acrylate-PEG-NH2 (MW 10000)</p> <p style="text-align: right;">Cat. No.: HY-140637</p> <p>Acrylate-PEG-NH2 (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acrylate-PEG-NH2 (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140007</p> <p>Acrylate-PEG-NH2 (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acrylate-PEG-OH (MW 10000)</p> <p style="text-align: right;">Cat. No.: HY-140640</p> <p>Acrylate-PEG-OH (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acrylate-PEG-OH (MW 3400)</p> <p style="text-align: right;">Cat. No.: HY-140638</p> <p>Acrylate-PEG-OH (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Acrylate-PEG-OH (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140639</p> <p>Acrylate-PEG-OH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Acryloyl-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-138423</p> <p>Acryloyl-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Active-mono-sulfone-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140513</p> <p>Active-mono-sulfone-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>AEEA-AEEA</p> <p style="text-align: right;">Cat. No.: HY-W125504</p> <p>AEEA-AEEA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). AEEA-AEEA is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>Aeide-C1-NHS ester</p> <p>Cat. No.: HY-140755</p>	<p>Ald-C2-PEG4-azide (N3-PEG4-CH2CH2CHO)</p> <p>Cat. No.: HY-140633</p>
<p>Aeide-C1-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-C2-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Ald-CH2-PEG10-Boc</p> <p>Cat. No.: HY-140631</p>	<p>Ald-CH2-PEG3-azide</p> <p>Cat. No.: HY-130144</p>
<p>Ald-CH2-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-CH2-PEG3-azide is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ald-CH2-PEG3-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-CH2-PEG3-CH2-Boc</p> <p>Cat. No.: HY-130770</p>	<p>Ald-CH2-PEG4-Boc</p> <p>Cat. No.: HY-140630</p>
<p>Ald-CH2-PEG3-CH2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of SGK3 kinase PROTAC degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-CH2-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>ALD-CH2-PEG4-NHBOC</p> <p>Cat. No.: HY-138408</p>	<p>Ald-CH2-PEG5-Boc</p> <p>Cat. No.: HY-130330</p>
<p>ALD-CH2-PEG4-NHBOC is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-CH2-PEG5-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-CH2-PEG8-azide</p> <p>Cat. No.: HY-140635</p>	<p>Ald-PEG1-C2-Boc</p> <p>Cat. No.: HY-130758</p>
<p>Ald-CH2-PEG8-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-PEG1-C2-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Ald-Ph-amido-C2-PEG2-amine</p> <p>Cat. No.: HY-140632</p>	<p>Ald-Ph-amido-C2-PEG3-azide</p> <p>Cat. No.: HY-130667</p>
<p>Ald-Ph-amido-C2-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-Ph-amido-C2-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-Ph-amido-C2-PEG3-NH-Boc</p> <p>Cat. No.: HY-130669</p>	<p>Ald-Ph-amido-PEG2-C2-acid</p> <p>Cat. No.: HY-130154</p>
<p>Ald-Ph-amido-C2-PEG3-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-Ph-amido-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-Ph-amido-PEG2-C2-Boc</p> <p>Cat. No.: HY-130202</p>	<p>Ald-Ph-amido-PEG24-acid</p> <p>Cat. No.: HY-140622</p>
<p>Ald-Ph-amido-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-Ph-amido-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-Ph-amido-PEG3-C2-NH2</p> <p>Cat. No.: HY-130174</p>	<p>Ald-Ph-PEG12-TFP ester</p> <p>Cat. No.: HY-140624</p>
<p>Ald-Ph-amido-PEG3-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ald-Ph-PEG12-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Ald-Ph-PEG2-Boc</p> <p>Cat. No.: HY-140628</p>	<p>Ald-Ph-PEG2-NH-Boc</p> <p>Cat. No.: HY-140636</p>
<p>Ald-Ph-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-Ph-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>









<p>Ald-Ph-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140623</p>	<p>Ald-Ph-PEG24-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140625</p>
<p>Ald-Ph-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-Ph-PEG24-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Ald-Ph-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140626</p>	<p>Ald-Ph-PEG4-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-130527</p>
<p>Ald-Ph-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-Ph-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-Ph-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140629</p>	<p>Ald-Ph-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-130496</p>
<p>Ald-Ph-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Ald-Ph-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ald-Ph-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-140627</p>	<p>Aldehyde-benzyl-PEG5-alkyne</p> <p style="text-align: right;">Cat. No.: HY-136140</p>
<p>Ald-Ph-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aldehyde-benzyl-PEG5-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Alkyne-ethyl-PEG1-Boc (Alkyne-ethyl-PEG1-t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140032</p>	<p>Alkyne-PEG4-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133399</p>
<p>Alkyne-ethyl-PEG1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Alkyne-PEG4-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Alkynyl myristic acid</p> <p>Cat. No.: HY-140335</p>	<p>Alkynyl Palmitic Acid</p> <p>Cat. No.: HY-W040304</p>
<p>Alkynyl myristic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>	<p>Alkynyl Palmitic Acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>AM-Imidazole-PA-Boc</p> <p>Cat. No.: HY-129968</p>	<p>Amine-PEG-amine (MW 2000)</p> <p>Cat. No.: HY-140646</p>
<p>AM-Imidazole-PA-Boc is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Amine-PEG-amine (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amine-PEG-amine (MW 20000)</p> <p>Cat. No.: HY-140649</p>	<p>Amine-PEG-amine (MW 3400)</p> <p>Cat. No.: HY-140647</p>
<p>Amine-PEG-amine (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amine-PEG-amine (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 3400</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amine-PEG-amine (MW 35000)</p> <p>Cat. No.: HY-140650</p>	<p>Amine-PEG-amine (MW 5000)</p> <p>Cat. No.: HY-140648</p>
<p>Amine-PEG-amine (MW 35000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 35000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amine-PEG-amine (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g</p>
<p>Amine-PEG-CH2COOH (MW 2000)</p> <p>Cat. No.: HY-140643</p>	<p>Amine-PEG-CH2COOH (MW 3400)</p> <p>Cat. No.: HY-140644</p>
<p>Amine-PEG-CH2COOH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amine-PEG-CH2COOH (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 3400</p> <p>Purity: ≥99.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>

<p>Amine-PEG-CH₂COOH (MW 5000)</p> <p>Cat. No.: HY-140645</p>	<p>Amine-PEG-thiol (MW 2000)</p> <p>Cat. No.: HY-140651</p>
<p>Amine-PEG-CH₂COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amine-PEG-thiol (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: ≥93.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Amine-PEG-thiol (MW 3400)</p> <p>Cat. No.: HY-140652</p>	<p>Amine-PEG-thiol (MW 5000)</p> <p>Cat. No.: HY-140653</p>
<p>Amine-PEG-thiol (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 3400</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Amine-PEG-thiol (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amine-PEG3-Desthiobiotin</p> <p>Cat. No.: HY-134721</p>	<p>Amine-PEG4-Desthiobiotin</p> <p>Cat. No.: HY-134720</p>
<p>Amine-PEG3-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Amine-PEG4-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amine-PEG6-thiol</p> <p>Cat. No.: HY-134711</p>	<p>Amino-PEG1-C2-acid</p> <p>Cat. No.: HY-140002</p>
<p>Amine-PEG6-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG1-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>
<p>Amino-PEG10-acid</p> <p>Cat. No.: HY-140176</p>	<p>Amino-PEG10-amine</p> <p>Cat. No.: HY-W040270</p>
<p>Amino-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG10-amine, a PEG-based PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Amino-PEG10-Boc</p> <p style="text-align: right;">Cat. No.: HY-140196</p>	<p>Amino-PEG10-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-133335</p>
<p>Amino-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG10-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG10-OH</p> <p style="text-align: right;">Cat. No.: HY-120761</p>	<p>Amino-PEG11-acid</p> <p style="text-align: right;">Cat. No.: HY-W190901</p>
<p>Amino-PEG10-OH is non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG10-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG11-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG11-amine</p> <p style="text-align: right;">Cat. No.: HY-130411</p>	<p>Amino-PEG11-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133332</p>
<p>Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Amino-PEG11-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg, 100 mg</p>
<p>Amino-PEG11-OH</p> <p style="text-align: right;">Cat. No.: HY-130298</p>	<p>Amino-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140177</p>
<p>Amino-PEG11-OH is non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG11-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140205</p>	<p>Amino-PEG12-amine (H2N-PEG12-CH2CH2NH2)</p> <p style="text-align: right;">Cat. No.: HY-133327</p>
<p>Amino-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG12-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>Amino-PEG12-Boc</p> <p style="text-align: right;">Cat. No.: HY-140197</p> <p>Amino-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg</p>	<p>Amino-PEG12-C2-azide</p> <p style="text-align: right;">Cat. No.: HY-138425</p> <p>Amino-PEG12-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG12-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-133336</p> <p>Amino-PEG12-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG12-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133333</p> <p>Amino-PEG12-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG13-amine (H2N-PEG13-CH2CH2NH2)</p> <p style="text-align: right;">Cat. No.: HY-133328</p> <p>Amino-PEG13-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Amino-PEG14-acid</p> <p style="text-align: right;">Cat. No.: HY-140178</p> <p>Amino-PEG14-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG14-alcohol (H2N-PEG14-OH)</p> <p style="text-align: right;">Cat. No.: HY-133298</p> <p>Amino-PEG14-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG15-amine (H2N-PEG15-CH2CH2NH2)</p> <p style="text-align: right;">Cat. No.: HY-133329</p> <p>Amino-PEG15-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG16-acid</p> <p style="text-align: right;">Cat. No.: HY-140179</p> <p>Amino-PEG16-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG2-(CH2)3COOH</p> <p style="text-align: right;">Cat. No.: HY-140190</p> <p>Amino-PEG2-(CH2)3COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Amino-PEG2-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-W040168</p>	<p>Amino-PEG2-C2-hydrazide-Boc</p> <p style="text-align: right;">Cat. No.: HY-140222</p>
<p>Amino-PEG2-C2-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG2-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Amino-PEG2-C2-hydrazide-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG2-CH2CH2-SH hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-132120</p>	<p>Amino-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-W008279</p>
<p>Amino-PEG2-CH2CH2-SH (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG2-NH-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Amino-PEG20-acid</p> <p style="text-align: right;">Cat. No.: HY-140180</p>	<p>Amino-PEG20-Boc</p> <p style="text-align: right;">Cat. No.: HY-140198</p>
<p>Amino-PEG20-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG20-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG23-acid</p> <p style="text-align: right;">Cat. No.: HY-140181</p>	<p>Amino-PEG23-amine</p> <p style="text-align: right;">Cat. No.: HY-140211</p>
<p>Amino-PEG23-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG23-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-140182</p>	<p>Amino-PEG24-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140206</p>
<p>Amino-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG24-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Amino-PEG24-Boc</p> <p style="text-align: right;">Cat. No.: HY-140199</p> <p>Amino-PEG24-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG24-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-133337</p> <p>Amino-PEG24-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG25-acid</p> <p style="text-align: right;">Cat. No.: HY-140183</p> <p>Amino-PEG25-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG27-amine (H2N-PEG27-CH2CH2NH2)</p> <p style="text-align: right;">Cat. No.: HY-133330</p> <p>Amino-PEG27-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG28-acid</p> <p style="text-align: right;">Cat. No.: HY-140184</p> <p>Amino-PEG28-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG3-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-W040165</p> <p>Amino-PEG3-C2-acid is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG3-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>Amino-PEG3-C2-Amine</p> <p style="text-align: right;">Cat. No.: HY-W015088</p> <p>Amino-PEG3-C2-Amine is a PEG-based (3 units) PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.32% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>Amino-PEG3-C2-Azido</p> <p style="text-align: right;">Cat. No.: HY-W021401</p> <p>Amino-PEG3-C2-Azido is a PEG-based PROTAC linker can be used in the synthesis of the PARP1 degrader iRucaparib-TP3 (HY-130645).</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Amino-PEG3-C2-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140001</p> <p>Amino-PEG3-C2-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140189</p> <p>Amino-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>



<p>Amino-PEG32-acid</p> <p style="text-align: right;">Cat. No.: HY-140185</p> <p>Amino-PEG32-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG36-acid</p> <p style="text-align: right;">Cat. No.: HY-140186</p> <p>Amino-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG36-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140207</p> <p>Amino-PEG36-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG36-Boc</p> <p style="text-align: right;">Cat. No.: HY-140200</p> <p>Amino-PEG36-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG36-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-133338</p> <p>Amino-PEG36-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG36-CONH-PEG36-acid</p> <p style="text-align: right;">Cat. No.: HY-140187</p> <p>Amino-PEG36-CONH-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG4-(CH2)3CO2H</p> <p style="text-align: right;">Cat. No.: HY-140191</p> <p>Amino-PEG4-(CH2)3CO2H is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W008005</p> <p>Amino-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG4-alcohol is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Amino-PEG4-benzyl ester</p> <p style="text-align: right;">Cat. No.: HY-140239</p> <p>Amino-PEG4-benzyl ester is a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140193</p> <p>Amino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>

<p>Amino-PEG4-C1-Boc</p> <p style="text-align: right;">Cat. No.: HY-42619</p>	<p>Amino-PEG4-C2-amine</p> <p style="text-align: right;">Cat. No.: HY-22335</p>
<p>Amino-PEG4-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg, 1 g</p>	<p>Amino-PEG4-C2-amine is a PEG-based (4 units) PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 100 mg, 250 mg</p>
<p>Amino-PEG4-C2-SH hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-138446</p>	<p>Amino-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130524</p>
<p>Amino-PEG4-C2-SH hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg</p>	<p>Amino-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Amino-PEG4-CH2COOH is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Amino-PEG4-hydrazide-Boc</p> <p style="text-align: right;">Cat. No.: HY-140223</p>	<p>Amino-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-130447</p>
<p>Amino-PEG4-hydrazide-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Amino-PEG5-amine is a PEG-based (5 units) PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Amino-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140194</p>	<p>Amino-PEG5-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-115384</p>
<p>Amino-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Amino-PEG5-C2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG5-C2-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Amino-PEG5-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130577</p>	<p>Amino-PEG6-acetic acid</p> <p style="text-align: right;">Cat. No.: HY-W190960</p>
<p>Amino-PEG5-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>	<p>Amino-PEG6-acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>Amino-PEG6-alcohol</p> <p style="text-align: right;">Cat. No.: HY-126942</p>	<p>Amino-PEG6-amido-C16-Boc</p> <p style="text-align: right;">Cat. No.: HY-140201</p>
<p>Amino-PEG6-alcohol is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG6-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG6-amido-C16-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG6-amido-C16-COOH (17-(Amino-PEG6-ethylcarbonyl)heptadecanoic acid)</p> <p style="text-align: right;">Cat. No.: HY-140188</p>	<p>Amino-PEG6-amine</p> <p style="text-align: right;">Cat. No.: HY-23105</p>
<p>Amino-PEG6-amido-C16-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG6-amine is a PEG-based (6 units) PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG6-Thalidomide</p> <p style="text-align: right;">Cat. No.: HY-140240</p>	<p>Amino-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-133334</p>
<p>Amino-PEG6-Thalidomide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG7-amine</p> <p style="text-align: right;">Cat. No.: HY-140209</p>	<p>Amino-PEG7-C2-SH hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-138451</p>
<p>Amino-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG7-C2-SH hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG7-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132101</p>	<p>Amino-PEG8-amine</p> <p style="text-align: right;">Cat. No.: HY-130659</p>
<p>Amino-PEG7-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Amino-PEG8-amine is a PEG-based (8 units) PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Amino-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-W019799</p>	<p>Amino-PEG8-hydrazide-Boc</p> <p style="text-align: right;">Cat. No.: HY-140224</p>
<p>Amino-PEG8-Boc is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG8-Boc is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Amino-PEG8-hydrazide-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-130166</p>	<p>Amino-PEG9-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140204</p>
<p>Amino-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG9-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Amino-PEG9-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-PEG9-amido-C16-Boc</p> <p style="text-align: right;">Cat. No.: HY-140202</p>	<p>Amino-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-140210</p>
<p>Amino-PEG9-amido-C16-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-PEG9-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Amino-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-140195</p>	<p>Amino-Tri-(carboxyethoxymethyl)-methane</p> <p style="text-align: right;">Cat. No.: HY-117519</p>
<p>Amino-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Amino-Tri-(carboxyethoxymethyl)-methane is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(carboxyethoxymethyl)-methane is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Amino-Tri-(m-PEG4-ethoxymethyl)-methane</p> <p style="text-align: right;">Cat. No.: HY-140262</p>	<p>Aminoxy-PEG-OH (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140642</p>
<p>Amino-Tri-(m-PEG4-ethoxymethyl)-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG-OH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Aminoxy-PEG1-azide</p> <p style="text-align: right;">Cat. No.: HY-126948</p>	<p>Aminoxy-PEG1-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140056</p>
<p>Aminoxy-PEG1-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG1-propargyl is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG2-alcohol</p> <p style="text-align: right;">Cat. No.: HY-126951</p>	<p>Aminoxy-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-113931</p>
<p>Aminoxy-PEG2-alcohol is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminoxy-PEG2-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Aminoxy-PEG2-azide is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-140005</p>	<p>Aminoxy-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-126949</p>
<p>Aminoxy-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG3-azide is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminoxy-C2-PEG3-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG3-bromide</p> <p style="text-align: right;">Cat. No.: HY-140396</p>	<p>Aminoxy-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140401</p>
<p>Aminoxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG3-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG3-C2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140406</p>	<p>Aminoxy-PEG3-C2-thiol</p> <p style="text-align: right;">Cat. No.: HY-134512</p>
<p>Aminoxy-PEG3-C2-NH-Boc is a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG3-C2-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>






<p>Aminoxy-PEG3-methyl ester</p> <p>Cat. No.: HY-140404</p>	<p>Aminoxy-PEG3-propargyl</p> <p>Cat. No.: HY-140057</p>
<p>Aminoxy-PEG3-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG3-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG4-acid</p> <p>Cat. No.: HY-140394</p>	<p>Aminoxy-PEG4-alcohol</p> <p>Cat. No.: HY-124123</p>
<p>Aminoxy-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG4-alcohol is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminoxy-PEG4-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG4-azide</p> <p>Cat. No.: HY-126950</p>	<p>Aminoxy-PEG4-C2-Boc</p> <p>Cat. No.: HY-140402</p>
<p>Aminoxy-PEG4-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG4-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG4-CH2-Boc</p> <p>Cat. No.: HY-140403</p>	<p>Aminoxy-PEG4-propargyl</p> <p>Cat. No.: HY-140058</p>
<p>Aminoxy-PEG4-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Aminoxy-PEG5-azide</p> <p>Cat. No.: HY-130507</p>	<p>Aminoxy-PEG7-methane</p> <p>Cat. No.: HY-140399</p>
<p>Aminoxy-PEG5-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>	<p>Aminoxy-PEG7-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Aminoxy-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140395</p>	<p>Aminoxy-PEG8-methane</p> <p style="text-align: right;">Cat. No.: HY-140400</p>
<p>Aminoxy-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Aminoxy-PEG8-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>ANB-NOS</p> <p style="text-align: right;">Cat. No.: HY-140339</p>	<p>APN-C3-NH-Boc (tert-Butyl 3-(4-(2-cyanoethynyl)phenylcarbamoyl)propylcarbamate)</p> <p style="text-align: right;">Cat. No.: HY-140347</p>
<p>ANB-NOS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>APN-C3-NH-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>APN-C3-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-116025</p>	<p>APN-C3-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-140841</p>
<p>APN-C3-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>APN-C3-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p>
<p>APN-PEG4-PFP</p> <p style="text-align: right;">Cat. No.: HY-136030</p>	<p>APN-NH2</p> <p style="text-align: right;">Cat. No.: HY-140348</p>
<p>APN-PEG4-PFP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>APN-NH2 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>ATP-PEG8-Biotin</p> <p style="text-align: right;">Cat. No.: HY-145249</p>	<p>AZD-CO-C2-Ph-amido-Ph-azide</p> <p style="text-align: right;">Cat. No.: HY-140349</p>
<p>ATP-PEG8-Biotin is a PEG-based linker that incorporates ATP. ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.</p>  <p>Purity: ≥93.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>AZD-CO-C2-Ph-amido-Ph-azide is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>





<p>Azetidin-3-ol hydrochloride</p> <p>Cat. No.: HY-40144</p>	<p>Azetidine-3-carboxylic acid</p> <p>Cat. No.: HY-Y0530</p>
<p>Azetidin-3-ol hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetid-3-ol hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the syntheses PROTAC.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 1 g</p>	<p>Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetid-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs¹².</p> <p>Purity: ≥97.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Azide-PEG-alcohol (MW 2000)</p> <p>Cat. No.: HY-140660</p>	<p>Azide-PEG-amine (MW 2000)</p> <p>Cat. No.: HY-140661</p>
<p>Azide-PEG-alcohol (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Azide-PEG-amine (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Azide-PEG-amine (MW 3500)</p> <p>Cat. No.: HY-140662</p>	<p>Azide-PEG-amine (MW 5000)</p> <p>Cat. No.: HY-140663</p>
<p>Azide-PEG-amine (MW 3500) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Azide-PEG-amine (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Azide-PEG-azide (MW 10000)</p> <p>Cat. No.: HY-140666</p>	<p>Azide-PEG-azide (MW 2000)</p> <p>Cat. No.: HY-140664</p>
<p>Azide-PEG-azide (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Azide-PEG-azide (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Azide-PEG-azide (MW 20000)</p> <p>Cat. No.: HY-140667</p>	<p>Azide-PEG-azide (MW 5000)</p> <p>Cat. No.: HY-140665</p>
<p>Azide-PEG-azide (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Azide-PEG-azide (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>











<p>Azide-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140803</p> <p>Azide-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG12-Tos</p> <p style="text-align: right;">Cat. No.: HY-140355</p> <p>Azide-PEG12-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azide-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140804</p> <p>Azide-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azide-PEG2-Ms</p> <p style="text-align: right;">Cat. No.: HY-140381</p> <p>Azide-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azide-PEG3-C1-Ala</p> <p style="text-align: right;">Cat. No.: HY-140850</p> <p>Azide-PEG3-C1-Ala is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG3-Desthiobiotin</p> <p style="text-align: right;">Cat. No.: HY-W096120</p> <p>Azide-PEG3-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Azide-PEG3-L-alanine-Fmoc</p> <p style="text-align: right;">Cat. No.: HY-140848</p> <p>Azide-PEG3-L-alanine-Fmoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG3-Sulfone-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140603</p> <p>Azide-PEG3-Sulfone-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azide-PEG3-Tos</p> <p style="text-align: right;">Cat. No.: HY-140004</p> <p>Azide-PEG3-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azide-PEG3-Tos is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azide-PEG4-Tos</p> <p style="text-align: right;">Cat. No.: HY-140351</p> <p>Azide-PEG4-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Azide-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140778</p> <p>Azide-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG6-amido-C16-Boc</p> <p style="text-align: right;">Cat. No.: HY-140787</p> <p>Azide-PEG6-amido-C16-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azide-PEG6-Tos</p> <p style="text-align: right;">Cat. No.: HY-140353</p> <p>Azide-PEG6-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG7-Tos</p> <p style="text-align: right;">Cat. No.: HY-140354</p> <p>Azide-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azide-PEG8-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140799</p> <p>Azide-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG9-amido-C12-Boc (13-(Azide-PEG9-ethylcarbamoyl)tridecanoic t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140790</p> <p>Azide-PEG9-amido-C12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azide-PEG9-amido-C16-Boc</p> <p style="text-align: right;">Cat. No.: HY-140791</p> <p>Azide-PEG9-amido-C16-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azide-PEG9-amido-C4-Boc (5-(Azide-PEG9-ethylcarbamoyl)pentanoic t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140788</p> <p>Azide-PEG9-amido-C4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azide-PEG9-amido-C8-Boc (9-(Azide-PEG9-ethylcarbamoyl)nonanoic t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140789</p> <p>Azide-PEG9-amido-C8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-C1-PEG3-C3-NH2</p> <p style="text-align: right;">Cat. No.: HY-134692</p> <p>Azido-C1-PEG3-C3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>




<p>Azido-C1-PEG4-C3-NH2</p> <p>Cat. No.: HY-134693</p>	<p>Azido-C3-UV-biotin (UV Cleavable Biotin-PEG2-alkyne)</p> <p>Cat. No.: HY-140927</p>
<p>Azido-C1-PEG4-C3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-C3-UV-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG1</p> <p>Cat. No.: HY-138461</p>	<p>Azido-PEG1-amine</p> <p>Cat. No.: HY-140212</p>
<p>Azido-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.06% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>Azido-PEG1-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG1-azide</p> <p>Cat. No.: HY-133390</p>	<p>Azido-PEG1-Boc</p> <p>Cat. No.: HY-140775</p>
<p>Azido-PEG1-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Azido-PEG1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG1-C1-Boc</p> <p>Cat. No.: HY-140792</p>	<p>Azido-PEG1-C2-acid</p> <p>Cat. No.: HY-140009</p>
<p>Azido-PEG1-C1-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG1-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>
<p>Azido-PEG1-C2-methylamine</p> <p>Cat. No.: HY-140221</p>	<p>Azido-PEG1-CH2CO2-NHS</p> <p>Cat. No.: HY-140763</p>
<p>Azido-PEG1-C2-methylamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG1-CH2CO2-NHS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>



<p>Azido-PEG1-CH2CO2H</p> <p>Cat. No.: HY-108369</p>	<p>Azido-PEG1-CH2COO-Cl</p> <p>Cat. No.: HY-130984</p>
<p>Azido-PEG1-CH2CO2H is a PROTAC linker, which refers to the alkyl/ether composition. Azido-PEG1-CH2CO2H can be used in the synthesis of PROTAC BRD4 Degradator-1.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG1-CH2COO-Cl (compound 43a) is an alkyl/ether-based PROTAC linker. Azido-PEG1-CH2COO-Cl can be used in the synthesis of PROTAC BRD4 Degradator-1 (HY-133131).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG1-methyl ester</p> <p>Cat. No.: HY-140851</p>	<p>Azido-PEG1-NHS ester</p> <p>Cat. No.: HY-140756</p>
<p>Azido-PEG1-methyl ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG1-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG1-PFP ester</p> <p>Cat. No.: HY-140771</p>	<p>Azido-PEG10-acid</p> <p>Cat. No.: HY-140455</p>
<p>Azido-PEG1-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG10-alcohol</p> <p>Cat. No.: HY-140801</p>	<p>Azido-PEG10-amine</p> <p>Cat. No.: HY-140217</p>
<p>Azido-PEG10-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Azido-PEG10-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG10-azide</p> <p>Cat. No.: HY-132076</p>	<p>Azido-PEG10-Boc</p> <p>Cat. No.: HY-140781</p>
<p>Azido-PEG10-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG10-CH2CO2-NHS</p> <p style="text-align: right;">Cat. No.: HY-138350</p>	<p>Azido-PEG10-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138416</p>
<p>Azido-PEG10-CH2CO2-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG10-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140759</p>	<p>Azido-PEG10-propargyl</p> <p style="text-align: right;">Cat. No.: HY-138739</p>
<p>Azido-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG10-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG11-acid (N3-PEG11-CH2CH2COOH)</p> <p style="text-align: right;">Cat. No.: HY-133317</p>	<p>Azido-PEG11-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140802</p>
<p>Azido-PEG11-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG11-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG11-amine</p> <p style="text-align: right;">Cat. No.: HY-140218</p>	<p>Azido-PEG11-azide</p> <p style="text-align: right;">Cat. No.: HY-133396</p>
<p>Azido-PEG11-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG11-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG11-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138415</p>	<p>Azido-PEG11-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132062</p>
<p>Azido-PEG11-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG11-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140456</p>	<p>Azido-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-138769</p>
<p>Azido-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG12-Boc</p> <p style="text-align: right;">Cat. No.: HY-140782</p>	<p>Azido-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140760</p>
<p>Azido-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG12-propargyl</p> <p style="text-align: right;">Cat. No.: HY-138741</p>	<p>Azido-PEG12-THP</p> <p style="text-align: right;">Cat. No.: HY-138374</p>
<p>Azido-PEG12-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG12-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG13-acid</p> <p style="text-align: right;">Cat. No.: HY-138435</p>	<p>Azido-PEG13-azide</p> <p style="text-align: right;">Cat. No.: HY-132059</p>
<p>Azido-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG13-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG14-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132061</p>	<p>Azido-PEG15-azide</p> <p style="text-align: right;">Cat. No.: HY-133397</p>
<p>Azido-PEG14-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG15-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG15-t-butyl ester</p> <p>Cat. No.: HY-140783</p>	<p>Azido-PEG16-acid (N3-PEG16-CH2CH2COOH)</p> <p>Cat. No.: HY-133318</p>
<p>Azido-PEG15-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG16-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG16-Boc</p> <p>Cat. No.: HY-140784</p>	<p>Azido-PEG16-NHS ester</p> <p>Cat. No.: HY-140761</p>
<p>Azido-PEG16-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG16-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG2-alcohol</p> <p>Cat. No.: HY-140797</p>	<p>Azido-PEG2-azide</p> <p>Cat. No.: HY-W044155</p>
<p>Azido-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.23% Clinical Data: Size: 50 mg, 100 mg</p>	<p>Azido-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.08% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>
<p>Azido-PEG2-C1-Boc</p> <p>Cat. No.: HY-140793</p>	<p>Azido-PEG2-C2-acid</p> <p>Cat. No.: HY-140452</p>
<p>Azido-PEG2-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg, 500 mg</p>
<p>Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2)</p> <p>Cat. No.: HY-140213</p>	<p>Azido-PEG2-C2-Boc</p> <p>Cat. No.: HY-140776</p>
<p>Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG2-C2-amine is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>Azido-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Azido-PEG2-C2-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140164</p>	<p>Azido-PEG2-C6-Cl</p> <p style="text-align: right;">Cat. No.: HY-138470</p>
<p>Azido-PEG2-C2-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG2-C6-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG2-C6-OH</p> <p style="text-align: right;">Cat. No.: HY-138471</p>	<p>Azido-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-108368</p>
<p>Azido-PEG2-C6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG2-hydrazide-Boc</p> <p style="text-align: right;">Cat. No.: HY-140816</p>	<p>Azido-PEG2-propargyl</p> <p style="text-align: right;">Cat. No.: HY-138740</p>
<p>Azido-PEG2-hydrazide-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG2-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG20-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140805</p>	<p>Azido-PEG20-Boc</p> <p style="text-align: right;">Cat. No.: HY-138457</p>
<p>Azido-PEG20-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG20-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG23-amine</p> <p style="text-align: right;">Cat. No.: HY-140219</p>	<p>Azido-PEG23-C2-azide</p> <p style="text-align: right;">Cat. No.: HY-138358</p>
<p>Azido-PEG23-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG23-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-140457</p> <p>Azido-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG24-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140806</p> <p>Azido-PEG24-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG24-Boc</p> <p style="text-align: right;">Cat. No.: HY-133319</p> <p>Azido-PEG24-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140762</p> <p>Azido-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 25 mg</p>
<p>Azido-PEG3-Ala-Boc</p> <p style="text-align: right;">Cat. No.: HY-140849</p> <p>Azido-PEG3-Ala-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W016735</p> <p>Azido-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Azido-PEG3-aldehyde</p> <p style="text-align: right;">Cat. No.: HY-138518</p> <p>Azido-PEG3-aldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-amide-C3-triethoxysilane</p> <p style="text-align: right;">Cat. No.: HY-140019</p> <p>Azido-PEG3-amide-C3-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-amino-OPSS</p> <p style="text-align: right;">Cat. No.: HY-138438</p> <p>Azido-PEG3-amino-OPSS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-aminoacetic acid-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140770</p> <p>Azido-PEG3-aminoacetic acid-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Azido-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-133391</p>	<p>Azido-PEG3-C-Boc</p> <p style="text-align: right;">Cat. No.: HY-140794</p>
<p>Azido-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 99.11% Clinical Data: Size: 100 mg, 500 mg</p>	<p>Azido-PEG3-C-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-C3-OH</p> <p style="text-align: right;">Cat. No.: HY-140808</p>	<p>Azido-PEG3-C6-Cl</p> <p style="text-align: right;">Cat. No.: HY-138466</p>
<p>Azido-PEG3-C3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-C6-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Azido-PEG3-CH2CO2Me</p> <p style="text-align: right;">Cat. No.: HY-140853</p>	<p>Azido-PEG3-chloroacetamide</p> <p style="text-align: right;">Cat. No.: HY-132085</p>
<p>Azido-PEG3-CH2CO2Me is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-chloroacetamide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-maleimide</p> <p style="text-align: right;">Cat. No.: HY-140811</p>	<p>Azido-PEG3-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140852</p>
<p>Azido-PEG3-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG3-maleimide is also a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>	<p>Azido-PEG3-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-MS</p> <p style="text-align: right;">Cat. No.: HY-138343</p>	<p>Azido-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140764</p>
<p>Azido-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Azido-PEG3-O-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140768</p>	<p>Azido-PEG3-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-140813</p>
<p>Azido-PEG3-O-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-S-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140590</p>	<p>Azido-PEG3-S-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140591</p>
<p>Azido-PEG3-S-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-S-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-S-PEG4-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-140592</p>	<p>Azido-PEG3-SS-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140106</p>
<p>Azido-PEG3-S-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-SS-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg</p>
<p>Azido-PEG3-Sulfone-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140602</p>	<p>Azido-PEG3-Sulfone-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140604</p>
<p>Azido-PEG3-Sulfone-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG3-Sulfone-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG3-Val-Cit-PAB-PNP</p> <p style="text-align: right;">Cat. No.: HY-140150</p>	<p>Azido-PEG35-amine</p> <p style="text-align: right;">Cat. No.: HY-140220</p>
<p>Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Azido-PEG35-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Azido-PEG36-acid</p> <p style="text-align: right;">Cat. No.: HY-140458</p>	<p>Azido-PEG36-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140807</p>
<p>Azido-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG36-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG36-Boc</p> <p style="text-align: right;">Cat. No.: HY-140785</p>	<p>Azido-PEG36-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138463</p>
<p>Azido-PEG36-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG36-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-(CH2)3-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140854</p>	<p>Azido-PEG4-(CH2)3OH</p> <p style="text-align: right;">Cat. No.: HY-140809</p>
<p>Azido-PEG4-(CH2)3-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-(CH2)3OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-4-nitrophenyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-140858</p>	<p>Azido-PEG4-acyl chloride</p> <p style="text-align: right;">Cat. No.: HY-132096</p>
<p>Azido-PEG4-4-nitrophenyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-acyl chloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-22340</p>	<p>Azido-PEG4-alpha-D-mannose</p> <p style="text-align: right;">Cat. No.: HY-141126</p>
<p>Azido-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Azido-PEG4-alpha-D-mannose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 25 mg, 50 mg</p>




<p>Azido-PEG4-amido-PEG4-Boc</p> <p>Cat. No.: HY-140786</p>	<p>Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane</p> <p>Cat. No.: HY-140523</p>
<p>Azido-PEG4-amido-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane</p> <p>Cat. No.: HY-140874</p>	<p>Azido-PEG4-Amido-Tris</p> <p>Cat. No.: HY-141249</p>
<p>Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-Amido-Tris is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-azide</p> <p>Cat. No.: HY-138692</p>	<p>Azido-PEG4-beta-D-glucose</p> <p>Cat. No.: HY-140012</p>
<p>Azido-PEG4-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-Boc</p> <p>Cat. No.: HY-140777</p>	<p>Azido-PEG4-C2-acid</p> <p>Cat. No.: HY-130653</p>
<p>Azido-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-C2-acid a PEG-based PROTAC linker can be used in the synthesis of vRucaparib-TP4. Azido-PEG4-C2-acid is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>
<p>Azido-PEG4-CH2-Boc</p> <p>Cat. No.: HY-42618</p>	<p>Azido-PEG4-formylhydrazine-Boc</p> <p>Cat. No.: HY-138388</p>
<p>Azido-PEG4-CH2-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-CH2-Boc is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Azido-PEG4-formylhydrazine-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG4-hydrazide</p> <p style="text-align: right;">Cat. No.: HY-140814</p>	<p>Azido-PEG4-hydrazide-Boc</p> <p style="text-align: right;">Cat. No.: HY-140817</p>
<p>Azido-PEG4-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 50 mg, 100 mg</p>	<p>Azido-PEG4-hydrazide-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-NHS-ester</p> <p style="text-align: right;">Cat. No.: HY-140765</p>	<p>Azido-PEG4-nitrile</p> <p style="text-align: right;">Cat. No.: HY-140842</p>
<p>Azido-PEG4-NHS-ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Azido-PEG4-nitrile is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-132050</p>	<p>Azido-PEG4-tetra-Ac-beta-D-glucose</p> <p style="text-align: right;">Cat. No.: HY-141127</p>
<p>Azido-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-tetra-Ac-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-Thiol</p> <p style="text-align: right;">Cat. No.: HY-138525</p>	<p>Azido-PEG4-THP</p> <p style="text-align: right;">Cat. No.: HY-138472</p>
<p>Azido-PEG4-Thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG4-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG4-Val-Cit-PAB-OH</p> <p style="text-align: right;">Cat. No.: HY-140149</p>	<p>Azido-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-130572</p>
<p>Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Azido-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Azido-PEG5-alcohol</p> <p style="text-align: right;">Cat. No.: HY-130211</p>	<p>Azido-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-140214</p>
<p>Azido-PEG5-alcohol is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-133392</p>	<p>Azido-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140795</p>
<p>Azido-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: Size: 50 mg, 100 mg</p>	<p>Azido-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG5-CH2CO2-NHS</p> <p style="text-align: right;">Cat. No.: HY-140766</p>	<p>Azido-PEG5-CH2CO2-PFP</p> <p style="text-align: right;">Cat. No.: HY-130693</p>
<p>Azido-PEG5-CH2CO2-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG5-CH2CO2-PFP is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG5-CH2CO2H</p> <p style="text-align: right;">Cat. No.: HY-130194</p>	<p>Azido-PEG5-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133398</p>
<p>Azido-PEG5-CH2CO2H is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-CH2CO2H is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 99.60% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Azido-PEG5-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140757</p>	<p>Azido-PEG5-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-130420</p>
<p>Azido-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG5-PFP ester is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG5-S-methyl ethanethioate</p> <p>Cat. No.: HY-132093</p>	<p>Azido-PEG5-succinimidyl carbonate</p> <p>Cat. No.: HY-140769</p>
<p>Azido-PEG5-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG5-succinimidyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG5-triethoxysilane</p> <p>Cat. No.: HY-140856</p>	<p>Azido-PEG6-acid</p> <p>Cat. No.: HY-140453</p>
<p>Azido-PEG5-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg</p>	<p>Azido-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG6-alcohol</p> <p>Cat. No.: HY-130537</p>	<p>Azido-PEG6-amine</p> <p>Cat. No.: HY-140215</p>
<p>Azido-PEG6-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG6-alcohol is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG6-amine is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 200 mg, 500 mg</p>
<p>Azido-PEG6-azide</p> <p>Cat. No.: HY-133393</p>	<p>Azido-PEG6-C1-Boc</p> <p>Cat. No.: HY-140796</p>
<p>Azido-PEG6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG6-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG6-C2-Boc</p> <p>Cat. No.: HY-140779</p>	<p>Azido-PEG6-CH2COOH</p> <p>Cat. No.: HY-134696</p>
<p>Azido-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG6-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG6-MS</p> <p style="text-align: right;">Cat. No.: HY-138363</p> <p>Azido-PEG6-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130474</p> <p>Azido-PEG6-NHS ester is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG6-NHS ester is also a PEG- and Alkyl/ether based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.85% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Azido-PEG6-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140772</p> <p>Azido-PEG6-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG6-THP</p> <p style="text-align: right;">Cat. No.: HY-138325</p> <p>Azido-PEG6-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-132078</p> <p>Azido-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140798</p> <p>Azido-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG7-amine</p> <p style="text-align: right;">Cat. No.: HY-130324</p> <p>Azido-PEG7-amine is a non-cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG7-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Azido-PEG7-azide</p> <p style="text-align: right;">Cat. No.: HY-133394</p> <p>Azido-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG7-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138418</p> <p>Azido-PEG7-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Azido-PEG7-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138707</p> <p>Azido-PEG7-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG7-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-138333</p>	<p>Azido-PEG7-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132060</p>
<p>Azido-PEG7-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG7-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140454</p>	<p>Azido-PEG8-amine</p> <p style="text-align: right;">Cat. No.: HY-140216</p>
<p>Azido-PEG8-acid is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Azido-PEG8-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Azido-PEG8-azide</p> <p style="text-align: right;">Cat. No.: HY-138706</p>	<p>Azido-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-130742</p>
<p>Azido-PEG8-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG8-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>
<p>Azido-PEG8-C-Boc</p> <p style="text-align: right;">Cat. No.: HY-138377</p>	<p>Azido-PEG8-C1-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140767</p>
<p>Azido-PEG8-C-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG8-C1-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG8-CH2COO-PFP</p> <p style="text-align: right;">Cat. No.: HY-140774</p>	<p>Azido-PEG8-hydrazide</p> <p style="text-align: right;">Cat. No.: HY-140815</p>
<p>Azido-PEG8-CH2COO-PFP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Azido-PEG8-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Azido-PEG8-Mal</p> <p style="text-align: right;">Cat. No.: HY-138499</p>	<p>Azido-PEG8-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138708</p>
<p>Azido-PEG8-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG8-NHBoc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130184</p>	<p>Azido-PEG8-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140773</p>
<p>Azido-PEG8-NHS ester is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-NHS ester is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Azido-PEG8-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.12% Clinical Data: Size: 100 mg</p>
<p>Azido-PEG8-propargyl</p> <p style="text-align: right;">Cat. No.: HY-138391</p>	<p>Azido-PEG8-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-138437</p>
<p>Azido-PEG8-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG8-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG8-THP</p> <p style="text-align: right;">Cat. No.: HY-132055</p>	<p>Azido-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-130475</p>
<p>Azido-PEG8-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG9-acid is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Azido-PEG9-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140800</p>	<p>Azido-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-130169</p>
<p>Azido-PEG9-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG9-amine is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Azido-PEG9-azide</p> <p style="text-align: right;">Cat. No.: HY-133395</p>	<p>Azido-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-140780</p>
<p>Azido-PEG9-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Azido-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG9-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138417</p>	<p>Azido-PEG9-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140758</p>
<p>Azido-PEG9-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azido-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Azido-PEG9-S-methyl ethanethioate</p> <p style="text-align: right;">Cat. No.: HY-132094</p>	<p>Azidoethyl-SS-PEG2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140107</p>
<p>Azido-PEG9-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Azidoethyl-SS-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>BCN-PEG3-Val-Cit</p> <p style="text-align: right;">Cat. No.: HY-140151</p>	<p>BCN-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-133437</p>
<p>BCN-PEG3-Val-Cit is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. BCN-PEG3-Val-Cit is also a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BCN-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>BCN-PEG4-hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133438</p>	<p>BCN-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133439</p>
<p>BCN-PEG4-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BCN-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>BCN-exo-PEG3-NH2</p> <p style="text-align: right;">Cat. No.: HY-133402</p>	<p>BDP FL-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-135083</p>
<p>BCN-exo-PEG3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BDP FL-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>BDP FL-PEG4-TCO</p> <p style="text-align: right;">Cat. No.: HY-141088</p>	<p>BDP FL-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-141086</p>
<p>BDP FL-PEG4-TCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BDP FL-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>BDP FL-PEG5-propargyl</p> <p style="text-align: right;">Cat. No.: HY-141087</p>	<p>Benzaldehyde-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-133455</p>
<p>BDP FL-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzaldehyde-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Benzenedimethanamine-diethylamine</p> <p style="text-align: right;">Cat. No.: HY-140338</p>	<p>Benzyl-N-bis(PEG3-Boc) (N-Benzyl-N-bis(PEG3-t-butyl ester))</p> <p style="text-align: right;">Cat. No.: HY-140588</p>
<p>Benzenedimethanamine-diethylamine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Benzyl-N-bis(PEG3-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG1-Ms</p> <p style="text-align: right;">Cat. No.: HY-138342</p>	<p>Benzyl-PEG1-propanol</p> <p style="text-align: right;">Cat. No.: HY-138433</p>
<p>Benzyl-PEG1-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Benzyl-PEG1-propanol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>











<p>Benzyl-PEG1-Tos</p> <p style="text-align: right;">Cat. No.: HY-114843</p> <p>Benzyl-PEG1-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG10-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W096081</p> <p>Benzyl-PEG10-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG10-Ots</p> <p style="text-align: right;">Cat. No.: HY-138713</p> <p>Benzyl-PEG10-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG10-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132081</p> <p>Benzyl-PEG10-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG10-THP</p> <p style="text-align: right;">Cat. No.: HY-138341</p> <p>Benzyl-PEG10-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG11-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132074</p> <p>Benzyl-PEG11-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG11-Boc</p> <p style="text-align: right;">Cat. No.: HY-138345</p> <p>Benzyl-PEG11-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG11-MS</p> <p style="text-align: right;">Cat. No.: HY-132023</p> <p>Benzyl-PEG11-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132052</p> <p>Benzyl-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG12-MS</p> <p style="text-align: right;">Cat. No.: HY-138376</p> <p>Benzyl-PEG12-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Benzyl-PEG12-Ots</p> <p style="text-align: right;">Cat. No.: HY-138714</p> <p>Benzyl-PEG12-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG13-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132035</p> <p>Benzyl-PEG13-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG13-azide</p> <p style="text-align: right;">Cat. No.: HY-132082</p> <p>Benzyl-PEG13-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG13-Boc</p> <p style="text-align: right;">Cat. No.: HY-138480</p> <p>Benzyl-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG13-THP</p> <p style="text-align: right;">Cat. No.: HY-132011</p> <p>Benzyl-PEG13-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG14-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132051</p> <p>Benzyl-PEG14-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG14-t-butyl-ester</p> <p style="text-align: right;">Cat. No.: HY-132073</p> <p>Benzyl-PEG14-t-butyl-ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG15-alcohol</p> <p style="text-align: right;">Cat. No.: HY-134697</p> <p>Benzyl-PEG15-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132053</p> <p>Benzyl-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG16-THP</p> <p style="text-align: right;">Cat. No.: HY-138442</p> <p>Benzyl-PEG16-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Benzyl-PEG17-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132054</p>	<p>Benzyl-PEG18-alcohol</p> <p style="text-align: right;">Cat. No.: HY-138444</p>
<p>Benzyl-PEG17-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG18-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG18-MS</p> <p style="text-align: right;">Cat. No.: HY-138328</p>	<p>Benzyl-PEG18-THP</p> <p style="text-align: right;">Cat. No.: HY-138360</p>
<p>Benzyl-PEG18-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG18-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-W096142</p>	<p>Benzyl-PEG2-amine</p> <p style="text-align: right;">Cat. No.: HY-140742</p>
<p>Benzyl-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-130188</p>	<p>Benzyl-PEG2-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130172</p>
<p>Benzyl-PEG2-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG2-CH2-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135339</p>	<p>Benzyl-PEG2-ethanol</p> <p style="text-align: right;">Cat. No.: HY-138479</p>
<p>Benzyl-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG2-ethanol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Benzyl-PEG2-ethoxyethane-PEG2</p> <p style="text-align: right;">Cat. No.: HY-138476</p>	<p>Benzyl-PEG2-MS</p> <p style="text-align: right;">Cat. No.: HY-W096072</p>
<p>Benzyl-PEG2-ethoxyethane-PEG2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG2-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG2-Tos</p> <p style="text-align: right;">Cat. No.: HY-W043841</p>	<p>Benzyl-PEG20-alcohol</p> <p style="text-align: right;">Cat. No.: HY-138456</p>
<p>Benzyl-PEG2-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG20-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG24-alcohol</p> <p style="text-align: right;">Cat. No.: HY-134710</p>	<p>Benzyl-PEG24-azide</p> <p style="text-align: right;">Cat. No.: HY-134717</p>
<p>Benzyl-PEG24-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG24-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG24-MS</p> <p style="text-align: right;">Cat. No.: HY-138332</p>	<p>Benzyl-PEG24-THP</p> <p style="text-align: right;">Cat. No.: HY-138477</p>
<p>Benzyl-PEG24-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG24-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG25-amine</p> <p style="text-align: right;">Cat. No.: HY-138319</p>	<p>Benzyl-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-W096089</p>
<p>Benzyl-PEG25-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Benzyl-PEG3-amine</p> <p style="text-align: right;">Cat. No.: HY-W190795</p>	<p>Benzyl-PEG3-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130738</p>
<p>Benzyl-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG3-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG3-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-138367</p>	<p>Benzyl-PEG3-MS</p> <p style="text-align: right;">Cat. No.: HY-132108</p>
<p>Benzyl-PEG3-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG36-alcohol</p> <p style="text-align: right;">Cat. No.: HY-138323</p>	<p>Benzyl-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130595</p>
<p>Benzyl-PEG36-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG4-acyl chloride</p> <p style="text-align: right;">Cat. No.: HY-138513</p>	<p>Benzyl-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-W096073</p>
<p>Benzyl-PEG4-acyl chloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG4-Azido</p> <p style="text-align: right;">Cat. No.: HY-138715</p>	<p>Benzyl-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-138346</p>
<p>Benzyl-PEG4-Azido is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Benzyl-PEG4-MS</p> <p style="text-align: right;">Cat. No.: HY-W096090</p>	<p>Benzyl-PEG4-Ots</p> <p style="text-align: right;">Cat. No.: HY-W108219</p>
<p>Benzyl-PEG4-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG4-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG4-THP</p> <p style="text-align: right;">Cat. No.: HY-132008</p>	<p>Benzyl-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-138487</p>
<p>Benzyl-PEG4-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-140743</p>	<p>Benzyl-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140744</p>
<p>Benzyl-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG5-Ms</p> <p style="text-align: right;">Cat. No.: HY-140751</p>	<p>Benzyl-PEG5-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138378</p>
<p>Benzyl-PEG5-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG5-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG5-Ots</p> <p style="text-align: right;">Cat. No.: HY-W108220</p>	<p>Benzyl-PEG5-THP</p> <p style="text-align: right;">Cat. No.: HY-W096075</p>
<p>Benzyl-PEG5-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG5-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>



<p>Benzyl-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-138393</p> <p>Benzyl-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG6-amine</p> <p style="text-align: right;">Cat. No.: HY-132029</p> <p>Benzyl-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG6-azide</p> <p style="text-align: right;">Cat. No.: HY-W096070</p> <p>Benzyl-PEG6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG6-bromide</p> <p style="text-align: right;">Cat. No.: HY-132028</p> <p>Benzyl-PEG6-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG6-MS</p> <p style="text-align: right;">Cat. No.: HY-132026</p> <p>Benzyl-PEG6-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG6-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-132030</p> <p>Benzyl-PEG6-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG6-Ots</p> <p style="text-align: right;">Cat. No.: HY-138709</p> <p>Benzyl-PEG6-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG6-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132034</p> <p>Benzyl-PEG6-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG6-THP</p> <p style="text-align: right;">Cat. No.: HY-132105</p> <p>Benzyl-PEG6-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-132027</p> <p>Benzyl-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Benzyl-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W096067</p> <p>Benzyl-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Benzyl-PEG7-amine</p> <p style="text-align: right;">Cat. No.: HY-W096077</p> <p>Benzyl-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG7-azide</p> <p style="text-align: right;">Cat. No.: HY-132049</p> <p>Benzyl-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG7-bromide</p> <p style="text-align: right;">Cat. No.: HY-132009</p> <p>Benzyl-PEG7-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG7-MS</p> <p style="text-align: right;">Cat. No.: HY-132048</p> <p>Benzyl-PEG7-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG7-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-132021</p> <p>Benzyl-PEG7-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG7-Ots</p> <p style="text-align: right;">Cat. No.: HY-138710</p> <p>Benzyl-PEG7-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG7-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132025</p> <p>Benzyl-PEG7-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG7-THP</p> <p style="text-align: right;">Cat. No.: HY-132106</p> <p>Benzyl-PEG7-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-132015</p> <p>Benzyl-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Benzyl-PEG8-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W096107</p> <p>Benzyl-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG8-amine</p> <p style="text-align: right;">Cat. No.: HY-132013</p> <p>Benzyl-PEG8-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG8-azide</p> <p style="text-align: right;">Cat. No.: HY-132010</p> <p>Benzyl-PEG8-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG8-Br</p> <p style="text-align: right;">Cat. No.: HY-138339</p> <p>Benzyl-PEG8-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG8-Ms</p> <p style="text-align: right;">Cat. No.: HY-134741</p> <p>Benzyl-PEG8-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-132016</p> <p>Benzyl-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG8-Ots</p> <p style="text-align: right;">Cat. No.: HY-138711</p> <p>Benzyl-PEG8-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG8-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132044</p> <p>Benzyl-PEG8-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG8-THP</p> <p style="text-align: right;">Cat. No.: HY-W096066</p> <p>Benzyl-PEG8-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-132012</p> <p>Benzyl-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Benzyl-PEG9-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W093833</p> <p>Benzyl-PEG9-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-134752</p> <p>Benzyl-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyl-PEG9-Ots</p> <p style="text-align: right;">Cat. No.: HY-138712</p> <p>Benzyl-PEG9-Ots is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyl-PEG9-THP</p> <p style="text-align: right;">Cat. No.: HY-138338</p> <p>Benzyl-PEG9-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyloxy carbonyl-PEG3-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-140745</p> <p>Benzyloxy carbonyl-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyloxy carbonyl-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140750</p> <p>Benzyloxy carbonyl-PEG3-C2-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Benzyloxy carbonyl-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140746</p> <p>Benzyloxy carbonyl-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Benzyloxy-C5-PEG1</p> <p style="text-align: right;">Cat. No.: HY-W096134</p> <p>Benzyloxy-C5-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin alkyne</p> <p style="text-align: right;">Cat. No.: HY-138749</p> <p>Biotin alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.03% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg</p>	<p>Biotin-amido-PEG4-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140937</p> <p>Biotin-amido-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-bis-amido-SS-NHS</p> <p>Cat. No.: HY-130490</p>	<p>Biotin-C1-PEG3-C3-amine TFA</p> <p>Cat. No.: HY-133403A</p>
<p>Biotin-bis-amido-SS-NHS is an Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-C1-PEG3-C3-amine (TFA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Biotin-C10-NHS Ester</p> <p>Cat. No.: HY-135920</p>	<p>Biotin-C5-amino-C5-amino</p> <p>Cat. No.: HY-135916</p>
<p>Biotin-C10-NHS Ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-C5-amino-C5-amino is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-C5-NHS Ester</p> <p>Cat. No.: HY-135915</p>	<p>Biotin-EDA</p> <p>Cat. No.: HY-130893</p>
<p>Biotin-C5-NHS Ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-EDA is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG-amine (MW 2000)</p> <p>Cat. No.: HY-140654</p>	<p>Biotin-PEG-amine (MW 3400)</p> <p>Cat. No.: HY-140655</p>
<p>Biotin-PEG-amine (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG-amine (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG-Biotin (MW 1000)</p> <p>Cat. No.: HY-140656</p>	<p>Biotin-PEG-triethoxysilane (MW 1000)</p> <p>Cat. No.: HY-140657</p>
<p>Biotin-PEG-Biotin (MW 1000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG-triethoxysilane (MW 1000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-PEG-triethoxysilane (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140658</p> <p>Biotin-PEG-triethoxysilane (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG-triethoxysilane (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140659</p> <p>Biotin-PEG-triethoxysilane (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG10-amine</p> <p style="text-align: right;">Cat. No.: HY-143827</p> <p>Biotin-PEG10-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-143855</p> <p>Biotin-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG11-amine</p> <p style="text-align: right;">Cat. No.: HY-140900</p> <p>Biotin-PEG11-amine is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG11-azide</p> <p style="text-align: right;">Cat. No.: HY-140912</p> <p>Biotin-PEG11-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG11-Mal</p> <p style="text-align: right;">Cat. No.: HY-140909</p> <p>Biotin-PEG11-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG11-oxyamine</p> <p style="text-align: right;">Cat. No.: HY-140939</p> <p>Biotin-PEG11-oxyamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140493</p> <p>Biotin-PEG12-acid is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG12-hydrazide</p> <p style="text-align: right;">Cat. No.: HY-140933</p> <p>Biotin-PEG12-hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-PEG12-Mal</p> <p style="text-align: right;">Cat. No.: HY-133379</p>	<p>Biotin-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140892</p>
<p>Biotin-PEG12-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg</p>
<p>Biotin-PEG12-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140904</p>	<p>Biotin-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-126958</p>
<p>Biotin-PEG12-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-acid is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Biotin-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 96.14% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>
<p>Biotin-PEG2-aldehyde</p> <p style="text-align: right;">Cat. No.: HY-133456</p>	<p>Biotin-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-126957</p>
<p>Biotin-PEG2-aldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>	<p>Biotin-PEG2-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG2-C1-aldehyde</p> <p style="text-align: right;">Cat. No.: HY-133457</p>	<p>Biotin-PEG2-C2-iodoacetamide</p> <p style="text-align: right;">Cat. No.: HY-140941</p>
<p>Biotin-PEG2-C1-aldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-C2-iodoacetamide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg, 250 mg</p>
<p>Biotin-PEG2-C4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-113828</p>	<p>Biotin-PEG2-C6-azide</p> <p style="text-align: right;">Cat. No.: HY-117042</p>
<p>Biotin-PEG2-C4-alkyne is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-C6-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-PEG2-CH2CH2N3</p> <p style="text-align: right;">Cat. No.: HY-135912</p> <p>Biotin-PEG2-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-Mal</p> <p style="text-align: right;">Cat. No.: HY-W010764</p> <p>Biotin-PEG2-Mal is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Biotin-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140934</p> <p>Biotin-PEG2-NH-Boc is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140888</p> <p>Biotin-PEG2-NHS ester is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG2-OH</p> <p style="text-align: right;">Cat. No.: HY-135911</p> <p>Biotin-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG2-SH</p> <p style="text-align: right;">Cat. No.: HY-132112</p> <p>Biotin-PEG2-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Biotin-PEG23-amine</p> <p style="text-align: right;">Cat. No.: HY-140901</p> <p>Biotin-PEG23-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG23-azide</p> <p style="text-align: right;">Cat. No.: HY-140913</p> <p>Biotin-PEG23-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Biotin-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-133377</p> <p>Biotin-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133378</p> <p>Biotin-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Biotin-PEG24-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140905</p> <p>Biotin-PEG24-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-116027</p> <p>Biotin-PEG3-acid is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg</p>
<p>Biotin-PEG3-alcohol ((+)-Biotin-PEG3-OH)</p> <p style="text-align: right;">Cat. No.: HY-135179</p> <p>Biotin-PEG3-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG3-amido-SS-amido-azide</p> <p style="text-align: right;">Cat. No.: HY-133458</p> <p>Biotin-PEG3-amido-SS-amido-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Biotin-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-130143</p> <p>Biotin-PEG3-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>Biotin-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W096098</p> <p>Biotin-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG3-Mal</p> <p style="text-align: right;">Cat. No.: HY-140907</p> <p>Biotin-PEG3-Mal is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Biotin-PEG3-methyl ethanethioate</p> <p style="text-align: right;">Cat. No.: HY-132116</p> <p>Biotin-PEG3-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130291</p> <p>Biotin-PEG3-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG3-OH</p> <p style="text-align: right;">Cat. No.: HY-135924</p> <p>Biotin-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Biotin-PEG3-oxyamine</p> <p style="text-align: right;">Cat. No.: HY-140938</p> <p>Biotin-PEG3-oxyamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG3-propargyl</p> <p style="text-align: right;">Cat. No.: HY-138503</p> <p>Biotin-PEG3-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG3-propionic hydrazide</p> <p style="text-align: right;">Cat. No.: HY-130560</p> <p>Biotin-PEG3-propionic hydrazide is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG3-pyridinrthiol</p> <p style="text-align: right;">Cat. No.: HY-132114</p> <p>Biotin-PEG3-pyridinrthiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG3-SH</p> <p style="text-align: right;">Cat. No.: HY-132115</p> <p>Biotin-PEG3-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG36-acid</p> <p style="text-align: right;">Cat. No.: HY-140494</p> <p>Biotin-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG36-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140906</p> <p>Biotin-PEG36-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-126959</p> <p>Biotin-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-140922</p> <p>Biotin-PEG4-alkyne is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.88% Clinical Data: No Development Reported Size: 10 mg, 50 mg, 100 mg</p>	<p>Biotin-PEG4-allyl</p> <p style="text-align: right;">Cat. No.: HY-138426</p> <p>Biotin-PEG4-allyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Biotin-PEG4-amide-Alkyne</p> <p style="text-align: right;">Cat. No.: HY-140923</p> <p>Biotin-PEG4-amide-Alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG4-Amide-C6-Azide</p> <p style="text-align: right;">Cat. No.: HY-140914</p> <p>Biotin-PEG4-Amide-C6-Azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.37% Clinical Data: Size: 5 mg, 10 mg</p>
<p>Biotin-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-140895</p> <p>Biotin-PEG4-amine is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Biotin-PEG4-amino-t-Bu-DADPS-C3-alkyne</p> <p style="text-align: right;">Cat. No.: HY-140928</p> <p>Biotin-PEG4-amino-t-Bu-DADPS-C3-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG4-amino-t-Bu-DADPS-C6-azide</p> <p style="text-align: right;">Cat. No.: HY-140921</p> <p>Biotin-PEG4-amino-t-Bu-DADPS-C6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>Biotin-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-140910</p> <p>Biotin-PEG4-azide is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Biotin-PEG4-hydrazide</p> <p style="text-align: right;">Cat. No.: HY-140932</p> <p>Biotin-PEG4-hydrazide is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG4-hydrazide TFA</p> <p style="text-align: right;">Cat. No.: HY-140932A</p> <p>Biotin-PEG4-hydrazide (TFA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG4-methyltetrazine</p> <p style="text-align: right;">Cat. No.: HY-140940</p> <p>Biotin-PEG4-methyltetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.04% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>Biotin-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140889</p> <p>Biotin-PEG4-NHS ester is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.08% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>











<p>Biotin-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-130290</p>	<p>Biotin-PEG4-PC-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-140131</p>
<p>Biotin-PEG4-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG4-PC-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG4-Picolyl azide</p> <p style="text-align: right;">Cat. No.: HY-140915</p>	<p>Biotin-PEG4-SH</p> <p style="text-align: right;">Cat. No.: HY-134704</p>
<p>Biotin-PEG4-Picolyl azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 5 mg, 10 mg</p>	<p>Biotin-PEG4-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG4-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140903</p>	<p>Biotin-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-140896</p>
<p>Biotin-PEG4-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG5-amine is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-133174</p>	<p>Biotin-PEG5-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140935</p>
<p>Biotin-PEG5-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Biotin-PEG5-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-133176</p>	<p>Biotin-PEG6-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140893</p>
<p>Biotin-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG6-alcohol is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>



<p>Biotin-PEG6-amine</p> <p>Cat. No.: HY-140897</p>	<p>Biotin-PEG6-azide</p> <p>Cat. No.: HY-140911</p>
<p>Biotin-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PEG6-azide is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG6-Boc</p> <p>Cat. No.: HY-140936</p>	<p>Biotin-PEG6-Mal</p> <p>Cat. No.: HY-140908</p>
<p>Biotin-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG6-Mal is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Biotin-PEG6-NH-Boc</p> <p>Cat. No.: HY-W190945</p>	<p>Biotin-PEG6-NHS ester</p> <p>Cat. No.: HY-140890</p>
<p>Biotin-PEG6-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Biotin-PEG6-Silane</p> <p>Cat. No.: HY-138419</p>	<p>Biotin-PEG6-Thalidomide</p> <p>Cat. No.: HY-140942</p>
<p>Biotin-PEG6-Silane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG6-Thalidomide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: Size: 5 mg, 10 mg, 25 mg</p>
<p>Biotin-PEG7-amine</p> <p>Cat. No.: HY-140898</p>	<p>Biotin-PEG7-azide</p> <p>Cat. No.: HY-133175</p>
<p>Biotin-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-PEG7-C2-NH-Vidarabine-S-CH3</p> <p style="text-align: right;">Cat. No.: HY-145248</p>	<p>Biotin-PEG7-C2-S-Vidarabine</p> <p style="text-align: right;">Cat. No.: HY-145247</p>
<p>Biotin-PEG7-C2-NH-Vidarabine-S-CH3 is a PEG-based linker that incorporates adenosine analog Vidarabine. Vidarabine is an antiviral agent which is active against herpes simplex and varicella zoster viruses.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG7-C2-S-Vidarabine is a PEG-based linker that incorporates adenosine analog Vidarabine. Vidarabine is an antiviral agent which is active against herpes simplex and varicella zoster viruses.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG7-thiourea</p> <p style="text-align: right;">Cat. No.: HY-140943</p>	<p>Biotin-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140492</p>
<p>Biotin-PEG7-thiourea is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG8-acid is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG8-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140894</p>	<p>Biotin-PEG8-amine</p> <p style="text-align: right;">Cat. No.: HY-140899</p>
<p>Biotin-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG8-amine is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140891</p>	<p>Biotin-PEG8-Vidarabine</p> <p style="text-align: right;">Cat. No.: HY-145246</p>
<p>Biotin-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG8-Vidarabine is a PEG-based linker that incorporates adenosine analog Vidarabine. Vidarabine is an antiviral agent which is active against herpes simplex and varicella zoster viruses.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-W190970</p>	<p>Biotin-PEG9-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135937</p>
<p>Biotin-PEG9-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotin-PEG9-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Biotin-PEG9-NHS Ester</p> <p style="text-align: right;">Cat. No.: HY-135941</p> <p>Biotin-PEG9-NHS Ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Biotin-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-119343</p> <p>Biotin-PFP ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Biotin-Thalidomide</p> <p style="text-align: right;">Cat. No.: HY-145152</p> <p>Biotin-Thalidomide is a cereblon affinity probe for PROTAC and targeted protein degradation research.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Biotinyl-NH-PEG3-C3-amido-C3-COOH (DIPEA)</p> <p style="text-align: right;">Cat. No.: HY-130142</p> <p>Biotinyl-NH-PEG3-C3-amido-C3-COOH (DIPEA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis(2-bromoethyl) ether</p> <p style="text-align: right;">Cat. No.: HY-W013458</p> <p>Bis(2-bromoethyl) ether is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.35% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Bis(m-PEG4)-N-OH</p> <p style="text-align: right;">Cat. No.: HY-140580</p> <p>Bis(m-PEG4)-N-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-(m-PEG4)-amido-hexanoic acid</p> <p style="text-align: right;">Cat. No.: HY-140016</p> <p>Bis-(m-PEG4)-amido-hexanoic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-(m-PEG8-amido)-hexanoic acid</p> <p style="text-align: right;">Cat. No.: HY-141290</p> <p>Bis-(m-PEG8-amido)-hexanoic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-(Mal-PEG3)-PH-N-succinimidyl acetate</p> <p style="text-align: right;">Cat. No.: HY-138519</p> <p>Bis-(Mal-PEG3)-PH-N-succinimidyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-(N,N'-carboxyl-PEG4)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141042</p> <p>Bis-(N,N'-carboxyl-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bis-(N,N'-PEG4-NHS ester)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141047</p>	<p>Bis-(N,N'-amine-PEG3)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141057</p>
<p>Bis-(N,N'-PEG4-NHS ester)-Cy5 is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-(N,N'-amine-PEG3)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-acrylate-PEG5</p> <p style="text-align: right;">Cat. No.: HY-W096160</p>	<p>Bis-acrylate-PEG6</p> <p style="text-align: right;">Cat. No.: HY-W096166</p>
<p>Bis-acrylate-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-acrylate-PEG6 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-aminoxy-PEG1</p> <p style="text-align: right;">Cat. No.: HY-140407</p>	<p>Bis-aminoxy-PEG2</p> <p style="text-align: right;">Cat. No.: HY-140408</p>
<p>Bis-aminoxy-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>Bis-aminoxy-PEG2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-aminoxy-PEG3</p> <p style="text-align: right;">Cat. No.: HY-140409</p>	<p>Bis-aminoxy-PEG4</p> <p style="text-align: right;">Cat. No.: HY-140410</p>
<p>Bis-aminoxy-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-aminoxy-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-aminoxy-PEG7</p> <p style="text-align: right;">Cat. No.: HY-140411</p>	<p>Bis-BCN-PEG1-diamide</p> <p style="text-align: right;">Cat. No.: HY-133510</p>
<p>Bis-aminoxy-PEG7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-BCN-PEG1-diamide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bis-Biotin-PEG23</p> <p style="text-align: right;">Cat. No.: HY-140929</p>	<p>Bis-Bromoacetamido-PEG11</p> <p style="text-align: right;">Cat. No.: HY-141393</p>
<p>Bis-Biotin-PEG23 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-Bromoacetamido-PEG11 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-CH2-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-132102</p>	<p>Bis-isopropyl-PEG1</p> <p style="text-align: right;">Cat. No.: HY-138455</p>
<p>Bis-CH2-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-isopropyl-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-Mal-Lysine-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141001</p>	<p>Bis-Mal-Lysine-PEG4-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-141002</p>
<p>Bis-Mal-Lysine-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg</p>	<p>Bis-Mal-Lysine-PEG4-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-Mal-PEG11</p> <p style="text-align: right;">Cat. No.: HY-140995</p>	<p>Bis-Mal-PEG19</p> <p style="text-align: right;">Cat. No.: HY-140996</p>
<p>Bis-Mal-PEG11 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-Mal-PEG19 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-Mal-PEG3</p> <p style="text-align: right;">Cat. No.: HY-140993</p>	<p>Bis-Mal-PEG5</p> <p style="text-align: right;">Cat. No.: HY-130895</p>
<p>Bis-Mal-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-Mal-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bis-Mal-PEG6</p> <p style="text-align: right;">Cat. No.: HY-140994</p> <p>Bis-Mal-PEG6 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-Mal-PEG7 (Mal-NH-PEG7-NH-Mal)</p> <p style="text-align: right;">Cat. No.: HY-130896</p> <p>Bis-Mal-PEG7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-methacrylate-PEG5</p> <p style="text-align: right;">Cat. No.: HY-W096161</p> <p>Bis-methacrylate-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-NH2-C1-PEG3 (PROTAC Linker 24)</p> <p style="text-align: right;">Cat. No.: HY-128844</p> <p>Bis-NH2-C1-PEG3 (PROTAC Linker 24) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-NH2-PEG2 (PROTAC Linker 19)</p> <p style="text-align: right;">Cat. No.: HY-128833</p> <p>Bis-NH2-PEG2 (PROTAC Linker 19) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Bis-PEG-TFP ester (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140724</p> <p>Bis-PEG-TFP ester (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG1-acid</p> <p style="text-align: right;">Cat. No.: HY-23166</p> <p>Bis-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Bis-PEG1-C-PEG1-CH2COOH (PROTAC Linker 26)</p> <p style="text-align: right;">Cat. No.: HY-128847</p> <p>Bis-PEG1-C-PEG1-CH2COOH (PROTAC Linker 26) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg</p>
<p>Bis-PEG10-acid</p> <p style="text-align: right;">Cat. No.: HY-133231</p> <p>Bis-PEG10-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130824</p> <p>Bis-PEG10-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG10-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bis-PEG10-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132057</p>	<p>Bis-PEG11-acid</p> <p style="text-align: right;">Cat. No.: HY-141019</p>
<p>Bis-PEG10-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG11-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-PEG11-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141100</p>	<p>Bis-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-141020</p>
<p>Bis-PEG11-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG12-endo-BCN</p> <p style="text-align: right;">Cat. No.: HY-139060</p>	<p>Bis-PEG13-acid</p> <p style="text-align: right;">Cat. No.: HY-141021</p>
<p>Bis-PEG12-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-PEG13-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130825</p>	<p>Bis-PEG13-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-141256</p>
<p>Bis-PEG13-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG13-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG13-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-PEG14-acid</p> <p style="text-align: right;">Cat. No.: HY-141022</p>	<p>Bis-PEG15-acid</p> <p style="text-align: right;">Cat. No.: HY-141023</p>
<p>Bis-PEG14-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-PEG15-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Bis-PEG17-acid</p> <p style="text-align: right;">Cat. No.: HY-141024</p> <p>Bis-PEG17-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-PEG17-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130826</p> <p>Bis-PEG17-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG17-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG18-Boc</p> <p style="text-align: right;">Cat. No.: HY-138326</p> <p>Bis-PEG18-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-112559</p> <p>Bis-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 500 mg</p>
<p>Bis-PEG2-Boc</p> <p style="text-align: right;">Cat. No.: HY-138504</p> <p>Bis-PEG2-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG2-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-112560</p> <p>Bis-PEG2-PFP ester is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bis-PEG2-PFP ester is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG21-acid</p> <p style="text-align: right;">Cat. No.: HY-141025</p> <p>Bis-PEG21-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-PEG21-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130827</p> <p>Bis-PEG21-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG21-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG23-endo-BCN</p> <p style="text-align: right;">Cat. No.: HY-140079</p> <p>Bis-PEG23-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 50 mg</p>	<p>Bis-PEG25-acid</p> <p style="text-align: right;">Cat. No.: HY-141026</p> <p>Bis-PEG25-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Bis-PEG25-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130828</p>	<p>Bis-PEG25-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-141258</p>
<p>Bis-PEG25-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG25-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG25-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG29-acid</p> <p style="text-align: right;">Cat. No.: HY-141027</p>	<p>Bis-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-126891</p>
<p>Bis-PEG29-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Bis-PEG3-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-126997</p>	<p>Bis-PEG3-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140165</p>
<p>Bis-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG3-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-PEG3-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132066</p>	<p>Bis-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-119429</p>
<p>Bis-PEG3-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG4-acid is a PEG PROTAC linker.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Bis-PEG4-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-126998</p>	<p>Bis-PEG4-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140166</p>
<p>Bis-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>



<p>Bis-PEG4-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132067</p>	<p>Bis-PEG4-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-W190728</p>
<p>Bis-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG4-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG5-acid (PROTAC Linker 36)</p> <p style="text-align: right;">Cat. No.: HY-116006</p>	<p>Bis-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126889</p>
<p>Bis-PEG5-acid (PROTAC Linker 36) is a PROTAC linker, which belongs to a polyethylene glycol (PEG) linker. Bis-PEG5-acid (PROTAC Linker 36) can be used in the synthesis of the CP5V. CP5V is a PROTAC, and specifically degrades Cdc20.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>Bis-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG5-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-126999</p>	<p>Bis-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-120587</p>
<p>Bis-PEG5-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>Bis-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130410</p>	<p>Bis-PEG6-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-W096076</p>
<p>Bis-PEG6-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Bis-PEG6-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-126892</p>	<p>Bis-PEG7-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126890</p>
<p>Bis-PEG7-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG7-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG7-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>











<p>Bis-PEG7-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-133000</p> <p>Bis-PEG7-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG7-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132022</p> <p>Bis-PEG7-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-126893</p> <p>Bis-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG8-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG8-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132080</p> <p>Bis-PEG8-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-126894</p> <p>Bis-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG9-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-PEG9-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-117009</p> <p>Bis-PEG9-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG9-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Bis-PEG9-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-141255</p> <p>Bis-PEG9-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-propargyl-O-PEG17</p> <p style="text-align: right;">Cat. No.: HY-140042</p> <p>Bis-propargyl-O-PEG17 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-propargyl-PEG1</p> <p style="text-align: right;">Cat. No.: HY-140038</p> <p>Bis-propargyl-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Bis-propargyl-PEG10</p> <p style="text-align: right;">Cat. No.: HY-132098</p> <p>Bis-propargyl-PEG10 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bis-propargyl-PEG11</p> <p style="text-align: right;">Cat. No.: HY-140039</p> <p>Bis-propargyl-PEG11 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-propargyl-PEG12</p> <p style="text-align: right;">Cat. No.: HY-140040</p> <p>Bis-propargyl-PEG12 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bis-propargyl-PEG13</p> <p style="text-align: right;">Cat. No.: HY-140041</p> <p>Bis-propargyl-PEG13 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bis-propargyl-PEG2</p> <p style="text-align: right;">Cat. No.: HY-133191</p> <p>Bis-propargyl-PEG2 is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-propargyl-PEG2 is used for the synthesis of demethylvancomycin dimers.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-propargyl-PEG3</p> <p style="text-align: right;">Cat. No.: HY-133192</p> <p>Bis-propargyl-PEG3 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG3 is used in the synthesis of zinc-dipicolylamine (ZnDPA) complexes with antiplasmodial activity .</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 250 mg, 1 g</p>	<p>Bis-propargyl-PEG4</p> <p style="text-align: right;">Cat. No.: HY-120397</p> <p>Bis-propargyl-PEG4 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG4 is used for the synthesis of demethylvancomycin dimers.</p>  <p>Purity: 95.64% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>
<p>Bis-propargyl-PEG5</p> <p style="text-align: right;">Cat. No.: HY-133193</p> <p>Bis-propargyl-PEG5 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG5 is used for the synthesis of carbohydrate receptors (SCRs) with anti-Zika activity.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Bis-propargyl-PEG6</p> <p style="text-align: right;">Cat. No.: HY-117186</p> <p>Bis-propargyl-PEG6 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG6 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bis-propargyl-PEG7</p> <p style="text-align: right;">Cat. No.: HY-133190</p> <p>Bis-propargyl-PEG7 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG7 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 250 mg</p>	<p>Bis-propargyl-PEG8</p> <p style="text-align: right;">Cat. No.: HY-115414</p> <p>Bis-propargyl-PEG8 (compound 16e) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Bis-propargyl-PEG9</p> <p style="text-align: right;">Cat. No.: HY-133189</p> <p>Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-sulfone-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-138753</p> <p>Bis-sulfone-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>Bis-sulfone-PEG4-Tetrazine</p> <p style="text-align: right;">Cat. No.: HY-138747</p> <p>Bis-sulfone-PEG4-Tetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-Tos-PEG4 (PROTAC Linker 16)</p> <p style="text-align: right;">Cat. No.: HY-W004816</p> <p>Bis-Tos-PEG4 (PROTAC Linker 16) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.61% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Bis-Tos-PEG6</p> <p style="text-align: right;">Cat. No.: HY-140367</p> <p>Bis-Tos-PEG6 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bis-Tos-PEG7</p> <p style="text-align: right;">Cat. No.: HY-140368</p> <p>Bis-Tos-PEG7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>BM-PEG3 (1,11-Bis-maleimidotetraethyleneglycol)</p> <p style="text-align: right;">Cat. No.: HY-130898</p> <p>BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BnO-PEG1-CH2CO2tBu</p> <p style="text-align: right;">Cat. No.: HY-140747</p> <p>BnO-PEG1-CH2CO2tBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>BnO-PEG1-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-121957</p> <p>BnO-PEG1-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>BnO-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140748</p> <p>BnO-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>BnO-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-W040228</p> <p>BnO-PEG4-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>BnO-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140749</p> <p>BnO-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>BnO-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-W042714</p> <p>BnO-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BnO-PEG6-OH</p> <p style="text-align: right;">Cat. No.: HY-W042654</p> <p>BnO-PEG6-OH is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). BnO-PEG6-OH is also a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.88% Clinical Data: No Development Reported Size: 100 mg</p>
<p>BnOH-NH-bis-(C2-S)-propane-O-isoprene ester (PROTAC Linker 29)</p> <p style="text-align: right;">Cat. No.: HY-126313</p> <p>BnOH-NH-bis-(C2-S)-propane-O-isoprene ester (PROTAC Linker 29) is an alkyl ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-11-aminoundecanoic acid</p> <p style="text-align: right;">Cat. No.: HY-W013253</p> <p>Boc-11-aminoundecanoic acid is an Alkyl/ether-based PROTAC linker can be used in the synthesis of MS432 (HY-130602).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-6-aminohexanoic acid</p> <p style="text-align: right;">Cat. No.: HY-W007529</p> <p>Boc-6-aminohexanoic acid is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 1 g</p>	<p>Boc-amido-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-140233</p> <p>Boc-amido-PEG9-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG1-azide</p> <p style="text-align: right;">Cat. No.: HY-140430</p> <p>Boc-Aminoxy-PEG1-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG1-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-140425</p> <p>Boc-Aminoxy-PEG1-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Boc-aminoxy-PEG1-propargyl</p> <p>Cat. No.: HY-140049</p>	<p>Boc-Aminoxy-PEG2</p> <p>Cat. No.: HY-140421</p>
<p>Boc-aminoxy-PEG1-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG2-C2-amine</p> <p>Cat. No.: HY-140426</p>	<p>Boc-Aminoxy-PEG2-CH2COOH</p> <p>Cat. No.: HY-140415</p>
<p>Boc-Aminoxy-PEG2-C2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-aminoxy-PEG2-propargyl</p> <p>Cat. No.: HY-140050</p>	<p>Boc-Aminoxy-PEG3-acid</p> <p>Cat. No.: HY-140412</p>
<p>Boc-aminoxy-PEG2-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG3-azide</p> <p>Cat. No.: HY-140432</p>	<p>Boc-Aminoxy-PEG3-bromide</p> <p>Cat. No.: HY-140435</p>
<p>Boc-Aminoxy-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG3-C2-NH2</p> <p>Cat. No.: HY-140427</p>	<p>Boc-Aminoxy-PEG3-thiol</p> <p>Cat. No.: HY-140439</p>
<p>Boc-Aminoxy-PEG3-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG3-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-Aminoxy-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-140433</p>	<p>Boc-Aminoxy-PEG4-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140420</p>
<p>Boc-Aminoxy-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG4-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG4-CH2CO2H</p> <p style="text-align: right;">Cat. No.: HY-140416</p>	<p>Boc-Aminoxy-PEG4-NH2</p> <p style="text-align: right;">Cat. No.: HY-140438</p>
<p>Boc-Aminoxy-PEG4-CH2CO2H is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG4-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-aminoxy-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140052</p>	<p>Boc-Aminoxy-PEG4-Tos</p> <p style="text-align: right;">Cat. No.: HY-140377</p>
<p>Boc-aminoxy-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG4-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-Aminoxy-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-140428</p>	<p>Boc-aminoxy-PEG5-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140053</p>
<p>Boc-Aminoxy-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-aminoxy-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-aminoxy-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140413</p>	<p>Boc-Aminoxy-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-140423</p>
<p>Boc-aminoxy-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Aminoxy-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-bipiperidine-ethynylbenzoic acid</p> <p>Cat. No.: HY-139661</p>	<p>Boc-C1-PEG2-C4-Cl (PROTAC Linker 1)</p> <p>Cat. No.: HY-108371</p>
<p>Boc-bipiperidine-ethynylbenzoic acid is an Alkyl/ether-based PROTAC linker can be used in the synthesis of ARD-61.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-C1-PEG2-C4-Cl (PROTAC Linker 1) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Boc-C1-PEG3-C4-OBn</p> <p>Cat. No.: HY-130619</p>	<p>Boc-C1-PEG3-C4-OH</p> <p>Cat. No.: HY-130618</p>
<p>Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PROTAC linker, which refers to the PEG composition. Boc-C1-PEG3-C4-OBn can be used in the synthesis of a series of PROTACs, such as PROTAC SGK3 degrader-1 (HY-125878).</p>  <p>Purity: 95.77% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Boc-C1-PEG3-C4-OH is a PROTAC linker, which refers to the Alkyl/ether composition. Boc-C1-PEG3-C4-OH can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 250 mg</p>
<p>Boc-C14-COOH</p> <p>Cat. No.: HY-W034599</p>	<p>Boc-C16-COOH</p> <p>Cat. No.: HY-W045598</p>
<p>Boc-C14-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-C14-COOH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-C16-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-C16-COOH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs <su.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>
<p>Boc-C16-NHS ester</p> <p>Cat. No.: HY-140342</p>	<p>Boc-C2-NH2</p> <p>Cat. No.: HY-W017970</p>
<p>Boc-C16-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-C2-NH2 is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.66% Clinical Data: No Development Reported Size: 250 mg</p>
<p>Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2)</p> <p>Cat. No.: HY-108372</p>	<p>Boc-GABA-OH</p> <p>Cat. No.: HY-W004697</p>
<p>Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Boc-GABA-OH is a PROTAC linker which can be used to synthesis UNC6852, an EED-targeted PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>

<p>Boc-Gly-amido-C-PEG3-C3-amine</p> <p>Cat. No.: HY-140237</p>	<p>Boc-gly-PEG3-endo-BCN</p> <p>Cat. No.: HY-140081</p>
<p>Boc-Gly-amido-C-PEG3-C3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-gly-PEG3-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Boc-gly-PEG3-endo-BCN is also a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-HyNic-PEG1-mal</p> <p>Cat. No.: HY-133499</p>	<p>Boc-HyNic-PEG2-alkyne</p> <p>Cat. No.: HY-133500</p>
<p>Boc-HyNic-PEG1-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-HyNic-PEG2-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-HyNic-PEG2-DBCO</p> <p>Cat. No.: HY-133502</p>	<p>Boc-HyNic-PEG2-N3</p> <p>Cat. No.: HY-133501</p>
<p>Boc-HyNic-PEG2-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>	<p>Boc-HyNic-PEG2-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-Hyp-OH</p> <p>Cat. No.: HY-10781</p>	<p>Boc-Hyp-OMe</p> <p>Cat. No.: HY-65039</p>
<p>Boc-Hyp-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^{1/5}.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>	<p>Boc-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>
<p>Boc-N-Amido-PEG2-C2-azide</p> <p>Cat. No.: HY-140834</p>	<p>Boc-N-amido-PEG3-acid</p> <p>Cat. No.: HY-140468</p>
<p>Boc-N-Amido-PEG2-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-N-amido-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>

<p>Boc-N-Amido-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140835</p> <p>Boc-N-Amido-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-N-Amido-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140879</p> <p>Boc-N-Amido-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-N-Amido-PEG5-Ms</p> <p style="text-align: right;">Cat. No.: HY-140392</p> <p>Boc-N-Amido-PEG5-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-N-PEG1-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141116</p> <p>Boc-N-PEG1-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-N-PEG2-Ms</p> <p style="text-align: right;">Cat. No.: HY-140390</p> <p>Boc-N-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-N-PEG5-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126381</p> <p>Boc-N-PEG5-C2-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-C12-NH2</p> <p style="text-align: right;">Cat. No.: HY-133388</p> <p>Boc-NH-C12-NH2 is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-C4-acid</p> <p style="text-align: right;">Cat. No.: HY-W014099</p> <p>Boc-NH-C4-acid is a PROTAC linker, which belongs to a Alkyl/ether linker. Boc-NH-C4-acid can be used in the synthesis of the compound PROTAC1, and specifically degrades EED, EZH2, and SUZ12 in the PRC2 Complex.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Boc-NH-C4-Br</p> <p style="text-align: right;">Cat. No.: HY-W007803</p> <p>Boc-NH-C4-Br is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Boc-NH-C6-amido-C4-acid (PROTAC Linker 32)</p> <p style="text-align: right;">Cat. No.: HY-125888</p> <p>Boc-NH-C6-amido-C4-acid (PROTAC Linker 32) is an alkyl ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-NH-O-C1-NHS ester</p> <p>Cat. No.: HY-133405</p>	<p>Boc-NH-PEG-amine (MW 2000)</p> <p>Cat. No.: HY-140725</p>
<p>Boc-NH-O-C1-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>Boc-NH-PEG-amine (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG-amine (MW 3400)</p> <p>Cat. No.: HY-140726</p>	<p>Boc-NH-PEG-amine (MW 5000)</p> <p>Cat. No.: HY-140727</p>
<p>Boc-NH-PEG-amine (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG-amine (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG-Thiol (MW 10000)</p> <p>Cat. No.: HY-138311</p>	<p>Boc-NH-PEG1-C5-OH</p> <p>Cat. No.: HY-134737</p>
<p>Boc-NH-PEG-Thiol (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG1-C5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG1-CH2CH2COOH</p> <p>Cat. No.: HY-120775</p>	<p>Boc-NH-PEG1-CH2COOH</p> <p>Cat. No.: HY-140476</p>
<p>Boc-NH-PEG1-CH2CH2COOH is a cleavable (1 unit PEG) ADC linker and also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of antibody-drug conjugates (ADCs) or PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG1-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Boc-NH-PEG1-OH</p> <p>Cat. No.: HY-W007322</p>	<p>Boc-NH-PEG1-Ph-O-CH2COOH</p> <p>Cat. No.: HY-130637</p>
<p>Boc-NH-PEG1-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Boc-NH-PEG1-Ph-O-CH2COOH is a PROTAC Linker which is used for the EED-targeted PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>






<p>Boc-NH-PEG10-CH2CH2COOH</p> <p>Cat. No.: HY-140471</p>	<p>Boc-NH-PEG10-CH2CH2NH2</p> <p>Cat. No.: HY-135930</p>
<p>Boc-NH-PEG10-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG10-CH2CH2NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG10-NHS ester</p> <p>Cat. No.: HY-141120</p>	<p>Boc-NH-PEG11-C2-acid</p> <p>Cat. No.: HY-138410</p>
<p>Boc-NH-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG11-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG11-CH2CH2N3</p> <p>Cat. No.: HY-130897</p>	<p>Boc-NH-PEG11-NH2</p> <p>Cat. No.: HY-140234</p>
<p>Boc-NH-PEG11-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG11-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG11-NHS ester</p> <p>Cat. No.: HY-138441</p>	<p>Boc-NH-PEG11-OH</p> <p>Cat. No.: HY-135947</p>
<p>Boc-NH-PEG11-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG11-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG12-CH2CH2COOH</p> <p>Cat. No.: HY-140472</p>	<p>Boc-NH-PEG12-NH-Boc</p> <p>Cat. No.: HY-138494</p>
<p>Boc-NH-PEG12-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg, 250 mg</p>	<p>Boc-NH-PEG12-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-NH-PEG12-NH2</p> <p style="text-align: right;">Cat. No.: HY-133355</p> <p>Boc-NH-PEG12-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG12-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140885</p> <p>Boc-NH-PEG12-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG15-azide</p> <p style="text-align: right;">Cat. No.: HY-133356</p> <p>Boc-NH-PEG15-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG15-C1-acid</p> <p style="text-align: right;">Cat. No.: HY-138402</p> <p>Boc-NH-PEG15-C1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG15-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-138397</p> <p>Boc-NH-PEG15-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG15-NH2</p> <p style="text-align: right;">Cat. No.: HY-140235</p> <p>Boc-NH-PEG15-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG2 (PROTAC Linker 11)</p> <p style="text-align: right;">Cat. No.: HY-W004896</p> <p>Boc-NH-PEG2 (PROTAC Linker 11) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.82% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Boc-NH-PEG2-C2-amido-C4-acid (PROTAC Linker 30)</p> <p style="text-align: right;">Cat. No.: HY-125887</p> <p>Boc-NH-PEG2-C2-amido-C4-acid (PROTAC Linker 30) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG2-C2-NH2 (PROTAC Linker 13)</p> <p style="text-align: right;">Cat. No.: HY-W008474</p> <p>Boc-NH-PEG2-C2-NH2 (PROTAC Linker 13) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.01% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Boc-NH-PEG2-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141117</p> <p>Boc-NH-PEG2-C2-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Boc-NH-PEG2-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W025812</p> <p>Boc-NH-PEG2-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTAC.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Boc-NH-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W005056</p> <p>Boc-NH-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.87% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Boc-NH-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-141198</p> <p>Boc-NH-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>BOC-NH-PEG2-propene</p> <p style="text-align: right;">Cat. No.: HY-138398</p> <p>BOC-NH-PEG2-propene is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG20-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140473</p> <p>Boc-NH-PEG20-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG22-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-138399</p> <p>Boc-NH-PEG22-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG23-CH2CH2N3</p> <p style="text-align: right;">Cat. No.: HY-130899</p> <p>Boc-NH-PEG23-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG23-NH2</p> <p style="text-align: right;">Cat. No.: HY-140236</p> <p>Boc-NH-PEG23-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG24-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140474</p> <p>Boc-NH-PEG24-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg</p>	<p>Boc-NH-PEG26-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-138432</p> <p>Boc-NH-PEG26-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-NH-PEG3 (PROTAC Linker 10)</p> <p>Cat. No.: HY-W017772</p> <p>Boc-NH-PEG3 (PROTAC Linker 10) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA</p> <p>Cat. No.: HY-126677</p> <p>Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double cleavable 3-unit and 4-unit PEG linker for antibody-drug-conjugation (ADC). Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA also is a PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG3-CH2COOH</p> <p>Cat. No.: HY-33366</p> <p>Boc-NH-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Boc-NH-PEG3-NHS ester</p> <p>Cat. No.: HY-141118</p> <p>Boc-NH-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG3-propargyl</p> <p>Cat. No.: HY-140878</p> <p>Boc-NH-PEG3-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG3-sulfonic acid</p> <p>Cat. No.: HY-140172</p> <p>Boc-NH-PEG3-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG36-CH2CH2COOH</p> <p>Cat. No.: HY-140475</p> <p>Boc-NH-PEG36-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG4 (PROTAC Linker 12)</p> <p>Cat. No.: HY-W025896</p> <p>Boc-NH-PEG4 (PROTAC Linker 12) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Boc-NH-PEG4-azide</p> <p>Cat. No.: HY-140836</p> <p>Boc-NH-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG4-C2-Boc</p> <p>Cat. No.: HY-138370</p> <p>Boc-NH-PEG4-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-NH-PEG4-C3-acid</p> <p style="text-align: right;">Cat. No.: HY-140478</p>	<p>Boc-NH-PEG4-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040132</p>
<p>Boc-N-amido-PEG4-C3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG4-CH2CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC. Boc-NH-PEG4-CH2CH2COOH is also a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Boc-NH-PEG4-CH2CH2NH2</p> <p style="text-align: right;">Cat. No.: HY-W008352</p>	<p>Boc-NH-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-42640</p>
<p>Boc-NH-PEG4-CH2CH2NH2 a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-NH-PEG4-CH2CH2NH2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Boc-NH-PEG4-CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Boc-NH-PEG4-Ms</p> <p style="text-align: right;">Cat. No.: HY-140391</p>	<p>Boc-NH-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141119</p>
<p>Boc-NH-PEG4-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140837</p>	<p>Boc-NH-PEG5-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W022232</p>
<p>Boc-NH-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG5-CH2CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG5-Cl</p> <p style="text-align: right;">Cat. No.: HY-134709</p>	<p>Boc-NH-PEG5-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140880</p>
<p>Boc-NH-PEG5-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Boc-NH-PEG6-amine</p> <p style="text-align: right;">Cat. No.: HY-140231</p> <p>Boc-NH-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG6-azide</p> <p style="text-align: right;">Cat. No.: HY-140838</p> <p>Boc-NH-PEG6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG6-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040244</p> <p>Boc-NH-PEG6-CH2CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG6-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140477</p> <p>Boc-NH-PEG6-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG6-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140881</p> <p>Boc-NH-PEG6-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG7-acetic acid</p> <p style="text-align: right;">Cat. No.: HY-W190963</p> <p>Boc-NH-PEG7-acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-140469</p> <p>Boc-NH-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG7-azide</p> <p style="text-align: right;">Cat. No.: HY-140839</p> <p>Boc-NH-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG7-NH2</p> <p style="text-align: right;">Cat. No.: HY-140232</p> <p>Boc-NH-PEG7-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Boc-NH-PEG7-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140882</p> <p>Boc-NH-PEG7-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Boc-NH-PEG7-Tos</p> <p style="text-align: right;">Cat. No.: HY-140376</p>	<p>Boc-NH-PEG8-C2-Br</p> <p style="text-align: right;">Cat. No.: HY-138406</p>
<p>Boc-NH-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG8-C2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG8-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140470</p>	<p>Boc-NH-PEG8-CH2CH2NH2</p> <p style="text-align: right;">Cat. No.: HY-135933</p>
<p>Boc-NH-PEG8-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG8-CH2CH2NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Boc-NH-PEG8-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140883</p>	<p>Boc-NH-PEG9-azide</p> <p style="text-align: right;">Cat. No.: HY-140840</p>
<p>Boc-NH-PEG8-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PEG9-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Boc-NH-PEG9-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140884</p>	<p>Boc-NH-PPG2</p> <p style="text-align: right;">Cat. No.: HY-138492</p>
<p>Boc-NH-PEG9-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-NH-PPG2 is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-NHCH2CH2-PEG1-azide</p> <p style="text-align: right;">Cat. No.: HY-132119</p>	<p>Boc-PEG1-Boc</p> <p style="text-align: right;">Cat. No.: HY-138473</p>
<p>Boc-NHCH2CH2-PEG1-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG1-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-PEG1-PPG2-C2-azido</p> <p style="text-align: right;">Cat. No.: HY-138474</p> <p>Boc-PEG1-PPG2-C2-azido is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG1-PPG2-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-138485</p> <p>Boc-PEG1-PPG2-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-PEG2-ethoxyethane-PEG2-benzyl</p> <p style="text-align: right;">Cat. No.: HY-138475</p> <p>Boc-PEG2-ethoxyethane-PEG2-benzyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG2-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140173</p> <p>Boc-PEG2-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-PEG25-benzyl</p> <p style="text-align: right;">Cat. No.: HY-138468</p> <p>Boc-PEG25-benzyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-138379</p> <p>Boc-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-PEG4-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141122</p> <p>Boc-PEG4-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG4-methyl propionate</p> <p style="text-align: right;">Cat. No.: HY-138481</p> <p>Boc-PEG4-methyl propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-PEG4-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141304</p> <p>Boc-PEG4-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-PEG4-sulfone-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140613</p> <p>Boc-PEG4-sulfone-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Boc-PEG4-sulfonic acid</p> <p>Cat. No.: HY-140174</p>	<p>Boc-PEG5-methyl ester</p> <p>Cat. No.: HY-138373</p>
<p>Boc-PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Boc-PEG5-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-PEG8-Boc</p> <p>Cat. No.: HY-138335</p>	<p>Boc-Pip-alkyne-Ph-COOH</p> <p>Cat. No.: HY-133044</p>
<p>Boc-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-piperazine-benzoic acid</p> <p>Cat. No.: HY-W013249</p>	<p>Boc-Pyrrolidine-PEG2-COOH</p> <p>Cat. No.: HY-134744</p>
<p>Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128 (HY-13229).</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg, 1 g</p>	<p>Boc-Pyrrolidine-PEG2-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Boc-trans-D-Hyp-OMe</p> <p>Cat. No.: HY-W017882</p>	<p>BocNH-PEG5-CH2CH2Br</p> <p>Cat. No.: HY-W096092</p>
<p>Boc-trans-D-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-trans-D-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>BocNH-PEG5-CH2CH2Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-Boc-C2-azido</p> <p>Cat. No.: HY-138464</p>	<p>Br-C10-methyl ester</p> <p>Cat. No.: HY-130641</p>
<p>Br-Boc-C2-azido is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-C10-methyl ester is a PROTAC linker, which refers to the alkyl/ether composition. Br-C10-methyl ester is used in the synthesis of a series of PROTACs (MS432).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>











<p>Br-C3-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-W004701</p>	<p>Br-PEG2-oxazolidin-2-one</p> <p style="text-align: right;">Cat. No.: HY-134740</p>
<p>Br-C3-methyl ester is a Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p> <p style="text-align: center;"></p> <p>Purity: 96.86% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Br-PEG2-oxazolidin-2-one is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130483</p>	<p>Br-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130500</p>
<p>Br-PEG3-C2-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Br-PEG3-CH2COOH (compound 28) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG3-ethyl acetate</p> <p style="text-align: right;">Cat. No.: HY-W096139</p>	<p>Br-PEG3-MS</p> <p style="text-align: right;">Cat. No.: HY-138336</p>
<p>Br-PEG3-ethyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG3-OH</p> <p style="text-align: right;">Cat. No.: HY-135142</p>	<p>Br-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-138486</p>
<p>Br-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG4-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130315</p>	<p>Br-PEG4-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130536</p>
<p>Br-PEG4-C2-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>Br-PEG4-CH2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Br-PEG4-methyl acetate</p> <p style="text-align: right;">Cat. No.: HY-138450</p> <p>Br-PEG4-methyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-130512</p> <p>Br-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG4-THP</p> <p style="text-align: right;">Cat. No.: HY-138372</p> <p>Br-PEG4-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG6-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-138362</p> <p>Br-PEG6-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG6-C2-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138381</p> <p>Br-PEG6-C2-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG6-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-W190969</p> <p>Br-PEG6-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG7-Br</p> <p style="text-align: right;">Cat. No.: HY-133299</p> <p>Br-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Br-PEG7-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138515</p> <p>Br-PEG7-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Br-PEG9-C2-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138384</p> <p>Br-PEG9-C2-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-C10-OBn</p> <p style="text-align: right;">Cat. No.: HY-132859</p> <p>Bromo-C10-OBn is a PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Bromo-C4-PEG4-t-butyl ester</p> <p>Cat. No.: HY-144079</p>	<p>Bromo-PEG1-acid</p> <p>Cat. No.: HY-130425</p>
<p>Bromo-C4-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Bromo-PEG1-C2-azide</p> <p>Cat. No.: HY-140819</p>	<p>Bromo-PEG1-C2-Boc</p> <p>Cat. No.: HY-141364</p>
<p>Bromo-PEG1-C2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromo-PEG1-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.58% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Bromo-PEG1-CH2-Boc</p> <p>Cat. No.: HY-141370</p>	<p>Bromo-PEG1-CH2COOH</p> <p>Cat. No.: HY-130163</p>
<p>Bromo-PEG1-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Bromo-PEG1-CH2COOH is a PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG1-NH2 hydrobromide</p> <p>Cat. No.: HY-134736</p>	<p>Bromo-PEG10-t-butyl ester</p> <p>Cat. No.: HY-132118</p>
<p>Bromo-PEG1-NH2 hydrobromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG10-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG12-acid</p> <p>Cat. No.: HY-134754</p>	<p>Bromo-PEG12-t-butyl ester</p> <p>Cat. No.: HY-132117</p>
<p>Bromo-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG12-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Bromo-PEG2-acetic acid</p> <p style="text-align: right;">Cat. No.: HY-W190843</p>	<p>Bromo-PEG2-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141213</p>
<p>Bromo-PEG2-acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg</p>
<p>Bromo-PEG2-bromide</p> <p style="text-align: right;">Cat. No.: HY-130589</p>	<p>Bromo-PEG2-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-141362</p>
<p>Bromo-PEG2-bromide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 97.78% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Bromo-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG2-C2-azide</p> <p style="text-align: right;">Cat. No.: HY-130485</p>	<p>Bromo-PEG2-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141365</p>
<p>Bromo-PEG2-C2-azide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bromo-PEG2-C2-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.10% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Bromo-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: Size: 100 mg</p>
<p>Bromo-PEG2-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141371</p>	<p>Bromo-PEG2-MS</p> <p style="text-align: right;">Cat. No.: HY-132042</p>
<p>Bromo-PEG2-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG2-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG2-NH2 hydrobromide</p> <p style="text-align: right;">Cat. No.: HY-134694</p>	<p>Bromo-PEG2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-132018</p>
<p>Bromo-PEG2-NH2 hydrobromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>

Bromo-PEG2-phosphonic acid Cat. No.: HY-141297	Bromo-PEG2-phosphonic acid diethyl ester Cat. No.: HY-141299
<p>Bromo-PEG2-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG2-phosphonic acid diethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
Bromo-PEG2-THP Cat. No.: HY-W096071	Bromo-PEG24-Boc Cat. No.: HY-141369
<p>Bromo-PEG2-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG24-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
Bromo-PEG3-azide Cat. No.: HY-140820	Bromo-PEG3-bromide Cat. No.: HY-141373
<p>Bromo-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.10% Clinical Data: Size: 100 mg, 250 mg, 500 mg</p>
Bromo-PEG3-C2-acid Cat. No.: HY-W039168	Bromo-PEG3-C2-phosphonic acid Cat. No.: HY-130164
<p>Bromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Bromo-PEG3-C2-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
Bromo-PEG3-CH2-Boc Cat. No.: HY-141372	Bromo-PEG3-CO-NH2 Cat. No.: HY-134708
<p>Bromo-PEG3-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Bromo-PEG3-CO-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>









<p>Bromo-PEG3-phosphonic acid diethyl ester</p> <p>Cat. No.: HY-141300</p>	<p>Bromo-PEG3-THP</p> <p>Cat. No.: HY-132033</p>
<p>Bromo-PEG3-phosphonic acid diethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG3-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG4-acid</p> <p>Cat. No.: HY-141363</p>	<p>Bromo-PEG4-azide</p> <p>Cat. No.: HY-140821</p>
<p>Bromo-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>Bromo-PEG4-bromide</p> <p>Cat. No.: HY-W040527</p>	<p>Bromo-PEG4-MS</p> <p>Cat. No.: HY-132024</p>
<p>Bromo-PEG4-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG4-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG4-NHS ester</p> <p>Cat. No.: HY-132017</p>	<p>Bromo-PEG4-PFP ester</p> <p>Cat. No.: HY-132097</p>
<p>Bromo-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG5-alcohol</p> <p>Cat. No.: HY-141214</p>	<p>Bromo-PEG5-azide</p> <p>Cat. No.: HY-140822</p>
<p>Bromo-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>











<p>Bromo-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-141366</p> <p>Bromo-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG5-bromide</p> <p style="text-align: right;">Cat. No.: HY-141374</p> <p>Bromo-PEG5-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromo-PEG5-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-130489</p> <p>Bromo-PEG5-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG5-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-144080</p> <p>Bromo-PEG5-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG5-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141298</p> <p>Bromo-PEG5-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromo-PEG5-phosphonic acid diethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141301</p> <p>Bromo-PEG5-phosphonic acid diethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromo-PEG6-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141215</p> <p>Bromo-PEG6-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromo-PEG6-azide</p> <p style="text-align: right;">Cat. No.: HY-140823</p> <p>Bromo-PEG6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-141367</p> <p>Bromo-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG6-bromide</p> <p style="text-align: right;">Cat. No.: HY-135049</p> <p>Bromo-PEG6-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bromo-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132087</p>	<p>Bromo-PEG7-amine</p> <p style="text-align: right;">Cat. No.: HY-143844</p>
<p>Bromo-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG7-azide</p> <p style="text-align: right;">Cat. No.: HY-W096078</p>	<p>Bromo-PEG7-Boc</p> <p style="text-align: right;">Cat. No.: HY-134677</p>
<p>Bromo-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG7-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG7-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-144077</p>	<p>Bromo-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-141368</p>
<p>Bromo-PEG7-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromo-PEG8-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-144078</p>	<p>Bromo-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-134755</p>
<p>Bromo-PEG8-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromo-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromoacetamide-PEG3-C1-acid</p> <p style="text-align: right;">Cat. No.: HY-133506</p>	<p>Bromoacetamide-PEG3-propargyl</p> <p style="text-align: right;">Cat. No.: HY-130942</p>
<p>Bromoacetamide-PEG3-C1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamide-PEG3-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bromoacetamido-C2-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-141199</p> <p>Bromoacetamido-C2-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG2-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-141380</p> <p>Bromoacetamido-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.11% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>
<p>Bromoacetamido-PEG2-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141386</p> <p>Bromoacetamido-PEG2-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140825</p> <p>Bromoacetamido-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG3-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-141381</p> <p>Bromoacetamido-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141388</p> <p>Bromoacetamido-PEG3-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG3-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-141200</p> <p>Bromoacetamido-PEG3-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141382</p> <p>Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG4-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130520</p> <p>Bromoacetamido-PEG4-C2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141387</p> <p>Bromoacetamido-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Bromoacetamido-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140826</p> <p>Bromoacetamido-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG5-DOTA</p> <p style="text-align: right;">Cat. No.: HY-140754</p> <p>Bromoacetamido-PEG5-DOTA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-141383</p> <p>Bromoacetamido-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-141389</p> <p>Bromoacetamido-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG8-t-butyl acetate</p> <p style="text-align: right;">Cat. No.: HY-132084</p> <p>Bromoacetamido-PEG8-t-butyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG9-ethylcarbamoyl-C12-Boc</p> <p style="text-align: right;">Cat. No.: HY-141392</p> <p>Bromoacetamido-PEG9-ethylcarbamoyl-C12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromoacetamido-PEG9-ethylcarbamoyl-C4-Boc</p> <p style="text-align: right;">Cat. No.: HY-141390</p> <p>Bromoacetamido-PEG9-ethylcarbamoyl-C4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Bromoacetamido-PEG9-ethylcarbamoyl-C8-Boc</p> <p style="text-align: right;">Cat. No.: HY-141391</p> <p>Bromoacetamido-PEG9-ethylcarbamoyl-C8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Bromoacetic-PEG1-CH2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138414</p> <p>Bromoacetic-PEG1-CH2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Bromoacetic-PEG2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138412</p> <p>Bromoacetic-PEG2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Bromoacetyl-PEG3-DBCO</p> <p style="text-align: right;">Cat. No.: HY-133480</p> <p>Bromoacetyl-PEG3-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Butane-1,4-diyldiphosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-W075674</p> <p>Butane-1,4-diyldiphosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Butoxycarbonyl-PEG5-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140175</p> <p>Butoxycarbonyl-PEG5-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>C-NH-Boc-C-Bis-(C-PEG1-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140336</p> <p>C-NH-Boc-C-Bis-(C-PEG1-Boc) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>C-NH-Boc-C-Bis-(C1-PEG1-PFP)</p> <p style="text-align: right;">Cat. No.: HY-141259</p> <p>C-NH-Boc-C-Bis-(C1-PEG1-PFP) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>C18-PEG13-acid</p> <p style="text-align: right;">Cat. No.: HY-144082</p> <p>C18-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>C2-Bis-phosphoramidic acid diethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141323</p> <p>C2-Bis-phosphoramidic acid diethyl ester is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>C6-Bis-phosphoramidic acid diethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141325</p> <p>C6-Bis-phosphoramidic acid diethyl ester is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Carboxy-PEG2-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140167</p> <p>Carboxy-PEG2-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Carboxy-PEG4-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141302</p> <p>Carboxy-PEG4-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Carboxy-PEG4-phosphonic acid ethyl ester</p> <p>Cat. No.: HY-141303</p>	<p>Carboxy-PEG4-sulfonic acid</p> <p>Cat. No.: HY-140168</p>
<p>Carboxy-PEG4-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Carboxy-PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Carboxy-PEG5-sulfonic acid</p> <p>Cat. No.: HY-140169</p>	<p>Carboxyfluorescein-PEG12-NHS</p> <p>Cat. No.: HY-141085</p>
<p>Carboxy-PEG5-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Carboxyfluorescein-PEG12-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 5 mg</p>
<p>Carboxymethyl-PEG-Carboxymethyl (MW 5000)</p> <p>Cat. No.: HY-140723</p>	<p>Carboxyrhodamine 110-PEG3-Azide</p> <p>Cat. No.: HY-141090</p>
<p>Carboxymethyl-PEG-Carboxymethyl (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Carboxyrhodamine 110-PEG3-Azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Carboxyrhodamine 110-PEG4-alkyne</p> <p>Cat. No.: HY-141089</p>	<p>Carboxyrhodamine 110-PEG4-DBCO</p> <p>Cat. No.: HY-140297</p>
<p>Carboxyrhodamine 110-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Carboxyrhodamine 110-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cbz-aminoxy-PEG8-acid</p> <p>Cat. No.: HY-140443</p>	<p>Cbz-aminoxy-PEG8-Boc</p> <p>Cat. No.: HY-140444</p>
<p>Cbz-aminoxy-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cbz-aminoxy-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Cbz-N-amido-PEG20-acid</p> <p>Cat. No.: HY-140491</p>	<p>Cbz-N-PEG10-acid</p> <p>Cat. No.: HY-140490</p>
<p>Cbz-N-amido-PEG20-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-N-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cbz-N-PEG15-amine</p> <p>Cat. No.: HY-140238</p>	<p>Cbz-NH-PEG1-CH2CH2COOH</p> <p>Cat. No.: HY-135926</p>
<p>Cbz-N-PEG15-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG1-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG1-CH2COOH</p> <p>Cat. No.: HY-135925</p>	<p>Cbz-NH-PEG10-CH2COOH</p> <p>Cat. No.: HY-133357</p>
<p>Cbz-NH-PEG1-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.64% Clinical Data: Size: 250 mg, 500 mg</p>	<p>Cbz-NH-PEG10-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG12-C2-acid</p> <p>Cat. No.: HY-133358</p>	<p>Cbz-NH-PEG2-C2-acid</p> <p>Cat. No.: HY-140487</p>
<p>Cbz-NH-PEG12-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG2-CH2COOH</p> <p>Cat. No.: HY-135923</p>	<p>Cbz-NH-PEG24-C2-acid</p> <p>Cat. No.: HY-133359</p>
<p>Cbz-NH-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG24-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Cbz-NH-PEG3-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-140488</p>	<p>Cbz-NH-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135913</p>
<p>Cbz-NH-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG36-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-133360</p>	<p>Cbz-NH-PEG4-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-W019796</p>
<p>Cbz-NH-PEG36-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG4-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG5-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-140489</p>	<p>Cbz-NH-PEG5-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135919</p>
<p>Cbz-NH-PEG5-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG5-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG6-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-130443</p>	<p>Cbz-NH-PEG8-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-130192</p>
<p>Cbz-NH-PEG6-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cbz-NH-PEG8-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cbz-NH-PEG8-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135942</p>	<p>Cbz-PEG2-bromide</p> <p style="text-align: right;">Cat. No.: HY-W190968</p>
<p>Cbz-NH-PEG8-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cbz-PEG2-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Cbz-PEG5-Br</p> <p style="text-align: right;">Cat. No.: HY-143832</p>	<p>CG-PEG5-azido</p> <p style="text-align: right;">Cat. No.: HY-138516</p>
<p>Cbz-PEG5-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CG-PEG5-azido is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CH2COOH-PEG12-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-132113</p>	<p>CH2COOH-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-122696</p>
<p>CH2COOH-PEG12-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CH2COOH-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CH2COOH-PEG6-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W096106</p>	<p>CH2COOH-PEG9-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138514</p>
<p>CH2COOH-PEG6-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CH2COOH-PEG9-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Chloro-PEG2-Boc</p> <p style="text-align: right;">Cat. No.: HY-W096145</p>	<p>Chloro-PEG5-chloride</p> <p style="text-align: right;">Cat. No.: HY-W096131</p>
<p>Chloro-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Chloro-PEG5-chloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Chloroacetamido-C-PEG3-C3-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-W096151</p>	<p>Chloroacetamido-C4-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-W096152</p>
<p>Chloroacetamido-C-PEG3-C3-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Chloroacetamido-C4-NHBoc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Chloroacetamido-PEG4-C2-Boc</p> <p>Cat. No.: HY-130470</p>	<p>Chloroacetamido-PEG4-NHS ester</p> <p>Cat. No.: HY-141394</p>
<p>Chloroacetamido-PEG4-C2-Boc is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Chloroacetamido-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CHO-C-PEG2-C-CHO</p> <p>Cat. No.: HY-138383</p>	<p>CHO-CH2-PEG1-CH2-Boc</p> <p>Cat. No.: HY-138355</p>
<p>CHO-C-PEG2-C-CHO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CHO-CH2-PEG1-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CHO-PEG12-Boc</p> <p>Cat. No.: HY-134707</p>	<p>cis-4-Hydroxy-D-proline hydrochloride</p> <p>Cat. No.: HY-76104</p>
<p>CHO-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>cis-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>
<p>cis-4-Hydroxy-L-proline hydrochloride</p> <p>Cat. No.: HY-W019213</p>	<p>Cl-C6-PEG4-C3-COOH</p> <p>Cat. No.: HY-135306</p>
<p>cis-4-Hydroxy-L-proline hydrochloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-L-proline hydrochloride is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>Cl-C6-PEG4-C3-COOH is a PROTAC linker can be used in the synthesis of chloroalkane-containing PROTACs (HaloPROTACs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4)</p> <p>Cat. No.: HY-112496</p>	<p>Cl-PEG2-acid</p> <p>Cat. No.: HY-43055</p>
<p>Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4) is a PEG-based PROTAC linker can be used in the synthesis of chloroalkane-containing PROTACs (HaloPROTACs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Cl-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>

<p>Cl-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-W096129</p>	<p>Cl-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-138411</p>
<p>Cl-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cl-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cy5-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-141058</p>	<p>Cy5-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141033</p>
<p>Cy5-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 5 mg, 10 mg</p>	<p>Cy5-PEG4-acid (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cy5-PEG5-amine hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-141055</p>	<p>Cy5-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-141059</p>
<p>Cy5-PEG5-amine (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Cy5-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Cy5-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-141034</p>	<p>Cy5-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141044</p>
<p>Cy5-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cy5-PEG6-NHS ester (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Cyclohexane-PEG1-Br</p> <p style="text-align: right;">Cat. No.: HY-W092895</p>	<p>Cystamine</p> <p style="text-align: right;">Cat. No.: HY-124476</p>
<p>Cyclohexane-PEG1-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Cystamine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 96.78% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>

<p>D-Proline, 4-hydroxy-, methyl ester hydrochloride</p> <p>Cat. No.: HY-76105</p> <p>D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-(PEG2-Val-Cit-PAB)2</p> <p>Cat. No.: HY-126676</p> <p>DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable ADC linker for antibody-drug conjugates (ADCs). DBCO-(PEG2-Val-Cit-PAB)2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-Biotin</p> <p>Cat. No.: HY-123916</p> <p>DBCO-Biotin is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>	<p>DBCO-C-PEG1</p> <p>Cat. No.: HY-140281</p> <p>DBCO-C-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-C2-PEG4-amine</p> <p>Cat. No.: HY-140287</p> <p>DBCO-C2-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-C2-PEG4-NH-Boc</p> <p>Cat. No.: HY-140294</p> <p>DBCO-C2-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-C2-SulfoNHS ester</p> <p>Cat. No.: HY-133509</p> <p>DBCO-C2-SulfoNHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-C3-PEG4-amine</p> <p>Cat. No.: HY-140288</p> <p>DBCO-C3-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-C3-PEG4-NH-Boc</p> <p>Cat. No.: HY-140295</p> <p>DBCO-C3-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-mPEG (MW 10kDa)</p> <p>Cat. No.: HY-140320</p> <p>DBCO-mPEG (MW 10kDa) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>DBCO-mPEG (MW 20kDa)</p> <p style="text-align: right;">Cat. No.: HY-140321</p> <p>DBCO-mPEG (MW 20kDa) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 20kDa</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-mPEG (MW 2kDa)</p> <p style="text-align: right;">Cat. No.: HY-140318</p> <p>DBCO-mPEG (MW 2kDa) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 2kDa</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-mPEG (MW 30kDa)</p> <p style="text-align: right;">Cat. No.: HY-140322</p> <p>DBCO-mPEG (MW 30kDa) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 30kDa</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>	<p>DBCO-mPEG (MW 5kDa)</p> <p style="text-align: right;">Cat. No.: HY-140319</p> <p>DBCO-mPEG (MW 5kDa) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 5kDa</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-N-bis(PEG4-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-145090</p> <p>DBCO-N-bis(PEG4-NHS ester) is a PEG linker which contains two PEG4-NHS ester and a DBCO group. DBCO-N-bis(PEG4-NHS ester) is useful for protein modification or labeling.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NH-(CH2)4COOH</p> <p style="text-align: right;">Cat. No.: HY-130912</p> <p>DBCO-NH-(CH₂)₄COOH is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140293</p> <p>DBCO-NH-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NH-PEG7-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-135959</p> <p>DBCO-NH-PEG7-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-C4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133371</p> <p>DBCO-NHCO-C4-NHS ester is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG12-amine</p> <p style="text-align: right;">Cat. No.: HY-133368</p> <p>DBCO-NHCO-PEG12-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DBCO-NHCO-PEG12-biotin</p> <p style="text-align: right;">Cat. No.: HY-133376</p>	<p>DBCO-NHCO-PEG12-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133374</p>
<p>DBCO-NHCO-PEG12-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG12-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg</p>
<p>DBCO-NHCO-PEG13-acid</p> <p style="text-align: right;">Cat. No.: HY-140270</p>	<p>DBCO-NHCO-PEG13-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140276</p>
<p>DBCO-NHCO-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG13-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG2-amine</p> <p style="text-align: right;">Cat. No.: HY-133366</p>	<p>DBCO-NHCO-PEG2-Biotin</p> <p style="text-align: right;">Cat. No.: HY-135939</p>
<p>DBCO-NHCO-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG2-Biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-135935</p>	<p>DBCO-NHCO-PEG2-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133372</p>
<p>DBCO-NHCO-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG2-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133375</p>	<p>DBCO-NHCO-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-133369</p>
<p>DBCO-NHCO-PEG2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>





<p>DBCO-NHCO-PEG3-Fmoc</p> <p style="text-align: right;">Cat. No.: HY-133472</p> <p>DBCO-NHCO-PEG3-Fmoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-125541</p> <p>DBCO-Amide-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-Amide-PEG5-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-124386</p> <p>DBCO-NHCO-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-amine is a cleavable ADC linker used to conjugate MMAE (HY-15162) and antibody (e.g).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG4-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-126884</p> <p>DBCO-NHCO-PEG4-NH-Boc is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NH-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-111456</p> <p>DBCO-NHCO-PEG4-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140275</p> <p>DBCO-NHCO-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG6-amine</p> <p style="text-align: right;">Cat. No.: HY-133367</p> <p>DBCO-NHCO-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG6-Biotin</p> <p style="text-align: right;">Cat. No.: HY-135958</p> <p>DBCO-NHCO-PEG6-Biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-NHCO-PEG6-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133373</p> <p>DBCO-NHCO-PEG6-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-NHCO-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-133370</p> <p>DBCO-NHCO-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>










<p>DBCO-PEG1</p> <p style="text-align: right;">Cat. No.: HY-140280</p>	<p>DBCO-PEG1-acid</p> <p style="text-align: right;">Cat. No.: HY-140265</p>
<p>DBCO-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG1-amine</p> <p style="text-align: right;">Cat. No.: HY-140282</p>	<p>DBCO-PEG1-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140289</p>
<p>DBCO-PEG1-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG1-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG1-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140271</p>	<p>DBCO-PEG10-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140304</p>
<p>DBCO-PEG1-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG10-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140269</p>	<p>DBCO-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140274</p>
<p>DBCO-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-PEG13-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140305</p>	<p>DBCO-PEG13-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138744</p>
<p>DBCO-PEG13-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG13-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>




<p>DBCO-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-140266</p>	<p>DBCO-PEG2-amine</p> <p style="text-align: right;">Cat. No.: HY-140283</p>
<p>DBCO-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140290</p>	<p>DBCO-PEG3-amide-N-Fmoc</p> <p style="text-align: right;">Cat. No.: HY-138318</p>
<p>DBCO-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-PEG3-amide-N-Fmoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG3-amine</p> <p style="text-align: right;">Cat. No.: HY-134714</p>	<p>DBCO-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-120678</p>
<p>DBCO-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DBCO-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140279</p>	<p>DBCO-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-130435</p>
<p>DBCO-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg, 500 mg</p>	<p>DBCO-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-PEG4-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>DBCO-PEG4-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-130396</p>	<p>DBCO-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-130346</p>
<p>DBCO-PEG4-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>DBCO-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-PEG4-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>DBCO-PEG4-Desthiobiotin</p> <p>Cat. No.: HY-140301</p>	<p>DBCO-PEG4-NH-Boc</p> <p>Cat. No.: HY-140291</p>
<p>DBCO-PEG4-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG4-NHS ester</p> <p>Cat. No.: HY-140272</p>	<p>DBCO-PEG4-PFP ester</p> <p>Cat. No.: HY-140278</p>
<p>DBCO-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.97% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>DBCO-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 100 mg, 250 mg</p>
<p>DBCO-PEG4-triethoxysilane</p> <p>Cat. No.: HY-140308</p>	<p>DBCO-PEG5-acid</p> <p>Cat. No.: HY-140267</p>
<p>DBCO-PEG4-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DBCO-PEG5-DBCO</p> <p>Cat. No.: HY-140302</p>	<p>DBCO-PEG5-NHS ester</p> <p>Cat. No.: HY-126885</p>
<p>DBCO-PEG5-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>DBCO-PEG6-amine</p> <p>Cat. No.: HY-140284</p>	<p>DBCO-PEG6-amine TFA</p> <p>Cat. No.: HY-140284A</p>
<p>DBCO-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg, 100 mg</p>	<p>DBCO-PEG6-amine TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>DBCO-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140268</p>	<p>DBCO-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140273</p>
<p>DBCO-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg, 100 mg</p>
<p>DBCO-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-140285</p>	<p>DBCO-PEG9-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140303</p>
<p>DBCO-PEG9-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 95.90% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>DBCO-PEG9-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DBCO-PEG9-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140292</p>	<p>DBCO-S-S-PEG3-biotin</p> <p style="text-align: right;">Cat. No.: HY-140128</p>
<p>DBCO-PEG9-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DBCO-S-S-PEG3-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 95.07% Clinical Data: Size: 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Dde Biotin-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-140924</p>	<p>Dde Biotin-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-140916</p>
<p>Dde Biotin-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 5 mg, 10 mg</p>	<p>Dde Biotin-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Dde Biotin-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140931</p>	<p>Dde Biotin-PEG4-Picolyl azide</p> <p style="text-align: right;">Cat. No.: HY-140917</p>
<p>Dde Biotin-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Dde Biotin-PEG4-Picolyl azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Dde Biotin-PEG4-TAMRA-PEG4 Alkyne</p> <p>Cat. No.: HY-140877</p>	<p>Decaethylene glycol (HO-PEG10-OH)</p> <p>Cat. No.: HY-141232</p>
<p>Dde Biotin-PEG4-TAMRA-PEG4 Alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Decaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.09% Clinical Data: Size: 100 mg</p>
<p>Decaethylene glycol dodecyl ether (PEG10-dodecyl)</p> <p>Cat. No.: HY-132065</p>	<p>Desthiobiotin-PEG4-acid</p> <p>Cat. No.: HY-138507</p>
<p>Decaethylene glycol dodecyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Desthiobiotin-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 95.91% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>
<p>Desthiobiotin-PEG4-propargyl</p> <p>Cat. No.: HY-W096125</p>	<p>Di(N-succinimidyl)adipate</p> <p>Cat. No.: HY-141099</p>
<p>Desthiobiotin-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Di(N-succinimidyl)adipate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Diazo Biotin-PEG3-alkyne</p> <p>Cat. No.: HY-140925</p>	<p>Diazo Biotin-PEG3-azide</p> <p>Cat. No.: HY-140918</p>
<p>Diazo Biotin-PEG3-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Diazo Biotin-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Diethoxy-phosphorylethyl-PEG5-ethylphosphonic acid</p> <p>Cat. No.: HY-141305</p>	<p>Diethyl 10-bromodecylphosphonate</p> <p>Cat. No.: HY-140333</p>
<p>Diethoxy-phosphorylethyl-PEG5-ethylphosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Diethyl 10-bromodecylphosphonate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Diethyl 12-bromododecylphosphonate</p> <p>Cat. No.: HY-140334</p> <p>Diethyl 12-bromododecylphosphonate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Diethyl 7-bromoheptylphosphonate</p> <p>Cat. No.: HY-W035417</p> <p>Diethyl 7-bromoheptylphosphonate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Diethyl 8-bromooctylphosphonate</p> <p>Cat. No.: HY-140332</p> <p>Diethyl 8-bromooctylphosphonate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Diethylene glycol bis(p-toluenesulfonate) (Diethylene glycol di(p-toluenesulfonate); Bis-Tos-PEG2)</p> <p>Cat. No.: HY-W010948</p> <p>Diethylene glycol bis(p-toluenesulfonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.44% Clinical Data: No Development Reported Size: 500 mg</p>
<p>Diethylene glycol diacetate</p> <p>Cat. No.: HY-W096085</p> <p>Diethylene glycol diacetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Diethylene Glycol Monobenzyl Ether</p> <p>Cat. No.: HY-22393</p> <p>Diethylene Glycol Monobenzyl Ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.41% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Diketone-PEG11-Diketone</p> <p>Cat. No.: HY-140451</p> <p>Diketone-PEG11-Diketone is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Diketone-PEG11-PFP ester</p> <p>Cat. No.: HY-140447</p> <p>Diketone-PEG11-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Diketone-PEG12-Biotin</p> <p>Cat. No.: HY-140449</p> <p>Diketone-PEG12-Biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Diketone-PEG12-DBCO</p> <p>Cat. No.: HY-140450</p> <p>Diketone-PEG12-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>




<p>Diketone-PEG4-Biotin</p> <p style="text-align: right;">Cat. No.: HY-140448</p> <p>Diketone-PEG4-Biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Diketone-PEG4-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140006</p> <p>Diketone-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Dimethylamine-PEG19</p> <p style="text-align: right;">Cat. No.: HY-138401</p> <p>Dimethylamine-PEG19 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Dimethylamino-PEG11</p> <p style="text-align: right;">Cat. No.: HY-138409</p> <p>Dimethylamino-PEG11 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Dimethylamino-PEG2-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-W096132</p> <p>Dimethylamino-PEG2-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Dimethylamino-PEG3</p> <p style="text-align: right;">Cat. No.: HY-W096150</p> <p>Dimethylamino-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Dioxoisindolin-O-PEG-OH (MW 2000) ((1,3-dioxoisindolin-2-yl)-O-PEG-OH (MW 2000))</p> <p style="text-align: right;">Cat. No.: HY-140732</p> <p>Dioxoisindolin-O-PEG-OH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Dioxoisindolin-O-PEG-OMe (MW 2000) ((1,3-dioxoisindolin-2-yl)-O-PEG-OMe (MW 2000))</p> <p style="text-align: right;">Cat. No.: HY-140733</p> <p>Dioxoisindolin-O-PEG-OMe (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DNP-NH-PEG2-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-130467</p> <p>DNP-NH-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DNP-NH-PEG4-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130491</p> <p>DNP-NH-PEG4-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DNP-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140496</p>	<p>DNP-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140615</p>
<p>DNP-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DNP-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DNP-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140617</p>	<p>DNP-PEG3-DNP</p> <p style="text-align: right;">Cat. No.: HY-130350</p>
<p>DNP-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.40% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>DNP-PEG3-DNP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DNP-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130198</p>	<p>DNP-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140618</p>
<p>DNP-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DNP-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DNP-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140619</p>	<p>DNP-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140614</p>
<p>DNP-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DNP-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DNP-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-140495</p>	<p>DNP-PEG6-Boc (DNP-PEG6-t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140616</p>
<p>DNP-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DNP-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Docosanedioic acid</p> <p style="text-align: right;">Cat. No.: HY-W034918</p> <p>Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Dodecaethylene glycol (HO-PEG12-OH)</p> <p style="text-align: right;">Cat. No.: HY-141233</p> <p>Dodecaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.36% Clinical Data: Size: 100 mg</p>
<p>Dodecylheptaglycol</p> <p style="text-align: right;">Cat. No.: HY-W140896</p> <p>Dodecylheptaglycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DOTA-(t-butyl)3-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140753</p> <p>DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DOTA-PEG5-amine</p> <p style="text-align: right;">Cat. No.: HY-140008</p> <p>DOTA-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>DOTA-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140752</p> <p>DOTA-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 10 mg</p>
<p>DOTA-PEG5-C4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140314</p> <p>DOTA-PEG5-C4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg</p>	<p>Dox-Ph-PEG1-Cl (PROTAC Linker 34)</p> <p style="text-align: right;">Cat. No.: HY-125907</p> <p>Dox-Ph-PEG1-Cl (PROTAC Linker 34) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG-2-Aminoethyl-alpha-mannopyranoside (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140960</p> <p>DSPE-PEG-2-Aminoethyl-alpha-mannopyranoside (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG-Amine (MW 3400)</p> <p style="text-align: right;">Cat. No.: HY-140734</p> <p>DSPE-PEG-Amine (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DSPE-PEG-Amine (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140735</p>	<p>DSPE-PEG-Biotin (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140736</p>
<p>DSPE-PEG-Amine (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG-Biotin (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG-CH2COOH (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140737</p>	<p>DSPE-PEG-CH2COOH (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140738</p>
<p>DSPE-PEG-CH2COOH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG-CH2COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG-Maleimide (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140740</p>	<p>DSPE-PEG-OH (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140741</p>
<p>DSPE-PEG-Maleimide (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG-OH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG13-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140959</p>	<p>DSPE-PEG14-COOH</p> <p style="text-align: right;">Cat. No.: HY-134700</p>
<p>DSPE-PEG13-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG14-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>DSPE-PEG2-mal</p> <p style="text-align: right;">Cat. No.: HY-134745</p>	<p>DSPE-PEG36-DBCO</p> <p style="text-align: right;">Cat. No.: HY-133381</p>
<p>DSPE-PEG2-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG36-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DSPE-PEG36-mal</p> <p style="text-align: right;">Cat. No.: HY-133380</p>	<p>DSPE-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140953</p>
<p>DSPE-PEG36-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DSPE-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140955</p>	<p>DSPE-PEG46-DBCO</p> <p style="text-align: right;">Cat. No.: HY-133382</p>
<p>DSPE-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DSPE-PEG46-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DSPE-PEG46-Folate</p> <p style="text-align: right;">Cat. No.: HY-133383</p>	<p>DSPE-PEG46-N3</p> <p style="text-align: right;">Cat. No.: HY-130906</p>
<p>DSPE-PEG46-Folate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG46-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>DSPE-PEG46-NH2</p> <p style="text-align: right;">Cat. No.: HY-130905</p>	<p>DSPE-PEG47-acid</p> <p style="text-align: right;">Cat. No.: HY-130904</p>
<p>DSPE-PEG46-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG47-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>DSPE-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-140954</p>	<p>DSPE-PEG5-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140958</p>
<p>DSPE-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>DSPE-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>DSPE-PEG6-Mal</p> <p style="text-align: right;">Cat. No.: HY-138395</p> <p>DSPE-PEG6-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>DSPE-PEG8-Mal</p> <p style="text-align: right;">Cat. No.: HY-140956</p> <p>DSPE-PEG8-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>EGNHS (EGS crosslinker)</p> <p style="text-align: right;">Cat. No.: HY-130458</p> <p>EGNHS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Eicosanedioic acid</p> <p style="text-align: right;">Cat. No.: HY-W034595</p> <p>Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Eicosanedioic acid-d4</p> <p style="text-align: right;">Cat. No.: HY-W034595S</p> <p>Eicosanedioic acid-d4 is the deuterium labeled Eicosanedioic acid. Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-O-PNB</p> <p style="text-align: right;">Cat. No.: HY-43581</p> <p>endo-BCN-O-PNB is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140066</p> <p>endo-BCN-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG12-NH2 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-138386</p> <p>endo-BCN-PEG12-NH2 hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140071</p> <p>endo-BCN-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-130557</p> <p>endo-BCN-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>endo-BCN-PEG2-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140076</p>	<p>endo-BCN-PEG2-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140067</p>
<p>endo-BCN-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG2-C2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG2-NH2</p> <p style="text-align: right;">Cat. No.: HY-W072752</p>	<p>endo-BCN-PEG2-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140072</p>
<p>endo-BCN-PEG2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG2-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-133008</p>	<p>endo-BCN-PEG3-mal</p> <p style="text-align: right;">Cat. No.: HY-133400</p>
<p>endo-BCN-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG3-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG3-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-140077</p>	<p>endo-BCN-PEG3-NH2</p> <p style="text-align: right;">Cat. No.: HY-133401</p>
<p>endo-BCN-PEG3-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140068</p>	<p>endo-BCN-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-133009</p>
<p>endo-BCN-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>endo-BCN-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>endo-BCN-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140074</p> <p>endo-BCN-PEG4-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140069</p> <p>endo-BCN-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG4-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-140073</p> <p>endo-BCN-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-140075</p> <p>endo-BCN-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>endo-BCN-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-140065</p> <p>endo-BCN-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>endo-BCN-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140070</p> <p>endo-BCN-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Ethyl acetate-PEG1</p> <p style="text-align: right;">Cat. No.: HY-W096086</p> <p>Ethyl acetate-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ethyl azetidine-3-carboxylate hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-W052600</p> <p>Ethyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ethyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^{4/5}.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg</p>
<p>Ethyl-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W096083</p> <p>Ethyl-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>exo BCN-O-PNB</p> <p style="text-align: right;">Cat. No.: HY-133406</p> <p>exo BCN-O-PNB is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>F-PEG2-COOH</p> <p style="text-align: right;">Cat. No.: HY-138498</p>	<p>F-PEG2-S-Boc</p> <p style="text-align: right;">Cat. No.: HY-138493</p>
<p>F-PEG2-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>F-PEG2-S-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>F-PEG2-S-COOH</p> <p style="text-align: right;">Cat. No.: HY-138497</p>	<p>F-PEG2-SO-COOH</p> <p style="text-align: right;">Cat. No.: HY-138496</p>
<p>F-PEG2-S-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>F-PEG2-SO-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>F-PEG2-SO2-COOH</p> <p style="text-align: right;">Cat. No.: HY-138495</p>	<p>FA-PEG5-Mal (Folic acid-PEG5-Mal)</p> <p style="text-align: right;">Cat. No.: HY-132070</p>
<p>F-PEG2-SO2-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FA-PEG5-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fluorescein-PEG3-amine</p> <p style="text-align: right;">Cat. No.: HY-141080</p>	<p>Fluorescein-PEG3-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-141081</p>
<p>Fluorescein-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fluorescein-PEG3-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fluorescein-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-120368</p>	<p>Fluorescein-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-133006</p>
<p>Fluorescein-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fluorescein-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Fluorescein-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141082</p> <p>Fluorescein-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fluorescein-PEG6-bis-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141084</p> <p>Fluorescein-PEG6-bis-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fluorescein-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141083</p> <p>Fluorescein-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fluorescein-thiourea-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-130160</p> <p>Fluorescein-thiourea-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fluorescein-thiourea-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-120781</p> <p>Fluorescein-thiourea-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fluorescein-thiourea-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-133061</p> <p>Fluorescein-thiourea-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG2-CH2COOH)</p> <p style="text-align: right;">Cat. No.: HY-W007713</p> <p>Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG2-CH2COOH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-8-amino-3,6-dioxaoctanoic acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.65% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>Fmoc-amino-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W008568</p> <p>Fmoc-amino-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.14% Clinical Data: No Development Reported Size: 500 mg</p>
<p>Fmoc-amino-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-W040245</p> <p>Fmoc-amino-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.51% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Fmoc-aminooxy-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140441</p> <p>Fmoc-aminooxy-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>


<p>Fmoc-aminoxy-PEG12-NHS ester</p> <p>Cat. No.: HY-140442</p>	<p>Fmoc-aminoxy-PEG4-acid</p> <p>Cat. No.: HY-140440</p>
<p>Fmoc-aminoxy-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fmoc-aminoxy-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fmoc-aminoxy-PFP ester</p> <p>Cat. No.: HY-133404</p>	<p>Fmoc-azetidine-3-carboxylic acid</p> <p>Cat. No.: HY-W011277</p>
<p>Fmoc-aminoxy-PFP ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fmoc-azetidine-3-carboxylic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Fmoc-Hyp(Bom)-OH</p> <p>Cat. No.: HY-79125</p>	<p>Fmoc-Lys (biotin-PEG12)-OH</p> <p>Cat. No.: HY-140945</p>
<p>Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-Lys (biotin-PEG12)-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fmoc-Lys (biotin-PEG4)-OH</p> <p>Cat. No.: HY-130477</p>	<p>Fmoc-Lys(Pal-Glu-OtBu)-OH</p> <p>Cat. No.: HY-W045822</p>
<p>Fmoc-Lys (biotin-PEG4)-OH is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-Lys(Pal-Glu-OtBu)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Lys(Pal-Glu-OtBu)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-Lys-OH hydrochloride</p> <p>Cat. No.: HY-W010975</p>	<p>Fmoc-N-amido-PEG2-alcohol</p> <p>Cat. No.: HY-W096094</p>
<p>Fmoc-Lys-OH hydrochloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Lys-OH hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 1 g, 5 g</p>	<p>Fmoc-N-amido-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Fmoc-N-amido-PEG2-azide</p> <p>Cat. No.: HY-132099</p>	<p>Fmoc-N-amido-PEG3-azide</p> <p>Cat. No.: HY-132110</p>
<p>Fmoc-N-amido-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-N-amido-PEG36-Boc</p> <p>Cat. No.: HY-138320</p>	<p>Fmoc-N-amido-PEG4-amine</p> <p>Cat. No.: HY-134715</p>
<p>Fmoc-N-amido-PEG36-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-N-amido-PEG5-azide</p> <p>Cat. No.: HY-132111</p>	<p>Fmoc-N-amido-PEG6-amine</p> <p>Cat. No.: HY-138331</p>
<p>Fmoc-N-amido-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-N-methyl-PEG3-CH2CH2COOH</p> <p>Cat. No.: HY-W035378</p>	<p>Fmoc-N-PEG-CH2COOH (MW 3400)</p> <p>Cat. No.: HY-140668</p>
<p>Fmoc-N-methyl-PEG3-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-N-methyl-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG-CH2COOH (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Fmoc-N-PEG-CH2COOH (MW 5000)</p> <p>Cat. No.: HY-140669</p>	<p>Fmoc-N-PEG20-acid</p> <p>Cat. No.: HY-140462</p>
<p>Fmoc-N-amido-PEG-CH2COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG20-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Fmoc-N-PEG23-acid</p> <p>Cat. No.: HY-140463</p>	<p>Fmoc-N-PEG24-acid</p> <p>Cat. No.: HY-130907</p>
<p>Fmoc-N-amido-PEG23-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-N-PEG3-CH2-NHS ester</p> <p>Cat. No.: HY-135029</p>	<p>Fmoc-N-PEG36-acid</p> <p>Cat. No.: HY-140464</p>
<p>Fmoc-N-PEG3-CH2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-N-amido-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-N-PEG7-acid</p> <p>Cat. No.: HY-140460</p>	<p>Fmoc-NH-PEG1-C2-acid</p> <p>Cat. No.: HY-140013</p>
<p>Fmoc-N-amido-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Fmoc-NH-PEG1-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-PEG1-CH2COOH</p> <p>Cat. No.: HY-W055861</p>	<p>Fmoc-NH-PEG10-acid</p> <p>Cat. No.: HY-140461</p>
<p>Fmoc-NH-PEG1-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG1-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.91% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Fmoc-NH-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-PEG11-CH2CH2COOH</p> <p>Cat. No.: HY-130870</p>	<p>Fmoc-NH-PEG11-CH2COOH</p> <p>Cat. No.: HY-140466</p>
<p>Fmoc-NH-PEG11-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Fmoc-NH-PEG11-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

Fmoc-NH-PEG12-CH2CH2COOH
Cat. No.: HY-135821


Fmoc-NH-PEG12-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG12-CH2COOH
Cat. No.: HY-140467


Fmoc-NH-PEG12-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG14-acid
Cat. No.: HY-138434


Fmoc-NH-PEG14-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG15-CH2CH2COOH
Cat. No.: HY-133361


Fmoc-NH-PEG15-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG16-CH2CH2COOH
Cat. No.: HY-133362


Fmoc-NH-PEG16-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG19-CH2CH2COOH
Cat. No.: HY-133363


Fmoc-NH-PEG19-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG2-CH2CH2COOH
Cat. No.: HY-W040238


Fmoc-NH-PEG2-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG2-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 95.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Fmoc-NH-PEG25-CH2CH2COOH
Cat. No.: HY-133364


Fmoc-NH-PEG25-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG3-amide-CH2OCH2COOH
Cat. No.: HY-W096128


Fmoc-NH-PEG3-amide-CH2OCH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG3-C2-NH2
Cat. No.: HY-133471

Fmoc-NH-PEG3-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.













Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

<p>Fmoc-NH-PEG3-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040231</p>	<p>Fmoc-NH-PEG30-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133365</p>
<p>Fmoc-NH-PEG3-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.80% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>Fmoc-NH-PEG30-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-133470</p>	<p>Fmoc-NH-PEG4-CH2CH2COOH (Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid) Cat. No.: HY-W000434</p>
<p>Fmoc-NH-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fmoc-NH-PEG4-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.92% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Fmoc-NH-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130175</p>	<p>Fmoc-NH-PEG5-C2-NH2</p> <p style="text-align: right;">Cat. No.: HY-134682</p>
<p>Fmoc-NH-PEG4-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Fmoc-NH-PEG5-C2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-PEG5-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133062</p>	<p>Fmoc-NH-PEG5-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-134681</p>
<p>Fmoc-NH-PEG5-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-NH-PEG5-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-PEG6-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040246</p>	<p>Fmoc-NH-PEG6-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130364</p>
<p>Fmoc-NH-PEG6-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: 98.86% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g</p>	<p>Fmoc-NH-PEG6-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG6-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Fmoc-NH-PEG8-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040135</p> <p>Fmoc-NH-PEG8-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-NH-PEG8-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133063</p> <p>Fmoc-NH-PEG8-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG8-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.41% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Fmoc-NH-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126880</p> <p>Fmoc-NH-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-NH-PEG9-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130167</p> <p>Fmoc-NH-PEG9-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG9-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-NH-pentanoic acid-NHS-SO3Na</p> <p style="text-align: right;">Cat. No.: HY-140340</p> <p>Fmoc-NH-pentanoic acid-NHS-SO3Na is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fmoc-NMe-PEG4-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-140465</p> <p>Fmoc-NMe-PEG4-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fmoc-NMe-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141103</p> <p>Fmoc-NMe-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Fmoc-PEG1-CH2CH2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130077</p> <p>Fmoc-PEG1-CH2CH2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-PEG10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138721</p> <p>Fmoc-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141101</p> <p>Fmoc-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Fmoc-PEG2-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126881</p>	<p>Fmoc-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141102</p>
<p>Fmoc-PEG2-CH₂CH₂-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Fmoc-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W143484</p>	<p>Fmoc-PEG3-C2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-120773</p>
<p>Fmoc-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-PEG3-CH₂CH₂-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-122456</p>	<p>Fmoc-PEG5-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138330</p>
<p>Fmoc-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 95.35% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Fmoc-PEG5-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-122459</p>	<p>Fmoc-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126882</p>
<p>Fmoc-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Fmoc-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Fmoc-PEG9-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138720</p>	<p>FmocNH-PEG3-CH₂CH₂NH₂ hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-W190961</p>
<p>Fmoc-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FmocNH-PEG3-CH₂CH₂NH₂ (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>FmocNH-PEG4-t-butyl acetate</p> <p>Cat. No.: HY-132079</p>	<p>FmocNH-PEG4-t-butyl ester</p> <p>Cat. No.: HY-132064</p>
<p>FmocNH-PEG4-t-butyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FmocNH-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Folate-PEG1-mal</p> <p>Cat. No.: HY-133494</p>	<p>Folate-PEG2-amine</p> <p>Cat. No.: HY-133495</p>
<p>Folate-PEG1-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Folate-PEG2-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Folate-PEG3-alkyne</p> <p>Cat. No.: HY-133496</p>	<p>Folate-PEG3-azide</p> <p>Cat. No.: HY-133483</p>
<p>Folate-PEG3-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Folate-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg</p>
<p>Folate-PEG3-NHS ester</p> <p>Cat. No.: HY-133493</p>	<p>Gly-PEG3-endo-BCN</p> <p>Cat. No.: HY-140080</p>
<p>Folate-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Gly-PEG3-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Glycocholic acid-PEG10-iodoacetamide</p> <p>Cat. No.: HY-134718</p>	<p>H-cis-Hyp-OMe hydrochloride</p> <p>Cat. No.: HY-W016429</p>
<p>Glycocholic acid-PEG10-iodoacetamide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>H-cis-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-cis-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>











<p>H-Glu-OtBu</p> <p style="text-align: right;">Cat. No.: HY-W018154</p> <p>H-Glu-OtBu is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Glu-OtBu is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs².</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 1 g</p>	<p>H-Hyp-OMe hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-76043</p> <p>H-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs².</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>
<p>H2N-PEG12-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133343</p> <p>H2N-PEG12-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>H2N-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W006524</p> <p>H2N-PEG2-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>H2N-PEG2-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-135927</p> <p>H2N-PEG2-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>H2N-PEG4-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133339</p> <p>H2N-PEG4-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>H2N-PEG5-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133340</p> <p>H2N-PEG5-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>H2N-PEG6-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133341</p> <p>H2N-PEG6-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>H2N-PEG8-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133342</p> <p>H2N-PEG8-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Heptaethylene glycol (HO-PEG7-OH)</p> <p style="text-align: right;">Cat. No.: HY-141231</p> <p>Heptaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>

<p>Hexaethylene glycol</p> <p style="text-align: right;">Cat. No.: HY-141230</p>	<p>Hexaethylene glycol dimethyl ether</p> <p style="text-align: right;">Cat. No.: HY-134746</p>
<p>Hexaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.62% Clinical Data: Size: 100 mg</p>	<p>Hexaethylene glycol dimethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hexaethylene glycol monomethyl ether</p> <p style="text-align: right;">Cat. No.: HY-W042625</p>	<p>Hexane-1,6-diylidiphosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-140326</p>
<p>Hexaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hexane-1,6-diylidiphosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>HO-PEG-amine (MW 1000)</p> <p style="text-align: right;">Cat. No.: HY-140713</p>	<p>HO-PEG-amine (MW 10000)</p> <p style="text-align: right;">Cat. No.: HY-140641</p>
<p>HO-PEG-amine (MW 1000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 1000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG-amine (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG-amine (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140714</p>	<p>HO-PEG-amine (MW 3400)</p> <p style="text-align: right;">Cat. No.: HY-140715</p>
<p>HO-PEG-amine (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG-amine (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 3400</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG-amine (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140716</p>	<p>HO-PEG-CH2COOH (MW 3400)</p> <p style="text-align: right;">Cat. No.: HY-140711</p>
<p>HO-PEG-amine (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG-CH2COOH (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p style="text-align: center;">MW 3400</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>HO-PEG-CH₂COOH (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140712</p>	<p>HO-PEG-mal (MW 3400)</p> <p style="text-align: right;">Cat. No.: HY-140717</p>
<p>HO-PEG-CH₂COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  <p>MW 5000</p> </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG-mal (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  <p>MW 3400</p> </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG-mal (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140718</p>	<p>HO-PEG1-benzyl ester</p> <p style="text-align: right;">Cat. No.: HY-133315</p>
<p>HO-PEG-mal (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  <p>MW 5000</p> </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG1-benzyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG10-CH₂COOH</p> <p style="text-align: right;">Cat. No.: HY-133304</p>	<p>HO-PEG11-OH</p> <p style="text-align: right;">Cat. No.: HY-130342</p>
<p>HO-PEG10-CH₂COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG11-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg</p>
<p>HO-PEG12-CH₂COOH</p> <p style="text-align: right;">Cat. No.: HY-133303</p>	<p>HO-PEG13-OH</p> <p style="text-align: right;">Cat. No.: HY-141234</p>
<p>HO-PEG12-CH₂COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG13-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG14-OH</p> <p style="text-align: right;">Cat. No.: HY-120430</p>	<p>HO-PEG15-OH</p> <p style="text-align: right;">Cat. No.: HY-120724</p>
<p>HO-PEG14-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG15-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>HO-PEG16-OH</p> <p style="text-align: right;">Cat. No.: HY-141235</p>	<p>HO-PEG17-OH</p> <p style="text-align: right;">Cat. No.: HY-130600</p>
<p>HO-PEG16-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG17-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG18-OH</p> <p style="text-align: right;">Cat. No.: HY-144081</p>	<p>HO-PEG20-OH</p> <p style="text-align: right;">Cat. No.: HY-141236</p>
<p>HO-PEG18-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG20-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG21-OH</p> <p style="text-align: right;">Cat. No.: HY-141237</p>	<p>HO-PEG22-OH</p> <p style="text-align: right;">Cat. No.: HY-133300</p>
<p>HO-PEG21-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG22-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG24-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133309</p>	<p>HO-PEG24-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133305</p>
<p>HO-PEG24-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg</p>	<p>HO-PEG24-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG24-OH</p> <p style="text-align: right;">Cat. No.: HY-141238</p>	<p>HO-PEG4-benzyl ester</p> <p style="text-align: right;">Cat. No.: HY-133316</p>
<p>HO-PEG24-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>HO-PEG4-benzyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>HO-PEG5-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-134750</p>	<p>HO-PEG6-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133302</p>
<p>HO-PEG5-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG6-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG7-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-134748</p>	<p>HO-PEG8-CH2CH2COOH (Hydroxy-PEG8-acid)</p> <p style="text-align: right;">Cat. No.: HY-133053</p>
<p>HO-PEG7-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>HO-PEG8-CH2CH2COOH (Hydroxy-PEG8-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>HO-PEG8-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133301</p>	<p>HOOCH2O-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-124780</p>
<p>HO-PEG8-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>HOOCH2O-PEG4-CH2COOH, compound 5, is a symmetric PEG linker, used for the synthesis of the first class of Homo-PROTAC.</p>  <p>Purity: ≥95.0% Clinical Data: Size: 10 mg, 50 mg, 100 mg</p>
<p>HS-C6-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-133387</p>	<p>HS-PEG10-CH2CH2COOH (Thiol-PEG10-propionic acid)</p> <p style="text-align: right;">Cat. No.: HY-130876</p>
<p>HS-C6-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>HS-PEG10-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>HS-PEG11-CH2CH2N3</p> <p style="text-align: right;">Cat. No.: HY-130880</p>	<p>HS-PEG24-CH2CH2COOH (Thiol-PEG24-acid)</p> <p style="text-align: right;">Cat. No.: HY-130878</p>
<p>HS-PEG11-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>HS-PEG24-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>





HS-PEG3-CH2CH2NH2 (Thiol-PEG3-amine)	HS-PEG3-CH2CH2NH2 hydrochloride (Thiol-PEG3-amine hydrochloride)
Cat. No.: HY-130871 HS-PEG3-CH2CH2NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg	Cat. No.: HY-130871A HS-PEG3-CH2CH2NH2 hydrochloride (Thiol-PEG3-amine hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg
HS-PEG5-CH2CH2N3	HS-PEG5-CH2CH2NH2 (Thiol-PEG5-amine)
Cat. No.: HY-130879 HS-PEG5-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: Size: 1 mg, 5 mg	Cat. No.: HY-130872 HS-PEG5-CH2CH2NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: Size: 1 mg, 5 mg
HS-PEG6-CH2CH2-Boc	HS-PEG7-CH2CH2COOH (Thiol-PEG7-propionic acid)
Cat. No.: HY-130881 HS-PEG6-CH2CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: Size: 1 mg, 5 mg	Cat. No.: HY-130874 HS-PEG7-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg
HS-PEG7-CH2CH2N3	HS-PEG7-CH2CH2NH2 (Thiol-PEG7-amine)
Cat. No.: HY-130882 HS-PEG7-CH2CH2N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: Size: 1 mg, 5 mg	Cat. No.: HY-130873 HS-PEG7-CH2CH2NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg
HS-PEG9-CH2CH2COOH (Thiol-PEG9-propionic acid)	Hydrazide-PEG4-Desthiobiotin
Cat. No.: HY-130875 HS-PEG9-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	Cat. No.: HY-134722 Hydrazide-PEG4-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.  Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg

<p>Hydroxy-Amino-bis(PEG1-C2-Boc)</p> <p>Cat. No.: HY-141250</p>	<p>Hydroxy-Amino-bis(PEG2-propargyl)</p> <p>Cat. No.: HY-140082</p>
<p>Hydroxy-Amino-bis(PEG1-C2-Boc) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-Amino-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG1-(CH2)2-Boc</p> <p>Cat. No.: HY-W055870</p>	<p>Hydroxy-PEG1-C2-methyl ester (Methyl 3-(2-hydroxyethoxy)propanoate)</p> <p>Cat. No.: HY-141239</p>
<p>Hydroxy-PEG1-(CH2)2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Hydroxy-PEG1-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG1-CH2-Boc</p> <p>Cat. No.: HY-141208</p>	<p>Hydroxy-PEG10-acid (HO-PEG10-CH2CH2COOH)</p> <p>Cat. No.: HY-133307</p>
<p>Hydroxy-PEG1-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Hydroxy-PEG10-CH2-Boc (HO-PEG10-CH2COOtBu)</p> <p>Cat. No.: HY-133312</p>	<p>Hydroxy-PEG11-Boc</p> <p>Cat. No.: HY-141206</p>
<p>Hydroxy-PEG10-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG11-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG12-acid (HO-PEG12-CH2CH2COOH)</p> <p>Cat. No.: HY-133306</p>	<p>Hydroxy-PEG12-Boc</p> <p>Cat. No.: HY-130831</p>
<p>Hydroxy-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Hydroxy-PEG12-CH2-Boc (HO-PEG12-CH2COOtBu) Cat. No.: HY-133313</p> <p>Hydroxy-PEG12-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG13-Boc Cat. No.: HY-130832</p> <p>Hydroxy-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG14-t-butyl ester Cat. No.: HY-132056</p> <p>Hydroxy-PEG14-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG16-acid (HO-PEG16-CH2CH2COOH) Cat. No.: HY-133308</p> <p>Hydroxy-PEG16-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG16-Boc Cat. No.: HY-130833</p> <p>Hydroxy-PEG16-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG2-(CH2)2-Boc Cat. No.: HY-W067061</p> <p>Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg</p>
<p>Hydroxy-PEG2-acid Cat. No.: HY-124380</p> <p>Hydroxy-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>Hydroxy-PEG2-C2-methyl ester (Methyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate) Cat. No.: HY-141240</p> <p>Hydroxy-PEG2-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.00% Clinical Data: No Development Reported Size: 25 mg, 100 mg</p>
<p>Hydroxy-PEG2-C2-PFP ester Cat. No.: HY-130488</p> <p>Hydroxy-PEG2-C2-PFP ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG2-C2-sulfonic acid Cat. No.: HY-121507</p> <p>Hydroxy-PEG2-C2-sulfonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Hydroxy-PEG2-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130599</p>	<p>Hydroxy-PEG2-CH2CH2COO-PEG2-propionic acid</p> <p style="text-align: right;">Cat. No.: HY-132083</p>
<p>Hydroxy-PEG2-CH2-Boc is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG2-CH2CH2COO-PEG2-propionic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140497</p>	<p>Hydroxy-PEG2-CH2COONa (HO-PEG2-CH2COONa)</p> <p style="text-align: right;">Cat. No.: HY-140497A</p>
<p>Hydroxy-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG2-CH2COONa is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG20-Boc</p> <p style="text-align: right;">Cat. No.: HY-141207</p>	<p>Hydroxy-PEG24-Boc</p> <p style="text-align: right;">Cat. No.: HY-130834</p>
<p>Hydroxy-PEG20-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG24-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG24-CH2-Boc (HO-PEG24-CH2COOtBu)</p> <p style="text-align: right;">Cat. No.: HY-133314</p>	<p>Hydroxy-PEG3-(CH2)2-Boc</p> <p style="text-align: right;">Cat. No.: HY-42488</p>
<p>Hydroxy-PEG24-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Hydroxy-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-133052</p>	<p>Hydroxy-PEG3-acrylate</p> <p style="text-align: right;">Cat. No.: HY-141244</p>
<p>Hydroxy-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG3-acrylate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Hydroxy-PEG3-C2-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-141241</p> <p>Hydroxy-PEG3-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG3-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141209</p> <p>Hydroxy-PEG3-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG3-ethyl acetate</p> <p style="text-align: right;">Cat. No.: HY-W096154</p> <p>Hydroxy-PEG3-ethyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG3-MS</p> <p style="text-align: right;">Cat. No.: HY-W096069</p> <p>Hydroxy-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG3-NHS</p> <p style="text-align: right;">Cat. No.: HY-130672</p> <p>Hydroxy-PEG3-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG3-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-141212</p> <p>Hydroxy-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG4-(CH2)2-Boc</p> <p style="text-align: right;">Cat. No.: HY-W039178</p> <p>Hydroxy-PEG4-(CH2)2-Boc is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 191).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg</p>	<p>Hydroxy-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-117104</p> <p>Hydroxy-PEG4-acid is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG4-C2-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-141242</p> <p>Hydroxy-PEG4-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG4-C2-nitrile</p> <p style="text-align: right;">Cat. No.: HY-141245</p> <p>Hydroxy-PEG4-C2-nitrile is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Hydroxy-PEG4-CH2-Boc</p> <p>Cat. No.: HY-42617</p>	<p>Hydroxy-PEG4-CH2COOH</p> <p>Cat. No.: HY-140498</p>
<p>Hydroxy-PEG4-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Hydroxy-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG4-methyl acetate</p> <p>Cat. No.: HY-138421</p>	<p>Hydroxy-PEG4-methylamine</p> <p>Cat. No.: HY-140162</p>
<p>Hydroxy-PEG4-methyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG4-methylamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG4-O-Boc</p> <p>Cat. No.: HY-141210</p>	<p>Hydroxy-PEG5-acid</p> <p>Cat. No.: HY-133051</p>
<p>Hydroxy-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG5-Boc</p> <p>Cat. No.: HY-141202</p>	<p>Hydroxy-PEG5-C2-methyl ester</p> <p>Cat. No.: HY-141243</p>
<p>Hydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG5-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG6-acid</p> <p>Cat. No.: HY-133050</p>	<p>Hydroxy-PEG6-Boc</p> <p>Cat. No.: HY-141203</p>
<p>Hydroxy-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG7-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Hydroxy-PEG6-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141211</p> <p>Hydroxy-PEG6-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG7-Boc</p> <p style="text-align: right;">Cat. No.: HY-141204</p> <p>Hydroxy-PEG7-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Hydroxy-PEG7-CH2-Boc (HO-PEG7-CH2COOtBu)</p> <p style="text-align: right;">Cat. No.: HY-133310</p> <p>Hydroxy-PEG7-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-130662</p> <p>Hydroxy-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg, 1 g</p>
<p>Hydroxy-PEG8-CH2-Boc (HO-PEG8-CH2COOtBu)</p> <p style="text-align: right;">Cat. No.: HY-133311</p> <p>Hydroxy-PEG8-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Hydroxy-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-141205</p> <p>Hydroxy-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>HyNic-PEG2-DBCO</p> <p style="text-align: right;">Cat. No.: HY-133498</p> <p>HyNic-PEG2-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>	<p>HyNic-PEG2-TCO</p> <p style="text-align: right;">Cat. No.: HY-133497</p> <p>HyNic-PEG2-TCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>I-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-W096157</p> <p>I-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>I-PEG6-OH</p> <p style="text-align: right;">Cat. No.: HY-W096156</p> <p>I-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>ICG-Sulfo-OSu sodium</p> <p style="text-align: right;">Cat. No.: HY-134719</p>	<p>Iodo-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-133481</p>
<p>ICG-Sulfo-OSu sodium is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Iodo-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Iodo-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133482</p>	<p>Iodo-PEG4-N3</p> <p style="text-align: right;">Cat. No.: HY-130525</p>
<p>Iodo-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Iodo-PEG4-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Iodo-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-143833</p>	<p>Iodoacetamide-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140857</p>
<p>Iodo-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Iodoacetamide-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.93% Clinical Data: Size: 100 mg, 250 mg</p>
<p>Iodoacetamide-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-134687</p>	<p>Iodoacetamide-PEG5-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-134738</p>
<p>Iodoacetamide-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Iodoacetamide-PEG5-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Iodoacetamide-PEG5-NH2</p> <p style="text-align: right;">Cat. No.: HY-134688</p>	<p>Iodoacetamido-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-138505</p>
<p>Iodoacetamide-PEG5-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Iodoacetamido-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Iodoacetyl-PEG4-biotin</p> <p>Cat. No.: HY-138491</p>	<p>Iodoacetyl-PEG4-NHS ester</p> <p>Cat. No.: HY-138422</p>
<p>Iodoacetyl-PEG4-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Iodoacetyl-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Iodoacetyl-PEG8-biotin</p> <p>Cat. No.: HY-138490</p>	<p>L-Azidohomoalanine</p> <p>Cat. No.: HY-140346</p>
<p>Iodoacetyl-PEG8-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>L-Azidohomoalanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>L-Azidohomoalanine hydrochloride</p> <p>Cat. No.: HY-140346A</p>	<p>L-Azidohomoalanine-1,2,3,4-13C4 hydrochloride</p> <p>Cat. No.: HY-140346AS</p>
<p>L-Azidohomoalanine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.76% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg</p>	<p>L-Azidohomoalanine-1,2,3,4-13C4 hydrochloride is the 13C- and 15N-labeled L-Azidohomoalanine hydrochloride. L-Azidohomoalanine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>L-Homopropargylglycine</p> <p>Cat. No.: HY-140345</p>	<p>L-Homopropargylglycine hydrochloride</p> <p>Cat. No.: HY-140345A</p>
<p>L-Homopropargylglycine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. L-homopropargylglycine is an amino acid analog of methionine containing an alkyne moiety that can undergo a classic click chemical reaction with azide containing Alexa Fluor.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>L-Homopropargylglycine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>Leukotriene B4 (LTB4; 5(S),12(R)-DIHETE)</p> <p>Cat. No.: HY-107608</p>	<p>Leukotriene B4-d4 (LTB4-d4; 5(S),12(R)-DIHETE-d4)</p> <p>Cat. No.: HY-107608S</p>
<p>Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Phase 2 Size: 25 µg (297.2 µM * 250 µL in Ethanol)</p>	<p>Leukotriene B4-d4 (LTB4-d4) is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 µg</p>

LG-PEG10-click-DBCO-Oleic Cat. No.: HY-141130


LG-PEG10-click-DBCO-Oleic is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lipoamide-PEG11-Mal Cat. No.: HY-141339


Lipoamide-PEG11-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Lipoamide-PEG3-Mal Cat. No.: HY-141338


Lipoamide-PEG3-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Lipoamido-PEG12-acid Cat. No.: HY-141334


Lipoamido-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Lipoamido-PEG2-OH Cat. No.: HY-141337


Lipoamido-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 100 mg

Lipoamido-PEG24-acid Cat. No.: HY-141335


Lipoamido-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Lipoamido-PEG3-OH Cat. No.: HY-130407


Lipoamido-PEG3-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Lipoamido-PEG3-OH (compound TA-TEG-G2CN) can be used in the formation of a highly stable, dendronized gold nanoparticle (AuNP)-based drug delivery platform.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lipoamido-PEG4-acid Cat. No.: HY-141332


Lipoamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Lipoamido-PEG4-azide Cat. No.: HY-130197


Lipoamido-PEG4-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.













Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











Lipoamido-PEG8-acid Cat. No.: HY-141333











Lipoamido-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.


















Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg











<p>m-PEG-acid</p> <p>Cat. No.: HY-130292</p>	<p>m-PEG-acrylate (MW 10000)</p> <p>Cat. No.: HY-140671</p>
<p>m-PEG-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-acrylate (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-acrylate (MW 2000)</p> <p>Cat. No.: HY-140670</p>	<p>m-PEG-acrylate (MW 20000)</p> <p>Cat. No.: HY-140672</p>
<p>m-PEG-acrylate (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-acrylate (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-acrylate (MW 30000)</p> <p>Cat. No.: HY-140673</p>	<p>m-PEG-Aminoxy (MW 2000)</p> <p>Cat. No.: HY-140695</p>
<p>m-PEG-acrylate (MW 30000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 30000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-Aminoxy (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-azide (MW 10000)</p> <p>Cat. No.: HY-140684</p>	<p>m-PEG-azide (MW 2000)</p> <p>Cat. No.: HY-140682</p>
<p>m-PEG-azide (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-azide (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-azide (MW 20000)</p> <p>Cat. No.: HY-140685</p>	<p>m-PEG-azide (MW 5000)</p> <p>Cat. No.: HY-140683</p>
<p>m-PEG-azide (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-azide (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>







<p>m-PEG-Butyraldehyde (MW 5000)</p> <p>Cat. No.: HY-140674</p>	<p>m-PEG-CH₂COOH (MW 2000)</p> <p>Cat. No.: HY-140686</p>
<p>m-PEG-Butyraldehyde (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-CH₂COOH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-CH₂COOH (MW 20000)</p> <p>Cat. No.: HY-140688</p>	<p>m-PEG-CH₂COOH (MW 5000)</p> <p>Cat. No.: HY-140687</p>
<p>m-PEG-CH₂COOH (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-CH₂COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-Lys-NHS ester (MW 20000)</p> <p>Cat. No.: HY-140680</p>	<p>m-PEG-Lys-NHS ester (MW 40000)</p> <p>Cat. No.: HY-140681</p>
<p>m-PEG-Lys-NHS ester (MW 20000) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-Lys-NHS ester (MW 40000) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 40000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-mal (MW 10000)</p> <p>Cat. No.: HY-140691</p>	<p>m-PEG-mal (MW 2000)</p> <p>Cat. No.: HY-140689</p>
<p>m-PEG-mal (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-mal (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg</p>
<p>m-PEG-mal (MW 20000)</p> <p>Cat. No.: HY-140692</p>	<p>m-PEG-mal (MW 30000)</p> <p>Cat. No.: HY-140693</p>
<p>m-PEG-mal (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-mal (MW 30000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 30000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>m-PEG-mal (MW 5000)</p> <p>Cat. No.: HY-140690</p>	<p>m-PEG-NH2 (MW 1000)</p> <p>Cat. No.: HY-140675</p>
<p>m-PEG-mal (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-NH2 (MW 1000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 1000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-NH2 (MW 10000)</p> <p>Cat. No.: HY-140678</p>	<p>m-PEG-NH2 (MW 2000)</p> <p>Cat. No.: HY-140676</p>
<p>m-PEG-NH2 (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-NH2 (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>
<p>m-PEG-NH2 (MW 20000)</p> <p>Cat. No.: HY-140679</p>	<p>m-PEG-NH2 (MW 5000)</p> <p>Cat. No.: HY-140677</p>
<p>m-PEG-NH2 (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-NH2 (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>m-PEG-NHS ester (MW 10000)</p> <p>Cat. No.: HY-140699</p>	<p>m-PEG-NHS ester (MW 20000)</p> <p>Cat. No.: HY-140700</p>
<p>m-PEG-NHS ester (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-NHS ester (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-NHS ester (MW 5000)</p> <p>Cat. No.: HY-140698</p>	<p>m-PEG-NPC (MW 20000)</p> <p>Cat. No.: HY-140694</p>
<p>m-PEG-NHS ester (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: 99.58% Clinical Data: No Development Reported Size: 100 mg</p>	<p>m-PEG-NPC (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>






<p>m-PEG-OH (MW5000)</p> <p>Cat. No.: HY-140697</p>	<p>m-PEG-OH (MW 2000)</p> <p>Cat. No.: HY-140696</p>
<p>m-PEG-OH (MW5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-OH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg</p>
<p>m-PEG-Succinimidyl Succinate (MW 5000)</p> <p>Cat. No.: HY-140701</p>	<p>m-PEG-thiol (MW 10000)</p> <p>Cat. No.: HY-140708</p>
<p>m-PEG-Succinimidyl Succinate (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>m-PEG-thiol (MW 10000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 10000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-thiol (MW 2000)</p> <p>Cat. No.: HY-140706</p>	<p>m-PEG-thiol (MW 20000)</p> <p>Cat. No.: HY-140709</p>
<p>m-PEG-thiol (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-thiol (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 20000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-thiol (MW 5000)</p> <p>Cat. No.: HY-140707</p>	<p>m-PEG-Tos (MW 2000)</p> <p>Cat. No.: HY-140705</p>
<p>m-PEG-thiol (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-Tos (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG-Tresyl (MW 5000)</p> <p>Cat. No.: HY-140710</p>	<p>m-PEG-triethoxysilane (MW 1000)</p> <p>Cat. No.: HY-140702</p>
<p>m-PEG-Tresyl (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-triethoxysilane (MW 1000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 1000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG-triethoxysilane (MW 2000)</p> <p style="text-align: right;">Cat. No.: HY-140703</p>	<p>m-PEG-triethoxysilane (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-140704</p>
<p>m-PEG-triethoxysilane (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG-triethoxysilane (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p style="text-align: center;">MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG1-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-114512</p>	<p>m-PEG10-acid</p> <p style="text-align: right;">Cat. No.: HY-140500</p>
<p>m-PEG1-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>m-PEG10-acid is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG10-alcohol (Decaethylene glycol monomethyl ether)</p> <p style="text-align: right;">Cat. No.: HY-141218</p>	<p>m-PEG10-amine</p> <p style="text-align: right;">Cat. No.: HY-140226</p>
<p>m-PEG10-alcohol (Decaethylene glycol monomethyl ether) is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG10-amine is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG10-azide</p> <p style="text-align: right;">Cat. No.: HY-130424</p>	<p>m-PEG10-Boc</p> <p style="text-align: right;">Cat. No.: HY-141399</p>
<p>m-PEG10-azide a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG10-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG10-Br</p> <p style="text-align: right;">Cat. No.: HY-133278</p>	<p>m-PEG10-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133285</p>
<p>m-PEG10-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG10-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg</p>











<p>m-PEG10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141104</p>	<p>m-PEG10-SH</p> <p style="text-align: right;">Cat. No.: HY-133270</p>
<p>m-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG10-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG10-Tos</p> <p style="text-align: right;">Cat. No.: HY-140360</p>	<p>m-PEG1000-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-138312</p>
<p>m-PEG10-Tos is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG1000-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG11-acid</p> <p style="text-align: right;">Cat. No.: HY-140501</p>	<p>m-PEG11-Amine</p> <p style="text-align: right;">Cat. No.: HY-W040222</p>
<p>m-PEG11-acid is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG11-Amino is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-Amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG11-azide</p> <p style="text-align: right;">Cat. No.: HY-140829</p>	<p>m-PEG11-Br</p> <p style="text-align: right;">Cat. No.: HY-133279</p>
<p>m-PEG11-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG11-C2-NHS Ester</p> <p style="text-align: right;">Cat. No.: HY-135931</p>	<p>m-PEG11-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133347</p>
<p>m-PEG11-C2-NHS Ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG11-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG11-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141105</p>	<p>m-PEG11-OH</p> <p style="text-align: right;">Cat. No.: HY-141219</p>
<p>m-PEG11-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG11-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG11-SH</p> <p style="text-align: right;">Cat. No.: HY-133269</p>	<p>m-PEG11-Tos</p> <p style="text-align: right;">Cat. No.: HY-140361</p>
<p>m-PEG11-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG11-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG12-2-methylacrylate</p> <p style="text-align: right;">Cat. No.: HY-135824</p>	<p>m-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-135820</p>
<p>m-PEG12-2-methylacrylate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG12-amine</p> <p style="text-align: right;">Cat. No.: HY-140227</p>	<p>m-PEG12-azide</p> <p style="text-align: right;">Cat. No.: HY-140830</p>
<p>m-PEG12-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. m-PEG12-amine is also a non-cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG12-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG12-Boc</p> <p style="text-align: right;">Cat. No.: HY-141400</p>	<p>m-PEG12-Br</p> <p style="text-align: right;">Cat. No.: HY-141378</p>
<p>m-PEG12-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG12-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG12-COO-propanoic acid (3-(m-PEG12-ethoxycarbonyl)propanoic acid) Cat. No.: HY-140504</p> <p>m-PEG12-COO-propanoic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG12-DBCO Cat. No.: HY-140317</p> <p>m-PEG12-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.78% Clinical Data: Size: 50 mg, 100 mg</p>
<p>m-PEG12-DSPE Cat. No.: HY-140951</p> <p>m-PEG12-DSPE is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG12-Hydrazide Cat. No.: HY-133348</p> <p>m-PEG12-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG12-Mal Cat. No.: HY-140983</p> <p>m-PEG12-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG12-NH-C2-acid Cat. No.: HY-140508</p> <p>m-PEG12-NH-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG12-NHS ester Cat. No.: HY-141106</p> <p>m-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg, 500 mg</p>	<p>m-PEG12-OH Cat. No.: HY-141220</p> <p>m-PEG12-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. m-PEG12-OH is also a non-cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG12-Thiol Cat. No.: HY-141331</p> <p>m-PEG12-Thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>m-PEG13-azide Cat. No.: HY-138717</p> <p>m-PEG13-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>m-PEG13-Boc</p> <p style="text-align: right;">Cat. No.: HY-141401</p>	<p>m-PEG13-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133349</p>
<p>m-PEG13-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG13-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG13-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141107</p>	<p>m-PEG14-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138718</p>
<p>m-PEG13-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG14-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG15-acetic acid</p> <p style="text-align: right;">Cat. No.: HY-W190959</p>	<p>m-PEG15-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141221</p>
<p>m-PEG15-acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG15-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG15-amine</p> <p style="text-align: right;">Cat. No.: HY-138424</p>	<p>m-PEG15-COOH</p> <p style="text-align: right;">Cat. No.: HY-138314</p>
<p>m-PEG15-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>m-PEG15-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG15-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130829</p>	<p>m-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141222</p>
<p>m-PEG15-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG16-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG16-azide</p> <p style="text-align: right;">Cat. No.: HY-140831</p>	<p>m-PEG16-Br</p> <p style="text-align: right;">Cat. No.: HY-133281</p>
<p>m-PEG16-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG16-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG16-Mal</p> <p style="text-align: right;">Cat. No.: HY-133326</p>	<p>m-PEG16-NH2</p> <p style="text-align: right;">Cat. No.: HY-133288</p>
<p>m-PEG16-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG16-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG16-SH</p> <p style="text-align: right;">Cat. No.: HY-133274</p>	<p>m-PEG17-acid</p> <p style="text-align: right;">Cat. No.: HY-140502</p>
<p>m-PEG16-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG17-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG17-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133350</p>	<p>m-PEG17-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141108</p>
<p>m-PEG17-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG17-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG18-acid</p> <p style="text-align: right;">Cat. No.: HY-143815</p>	<p>m-PEG18-Mal</p> <p style="text-align: right;">Cat. No.: HY-138427</p>
<p>m-PEG18-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG18-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG19-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141223</p>	<p>m-PEG2-4-nitrophenyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-117023</p>
<p>m-PEG19-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-4-nitrophenyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-130231</p>	<p>m-PEG2-amido-Ph-NH2</p> <p style="text-align: right;">Cat. No.: HY-134705</p>
<p>m-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-amido-Ph-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG2-Amine</p> <p style="text-align: right;">Cat. No.: HY-W008429</p>	<p>m-PEG2-Amino</p> <p style="text-align: right;">Cat. No.: HY-140397</p>
<p>m-PEG2-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG2-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: 99.58% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>m-PEG2-Amino is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-130578</p>	<p>m-PEG2-Br</p> <p style="text-align: right;">Cat. No.: HY-133277</p>
<p>m-PEG2-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg</p>
<p>m-PEG2-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W043725</p>	<p>m-PEG2-Ms</p> <p style="text-align: right;">Cat. No.: HY-140362</p>
<p>m-PEG2-CH2CH2COOH is PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG2-O-Ph-3-NH2</p> <p style="text-align: right;">Cat. No.: HY-W096118</p>	<p>m-PEG2-O-Ph-NH2</p> <p style="text-align: right;">Cat. No.: HY-W096113</p>
<p>m-PEG2-O-Ph-3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-O-Ph-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>m-PEG2-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141306</p>	<p>m-PEG2-Tos</p> <p style="text-align: right;">Cat. No.: HY-42745</p>
<p>m-PEG2-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG2-Tos is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG2-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: 96.97% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>m-PEG20-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W096138</p>	<p>m-PEG21-acid</p> <p style="text-align: right;">Cat. No.: HY-133322</p>
<p>m-PEG20-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG21-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG21-OH</p> <p style="text-align: right;">Cat. No.: HY-134743</p>	<p>m-PEG23-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141224</p>
<p>m-PEG21-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG23-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-133323</p>	<p>m-PEG24-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141225</p>
<p>m-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>m-PEG24-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>









<p>m-PEG24-azide</p> <p style="text-align: right;">Cat. No.: HY-140832</p>	<p>m-PEG24-Br</p> <p style="text-align: right;">Cat. No.: HY-133282</p>
<p>m-PEG24-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG24-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG24-DSPE</p> <p style="text-align: right;">Cat. No.: HY-140952</p>	<p>m-PEG24-Mal</p> <p style="text-align: right;">Cat. No.: HY-140984</p>
<p>m-PEG24-DSPE is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG24-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG24-NH2</p> <p style="text-align: right;">Cat. No.: HY-140228</p>	<p>m-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130830</p>
<p>m-PEG24-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>m-PEG24-SH</p> <p style="text-align: right;">Cat. No.: HY-133275</p>	<p>m-PEG25-acid</p> <p style="text-align: right;">Cat. No.: HY-130938</p>
<p>m-PEG24-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG25-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG25-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133351</p>	<p>m-PEG25-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141109</p>
<p>m-PEG25-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG25-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>m-PEG25-Propargyl</p> <p>Cat. No.: HY-130901</p>	<p>m-PEG3-0-benzaldehyde</p> <p>Cat. No.: HY-140621</p>
<p>m-PEG25-Propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-0-benzaldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG3-aldehyde</p> <p>Cat. No.: HY-124011</p>	<p>m-PEG3-amido-C3-triethoxysilane</p> <p>Cat. No.: HY-141407</p>
<p>m-PEG3-aldehyde is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-amido-C3-triethoxysilane is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-Amine</p> <p>Cat. No.: HY-W018174</p>	<p>m-PEG3-Aminoxy</p> <p>Cat. No.: HY-140398</p>
<p>m-PEG3-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG3-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: 97.63% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>m-PEG3-Aminoxy is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-aminoxy-Boc</p> <p>Cat. No.: HY-141201</p>	<p>m-PEG3-azide</p> <p>Cat. No.: HY-140827</p>
<p>m-PEG3-aminoxy-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG3-Boc</p> <p>Cat. No.: HY-130404</p>	<p>m-PEG3-CH2-alcohol</p> <p>Cat. No.: HY-117191</p>
<p>m-PEG3-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-CH2-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG3-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W067509</p>	<p>m-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130445</p>
<p>m-PEG3-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>m-PEG3-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133344</p>	<p>m-PEG3-Mal</p> <p style="text-align: right;">Cat. No.: HY-135940</p>
<p>m-PEG3-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133064</p>	<p>m-PEG3-OH</p> <p style="text-align: right;">Cat. No.: HY-135796</p>
<p>m-PEG3-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-OMs</p> <p style="text-align: right;">Cat. No.: HY-140363</p>	<p>m-PEG3-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-W096153</p>
<p>m-PEG3-OMs is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-Propanoyl chloride</p> <p style="text-align: right;">Cat. No.: HY-140505</p>	<p>m-PEG3-S-Acetyl</p> <p style="text-align: right;">Cat. No.: HY-141351</p>
<p>m-PEG3-Propanoyl chloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-S-Acetyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>m-PEG3-S-PEG1-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140595</p>	<p>m-PEG3-S-PEG2-OH</p> <p style="text-align: right;">Cat. No.: HY-140593</p>
<p>m-PEG3-S-PEG1-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-S-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG3-S-PEG3-Boc</p> <p style="text-align: right;">Cat. No.: HY-140596</p>	<p>m-PEG3-S-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140594</p>
<p>m-PEG3-S-PEG3-Boc is a PEG- and Alkyl/ether -based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-S-PEG4-propargyl is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-SH</p> <p style="text-align: right;">Cat. No.: HY-133273</p>	<p>m-PEG3-succinimidyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-141112</p>
<p>m-PEG3-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-succinimidyl carbonate is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-Sulfone-PEG3</p> <p style="text-align: right;">Cat. No.: HY-140607</p>	<p>m-PEG3-Sulfone-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-140605</p>
<p>m-PEG3-Sulfone-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-Sulfone-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG3-Sulfone-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140606</p>	<p>m-PEG3-Sulfone-PEG3-Boc</p> <p style="text-align: right;">Cat. No.: HY-140609</p>
<p>m-PEG3-Sulfone-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG3-Sulfone-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>


<p>m-PEG3-Sulfone-PEG4-propargyl</p> <p>Cat. No.: HY-140608</p>	<p>m-PEG3-Tos</p> <p>Cat. No.: HY-W043277</p>
<p>m-PEG3-Sulfone-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG3-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG36-alcohol</p> <p>Cat. No.: HY-141226</p>	<p>m-PEG36-amine</p> <p>Cat. No.: HY-140229</p>
<p>m-PEG36-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG36-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG36-azide</p> <p>Cat. No.: HY-140833</p>	<p>m-PEG36-Br</p> <p>Cat. No.: HY-133283</p>
<p>m-PEG36-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG36-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG36-Mal</p> <p>Cat. No.: HY-140985</p>	<p>m-PEG36-OH</p> <p>Cat. No.: HY-133287</p>
<p>m-PEG36-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG36-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG37-acid</p> <p>Cat. No.: HY-133324</p>	<p>m-PEG37-hydrazide</p> <p>Cat. No.: HY-141403</p>
<p>m-PEG37-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG37-hydrazide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG37-NHS ester</p> <p>Cat. No.: HY-141110</p>	<p>m-PEG37-Propargyl</p> <p>Cat. No.: HY-130902</p>
<p>m-PEG37-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG37-Propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-(CH2)6-Phosphonic acid</p> <p>Cat. No.: HY-141309</p>	<p>m-PEG4-aldehyde</p> <p>Cat. No.: HY-140620</p>
<p>m-PEG4-(CH2)6-Phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-aldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-Amine</p> <p>Cat. No.: HY-W040214</p>	<p>m-PEG4-amino-Mal</p> <p>Cat. No.: HY-130181</p>
<p>m-PEG4-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG4-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-amino-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-azide (13-Azido-2,5,8,11-tetraoxatridecane)</p> <p>Cat. No.: HY-140828</p>	<p>m-PEG4-Boc</p> <p>Cat. No.: HY-141395</p>
<p>m-PEG4-azide (13-Azido-2,5,8,11-tetraoxatridecane) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG4-Boc is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-Br</p> <p>Cat. No.: HY-130161</p>	<p>m-PEG4-C6-phosphonic acid ethyl ester</p> <p>Cat. No.: HY-141314</p>
<p>m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-C6-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG4-CH2-acid</p> <p style="text-align: right;">Cat. No.: HY-140507</p>	<p>m-PEG4-CH2-alcohol</p> <p style="text-align: right;">Cat. No.: HY-133057</p>
<p>m-PEG4-CH2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-CH2-alcohol is PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-CH2-aldehyde</p> <p style="text-align: right;">Cat. No.: HY-117041</p>	<p>m-PEG4-CH2-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-141404</p>
<p>m-PEG4-CH2-aldehyde is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-CH2-methyl ester is a PEG- and Alkyl/ester-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130478</p>	<p>m-PEG4-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-141402</p>
<p>m-PEG4-CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>m-PEG4-Hydrazide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-Ms</p> <p style="text-align: right;">Cat. No.: HY-130457</p>	<p>m-PEG4-NH-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140315</p>
<p>m-PEG4-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG4-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-NH-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-124323</p>	<p>m-PEG4-O-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141113</p>
<p>m-PEG4-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-O-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG4-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-138382</p>	<p>m-PEG4-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141307</p>
<p>m-PEG4-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG4-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141311</p>	<p>m-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-113921</p>
<p>m-PEG4-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG4-SH</p> <p style="text-align: right;">Cat. No.: HY-133271</p>	<p>m-PEG4-sulfonic acid</p> <p style="text-align: right;">Cat. No.: HY-140170</p>
<p>m-PEG4-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG4-Tos</p> <p style="text-align: right;">Cat. No.: HY-114661</p>	<p>m-PEG48-amine</p> <p style="text-align: right;">Cat. No.: HY-140230</p>
<p>m-PEG4-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-b). m-PEG4-Tos is a PEG-based PROTAC linker that can be used in the synthesis of Silymarin (HY-W043277).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG48-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG48-Br</p> <p style="text-align: right;">Cat. No.: HY-133284</p>	<p>m-PEG48-Mal</p> <p style="text-align: right;">Cat. No.: HY-140986</p>
<p>m-PEG48-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG48-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>m-PEG48-OH</p> <p style="text-align: right;">Cat. No.: HY-133289</p>	<p>m-PEG49-acid</p> <p style="text-align: right;">Cat. No.: HY-133325</p>
<p>m-PEG48-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG49-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG49-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130903</p>	<p>m-PEG5-2-methylacrylate</p> <p style="text-align: right;">Cat. No.: HY-141406</p>
<p>m-PEG49-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-2-methylacrylate is a PEG- and Alkyl/ester-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-W040195</p>	<p>m-PEG5-amino-Mal</p> <p style="text-align: right;">Cat. No.: HY-138732</p>
<p>m-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-amino-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG5-azide</p> <p style="text-align: right;">Cat. No.: HY-130168</p>	<p>m-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-141396</p>
<p>m-PEG5-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG5-Br</p> <p style="text-align: right;">Cat. No.: HY-141375</p>	<p>m-PEG5-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W043840</p>
<p>m-PEG5-Br is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-CH2CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>m-PEG5-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-120537</p>	<p>m-PEG5-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-135921</p>
<p>m-PEG5-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG5-Ms</p> <p style="text-align: right;">Cat. No.: HY-116186</p>	<p>m-PEG5-NH2</p> <p style="text-align: right;">Cat. No.: HY-140225</p>
<p>m-PEG5-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG5-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133065</p>	<p>m-PEG5-nitrile</p> <p style="text-align: right;">Cat. No.: HY-130657</p>
<p>m-PEG5-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>m-PEG5-nitrile is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG5-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141308</p>	<p>m-PEG5-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141312</p>
<p>m-PEG5-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG5-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG5-Propyne</p> <p style="text-align: right;">Cat. No.: HY-138719</p>	<p>m-PEG5-SH</p> <p style="text-align: right;">Cat. No.: HY-133272</p>
<p>m-PEG5-Propyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG5-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>











<p>m-PEG5-succinimidyl carbonate</p> <p>Cat. No.: HY-130150</p>	<p>m-PEG5-sulfonic acid</p> <p>Cat. No.: HY-140171</p>
<p>m-PEG5-succinimidyl carbonate is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-succinimidyl carbonate is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>m-PEG5-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 
<p>m-PEG5-Tos</p> <p>Cat. No.: HY-W042501</p>	<p>m-PEG5-triethoxysilane</p> <p>Cat. No.: HY-141408</p>
<p>m-PEG5-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-c). m-PEG5-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>m-PEG5-triethoxysilane is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 
<p>m-PEG6-(CH2)6-Phosphonic acid</p> <p>Cat. No.: HY-141310</p>	<p>m-PEG6-2-methylacrylate</p> <p>Cat. No.: HY-130548</p>
<p>m-PEG6-(CH2)6-Phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>m-PEG6-2-methylacrylate is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 
<p>m-PEG6-Amine</p> <p>Cat. No.: HY-130408</p>	<p>m-PEG6-amino-Mal</p> <p>Cat. No.: HY-130141</p>
<p>m-PEG6-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG6-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>m-PEG6-amino-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 
<p>m-PEG6-Boc</p> <p>Cat. No.: HY-138449</p>	<p>m-PEG6-Br</p> <p>Cat. No.: HY-141376</p>
<p>m-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>m-PEG6-Br is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 






<p>m-PEG6-C6-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141315</p> <p>m-PEG6-C6-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG6-CH2CH2CHO</p> <p style="text-align: right;">Cat. No.: HY-W035376</p> <p>m-PEG6-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG6-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040239</p> <p>m-PEG6-CH2CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG6-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-135922</p> <p>m-PEG6-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG6-Ms</p> <p style="text-align: right;">Cat. No.: HY-140364</p> <p>m-PEG6-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133066</p> <p>m-PEG6-NHS ester is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG6-O-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140506</p> <p>m-PEG6-O-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG6-thiol</p> <p style="text-align: right;">Cat. No.: HY-141329</p> <p>m-PEG6-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG6-Tos</p> <p style="text-align: right;">Cat. No.: HY-130336</p> <p>m-PEG6-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG7-4-nitrophenyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-141405</p> <p>m-PEG7-4-nitrophenyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>m-PEG7-alcohol (O-Methyl-heptaethylene glycol) Cat. No.: HY-141217</p> <p>m-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.33% Clinical Data: Size: 100 mg</p>	<p>m-PEG7-Amine Cat. No.: HY-120237</p> <p>m-PEG7-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG7-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG7-azide Cat. No.: HY-130561</p> <p>m-PEG7-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG7-Boc Cat. No.: HY-130513</p> <p>m-PEG7-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG7-Br Cat. No.: HY-133276</p> <p>m-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG7-CH2-OH Cat. No.: HY-133058</p> <p>m-PEG7-CH2-OH a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG7-CH2CH2CHO Cat. No.: HY-130185</p> <p>m-PEG7-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG7-CH2CH2COOH Cat. No.: HY-130151</p> <p>m-PEG7-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG7-Hydrazide Cat. No.: HY-133345</p> <p>m-PEG7-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG7-Ms Cat. No.: HY-130528</p> <p>m-PEG7-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG7-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>m-PEG7-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-122413</p>	<p>m-PEG7-Silane</p> <p style="text-align: right;">Cat. No.: HY-138420</p>
<p>m-PEG7-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG7-Silane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG7-thiol</p> <p style="text-align: right;">Cat. No.: HY-W052006</p>	<p>m-PEG7-Tos</p> <p style="text-align: right;">Cat. No.: HY-140359</p>
<p>m-PEG7-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 500 mg</p>	<p>m-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG750-Br</p> <p style="text-align: right;">Cat. No.: HY-138448</p>	<p>m-PEG8-(CH₂)₁₂-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141316</p>
<p>m-PEG750-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG8-(CH₂)₁₂-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG8-amide-C10-Thiol</p> <p style="text-align: right;">Cat. No.: HY-138532</p>	<p>m-PEG8-Amine</p> <p style="text-align: right;">Cat. No.: HY-W040236</p>
<p>m-PEG8-amide-C10-Thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG8-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>
<p>m-PEG8-azide</p> <p style="text-align: right;">Cat. No.: HY-130204</p>	<p>m-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-141397</p>
<p>m-PEG8-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





















<p>m-PEG8-succinimidyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-141114</p>	<p>m-PEG8-thiol</p> <p style="text-align: right;">Cat. No.: HY-141330</p>
<p>m-PEG8-succinimidyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG8-thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>m-PEG8-Tos</p> <p style="text-align: right;">Cat. No.: HY-135090</p>	<p>m-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-140499</p>
<p>Tos-PEG8-m is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-d). Tos-PEG8-m is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG9-Amine</p> <p style="text-align: right;">Cat. No.: HY-130571</p>	<p>m-PEG9-azide</p> <p style="text-align: right;">Cat. No.: HY-138716</p>
<p>m-PEG9-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG9-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>	<p>m-PEG9-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG9-Boc</p> <p style="text-align: right;">Cat. No.: HY-141398</p>	<p>m-PEG9-Br</p> <p style="text-align: right;">Cat. No.: HY-141377</p>
<p>m-PEG9-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG9-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG9-C4-SH</p> <p style="text-align: right;">Cat. No.: HY-135936</p>	<p>m-PEG9-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-133286</p>
<p>m-PEG9-C4-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>m-PEG9-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>m-PEG9-Hydrazide</p> <p style="text-align: right;">Cat. No.: HY-133346</p> <p>m-PEG9-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG9-Mal</p> <p style="text-align: right;">Cat. No.: HY-138428</p> <p>m-PEG9-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG9-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130446</p> <p>m-PEG9-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG9-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-130554</p> <p>m-PEG9-phosphonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEG9-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141313</p> <p>m-PEG9-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>m-PEG9-SH</p> <p style="text-align: right;">Cat. No.: HY-133280</p> <p>m-PEG9-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>m-PEGn-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-W019795</p> <p>m-PEGn-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amide-PEG2-oxyamine</p> <p style="text-align: right;">Cat. No.: HY-133507</p> <p>Mal-amide-PEG2-oxyamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amide-PEG2-oxyamine-Boc</p> <p style="text-align: right;">Cat. No.: HY-133503</p> <p>Mal-amide-PEG2-oxyamineBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG10-acid</p> <p style="text-align: right;">Cat. No.: HY-140973</p> <p>Mal-amido-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Mal-amido-PEG12-acid</p> <p>Cat. No.: HY-140974</p>	<p>Mal-amido-PEG12-NHS ester</p> <p>Cat. No.: HY-140977</p>
<p>Mal-amido-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG12-TFP ester</p> <p>Cat. No.: HY-140980</p>	<p>Mal-amido-PEG15-acid</p> <p>Cat. No.: HY-143841</p>
<p>Mal-amido-PEG12-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG15-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG16-acid (Maleimide-NH-PEG16-CH₂CH₂COOH)</p> <p>Cat. No.: HY-130858</p>	<p>Mal-amido-PEG2-C2-acid</p> <p>Cat. No.: HY-42151</p>
<p>Mal-amido-PEG16-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.54% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg</p>
<p>Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD</p> <p>Cat. No.: HY-113697</p>	<p>Mal-amido-PEG2-TFP ester</p> <p>Cat. No.: HY-130232</p>
<p>Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.97% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Mal-amido-PEG2-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 95.09% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Mal-amido-PEG24-acid</p> <p>Cat. No.: HY-140975</p>	<p>Mal-amido-PEG24-TFP ester</p> <p>Cat. No.: HY-140981</p>
<p>Mal-amido-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG24-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Mal-amido-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-138727</p> <p>Mal-amido-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-143842</p> <p>Mal-amido-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138729</p> <p>Mal-amido-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130414</p> <p>Mal-amido-PEG4-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 97.01% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Mal-Amido-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140967</p> <p>Mal-Amido-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>Mal-amido-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-W040134</p> <p>Mal-amido-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG4-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-140978</p> <p>Mal-amido-PEG4-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.32% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-amido-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-138728</p> <p>Mal-amido-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-130399</p> <p>Mal-amido-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-W008879</p> <p>Mal-amido-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Mal-amido-PEG7-acid (Mal-NH-PEG7-COOH; Maleimide-NH-PEG7-CH₂CH₂COOH) Cat. No.: HY-130855</p> <p>Mal-amido-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG7-NHS ester Cat. No.: HY-138730</p> <p>Mal-amido-PEG7-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG8-NHS ester Cat. No.: HY-W040133</p> <p>Mal-amido-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.23% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>Mal-amido-PEG8-TFP ester Cat. No.: HY-140979</p> <p>Mal-amido-PEG8-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG9-acid (Maleimide-NH-PEG9-CH₂CH₂COOH) Cat. No.: HY-130856</p> <p>Mal-amido-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG9-amine Cat. No.: HY-140976</p> <p>Mal-amido-PEG9-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amido-PEG9-NH-Boc Cat. No.: HY-140972</p> <p>Mal-amido-PEG9-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG9-NHS ester Cat. No.: HY-138731</p> <p>Mal-amido-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-amino-sulfo Cat. No.: HY-136168</p> <p>Mal-amino-sulfo is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-C2-cyclohexylcarboxyl-hydrazide hydrochloride Cat. No.: HY-133410A</p> <p>Mal-C2-cyclohexylcarboxyl-hydrazide hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.23% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>











<p>Mal-C2-cyclohexylcarboxyl-hydrazide TFA</p> <p>Cat. No.: HY-133410</p>	<p>Mal-C4-NH-Boc</p> <p>Cat. No.: HY-140992</p>
<p>Mal-C2-cyclohexylcarboxyl-hydrazide (TFA) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-C4-NH-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-C6-amine TFA</p> <p>Cat. No.: HY-W018291</p>	<p>Mal-N-bis(PEG4-C2-acid)</p> <p>Cat. No.: HY-140530</p>
<p>Mal-C6-amine (TFA) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-N-bis(PEG4-C2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-NH-Boc</p> <p>Cat. No.: HY-140991</p>	<p>Mal-NH-PEG10-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130865</p>
<p>Mal-NH-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH-PEG10-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-NH-PEG12-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130864</p>	<p>Mal-NH-PEG14-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130866</p>
<p>Mal-NH-PEG12-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH-PEG14-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-NH-PEG16-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130867</p>	<p>Mal-NH-PEG2-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130860</p>
<p>Mal-NH-PEG16-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH-PEG2-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>




<p>Mal-NH-PEG24-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130868</p>	<p>Mal-NH-PEG4-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130861</p>
<p>Mal-NH-PEG24-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH-PEG4-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-NH-PEG6-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130862</p>	<p>Mal-NH-PEG8-Boc</p> <p>Cat. No.: HY-138447</p>
<p>Mal-NH-PEG6-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.37% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Mal-NH-PEG8-CH2CH2COOPFP ester</p> <p>Cat. No.: HY-130863</p>	<p>Mal-NH2 TFA</p> <p>Cat. No.: HY-140988</p>
<p>Mal-NH-PEG8-CH2CH2COOPFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-NH2 (TFA) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-NO2-Ph-PEG12-NHS</p> <p>Cat. No.: HY-141115</p>	<p>Mal-PEG-mal (MW 2000)</p> <p>Cat. No.: HY-140719</p>
<p>Mal-NO2-Ph-PEG12-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG-mal (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG-mal (MW 3400)</p> <p>Cat. No.: HY-140720</p>	<p>Mal-PEG-mal (MW 5000)</p> <p>Cat. No.: HY-140721</p>
<p>Mal-PEG-mal (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG-mal (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Mal-PEG-Succinimidyl Valerate (MW 20000)</p> <p>Cat. No.: HY-140722</p>	<p>Mal-PEG1-acid</p> <p>Cat. No.: HY-126960</p>
<p>Mal-PEG-Succinimidyl Valerate (MW 20000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Mal-PEG1-acid is a non-cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.40%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg</p>
<p>Mal-PEG1-Boc</p> <p>Cat. No.: HY-133162</p>	<p>Mal-PEG1-bromide</p> <p>Cat. No.: HY-140989</p>
<p>Mal-PEG1-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Mal-PEG1-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data:</p> <p>Size: 1 mg, 5 mg</p>
<p>Mal-PEG1-NHS ester</p> <p>Cat. No.: HY-126886</p>	<p>Mal-PEG1-PFP ester</p> <p>Cat. No.: HY-130568</p>
<p>Mal-PEG1-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.41%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg, 250 mg</p>	<p>Mal-PEG1-PFP ester is an Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Mal-PEG10-acid</p> <p>Cat. No.: HY-138723</p>	<p>Mal-PEG10-Boc</p> <p>Cat. No.: HY-138722</p>
<p>Mal-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Mal-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Mal-PEG10-NHS ester</p> <p>Cat. No.: HY-138726</p>	<p>Mal-PEG11-mal</p> <p>Cat. No.: HY-133354</p>
<p>Mal-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.01%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Mal-PEG11-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data:</p> <p>Size: 1 mg, 5 mg</p>











<p>Mal-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-140962</p>	<p>Mal-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140971</p>
<p>Mal-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>	<p>Mal-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-PEG12-Boc</p> <p style="text-align: right;">Cat. No.: HY-140966</p>	<p>Mal-PEG12-CHO</p> <p style="text-align: right;">Cat. No.: HY-134702</p>
<p>Mal-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG12-CHO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG12-DSPE</p> <p style="text-align: right;">Cat. No.: HY-140957</p>	<p>Mal-PEG12-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-138500</p>
<p>Mal-PEG12-DSPE is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG12-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-140963</p>	<p>Mal-PEG16-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-W019794</p>
<p>Mal-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG16-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-130442</p>	<p>Mal-PEG2-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140968</p>
<p>Mal-PEG2-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-acid can be conjugated to Tubulysin (HY-128914) and its derivative cytotoxic molecule. Mal-PEG2-acid is also a PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Mal-PEG2-C2-Boc</p> <p>Cat. No.: HY-140964</p>	<p>Mal-PEG2-NH-Boc</p> <p>Cat. No.: HY-130193</p>
<p>Mal-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG2-NH2</p> <p>Cat. No.: HY-35261</p>	<p>Mal-PEG2-NH2 TFA</p> <p>Cat. No.: HY-35261A</p>
<p>Mal-PEG2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg, 500 mg</p>	<p>Mal-PEG2-NH2 (TFA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.09% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Mal-PEG2-NHS</p> <p>Cat. No.: HY-138430</p>	<p>Mal-PEG2-oxyamine</p> <p>Cat. No.: HY-133454</p>
<p>Mal-PEG2-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG2-oxyamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg</p>
<p>Mal-PEG2-PFP ester</p> <p>Cat. No.: HY-130416</p>	<p>Mal-PEG2-Val-Cit-amido-PAB-OH</p> <p>Cat. No.: HY-130222</p>
<p>Mal-PEG2-PFP ester is a Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-Val-Cit-amido-PAB-OH also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG24-acid</p> <p>Cat. No.: HY-130857</p>	<p>Mal-PEG24-NHS ester</p> <p>Cat. No.: HY-135819</p>
<p>Mal-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Mal-PEG25-NH2 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-138392</p>	<p>Mal-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140969</p>
<p>Mal-PEG25-NH2 hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Mal-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-PEG3-Boc</p> <p style="text-align: right;">Cat. No.: HY-135169</p>	<p>Mal-PEG3-O-Ac</p> <p style="text-align: right;">Cat. No.: HY-134684</p>
<p>Mal-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG3-O-Ac is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG3-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-130586</p>	<p>Mal-PEG36-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133389</p>
<p>Mal-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Mal-PEG36-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-126961</p>	<p>Mal-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-130469</p>
<p>Mal-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.93% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Mal-PEG4-C2-NH2 TFA</p> <p style="text-align: right;">Cat. No.: HY-138380</p>	<p>Mal-PEG4-Glu(OH)-NH-m-PEG24</p> <p style="text-align: right;">Cat. No.: HY-140997</p>
<p>Mal-PEG4-C2-NH2 TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG4-Glu(OH)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Mal-PEG4-Glu(TFP ester)-NH-m-PEG24</p> <p style="text-align: right;">Cat. No.: HY-140998</p> <p>Mal-PEG4-Glu(TFP ester)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG4-Lys(t-Boc)-NH-m-PEG24</p> <p style="text-align: right;">Cat. No.: HY-140999</p> <p>Mal-PEG4-Lys(t-Boc)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG4-Lys(TFA)-NH-m-PEG24</p> <p style="text-align: right;">Cat. No.: HY-141000</p> <p>Mal-PEG4-Lys(TFA)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-135048</p> <p>Mal-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-126962</p> <p>Mal-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.12% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-PEG5-Boc</p> <p style="text-align: right;">Cat. No.: HY-140965</p> <p>Mal-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG5-C2-NH2 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-138375</p> <p>Mal-PEG5-C2-NH2 hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG5-mal</p> <p style="text-align: right;">Cat. No.: HY-133352</p> <p>Mal-PEG5-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126888</p> <p>Mal-PEG5-NHS ester is an Alkyl/ether and PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Mal-PEG5-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-133210</p> <p>Mal-PEG5-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Mal-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-126963</p>	<p>Mal-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-133211</p>
<p>Mal-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.96% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PEG6-mal</p> <p style="text-align: right;">Cat. No.: HY-133353</p>	<p>Mal-PEG6-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-130454</p>
<p>Mal-PEG6-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Mal-PEG6-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 96.89% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Mal-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-130334</p>	<p>Mal-PEG8-alcohol</p> <p style="text-align: right;">Cat. No.: HY-140970</p>
<p>Mal-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Mal-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Mal-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-133212</p>	<p>Mal-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126887</p>
<p>Mal-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 95.08% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Mal-PEG8-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Mal-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-138467</p>	<p>Mal-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140037</p>
<p>Mal-PFP ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Mal-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Maleimide-C10-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-W009037</p>	<p>Maleimido-tri(ethylene glycol)-propionic acid (Mal-PEG3-acid)</p> <p style="text-align: right;">Cat. No.: HY-130426</p>
<p>Maleimide-C10-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: 99.14% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Me-PEG18-NH2</p> <p style="text-align: right;">Cat. No.: HY-138400</p>	<p>Me-PEG4-Me</p> <p style="text-align: right;">Cat. No.: HY-W013522</p>
<p>Me-PEG18-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Me-PEG4-Me is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.57% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Methoxy-Tr-NH-PEG7</p> <p style="text-align: right;">Cat. No.: HY-141229</p>	<p>Methyl 1-Boc-azetidine-3-carboxylate</p> <p style="text-align: right;">Cat. No.: HY-40151</p>
<p>Methoxy-Tr-NH-PEG7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methyl 1-Boc-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Boc-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs¹.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 1 g</p>
<p>Methyl 1-Cbz-azetidine-3-carboxylate</p> <p style="text-align: right;">Cat. No.: HY-W019226</p>	<p>Methyl 3-hydroxypropanoate</p> <p style="text-align: right;">Cat. No.: HY-42569</p>
<p>Methyl 1-Cbz-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Cbz-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs¹.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyl 3-hydroxypropanoate is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 g</p>
<p>Methyl acetate-PEG1</p> <p style="text-align: right;">Cat. No.: HY-W096155</p>	<p>Methyl acetate-PEG1-methyl acetate</p> <p style="text-align: right;">Cat. No.: HY-134716</p>
<p>Methyl acetate-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyl acetate-PEG1-methyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>









<p>Methyl acetate-PEG2-propanol</p> <p>Cat. No.: HY-138462</p>	<p>Methyl azetidine-3-carboxylate hydrochloride</p> <p>Cat. No.: HY-33615</p>
<p>Methyl acetate-PEG2-propanol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>Methyl propionate-PEG12</p> <p>Cat. No.: HY-130186</p>	<p>Methyl-PEG2-alcohol</p> <p>Cat. No.: HY-W012862</p>
<p>Methyl propionate-PEG12 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyl-PEG2-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyl-PEG3-Ald</p> <p>Cat. No.: HY-132092</p>	<p>Methyl-PEG3-bromide</p> <p>Cat. No.: HY-W094307</p>
<p>Methyl-PEG3-Ald is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyl-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyl-PEG4-acyl chloride</p> <p>Cat. No.: HY-132095</p>	<p>Methylacetamide-PEG3-NH2</p> <p>Cat. No.: HY-134712</p>
<p>Methyl-PEG4-acyl chloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methylacetamide-PEG3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methylamino-PEG1-acid</p> <p>Cat. No.: HY-140000</p>	<p>Methylamino-PEG1-Boc (Methylamino-PEG1-t-butyl ester)</p> <p>Cat. No.: HY-140154</p>
<p>Methylamino-PEG1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methylamino-PEG1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Methylamino-PEG2-acid</p> <p>Cat. No.: HY-140153</p>	<p>Methylamino-PEG2-Boc (Methylamino-PEG2-t-butyl ester)</p> <p>Cat. No.: HY-140155</p>
<p>Methylamino-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methylamino-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methylamino-PEG3-acid</p> <p>Cat. No.: HY-132075</p>	<p>Methylamino-PEG3-azide</p> <p>Cat. No.: HY-140158</p>
<p>Methylamino-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methylamino-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methylamino-PEG3-t-butyl ester</p> <p>Cat. No.: HY-132071</p>	<p>Methylamino-PEG4-acid</p> <p>Cat. No.: HY-135153</p>
<p>Methylamino-PEG3-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methylamino-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methylamino-PEG4-Boc (Methylamino-PEG4-t-butyl ester)</p> <p>Cat. No.: HY-140156</p>	<p>Methylamino-PEG5-azide</p> <p>Cat. No.: HY-140159</p>
<p>Methylamino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methylamino-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methylamino-PEG7-benzyl</p> <p>Cat. No.: HY-132019</p>	<p>Methyltetrazine-acid</p> <p>Cat. No.: HY-141263</p>
<p>Methylamino-PEG7-benzyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.46% Clinical Data: Size: 25 mg, 100 mg</p>

<p>Methyltetrazine-amido-PEG5-alkyne</p> <p>Cat. No.: HY-141276</p>	<p>Methyltetrazine-amido-PEG7-azide</p> <p>Cat. No.: HY-141277</p>
<p>Methyltetrazine-amido-PEG5-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-amido-PEG7-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG12-DBCO</p> <p>Cat. No.: HY-140312</p>	<p>Methyltetrazine-PEG13-acid</p> <p>Cat. No.: HY-141266</p>
<p>Methyltetrazine-PEG12-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>Methyltetrazine-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG13-Boc</p> <p>Cat. No.: HY-141281</p>	<p>Methyltetrazine-PEG13-NHS ester</p> <p>Cat. No.: HY-141271</p>
<p>Methyltetrazine-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG13-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG24-amine</p> <p>Cat. No.: HY-141262</p>	<p>Methyltetrazine-PEG24-Boc</p> <p>Cat. No.: HY-141282</p>
<p>Methyltetrazine-PEG24-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG24-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG24-NH-Boc</p> <p>Cat. No.: HY-141280</p>	<p>Methyltetrazine-PEG24-NHS ester</p> <p>Cat. No.: HY-141272</p>
<p>Methyltetrazine-PEG24-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>









<p>Methyltetrazine-PEG25-acid</p> <p style="text-align: right;">Cat. No.: HY-141267</p> <p>Methyltetrazine-PEG25-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141264</p> <p>Methyltetrazine-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-141261</p> <p>Methyltetrazine-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG4-amine hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-133505</p> <p>Methyltetrazine-PEG4-amine (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG4-maleimide</p> <p style="text-align: right;">Cat. No.: HY-141278</p> <p>Methyltetrazine-PEG4-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 10 mg, 25 mg, 100 mg</p>	<p>Methyltetrazine-PEG4-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-141279</p> <p>Methyltetrazine-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG4-SSPy</p> <p style="text-align: right;">Cat. No.: HY-133508</p> <p>Methyltetrazine-PEG4-SSPy is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG5-alkyne</p> <p style="text-align: right;">Cat. No.: HY-141275</p> <p>Methyltetrazine-PEG5-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG5-methyltetrazine</p> <p style="text-align: right;">Cat. No.: HY-133467</p> <p>Methyltetrazine-PEG5-methyltetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141269</p> <p>Methyltetrazine-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>


<p>Methyltetrazine-PEG5-triethoxysilane</p> <p>Cat. No.: HY-141283</p>	<p>Methyltetrazine-PEG6-maleimide</p> <p>Cat. No.: HY-133468</p>
<p>Methyltetrazine-PEG5-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG6-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG8-acid</p> <p>Cat. No.: HY-141265</p>	<p>Methyltetrazine-PEG8-N3</p> <p>Cat. No.: HY-133469</p>
<p>Methyltetrazine-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG8-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-PEG8-NHS ester</p> <p>Cat. No.: HY-141270</p>	<p>Methyltetrazine-PEG8-PFP ester</p> <p>Cat. No.: HY-141273</p>
<p>Methyltetrazine-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-PEG8-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-Ph-NHS ester</p> <p>Cat. No.: HY-130283</p>	<p>Methyltetrazine-Ph-PEG4-azide</p> <p>Cat. No.: HY-130508</p>
<p>Methyltetrazine-Ph-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-Ph-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Methyltetrazine-propylamine</p> <p>Cat. No.: HY-141260</p>	<p>Methyltetrazine-Sulfo-NHS ester sodium</p> <p>Cat. No.: HY-141268</p>
<p>Methyltetrazine-propylamine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Methyltetrazine-Sulfo-NHS ester (sodium) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>ML 2-14</p> <p style="text-align: right;">Cat. No.: HY-132991</p>	<p>Monoethyl pimelate</p> <p style="text-align: right;">Cat. No.: HY-W016087</p>
<p>ML 2-14 is a PROTAC linker, which belongs to a polyethylene glycol (PEG) linker. ML 2-14 can be used in the synthesis of the PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Monoethyl pimelate is a PROTAC linker, which refers to the alkyl/ether composition. Monoethyl pimelate can be used in the synthesis of (S,R,S)-AHPc-Me-C7 ester, a specific BCL-X₁ PROTAC degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MS-PEG1-THP</p> <p style="text-align: right;">Cat. No.: HY-138482</p>	<p>Ms-PEG10-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-140386</p>
<p>MS-PEG1-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG10-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MS-PEG10-THP</p> <p style="text-align: right;">Cat. No.: HY-138344</p>	<p>Ms-PEG12-Boc</p> <p style="text-align: right;">Cat. No.: HY-140387</p>
<p>MS-PEG10-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ms-PEG12-m</p> <p style="text-align: right;">Cat. No.: HY-115392</p>	<p>MS-PEG12-THP</p> <p style="text-align: right;">Cat. No.: HY-138371</p>
<p>Ms-PEG12-m is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>MS-PEG12-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ms-PEG2-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140383</p>	<p>Ms-PEG2-Ms</p> <p style="text-align: right;">Cat. No.: HY-140382</p>
<p>Ms-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Ms-PEG3-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-134680</p>	<p>MS-PEG3-dodecyl</p> <p style="text-align: right;">Cat. No.: HY-132063</p>
<p>Ms-PEG3-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>MS-PEG3-dodecyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ms-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-134683</p>	<p>MS-PEG3-THP</p> <p style="text-align: right;">Cat. No.: HY-132107</p>
<p>Ms-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>MS-PEG3-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ms-PEG4-Ms (1,11-Bis(methanesulfonyloxy)-3,6,9-trioxadecane)</p> <p style="text-align: right;">Cat. No.: HY-42774</p>	<p>MS-PEG4-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132109</p>
<p>Ms-PEG4-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>MS-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MS-PEG4-THP</p> <p style="text-align: right;">Cat. No.: HY-W096074</p>	<p>Ms-PEG5-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-140384</p>
<p>MS-PEG4-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG5-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MS-PEG5-THP</p> <p style="text-align: right;">Cat. No.: HY-138385</p>	<p>Ms-PEG6-Ms</p> <p style="text-align: right;">Cat. No.: HY-138324</p>
<p>MS-PEG5-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG6-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Ms-PEG6-THP</p> <p style="text-align: right;">Cat. No.: HY-138315</p>	<p>Ms-PEG7-Ms</p> <p style="text-align: right;">Cat. No.: HY-130152</p>
<p>Ms-PEG6-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ms-PEG7-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ms-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-140385</p>	<p>MS-PEG8-THP</p> <p style="text-align: right;">Cat. No.: HY-138337</p>
<p>Ms-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>MS-PEG8-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N'-Boc-N-(Gly-Oleoyl)-Lys</p> <p style="text-align: right;">Cat. No.: HY-141291</p>	<p>N,N'-bis-(Acid-PEG3)-benzothiazole Cy5</p> <p style="text-align: right;">Cat. No.: HY-141043</p>
<p>N'-Boc-N-(Gly-Oleoyl)-Lys is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N,N'-bis-(Acid-PEG3)-benzothiazole Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N,N'-bis-(azide-PEG3)-chlorocyclohexenyl Cy7</p> <p style="text-align: right;">Cat. No.: HY-141079</p>	<p>N,N'-bis-(azide-PEG3)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141060</p>
<p>N,N'-bis-(azide-PEG3)-chlorocyclohexenyl Cy7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NN'-bis-(azide-PEG3)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N,N'-bis-(propargyl-PEG4)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141054</p>	<p>N,N'-DME-N,N'-Bis-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-141028</p>
<p>N,N'-bis-(propargyl-PEG4)-Cy5 (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N,N'-DME-N,N'-Bis-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N,N'-DME-N-PEG2-Boc</p> <p>Cat. No.: HY-140163</p>	<p>N,N-Diethanol amine-PEG4-Boc</p> <p>Cat. No.: HY-141252</p>
<p>N,N'-DME-N-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N,N-Diethanol amine-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(4-Carboxycyclohexylmethyl)maleimide</p> <p>Cat. No.: HY-42359</p>	<p>N-(Ac-PEG3)-N'-(azide-PEG3)-Cy7 chloride</p> <p>Cat. No.: HY-141077</p>
<p>N-(4-Carboxycyclohexylmethyl)maleimide is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Ac-PEG3)-N'-(azide-PEG3)-Cy7 (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Acid-PEG2)-N-bis(PEG3-azide)</p> <p>Cat. No.: HY-140521</p>	<p>N-(acid-PEG3)-N-bis(PEG3-azide)</p> <p>Cat. No.: HY-140520</p>
<p>N-(Acid-PEG2)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(acid-PEG3)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Amino-PEG1)-N-bis(PEG2-propargyl)</p> <p>Cat. No.: HY-140086</p>	<p>N-(Amino-PEG2)-N-bis(PEG3-azide)</p> <p>Cat. No.: HY-140087</p>
<p>N-(Amino-PEG1)-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Amino-PEG2)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>N-(Amino-PEG3)-N-bis(PEG3-acid)</p> <p>Cat. No.: HY-140245</p>	<p>N-(Amino-PEG3)-N-bis(PEG3-Boc)</p> <p>Cat. No.: HY-140253</p>
<p>N-(Amino-PEG3)-N-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Amino-PEG3)-N-bis(PEG3-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N-(Amino-PEG3)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140254</p>	<p>N-(Amino-PEG4)-N-Biotin-PEG4-acid</p> <p>Cat. No.: HY-140532</p>
<p>N-(Amino-PEG3)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Amino-PEG4)-N-Biotin-PEG4-acid is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Amino-PEG4)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140255</p>	<p>N-(Amino-PEG5)-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-130695</p>
<p>N-(Amino-PEG4)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Amino-PEG5)-N-bis(PEG4-acid) is a PEG-based PROTAC linker used in the synthesis of PROTACs. N-(Amino-PEG5)-N-bis(PEG4-acid) contains an amino group with two terminal carboxylic acids.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Aminoxy-PEG2)-N-bis(PEG3-propargyl)</p> <p>Cat. No.: HY-140091</p>	<p>N-(Aminoxy-PEG3)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140446</p>
<p>N-(Aminoxy-PEG2)-N-bis(PEG3-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Aminoxy-PEG3)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(azide-PEG3)-N'-(Amine-C3-Amide-PEG4)-Cy5</p> <p>Cat. No.: HY-141065</p>	<p>N-(azide-PEG3)-N'-(m-PEG4)-Benzothiazole Cy5</p> <p>Cat. No.: HY-141064</p>
<p>N-(azide-PEG3)-N'-(Amine-C3-Amide-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(azide-PEG3)-N'-(m-PEG4)-Benzothiazole Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(azide-PEG3)-N'-(Mal-PEG4)-Cy5</p> <p>Cat. No.: HY-141066</p>	<p>N-(Azide-PEG3)-N'-(PEG4-acid)-Cy5</p> <p>Cat. No.: HY-141041</p>
<p>N-(azide-PEG3)-N'-(Mal-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azide-PEG3)-N'-(PEG4-acid)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-(Azide-PEG3)-N'-(PEG4-NHS ester)-Cy5</p> <p>Cat. No.: HY-141048</p>	<p>N-(Azido-PEG2)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140867</p>
<p>N-(Azide-PEG3)-N'-(PEG4-NHS ester)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG2)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG2)-N-Boc-PEG3-acid</p> <p>Cat. No.: HY-140524</p>	<p>N-(Azido-PEG2)-N-Boc-PEG3-Boc</p> <p>Cat. No.: HY-140562</p>
<p>N-(Azido-PEG2)-N-Boc-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG2)-N-Boc-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG2)-N-Boc-PEG3-NHS ester</p> <p>Cat. No.: HY-140559</p>	<p>N-(Azido-PEG2)-N-Boc-PEG4-acid</p> <p>Cat. No.: HY-140525</p>
<p>N-(Azido-PEG2)-N-Boc-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG2)-N-Boc-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG2)-N-Boc-PEG4-Boc</p> <p>Cat. No.: HY-140563</p>	<p>N-(Azido-PEG2)-N-Boc-PEG4-NHS ester</p> <p>Cat. No.: HY-140560</p>
<p>N-(Azido-PEG2)-N-Boc-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG2)-N-Boc-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG2)-N-Fluorescein-PEG3-acid</p> <p>Cat. No.: HY-140544</p>	<p>N-(Azido-PEG3)-N-(PEG2-amine)-PEG3-acid</p> <p>Cat. No.: HY-140247</p>
<p>N-(Azido-PEG2)-N-Fluorescein-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-(PEG2-amine)-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.58% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-(Azido-PEG3)-N-(PEG2-NH-Boc)-PEG3-acid</p> <p>Cat. No.: HY-141287</p> <p>N-(Azido-PEG3)-N-(PEG2-NH-Boc)-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-Biotin-PEG4-methyl ester</p> <p>Cat. No.: HY-140581</p> <p>N-(Azido-PEG3)-N-Biotin-PEG4-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-N-bis(PEG1-t-butyl ester)</p> <p>Cat. No.: HY-140873</p> <p>N-(Azido-PEG3)-N-bis(PEG1-t-butyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-bis(PEG3-acid)</p> <p>Cat. No.: HY-140517</p> <p>N-(Azido-PEG3)-N-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-N-bis(PEG3-Boc)</p> <p>Cat. No.: HY-140868</p> <p>N-(Azido-PEG3)-N-bis(PEG3-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-140518</p> <p>N-(Azido-PEG3)-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140869</p> <p>N-(Azido-PEG3)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-Boc-PEG3-acid</p> <p>Cat. No.: HY-140526</p> <p>N-(Azido-PEG3)-N-Boc-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-N-Boc-PEG3-NHS ester</p> <p>Cat. No.: HY-140561</p> <p>N-(Azido-PEG3)-N-Boc-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-Boc-PEG3-t-butyl ester</p> <p>Cat. No.: HY-140564</p> <p>N-(Azido-PEG3)-N-Boc-PEG3-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N-(Azido-PEG3)-N-Boc-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130598</p>	<p>N-(Azido-PEG3)-N-Boc-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140565</p>
<p>N-(Azido-PEG3)-N-Boc-PEG4-acid is a PEG-based PROTAC linker with a terminal azide group and is used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG3)-N-Boc-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-N-Fluorescein-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-130768</p>	<p>N-(Azido-PEG3)-N-Fluorescein-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140546</p>
<p>N-(Azido-PEG3)-N-Fluorescein-PEG3-acid is a PEG-based PROTAC linker which contains azide, fluorescein and carboxylic acid moieties.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg</p>	<p>N-(Azido-PEG3)-N-Fluorescein-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG3)-NH-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-140552</p>	<p>N-(Azido-PEG4)-biotin</p> <p style="text-align: right;">Cat. No.: HY-140919</p>
<p>N-(Azido-PEG3)-NH-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG4)-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG4)-N-bis(PEG4-acid)</p> <p style="text-align: right;">Cat. No.: HY-140519</p>	<p>N-(Azido-PEG4)-N-bis(PEG4-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140866</p>
<p>N-(Azido-PEG4)-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG4)-N-bis(PEG4-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Azido-PEG4)-N-bis(PEG4-t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-140870</p>	<p>N-(Azido-PEG4)-N-Boc-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140567</p>
<p>N-(Azido-PEG4)-N-bis(PEG4-t-butyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Azido-PEG4)-N-Boc-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-(Azido-PEG4)-N-Boc-PEG4-NHS ester</p> <p>Cat. No.: HY-130312</p>	<p>N-(Biotin)-N-bis(PEG1-alcohol)</p> <p>Cat. No.: HY-140949</p>
<p>N-(Azido-PEG4)-N-Boc-PEG4-NHS ester is a PEG-based PROTAC linker with a terminal azide group. N-(Azido-PEG4)-N-Boc-PEG4-NHS ester is used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Biotin)-N-bis(PEG1-alcohol) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Biotin-PEG4)-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-140531</p>	<p>N-(Biotin-PEG4)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-141288</p>
<p>N-(Biotin-PEG4)-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Biotin-PEG4)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Boc-PEG1)-N-bis(PEG2-propargyl)</p> <p>Cat. No.: HY-140090</p>	<p>N-(Boc-PEG2)-N-bis(PEG3-azide)</p> <p>Cat. No.: HY-140872</p>
<p>N-(Boc-PEG1)-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Boc-PEG2)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Boc-PEG3)-N-bis(PEG2-alcohol)</p> <p>Cat. No.: HY-141254</p>	<p>N-(Boc-PEG3)-N-bis(PEG3-acid)</p> <p>Cat. No.: HY-140536</p>
<p>N-(Boc-PEG3)-N-bis(PEG2-alcohol) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Boc-PEG3)-N-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>
<p>N-(Boc-PEG3)-N-bis(PEG3-azide)</p> <p>Cat. No.: HY-140871</p>	<p>N-(Boc-PEG4)-NH-PEG4-NH-Boc</p> <p>Cat. No.: HY-140259</p>
<p>N-(Boc-PEG3)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(Boc-PEG4)-NH-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N-(Boc-PEG5)-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-140537</p>	<p>N-(DBCO-PEG4)-N-Biotin-PEG4-NHS</p> <p>Cat. No.: HY-140582</p>
<p>N-(Boc-PEG5)-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(DBCO-PEG4)-N-Biotin-PEG4-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(Hydroxy-PEG3)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-141251</p>	<p>N-(Hydroxy-PEG3)-N-Boc-PEG4-Boc (N-(Hydroxy-PEG3)-N-Boc-PEG4-t-butyl ester)</p> <p>Cat. No.: HY-140568</p>
<p>N-(Hydroxy-PEG3)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Hydroxy-PEG3)-N-Boc-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-3,3-Dimethyl-3H-indole-N'-(acid-PEG3)-benzothiazole</p> <p>Cat. No.: HY-141039</p>	<p>N-(m-PEG4)-N'-(4-Hydroxycyclohexyl-1-amido-PEG4)-Cy5</p> <p>Cat. No.: HY-141075</p>
<p>N-(m-PEG4)-3,3-Dimethyl-3H-indole-N'-(acid-PEG3)-benzothiazole is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(4-Hydroxycyclohexyl-1-amido-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(Acid-PEG3)-benzothiazole Cy5</p> <p>Cat. No.: HY-141038</p>	<p>N-(m-PEG4)-N'-(amino-PEG3)-Cy5</p> <p>Cat. No.: HY-141056</p>
<p>N-(m-PEG4)-N'-(Acid-PEG3)-benzothiazole Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(amino-PEG3)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(azide-PEG3)-Cy5</p> <p>Cat. No.: HY-141063</p>	<p>N-(m-PEG4)-N'-(azide-PEG4)-Cy3</p> <p>Cat. No.: HY-141030</p>
<p>N-(m-PEG4)-N'-(azide-PEG3)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg</p>	<p>N-(m-PEG4)-N'-(azide-PEG4)-Cy3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-(m-PEG4)-N'-(azide-PEG4)-Cy7</p> <p>Cat. No.: HY-141078</p>	<p>N-(m-PEG4)-N'-(Biotin-PEG2-amido-PEG4)-Cy5</p> <p>Cat. No.: HY-141069</p>
<p>N-(m-PEG4)-N'-(azide-PEG4)-Cy7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(Biotin-PEG2-amido-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(biotin-PEG3)-Cy5</p> <p>Cat. No.: HY-141070</p>	<p>N-(m-PEG4)-N'-(DBCO-PEG4)-Cy5</p> <p>Cat. No.: HY-141071</p>
<p>N-(m-PEG4)-N'-(biotin-PEG3)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(DBCO-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(hydroxy-PEG2)-Cy5</p> <p>Cat. No.: HY-141073</p>	<p>N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(azide-PEG4)-Cy5</p> <p>Cat. No.: HY-141068</p>
<p>N-(m-PEG4)-N'-(hydroxy-PEG2)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(azide-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5</p> <p>Cat. No.: HY-141053</p>	<p>N-(m-PEG4)-N'-(PEG2-acid)-Cy5</p> <p>Cat. No.: HY-141035</p>
<p>N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(PEG2-acid)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-(PEG2-NHS ester)-Cy5</p> <p>Cat. No.: HY-141045</p>	<p>N-(m-PEG4)-N'-(PEG3-Mal)-Cy5</p> <p>Cat. No.: HY-141076</p>
<p>N-(m-PEG4)-N'-(PEG2-NHS ester)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N-(m-PEG4)-N'-(PEG4-acid)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141036</p>	<p>N-(m-PEG4)-N'-(PEG4-NHS ester)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141046</p>
<p>N-(m-PEG4)-N'-(PEG4-acid)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(m-PEG4)-N'-(PEG4-NHS ester)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(m-PEG4)-N'-hydroxypropyl-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141074</p>	<p>N-(m-PEG9)-N'-(PEG5-acid)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141037</p>
<p>N-(m-PEG4)-N'-hydroxypropyl-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(m-PEG9)-N'-(PEG5-acid)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(m-PEG9)-N'-(propargyl-PEG8)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141051</p>	<p>N-(Mal-PEG6)-N-bis(PEG3-amine)</p> <p style="text-align: right;">Cat. No.: HY-140248</p>
<p>N-(m-PEG9)-N'-(propargyl-PEG8)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Mal-PEG6)-N-bis(PEG3-amine) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Mal-PEG6)-N-bis(PEG7-TCO)</p> <p style="text-align: right;">Cat. No.: HY-141009</p>	<p>N-(NHS-PEG3)-N-bis(PEG3-azide)</p> <p style="text-align: right;">Cat. No.: HY-140864</p>
<p>N-(Mal-PEG6)-N-bis(PEG7-TCO) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(NHS-PEG3)-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(PEG1-OH)-N-Boc-PEG2-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140569</p>	<p>N-(PEG2-Boc)-N-bis(PEG2-propargyl)</p> <p style="text-align: right;">Cat. No.: HY-140093</p>
<p>N-(PEG1-OH)-N-Boc-PEG2-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(PEG2-Boc)-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>N-(PEG2-C2-acid)-N-bis(PEG2-propargyl)</p> <p>Cat. No.: HY-140085</p>	<p>N-(PEG3-acid)-N-bis(PEG3-amine)</p> <p>Cat. No.: HY-140246</p>
<p>N-(PEG2-C2-acid)-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(PEG3-acid)-N-bis(PEG3-amine) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Propanoic acid)-N-bis(m-PEG12)</p> <p>Cat. No.: HY-141289</p>	<p>N-(Propargyl-PEG2)-N-Boc-PEG3-t-butyl ester</p> <p>Cat. No.: HY-140094</p>
<p>N-(Propanoic acid)-N-bis(m-PEG12) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Propargyl-PEG2)-N-Boc-PEG3-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Propargyl-PEG4)-biocytin</p> <p>Cat. No.: HY-140926</p>	<p>N-(Propargyl-PEG4)-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-140084</p>
<p>N-(Propargyl-PEG4)-biocytin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(Propargyl-PEG4)-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester)</p> <p>Cat. No.: HY-140095</p>	<p>N-(t-Boc-Aminoxy-PEG2)-N-bis(PEG3-propargyl)</p> <p>Cat. No.: HY-140092</p>
<p>N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-(t-Boc-Aminoxy-PEG2)-N-bis(PEG3-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-(Tos-PEG4)-N-bis(PEG4-Boc)</p> <p>Cat. No.: HY-140393</p>	<p>N-Acetylpyrrolidine-PEG2-Br</p> <p>Cat. No.: HY-134730</p>
<p>N-(Tos-PEG4)-N-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Acetylpyrrolidine-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-Azido-PEG4-N-Boc-N-PEG3-Boc</p> <p>Cat. No.: HY-140566</p>	<p>N-Benzyl-N-bis(PEG3-acid)</p> <p>Cat. No.: HY-140542</p>
<p>N-Azido-PEG4-N-Boc-N-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Benzyl-N-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Benzyl-N-bis-PEG2</p> <p>Cat. No.: HY-140586</p>	<p>N-Benzyl-N-bis-PEG4</p> <p>Cat. No.: HY-140587</p>
<p>N-Benzyl-N-bis-PEG2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Benzyl-N-bis-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Biotin-N-bis(PEG4-acid)</p> <p>Cat. No.: HY-140528</p>	<p>N-bis(t-boc-N-amido-PEG3)-N-(PEG3-acid) (hydrochloride)</p> <p>Cat. No.: HY-143849</p>
<p>N-Biotin-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-bis(t-boc-N-amido-PEG3)-N-(PEG3-acid) hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Boc-4-pentyne-1-amine</p> <p>Cat. No.: HY-43721</p>	<p>N-Boc-C1-PEG3-C3-NH2</p> <p>Cat. No.: HY-W004640</p>
<p>N-Boc-4-pentyne-1-amine is a PROTAC linker, which refers to the alkyl chain composition. N-Boc-4-pentyne-1-amine can be used in the synthesis of the PROTAC MG-277 (HY-130122).</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>N-Boc-C1-PEG3-C3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>N-Boc-C1-PEG5-C3-NH2</p> <p>Cat. No.: HY-134679</p>	<p>N-Boc-cis-4-Hydroxy-D-proline</p> <p>Cat. No.: HY-W002887</p>
<p>N-Boc-C1-PEG5-C3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-cis-4-Hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-Hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the synth.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 g</p>

N-Boc-cis-4-hydroxy-D-proline methyl ester

Cat. No.: HY-W002680

N-Boc-cis-4-hydroxy-D-proline methyl ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-D-proline methyl ester is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs¹.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

N-Boc-cis-4-hydroxy-L-proline

Cat. No.: HY-W002886

N-Boc-cis-4-hydroxy-L-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-L-proline is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs¹.




Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg

N-Boc-cis-4-hydroxy-L-proline methyl ester

Cat. No.: HY-Y0755

N-Boc-cis-4-hydroxy-L-proline methyl ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-L-proline methyl ester is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs².




Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

N-Boc-diethanolamine

Cat. No.: HY-W044078

N-Boc-diethanolamine is an Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-diethanolamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).




Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

N-Boc-N-bis(C2-PEG1-azide)

Cat. No.: HY-140554

N-Boc-N-bis(C2-PEG1-azide) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N-Boc-N-bis(PEG2-acid)

Cat. No.: HY-140538

N-Boc-N-bis(PEG2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N-Boc-N-bis(PEG2-OH)

Cat. No.: HY-117079

N-Boc-N-bis(PEG2-OH) is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG2-OH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-N-bis(PEG2-propargyl)

Cat. No.: HY-140089

N-Boc-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N-Boc-N-bis(PEG3-acid)

Cat. No.: HY-140539

N-Boc-N-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg











N-Boc-N-bis(PEG3-azide)











Cat. No.: HY-140555











N-Boc-N-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.






Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>N-Boc-N-bis(PEG3-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140557</p>	<p>N-Boc-N-bis(PEG4-acid)</p> <p style="text-align: right;">Cat. No.: HY-140540</p>
<p>N-Boc-N-bis(PEG3-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Boc-N-bis(PEG4-azide)</p> <p style="text-align: right;">Cat. No.: HY-140556</p>	<p>N-Boc-N-bis(PEG4-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140558</p>
<p>N-Boc-N-bis(PEG4-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Boc-N-bis(PEG4-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Boc-N-bis(PEG4-OH)</p> <p style="text-align: right;">Cat. No.: HY-130449</p>	<p>N-Boc-N-bis-PEG5</p> <p style="text-align: right;">Cat. No.: HY-140553</p>
<p>N-Boc-N-bis(PEG4-OH) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG4-OH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-N-bis-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132088</p>	<p>N-Boc-PEG10-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W190857</p>
<p>N-Boc-PEG-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG10-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141193</p>	<p>N-Boc-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141194</p>
<p>N-Boc-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>N-Boc-PEG2-bromide</p> <p style="text-align: right;">Cat. No.: HY-130503</p>	<p>N-Boc-PEG23-bromide</p> <p style="text-align: right;">Cat. No.: HY-141197</p>
<p>N-Boc-PEG2-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG2-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>N-Boc-PEG23-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG24-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141195</p>	<p>N-Boc-PEG3-bromide</p> <p style="text-align: right;">Cat. No.: HY-W006445</p>
<p>N-Boc-PEG24-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG3-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG3-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG3-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132089</p>	<p>N-Boc-PEG36-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141196</p>
<p>N-Boc-PEG3-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG36-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG4-bromide</p> <p style="text-align: right;">Cat. No.: HY-W046471</p>	<p>N-Boc-PEG5-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141191</p>
<p>N-Boc-PEG4-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG4-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 250 mg</p>	<p>N-Boc-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: Size: 100 mg</p>
<p>N-Boc-PEG5-bromide</p> <p style="text-align: right;">Cat. No.: HY-120702</p>	<p>N-Boc-PEG6-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W071584</p>
<p>N-Boc-PEG5-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG5-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG6-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG6-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>








<p>N-Boc-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-130505</p>	<p>N-Boc-PEG8-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141192</p>
<p>N-Boc-PEG7-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG7-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Boc-PEG9-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W071583</p>	<p>N-Boc-piperazine</p> <p style="text-align: right;">Cat. No.: HY-30105</p>
<p>N-Boc-PEG9-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG9-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-piperazine is a Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p>  <p>Purity: 99.96% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg</p>
<p>N-Boc-piperazine-C3-COOH</p> <p style="text-align: right;">Cat. No.: HY-131184</p>	<p>N-Boc-serinol</p> <p style="text-align: right;">Cat. No.: HY-W018464</p>
<p>N-Boc-piperazine-C3-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-N-piperazine-C3-COOH can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Boc-serinol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 500 mg</p>
<p>N-Bromoacetyl-β-alanine</p> <p style="text-align: right;">Cat. No.: HY-141379</p>	<p>N-DBCO-N-bis(PEG2-C2-acid)</p> <p style="text-align: right;">Cat. No.: HY-140543</p>
<p>N-Bromoacetyl-β-alanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. N-Bromoacetyl-β-alanine is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>N-DBCO-N-bis(PEG2-C2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-DBCO-N-bis(PEG2-C2-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140585</p>	<p>N-Desthiobiotin-N-bis(PEG4-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140583</p>
<p>N-DBCO-N-bis(PEG2-C2-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Desthiobiotin-N-bis(PEG4-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>






<p>N-Desthiobiotin-N-bis(PEG4-t-butyl ester)</p> <p>Cat. No.: HY-140584</p>	<p>N-Ethyl-3,3,3-trifluoro-N-methylpropanamide-PEG2-Br</p> <p>Cat. No.: HY-134739</p>
<p>N-Desthiobiotin-N-bis(PEG4-t-butyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Ethyl-333-trifluoro-N-methylpropanamide-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Ethyl-N-methylpropionamide-PEG1-Br</p> <p>Cat. No.: HY-134733</p>	<p>N-Ethylacetamide-PEG1-Br</p> <p>Cat. No.: HY-134735</p>
<p>N-Ethyl-N-methylpropionamide-PEG1-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Ethylacetamide-PEG1-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Ethylacetamide-PEG2-Br</p> <p>Cat. No.: HY-134731</p>	<p>N-Ethylpropionamide-PEG1-Br</p> <p>Cat. No.: HY-134732</p>
<p>N-Ethylacetamide-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Ethylpropionamide-PEG1-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Fmoc-N'-(azido-PEG4)-L-Lysine</p> <p>Cat. No.: HY-140846</p>	<p>N-Fmoc-N'-(azido-PEG4)-L-Lysine-PFP ester</p> <p>Cat. No.: HY-140847</p>
<p>N-Fmoc-N'-(azido-PEG4)-L-Lysine is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Fmoc-N'-(azido-PEG4)-L-Lysine-PFP ester is an alkyl/ether and PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Hydroxypropyl-N'-(azide-PEG3)-Cy3</p> <p>Cat. No.: HY-141029</p>	<p>N-Mal-N-bis(PEG2-acid)</p> <p>Cat. No.: HY-140529</p>
<p>N-Hydroxypropyl-N'-(azide-PEG3)-Cy3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Mal-N-bis(PEG2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>N-Mal-N-bis(PEG2-amine)</p> <p style="text-align: right;">Cat. No.: HY-140570</p>	<p>N-Mal-N-bis(PEG2-C2-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140576</p>
<p>N-Mal-N-bis(PEG2-amine) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Mal-N-bis(PEG2-C2-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Mal-N-bis(PEG2-NH-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140574</p>	<p>N-Mal-N-bis(PEG2-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140571</p>
<p>N-Mal-N-bis(PEG2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Mal-N-bis(PEG2-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.36% Clinical Data: Size: 25 mg</p>
<p>N-Mal-N-bis(PEG4-amine)</p> <p style="text-align: right;">Cat. No.: HY-140573</p>	<p>N-Mal-N-bis(PEG4-NH-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140575</p>
<p>N-Mal-N-bis(PEG4-amine) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Mal-N-bis(PEG4-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Mal-N-bis(PEG4-NHS ester)</p> <p style="text-align: right;">Cat. No.: HY-140572</p>	<p>N-Me-N-bis(PEG2-propargyl)</p> <p style="text-align: right;">Cat. No.: HY-140043</p>
<p>N-Mal-N-bis(PEG4-NHS ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Me-N-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Me-N-bis(PEG4-acid)</p> <p style="text-align: right;">Cat. No.: HY-140579</p>	<p>N-Me-N-bis(PEG4-C2-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140157</p>
<p>N-Me-N-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Me-N-bis(PEG4-C2-Boc) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>N-Me-N-bis-PEG3</p> <p style="text-align: right;">Cat. No.: HY-140577</p>	<p>N-Me-N-bis-PEG4</p> <p style="text-align: right;">Cat. No.: HY-140578</p>
<p>N-Me-N-bis-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Me-N-bis-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-methyl-N'-(azide-PEG3)-Cy3</p> <p style="text-align: right;">Cat. No.: HY-140010</p>	<p>N-Methyl-N'-(azido-PEG2-C5)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141062</p>
<p>N-methyl-N'-(azide-PEG3)-Cy3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-Methyl-N'-(azido-PEG2-C5)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-Methyl-N'-(hydroxy-PEG2)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141072</p>	<p>N-methyl-N'-(propargyl-PEG4)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141049</p>
<p>N-Methyl-N'-(hydroxy-PEG2)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-methyl-N'-(propargyl-PEG4)-Cy5 (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(acid-PEG5)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141040</p>	<p>N-Methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy3</p> <p style="text-align: right;">Cat. No.: HY-141031</p>
<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(acid-PEG5)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy5</p> <p style="text-align: right;">Cat. No.: HY-141067</p>	<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy3</p> <p style="text-align: right;">Cat. No.: HY-141032</p>
<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5 Cat. No.: HY-141052</p>	<p>N-Methyl-N-(t-Boc)-PEG4-acid Cat. No.: HY-140510</p>
<p>N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N-Methyl-N-(t-Boc)-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-PEG3-N'-(azide-PEG3)-Cy5 Cat. No.: HY-141061</p>	<p>N-PEG3-N'-(propargyl-PEG4)-Cy5 Cat. No.: HY-141050</p>
<p>N-PEG3-N'-(azide-PEG3)-Cy5 (chloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-PEG3-N'-(propargyl-PEG4)-Cy5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N-Succinimidyl 3-(Bromoacetamido)propionate (3-(2-Bromoacetamido)propanoic acid NHS ester) Cat. No.: HY-141385</p>	<p>N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline Cat. No.: HY-77593</p>
<p>N-Succinimidyl 3-(Bromoacetamido)propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. N-Succinimidyl 3-(Bromoacetamido)propionate is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 5 mg</p>
<p>N3-PEG12-Hydrazide Cat. No.: HY-130886</p>	<p>N3-PEG16-Hydrazide Cat. No.: HY-133320</p>
<p>N3-PEG12-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N3-PEG16-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>N3-PEG24-Hydrazide Cat. No.: HY-133321</p>	<p>N3-PEG3-CH2CH2-Boc Cat. No.: HY-42489</p>
<p>N3-PEG24-Hydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N3-PEG3-CH2CH2-Boc is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N3-PEG3-CH2CH2-Boc is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>N3-PEG3-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-42490</p>	<p>N3-PEG3-CH2COOH (PROTAC Linker 14)</p> <p style="text-align: right;">Cat. No.: HY-42637</p>
<p>N3-PEG3-CH2CH2COOH a PEG-based PROTAC linker can be used in the synthesis of BI-3663 (HY-111546), BI-4216 and BI-0319. Azido-PEG3-acid is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>N3-PEG3-CH2COOH (PROTAC Linker 14) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N3-PEG3-Propanehydrazide</p> <p style="text-align: right;">Cat. No.: HY-130883</p>	<p>N3-PEG4-C2-NH2 (PROTAC Linker 20)</p> <p style="text-align: right;">Cat. No.: HY-128834</p>
<p>N3-PEG3-Propanehydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>N3-PEG4-C2-NH2 (PROTAC Linker 20) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>N3-PEG6-Propanehydrazide</p> <p style="text-align: right;">Cat. No.: HY-130885</p>	<p>N3-PEG8-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130228</p>
<p>N3-PEG6-Propanehydrazide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>N3-PEG8-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>N33-TEG-COOH (N3-TEG-COOH; 14-Azido-3,6,9,12-tetraoxatetradecanoic acid)</p> <p style="text-align: right;">Cat. No.: HY-108370</p>	<p>NH-bis(C1-PEG1-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140252</p>
<p>N33-TEG-COOH (N3-TEG-COOH) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.08% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 250 mg</p>	<p>NH-bis(C1-PEG1-Boc) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH-bis(C2-PEG1-azide)</p> <p style="text-align: right;">Cat. No.: HY-140550</p>	<p>NH-bis(C2-PEG2-NH-Boc)</p> <p style="text-align: right;">Cat. No.: HY-130531</p>
<p>NH-bis(C2-PEG1-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NH-bis(C2-PEG2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>NH-bis(m-PEG4)</p> <p style="text-align: right;">Cat. No.: HY-140263</p> <p>NH-bis(m-PEG4) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NH-bis(m-PEG8)</p> <p style="text-align: right;">Cat. No.: HY-140264</p> <p>NH-bis(m-PEG8) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH-bis(PEG2-C2-acid)</p> <p style="text-align: right;">Cat. No.: HY-140514</p> <p>NH-bis(PEG2-C2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH-bis(PEG2-C2-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140256</p> <p>NH-bis(PEG2-C2-Boc) is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH-bis(PEG2-propargyl)</p> <p style="text-align: right;">Cat. No.: HY-140088</p> <p>NH-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NH-bis(PEG3-acid)</p> <p style="text-align: right;">Cat. No.: HY-140515</p> <p>NH-bis(PEG3-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH-bis(PEG3-azide)</p> <p style="text-align: right;">Cat. No.: HY-140551</p> <p>NH-bis(PEG3-azide) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NH-bis(PEG3-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140257</p> <p>NH-bis(PEG3-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>NH-bis(PEG3-C2-NH-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140260</p> <p>NH-bis(PEG3-C2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>NH-bis(PEG4-acid)</p> <p style="text-align: right;">Cat. No.: HY-140516</p> <p>NH-bis(PEG4-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>NH-bis(PEG4-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140258</p> <p>NH-bis(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH-bis(PEG4-C2-NH-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140261</p> <p>NH-bis(PEG4-C2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH-bis-PEG2</p> <p style="text-align: right;">Cat. No.: HY-130328</p> <p>NH-bis-PEG2 is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH-bis-PEG2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH-bis-PEG3</p> <p style="text-align: right;">Cat. No.: HY-140547</p> <p>NH-bis-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH-bis-PEG4</p> <p style="text-align: right;">Cat. No.: HY-140548</p> <p>NH-bis-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH-bis-PEG5</p> <p style="text-align: right;">Cat. No.: HY-140549</p> <p>NH-bis-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>NH2-C2-amido-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130712</p> <p>NH2-C2-amido-C2-Boc is a PROTAC linker, which refers to the alkyl/ether composition. NH2-C5-NH-Boc can be used in the synthesis of a series of PROTACs, such as the PROTAC CDK2/9 Degrader-1 (HY-130709).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-C2-NH-Boc (PROTAC Linker 22)</p> <p style="text-align: right;">Cat. No.: HY-40171</p> <p>NH2-C2-NH-Boc (PROTAC Linker 22) is a alkyl chain-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.52% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-C4-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-40178</p> <p>NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg</p>	<p>NH2-C5-NH-Boc (PROTAC Linker 23)</p> <p style="text-align: right;">Cat. No.: HY-W004710</p> <p>NH2-C5-NH-Boc (PROTAC Linker 23) is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.27% Clinical Data: No Development Reported Size: 100 mg</p>











<p>NH2-C6-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-W008296</p>	<p>NH2-O-C5-COOH hydrobromide (6-Aminoxy-hexanoic acid hydrobromide)</p> <p style="text-align: right;">Cat. No.: HY-133411A</p>
<p>NH2-C6-NH-Boc is a PROTAC linker which refers to the alkyl/ether composition. NH2-C6-NH-Boc can be used in the synthesis the Mcl-1 inhibitor based on PROTAC.</p> <p style="text-align: center;"></p> <p>Purity: 99.60% Clinical Data: No Development Reported Size: 100 mg</p>	<p>NH2-O-C5-COOH (hydrobromide) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH2-PEG-Strt (MW 10000)</p> <p style="text-align: right;">Cat. No.: HY-138307</p>	<p>NH2-PEG-Strt (MW 3000)</p> <p style="text-align: right;">Cat. No.: HY-138308</p>
<p>NH2-PEG-Strt (MW 10000) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG-Strt (MW 3000) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH2-PEG1-C1-Boc</p> <p style="text-align: right;">Cat. No.: HY-W073709</p>	<p>NH2-PEG1-CH2CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-W067489</p>
<p>NH2-PEG1-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG1-CH2CH2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>NH2-PEG10-C2-dimethylamino</p> <p style="text-align: right;">Cat. No.: HY-138390</p>	<p>NH2-PEG2-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-42149</p>
<p>NH2-PEG10-C2-dimethylamino is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG2-C2-Boc is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-PEG2-C6-Cl</p> <p style="text-align: right;">Cat. No.: HY-W096119</p>	<p>NH2-PEG2-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-42427</p>
<p>NH2-PEG2-C6-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>NH2-PEG2-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>











<p>NH2-PEG2-methyl acetate</p> <p style="text-align: right;">Cat. No.: HY-W096162</p>	<p>NH2-PEG3 (PROTAC Linker 35)</p> <p style="text-align: right;">Cat. No.: HY-W007545</p>
<p>NH2-PEG2-methyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG3 (PROTAC Linker 35) is a PROTAC linker, which belongs to a polyethylene glycol (PEG) linker. NH2-PEG3 (PROTAC Linker 35) can be used in the synthesis of the PROTAC (β-NF-JQ1).</p> <p style="text-align: center;"></p> <p>Purity: 97.58% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-PEG3 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-W096143</p>	<p>NH2-PEG3-C1-Boc (PROTAC Linker 5)</p> <p style="text-align: right;">Cat. No.: HY-128801</p>
<p>NH2-PEG3 hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG3-C1-Boc (PROTAC Linker 5) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: \geq98.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-PEG3-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-135804</p>	<p>NH2-PEG3-C2-NH-Boc (PROTAC Linker 15)</p> <p style="text-align: right;">Cat. No.: HY-42776</p>
<p>NH2-PEG3-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>NH2-PEG3-C2-NH-Boc (PROTAC Linker 15) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: \geq97.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH2-PEG3-C6-Cl</p> <p style="text-align: right;">Cat. No.: HY-138469</p>	<p>NH2-PEG3500-NH2</p> <p style="text-align: right;">Cat. No.: HY-138523</p>
<p>NH2-PEG3-C6-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG3500-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH2-PEG4-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W021787</p>	<p>NH2-PEG4-Glu(OH)-NH-m-PEG24</p> <p style="text-align: right;">Cat. No.: HY-140241</p>
<p>NH2-PEG4-CH2CH2COOH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: \geq98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>NH2-PEG4-Glu(OH)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>NH2-PEG5-C1-Boc</p> <p style="text-align: right;">Cat. No.: HY-135938</p>	<p>NH2-PEG5-C2-NH-Boc (PROTAC Linker 17)</p> <p style="text-align: right;">Cat. No.: HY-W022240</p>
<p>NH2-PEG5-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG5-C2-NH-Boc (PROTAC Linker 17) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-PEG5-C6-Cl</p> <p style="text-align: right;">Cat. No.: HY-129622</p>	<p>NH2-PEG5-C6-Cl hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-129622A</p>
<p>NH2-PEG5-C6-Cl (K-7) is a linker which refers to the PEG composition. NH2-PEG5-C6-Cl can be used in the synthesis of a series of compounds that induce degradation of intracellular molecules by autophagy.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG5-C6-Cl hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NH2-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-129637</p>	<p>NH2-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-130486</p>
<p>NH2-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG5-OH is also a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>NH2-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG6-Boc is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mg, 50 mg, 100 mg</p>
<p>NH2-PEG6-C1-Boc</p> <p style="text-align: right;">Cat. No.: HY-135918</p>	<p>NH2-PEG6-CH2CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-W040257</p>
<p>NH2-PEG6-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG6-CH2CH2COOH is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>NH2-PEG7</p> <p style="text-align: right;">Cat. No.: HY-120918</p>	<p>NH2-PEG8-C1-Boc</p> <p style="text-align: right;">Cat. No.: HY-135943</p>
<p>NH2-PEG7 is a PROTAC linker, which refers to the PEG composition. NH2-PEG7 can be used in the synthesis of the PROTAC PARP1 degrader iRucaparib-AP6.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>NH2-PEG8-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>NH2-PEG8-OH</p> <p style="text-align: right;">Cat. No.: HY-130200</p> <p>NH2-PEG8-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NH2-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-W019798</p> <p>NH2-PEG9-acid is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG9-acid also is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>
<p>NH2-Ph-C4-acid-NH2-Me (PROTAC Linker 31)</p> <p style="text-align: right;">Cat. No.: HY-128931</p> <p>NH2-Ph-C4-acid-NH2-Me (PROTAC Linker 31) is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NHS ester-PEG10-COOH</p> <p style="text-align: right;">Cat. No.: HY-138510</p> <p>NHS ester-PEG10-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NHS ester-PEG13-COOH</p> <p style="text-align: right;">Cat. No.: HY-138509</p> <p>NHS ester-PEG13-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NHS ester-PEG3-S-methyl ethanethioate</p> <p style="text-align: right;">Cat. No.: HY-132103</p> <p>NHS ester-PEG3-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NHS ester-PEG7-COOH</p> <p style="text-align: right;">Cat. No.: HY-138511</p> <p>NHS ester-PEG7-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NHS-bis-PEG2-amide-Mal</p> <p style="text-align: right;">Cat. No.: HY-138522</p> <p>NHS-bis-PEG2-amide-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NHS-PEG4-(m-PEG12)3-ester</p> <p style="text-align: right;">Cat. No.: HY-141125</p> <p>NHS-PEG4-(m-PEG12)3-ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NHS-PEG4-(m-PEG4)3-ester</p> <p style="text-align: right;">Cat. No.: HY-141124</p> <p>NHS-PEG4-(m-PEG4)3-ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Nonaethylene glycol</p> <p style="text-align: right;">Cat. No.: HY-116899</p> <p>Nonaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Nonaethylene glycol monomethyl ether</p> <p style="text-align: right;">Cat. No.: HY-120175</p> <p>Nonaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Nonylbenzene-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-W096105</p> <p>Nonylbenzene-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Nonylbenzene-PEG8-OH</p> <p style="text-align: right;">Cat. No.: HY-W096099</p> <p>Nonylbenzene-PEG8-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Octaethylene glycol</p> <p style="text-align: right;">Cat. No.: HY-W050087</p> <p>Octaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Octaethylene glycol monomethyl ether</p> <p style="text-align: right;">Cat. No.: HY-W042657</p> <p>Octaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Oleic-DBCO</p> <p style="text-align: right;">Cat. No.: HY-141293</p> <p>Oleic-DBCO is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>OPSS-PEG8-COOH</p> <p style="text-align: right;">Cat. No.: HY-130348</p> <p>OPSS-PEG8-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>OTs-C6-OBn</p> <p style="text-align: right;">Cat. No.: HY-130621</p> <p>OTs-C6-OBn is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC SGK3 degrader-1 (HY-125878).</p>  <p>Purity: 98.07% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg</p>	<p>PC Azido-PEG11-NHS carbonate ester</p> <p style="text-align: right;">Cat. No.: HY-140142</p> <p>PC Azido-PEG11-NHS carbonate ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>PC DBCO-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138756</p> <p>PC DBCO-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PC Methyltetrazine-PEG4-NHS carbonate ester</p> <p style="text-align: right;">Cat. No.: HY-140141</p> <p>PC Methyltetrazine-PEG4-NHS carbonate ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 25 mg, 50 mg, 100 mg</p>
<p>PC-Biotin-PEG4-NHS carbonate</p> <p style="text-align: right;">Cat. No.: HY-140135</p> <p>PC-Biotin-PEG4-NHS carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>PC-PEG11-Azide</p> <p style="text-align: right;">Cat. No.: HY-140863</p> <p>PC-PEG11-Azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>PEG12-Tos</p> <p style="text-align: right;">Cat. No.: HY-117050</p> <p>Tos-PEG12 is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). PEG12-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG2-bis(phosphonic acid diethyl ester)</p> <p style="text-align: right;">Cat. No.: HY-141320</p> <p>PEG2-bis(phosphonic acid diethyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>PEG2-Cl</p> <p style="text-align: right;">Cat. No.: HY-W096116</p> <p>PEG2-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG2-ethyl acetate</p> <p style="text-align: right;">Cat. No.: HY-138436</p> <p>PEG2-ethyl acetate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PEG20-Tos</p> <p style="text-align: right;">Cat. No.: HY-140358</p> <p>PEG20-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG3</p> <p style="text-align: right;">Cat. No.: HY-W096121</p> <p>PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>








<p>PEG3-bis(phosphonic acid diethyl ester)</p> <p>Cat. No.: HY-141321</p>	<p>PEG3-bis(phosphonic acid)</p> <p>Cat. No.: HY-141294</p>
<p>PEG3-bis(phosphonic acid diethyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>PEG3-bis(phosphonic acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>PEG3-bis-(ethyl phosphonate)</p> <p>Cat. No.: HY-141295</p>	<p>PEG3-C4-OBn</p> <p>Cat. No.: HY-130620</p>
<p>PEG3-bis-(ethyl phosphonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG3-C4-OBn is a polyethylene glycol (PEG)-based PROTAC linker. PEG3-C4-OBn can be used in the synthesis of the PROTAC SGK3 degrader-1 (HY-125878). PROTAC SGK3 degrader-1 is a potent SGK3 degrader based on PROTAC.</p>  <p>Purity: 99.29% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg</p>
<p>PEG3-methylamine</p> <p>Cat. No.: HY-140161</p>	<p>PEG3-O-CH2COOH (PROTAC Linker 8)</p> <p>Cat. No.: HY-128804</p>
<p>PEG3-methylamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG3-O-CH2COOH (PROTAC Linker 8) is a PEG-based PROTAC linker can be used in the synthesis of SNIPERS.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PEG4-bis(phosphonic acid diethyl ester)</p> <p>Cat. No.: HY-141322</p>	<p>PEG4-Ms</p> <p>Cat. No.: HY-140388</p>
<p>PEG4-bis(phosphonic acid diethyl ester) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>PEG4-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>PEG4-sulfonic acid</p> <p>Cat. No.: HY-133054</p>	<p>PEG5-bis-(Ethyl phosphonate)</p> <p>Cat. No.: HY-141296</p>
<p>PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG5-bis-(Ethyl phosphonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>PEG5-Tos</p> <p style="text-align: right;">Cat. No.: HY-23417</p>	<p>PEG6-(CH₂CO₂H)₂</p> <p style="text-align: right;">Cat. No.: HY-122702</p>
<p>PEG5-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.05% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>PEG6-(CH₂CO₂H)₂ is a symmetric PEG PROTAC linker, for the synthesis of Homo-PROTACs which is bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>PEG7-O-Ms</p> <p style="text-align: right;">Cat. No.: HY-140389</p>	<p>PEG8-Tos</p> <p style="text-align: right;">Cat. No.: HY-130555</p>
<p>PEG7-O-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PEG8-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pentaethylene glycol</p> <p style="text-align: right;">Cat. No.: HY-W007341</p>	<p>Pentaethylene glycol di(p-toluenesulfonate) (Penta(ethylene glycol) bis(p-toluenesulfonate); Bis-Tos-PEG5)</p> <p style="text-align: right;">Cat. No.: HY-W004447</p>
<p>Pentaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Pentaethylene glycol di(p-toluenesulfonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.34% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pentaethylene glycol monomethyl ether</p> <p style="text-align: right;">Cat. No.: HY-W042713</p>	<p>Ph-Bis(C1-N-(C2-NH-Boc)2)</p> <p style="text-align: right;">Cat. No.: HY-140337</p>
<p>Pentaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Ph-Bis(C1-N-(C2-NH-Boc)2) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Ph-PEG3</p> <p style="text-align: right;">Cat. No.: HY-W096158</p>	<p>Phenol-amido-C1-PEG3-N3 (PROTAC Linker 21)</p> <p style="text-align: right;">Cat. No.: HY-128835</p>
<p>Ph-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Phenol-amido-C1-PEG3-N3 (PROTAC Linker 21) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>Phthalamide-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140862</p>	<p>Phthalamide-PEG3-C2-OTs</p> <p style="text-align: right;">Cat. No.: HY-129772</p>
<p>Phthalamide-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Phthalamide-PEG3-C2-OTs (Compound 5) is a PROTAC linker, which refers to the PEGs composition. Phthalamide-PEG3-C2-OTs can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Phthalamide-PEG4-MPDM-OH</p> <p style="text-align: right;">Cat. No.: HY-129774</p>	<p>Phthalamide-PEG4-PDM-OTBS</p> <p style="text-align: right;">Cat. No.: HY-129773</p>
<p>Phthalamide-PEG4-MPDM-OH is a PROTAC linker, which refers to the PEGs composition. Phthalamide-PEG4-MPDM-OH can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Phthalamide-PEG4-PDM-OTBS is a PROTAC linker, which refers to the PEGs composition. Phthalamide-PEG4-PDM-OTBS can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pip-alkyne-Ph-COOCH3</p> <p style="text-align: right;">Cat. No.: HY-130846</p>	<p>Propanol-PEG3-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-134689</p>
<p>Pip-alkyne-Ph-COOCH3 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTAC ARD-266.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propanol-PEG3-CH2OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propanol-PEG4-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-134690</p>	<p>Propanol-PEG5-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-134678</p>
<p>Propanol-PEG4-CH2OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propanol-PEG5-CH2OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propanol-PEG6-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-134691</p>	<p>Propargyl-PEG-acid</p> <p style="text-align: right;">Cat. No.: HY-143820</p>
<p>Propanol-PEG6-CH2OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG-amine</p> <p>Cat. No.: HY-143819</p>	<p>Propargyl-PEG1-acid</p> <p>Cat. No.: HY-130504</p>
<p>Propargyl-PEG-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-CRBN PROTACs Ibrutinib(HY-10997)-based PROTAC 4 and PROTAC 5. PROTAC 5 causes the degradation of BTK and induces the degradation of CSK, LYN, and LAT2 at 10 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG1-acrylate</p> <p>Cat. No.: HY-140064</p>	<p>Propargyl-PEG1-Boc</p> <p>Cat. No.: HY-140026</p>
<p>Propargyl-PEG1-acrylate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG1-Boc is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG1-NH2</p> <p>Cat. No.: HY-116069</p>	<p>Propargyl-PEG1-SS-PEG1-C2-Boc</p> <p>Cat. No.: HY-130690</p>
<p>Propargyl-PEG1-NH2 is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG1-SS-PEG1-C2-Boc is a Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG1-SS-PEG1-C2-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG1-THP</p> <p>Cat. No.: HY-138334</p>	<p>Propargyl-PEG10-acid</p> <p>Cat. No.: HY-140020</p>
<p>Propargyl-PEG1-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG10-alcohol</p> <p>Cat. No.: HY-138460</p>	<p>Propargyl-PEG10-amine</p> <p>Cat. No.: HY-133230</p>
<p>Propargyl-PEG10-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG10-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG10-Boc</p> <p style="text-align: right;">Cat. No.: HY-140029</p> <p>Propargyl-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG11-acid</p> <p style="text-align: right;">Cat. No.: HY-138763</p> <p>Propargyl-PEG11-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG11-alcohol</p> <p style="text-align: right;">Cat. No.: HY-138366</p> <p>Propargyl-PEG11-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG11-amine</p> <p style="text-align: right;">Cat. No.: HY-138766</p> <p>Propargyl-PEG11-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG11-methane</p> <p style="text-align: right;">Cat. No.: HY-140061</p> <p>Propargyl-PEG11-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-138764</p> <p>Propargyl-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG12-amine</p> <p style="text-align: right;">Cat. No.: HY-140034</p> <p>Propargyl-PEG12-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG12-bromide</p> <p style="text-align: right;">Cat. No.: HY-135823</p> <p>Propargyl-PEG12-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG12-methane</p> <p style="text-align: right;">Cat. No.: HY-130894</p> <p>Propargyl-PEG12-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG12-OH</p> <p style="text-align: right;">Cat. No.: HY-117045</p> <p>Propargyl-PEG12-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>Propargyl-PEG12-SH</p> <p style="text-align: right;">Cat. No.: HY-130911</p> <p>Propargyl-PEG12-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG13-acid</p> <p style="text-align: right;">Cat. No.: HY-140021</p> <p>Propargyl-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG13-Boc</p> <p style="text-align: right;">Cat. No.: HY-138733</p> <p>Propargyl-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG13-OH</p> <p style="text-align: right;">Cat. No.: HY-138735</p> <p>Propargyl-PEG13-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG14-acid</p> <p style="text-align: right;">Cat. No.: HY-140022</p> <p>Propargyl-PEG14-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG14-Boc</p> <p style="text-align: right;">Cat. No.: HY-140030</p> <p>Propargyl-PEG14-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG17-methane</p> <p style="text-align: right;">Cat. No.: HY-140062</p> <p>Propargyl-PEG17-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-118764</p> <p>Propargyl-PEG2-acid is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>
<p>Propargyl-PEG2-amine</p> <p style="text-align: right;">Cat. No.: HY-W051634</p> <p>Propargyl-PEG2-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Propargyl-PEG2-beta-D-glucose</p> <p style="text-align: right;">Cat. No.: HY-141131</p> <p>Propargyl-PEG2-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Propargyl-PEG2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130597</p> <p>Propargyl-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG2-bromide</p> <p style="text-align: right;">Cat. No.: HY-W096164</p> <p>Propargyl-PEG2-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-41922</p> <p>Propargyl-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Propargyl-PEG2-Ms</p> <p style="text-align: right;">Cat. No.: HY-130584</p> <p>Propargyl-PEG2-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Propargyl-PEG2-N-bis(PEG2)</p> <p style="text-align: right;">Cat. No.: HY-140083</p> <p>Propargyl-PEG2-N-bis(PEG2) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG2-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-118808</p> <p>Propargyl-PEG2-NHBoc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-NHBoc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG2-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-138734</p> <p>Propargyl-PEG2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG2-OH</p> <p style="text-align: right;">Cat. No.: HY-130541</p> <p>Propargyl-PEG2-OH is a PEG-based PROTAC linker can be used in the synthesis of Thalidomide-O-PEG2-propargyl (HY-126458).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Propargyl-PEG2-Tos</p> <p style="text-align: right;">Cat. No.: HY-140374</p> <p>Propargyl-PEG2-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG2-urea-C3-triethoxysilane</p> <p style="text-align: right;">Cat. No.: HY-134749</p> <p>Propargyl-PEG2-urea-C3-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG24-amine</p> <p style="text-align: right;">Cat. No.: HY-140035</p> <p>Propargyl-PEG24-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 50 mg, 100 mg</p>	<p>Propargyl-PEG25-acid</p> <p style="text-align: right;">Cat. No.: HY-130909</p> <p>Propargyl-PEG25-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-1-o-(b-cyanoethyl-N,N-diisopropyl)phosphoramidite</p> <p style="text-align: right;">Cat. No.: HY-W096141</p> <p>Propargyl-PEG3-1-o-b-cyanoethyl-N,N-diisopropylphosphoramidite is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-126975</p> <p>Propargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne. 6-OHDA-PEG3-yne contains 6-OHDA (HY-B1081, HY-B1081A) and Propargyl-PEG3-acid.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Propargyl-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-41921</p> <p>Propargyl-PEG3-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 96.83% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>	<p>Propargyl-PEG3-amine</p> <p style="text-align: right;">Cat. No.: HY-140033</p> <p>Propargyl-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-118781</p> <p>Propargyl-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-Boc</p> <p style="text-align: right;">Cat. No.: HY-140027</p> <p>Propargyl-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-bromide</p> <p style="text-align: right;">Cat. No.: HY-140036</p> <p>Propargyl-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130563</p> <p>Propargyl-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>

<p>Propargyl-PEG3-methane</p> <p style="text-align: right;">Cat. No.: HY-140059</p> <p>Propargyl-PEG3-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140876</p> <p>Propargyl-PEG3-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126974</p> <p>Propargyl-PEG3-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG3-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-OCH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-140031</p> <p>Propargyl-PEG3-OCH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-132007</p> <p>Propargyl-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-133049</p> <p>Propargyl-PEG3-phosphonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG3-phosphonic acid diethyl ester</p> <p style="text-align: right;">Cat. No.: HY-130146</p> <p>Propargyl-PEG3-phosphonic acid diethyl ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG3-SH</p> <p style="text-align: right;">Cat. No.: HY-130900</p> <p>Propargyl-PEG3-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-peg3-sulfone-peg3-propargyl</p> <p style="text-align: right;">Cat. No.: HY-140611</p> <p>Propargyl-peg3-sulfone-peg3-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-5-nitrophenyl carbonate</p> <p style="text-align: right;">Cat. No.: HY-140048</p> <p>Propargyl-PEG4-5-nitrophenyl carbonate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130481</p> <p>Propargyl-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-IAP PROTACs Ibrutinib (HY-10997)-based PROTAC 2 and an analogue PROTAC 3. PROTAC 3 causes BTK degradation with a DC₅₀ of 200 nM in THP-1 cells.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>	<p>Propargyl-PEG4-alcohol</p> <p style="text-align: right;">Cat. No.: HY-133229</p> <p>Propargyl-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p>
<p>Propargyl-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-114670</p> <p>Propargyl-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥97.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Propargyl-PEG4-beta-D-glucose</p> <p style="text-align: right;">Cat. No.: HY-141132</p> <p>Propargyl-PEG4-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-140028</p> <p>Propargyl-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-Br</p> <p style="text-align: right;">Cat. No.: HY-130591</p> <p>Propargyl-PEG4-Br is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-Br is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Propargyl-PEG4-CH2-acid</p> <p style="text-align: right;">Cat. No.: HY-140024</p> <p>Propargyl-PEG4-CH2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-CH2-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140063</p> <p>Propargyl-PEG4-CH2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-CH2CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130293</p> <p>Propargyl-PEG4-CH2CH2-Boc is a non-cleavable ADC linker that can be used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG4-CH2CH2-Boc is a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-140023</p> <p>Propargyl-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG4-methylamine</p> <p>Cat. No.: HY-140045</p>	<p>Propargyl-PEG4-O-C1-Boc</p> <p>Cat. No.: HY-130389</p>
<p>Propargyl-PEG4-methylamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-O-C1-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-O-C1-NHS ester</p> <p>Cat. No.: HY-130390</p>	<p>Propargyl-PEG4-S-PEG4-acid</p> <p>Cat. No.: HY-140597</p>
<p>Propargyl-PEG4-O-C1-NHS ester (compound 8) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-S-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-S-PEG4-Boc</p> <p>Cat. No.: HY-140599</p>	<p>Propargyl-PEG4-S-PEG4-propargyl</p> <p>Cat. No.: HY-140598</p>
<p>Propargyl-PEG4-S-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-S-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-Sulfone-PEG4-acid</p> <p>Cat. No.: HY-140610</p>	<p>Propargyl-PEG4-Sulfone-PEG4-Boc</p> <p>Cat. No.: HY-140612</p>
<p>Propargyl-PEG4-Sulfone-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-Sulfone-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-sulfonic acid</p> <p>Cat. No.: HY-140047</p>	<p>Propargyl-PEG4-tetra-Ac-beta-D-galactose</p> <p>Cat. No.: HY-141135</p>
<p>Propargyl-PEG4-sulfonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-tetra-Ac-beta-D-galactose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Propargyl-PEG4-tetra-Ac-beta-D-glucose</p> <p>Cat. No.: HY-141133</p> <p>Propargyl-PEG4-tetra-Ac-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG4-thiol</p> <p>Cat. No.: HY-116427</p> <p>Propargyl-PEG4-thiol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-thiol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG4-Tos</p> <p>Cat. No.: HY-130387</p> <p>Propargyl-PEG4-Tos is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-Tos is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG5-1-o-(b-cyanoethyl-n,n-diisopropyl)phosphoramidite</p> <p>Cat. No.: HY-W096140</p> <p>Propargyl-PEG5-1-o-b-cyanoethyl-nn-diisopropylphosphoramidite is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG5-acid</p> <p>Cat. No.: HY-101157</p> <p>Propargyl-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can be used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Propargyl-PEG5-amine</p> <p>Cat. No.: HY-126976</p> <p>Propargyl-PEG5-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Propargyl-PEG5-azide</p> <p>Cat. No.: HY-138738</p> <p>Propargyl-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG5-Br</p> <p>Cat. No.: HY-138736</p> <p>Propargyl-PEG5-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG5-Ms</p> <p>Cat. No.: HY-140046</p> <p>Propargyl-PEG5-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG5-NHS ester</p> <p>Cat. No.: HY-130388</p> <p>Propargyl-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>







<p>Propargyl-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-130147</p>	<p>Propargyl-PEG5-PFP ester</p> <p style="text-align: right;">Cat. No.: HY-132043</p>
<p>Propargyl-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG5-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-130386</p>	<p>Propargyl-PEG6-alcohol</p> <p style="text-align: right;">Cat. No.: HY-130382</p>
<p>Propargyl-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG6-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG6-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG6-Boc</p> <p style="text-align: right;">Cat. No.: HY-130384</p>	<p>Propargyl-PEG6-Br</p> <p style="text-align: right;">Cat. No.: HY-138321</p>
<p>Propargyl-PEG6-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG6-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG6-N3</p> <p style="text-align: right;">Cat. No.: HY-130183</p>	<p>Propargyl-PEG6-NH2</p> <p style="text-align: right;">Cat. No.: HY-130180</p>
<p>Propargyl-PEG6-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG6-NH2 is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>
<p>Propargyl-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130385</p>	<p>Propargyl-PEG6-SH</p> <p style="text-align: right;">Cat. No.: HY-135917</p>
<p>Propargyl-PEG6-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG6-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG6-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Propargyl-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-130383</p> <p>Propargyl-PEG7-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG7-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-130378</p> <p>Propargyl-PEG7-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG7-amine</p> <p style="text-align: right;">Cat. No.: HY-138765</p> <p>Propargyl-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG7-Boc</p> <p style="text-align: right;">Cat. No.: HY-130380</p> <p>Propargyl-PEG7-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG7-Br</p> <p style="text-align: right;">Cat. No.: HY-138737</p> <p>Propargyl-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG7-methane</p> <p style="text-align: right;">Cat. No.: HY-140060</p> <p>Propargyl-PEG7-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG7-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130381</p> <p>Propargyl-PEG7-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG7-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-130379</p> <p>Propargyl-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). The ADCs can be used in bacterial infections caused by Gram-negative bacteria.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-130375</p> <p>Propargyl-PEG7-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG8-bromide</p> <p style="text-align: right;">Cat. No.: HY-130377</p> <p>Propargyl-PEG8-bromide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-bromide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>










<p>Propargyl-PEG8-NH2</p> <p style="text-align: right;">Cat. No.: HY-130182</p>	<p>Propargyl-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130376</p>
<p>Propargyl-PEG8-NH2 (compound 3b) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NH2 is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG8-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG8-OH</p> <p style="text-align: right;">Cat. No.: HY-130374</p>	<p>Propargyl-PEG8-SH</p> <p style="text-align: right;">Cat. No.: HY-130910</p>
<p>Propargyl-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG8-SH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-132091</p>	<p>Propargyl-PEG9-amine</p> <p style="text-align: right;">Cat. No.: HY-130373</p>
<p>Propargyl-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG9-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG9-bromide</p> <p style="text-align: right;">Cat. No.: HY-130372</p>	<p>Propargyl-PEG9-OH</p> <p style="text-align: right;">Cat. No.: HY-126977</p>
<p>Propargyl-PEG9-bromide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG9-bromide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propargyl-PEG9-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Propargyl-PEG9-THP</p> <p style="text-align: right;">Cat. No.: HY-138459</p>	<p>Propenyl-PEG3-Propenyl (Triethylene glycol diallyl ether)</p> <p style="text-align: right;">Cat. No.: HY-134676</p>
<p>Propargyl-PEG9-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Propenyl-PEG3-Propenyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Propynol Ethoxylate</p> <p>Cat. No.: HY-43614</p>	<p>Propynyl-PEG1-Ac</p> <p>Cat. No.: HY-W096146</p>
<p>Propynol Ethoxylate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 1 g</p>	<p>Propynyl-PEG1-Ac is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pyrene azide 3</p> <p>Cat. No.: HY-D1295</p>	<p>Pyrene-amido-PEG4-azide</p> <p>Cat. No.: HY-123609</p>
<p>Pyrene azide 3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pyrene-amido-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pyrene-amido-PEG4-CH2CH2COOH</p> <p>Cat. No.: HY-130397</p>	<p>Pyrene-PEG2-azide</p> <p>Cat. No.: HY-141092</p>
<p>Pyrene-amido-PEG4-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pyrene-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pyrene-PEG5-alcohol</p> <p>Cat. No.: HY-141093</p>	<p>Pyrene-PEG5-biotin</p> <p>Cat. No.: HY-141094</p>
<p>Pyrene-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pyrene-PEG5-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pyrene-PEG5-propargyl</p> <p>Cat. No.: HY-141095</p>	<p>Pyrroline-5-carboxylate</p> <p>Cat. No.: HY-138354</p>
<p>Pyrene-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pyrroline-5-carboxylate is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>



<p>rel-Biotin-PEG3-C3-NH2</p> <p style="text-align: right;">Cat. No.: HY-140902</p>	<p>Rhodamine B PEG2-NH2</p> <p style="text-align: right;">Cat. No.: HY-138396</p>
<p>rel-Biotin-PEG3-C3-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Rhodamine B PEG2-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>
<p>S-acetyl-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141342</p>	<p>S-acetyl-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141343</p>
<p>S-acetyl-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG2-Boc</p> <p style="text-align: right;">Cat. No.: HY-141345</p>	<p>S-acetyl-PEG20-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141344</p>
<p>S-acetyl-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG20-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-141340</p>	<p>S-Acetyl-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-140859</p>
<p>S-acetyl-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>S-Acetyl-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG3-Boc</p> <p style="text-align: right;">Cat. No.: HY-141346</p>	<p>S-Acetyl-PEG3-C2-acid</p> <p style="text-align: right;">Cat. No.: HY-141349</p>
<p>S-acetyl-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>S-Acetyl-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>S-acetyl-PEG3-phosphonic acid ethyl ester</p> <p>Cat. No.: HY-141317</p>	<p>S-acetyl-PEG4-alcohol</p> <p>Cat. No.: HY-141341</p>
<p>S-acetyl-PEG3-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG4-amine</p> <p>Cat. No.: HY-138752</p>	<p>S-acetyl-PEG4-Boc</p> <p>Cat. No.: HY-141347</p>
<p>S-acetyl-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG4-NHBoc</p> <p>Cat. No.: HY-138755</p>	<p>S-acetyl-PEG4-propargyl</p> <p>Cat. No.: HY-141350</p>
<p>S-acetyl-PEG4-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG4-Thiol</p> <p>Cat. No.: HY-138758</p>	<p>S-acetyl-PEG5-alcohol</p> <p>Cat. No.: HY-138748</p>
<p>S-acetyl-PEG4-Thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>S-acetyl-PEG6</p> <p>Cat. No.: HY-W096147</p>	<p>S-acetyl-PEG6-Boc</p> <p>Cat. No.: HY-141348</p>
<p>S-acetyl-PEG6 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>S-acetyl-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>S-acetyl-PEG6-Tos</p> <p style="text-align: right;">Cat. No.: HY-133473</p>	<p>S-Acetyl-PEG8-OH</p> <p style="text-align: right;">Cat. No.: HY-130209</p>
<p>S-acetyl-PEG6-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>S-Acetyl-PEG8-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>S-Bis-(PEG4-Boc)</p> <p style="text-align: right;">Cat. No.: HY-140600</p>	<p>SMPH Crosslinker</p> <p style="text-align: right;">Cat. No.: HY-124318</p>
<p>S-Bis-(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>SMPH Crosslinker is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SPDP-C6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-124377</p>	<p>SPDP-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141356</p>
<p>SPDP-C6-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.09% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>SPDP-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SPDP-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-141354</p>	<p>SPDP-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141357</p>
<p>SPDP-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SPDP-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SPDP-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141352</p>	<p>SPDP-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130195</p>
<p>SPDP-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>SPDP-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>SPDP-PEG5-acid</p> <p style="text-align: right;">Cat. No.: HY-133384</p> <p>SPDP-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>SPDP-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126717</p> <p>SPDP-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SPDP-PEG7-acid</p> <p style="text-align: right;">Cat. No.: HY-133385</p> <p>SPDP-PEG7-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SPDP-PEG9-acid</p> <p style="text-align: right;">Cat. No.: HY-133386</p> <p>SPDP-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Sulfo DBCO-amine</p> <p style="text-align: right;">Cat. No.: HY-127056</p> <p>Sulfo DBCO-amine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Sulfo DBCO-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-140286</p> <p>Sulfo DBCO-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 50 mg, 100 mg</p>
<p>Sulfo DBCO-PEG4-Maleimide</p> <p style="text-align: right;">Cat. No.: HY-140307</p> <p>Sulfo DBCO-PEG4-Maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Sulfo-NHS-Acetate</p> <p style="text-align: right;">Cat. No.: HY-140341</p> <p>Sulfo-NHS-Acetate is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Sulfone-Bis-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140601</p> <p>Sulfone-Bis-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-amido-PEG10-acid</p> <p style="text-align: right;">Cat. No.: HY-144076</p> <p>t-Boc-amido-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>t-Boc-Aminoxy-PEG11-amine</p> <p>Cat. No.: HY-143825</p>	<p>t-Boc-Aminoxy-PEG12-acid</p> <p>Cat. No.: HY-140414</p>
<p>t-Boc-Aminoxy-PEG11-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG12-Boc</p> <p>Cat. No.: HY-140419</p>	<p>t-Boc-Aminoxy-PEG12-NHS ester</p> <p>Cat. No.: HY-140418</p>
<p>t-Boc-Aminoxy-PEG12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG12-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG2-azide</p> <p>Cat. No.: HY-140431</p>	<p>t-Boc-Aminoxy-PEG3-alcohol</p> <p>Cat. No.: HY-140422</p>
<p>t-Boc-Aminoxy-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG4-amine</p> <p>Cat. No.: HY-143821</p>	<p>t-Boc-Aminoxy-PEG4-NHS ester</p> <p>Cat. No.: HY-140417</p>
<p>t-Boc-Aminoxy-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG4-t-butyl ester</p> <p>Cat. No.: HY-W190966</p>	<p>t-Boc-Aminoxy-PEG5-azide</p> <p>Cat. No.: HY-140434</p>
<p>t-Boc-Aminoxy-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>


<p>t-Boc-aminooxy-PEG6-propargyl</p> <p>Cat. No.: HY-140054</p>	<p>t-Boc-Aminoxy-PEG7-amine</p> <p>Cat. No.: HY-140429</p>
<p>t-Boc-aminoxy-PEG6-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG7-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG7-bromide</p> <p>Cat. No.: HY-140436</p>	<p>t-Boc-Aminoxy-PEG7-methane</p> <p>Cat. No.: HY-140437</p>
<p>t-Boc-Aminoxy-PEG7-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG7-methane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-Aminoxy-PEG8-alcohol</p> <p>Cat. No.: HY-140424</p>	<p>t-Boc-Aminoxy-PEG8-Ms</p> <p>Cat. No.: HY-140378</p>
<p>t-Boc-Aminoxy-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>t-Boc-Aminoxy-PEG8-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>t-Boc-N-amido-PEG10-Br</p> <p>Cat. No.: HY-143828</p>	<p>t-Boc-N-amido-PEG15-Br</p> <p>Cat. No.: HY-143829</p>
<p>t-Boc-N-amido-PEG10-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>t-Boc-N-amido-PEG15-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>t-Boc-N-amido-PEG2-C6-Cl</p> <p>Cat. No.: HY-143830</p>	<p>t-Boc-N-amido-PEG5-acetic acid</p> <p>Cat. No.: HY-W190962</p>
<p>t-Boc-N-amido-PEG2-C6-Cl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>BocNH-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>t-Boc-N-amido-PEG6-Tos</p> <p style="text-align: right;">Cat. No.: HY-W096165</p>	<p>t-Butyl acetate-PEG2-CH₂COOH</p> <p style="text-align: right;">Cat. No.: HY-W096080</p>
<p>t-Boc-N-amido-PEG6-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>t-Butyl acetate-PEG2-CH₂COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>t-Butyl acetate-PEG3-CH₂COOH</p> <p style="text-align: right;">Cat. No.: HY-W096082</p>	<p>TAMRA-Azide-PEG-biotin</p> <p style="text-align: right;">Cat. No.: HY-140947</p>
<p>t-Butyl acetate-PEG3-CH₂COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TAMRA-Azide-PEG-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TAMRA-PEG3-Azide</p> <p style="text-align: right;">Cat. No.: HY-123629</p>	<p>TAMRA-PEG3-biotin</p> <p style="text-align: right;">Cat. No.: HY-140946</p>
<p>TAMRA-PEG3-Azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TAMRA-PEG3-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TAMRA-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-140509</p>	<p>TAMRA-PEG4-Alkyne</p> <p style="text-align: right;">Cat. No.: HY-120666</p>
<p>TAMRA-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TAMRA-PEG4-Alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TAMRA-PEG4-methyltetrazine</p> <p style="text-align: right;">Cat. No.: HY-141286</p>	<p>TAMRA-PEG4-tetrazine</p> <p style="text-align: right;">Cat. No.: HY-141285</p>
<p>TAMRA-PEG4-methyltetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TAMRA-PEG4-tetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

tans-4-Hydroxy-D-proline hydrochloride

Cat. No.: HY-W003511

tans-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR.




Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

tans-4-Hydroxy-D-proline methyl ester hydrochloride

Cat. No.: HY-W006629

tans-4-Hydroxy-D-proline methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).




Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TBDMS-PEG4-OH

Cat. No.: HY-W042579

TBDMS-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-amine

Cat. No.: HY-141176

TCO-amine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-C3-PEG3-C3-amine

Cat. No.: HY-141182

TCO-C3-PEG3-C3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-NHS ester

Cat. No.: HY-141165

TCO-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

TCO-OH

Cat. No.: HY-141186

TCO-OH is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

TCO-PEG-TCO (MW 5000)

Cat. No.: HY-140731

TCO-PEG-TCO (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-PEG11-TCO

Cat. No.: HY-133478

TCO-PEG11-TCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg


TCO-PEG12-acid


Cat. No.: HY-141162

TCO-PEG12-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.













Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg









<p>TCO-PEG12-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141170</p> <p>TCO-PEG12-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG12-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>TCO-PEG12-TFP ester</p> <p style="text-align: right;">Cat. No.: HY-141174</p> <p>TCO-PEG12-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>TCO-PEG2-amine</p> <p style="text-align: right;">Cat. No.: HY-141177</p> <p>TCO-PEG2-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>TCO-PEG2-Sulfo-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141172</p> <p>TCO-PEG2-Sulfo-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p> 
<p>TCO-PEG2-Sulfo-NHS ester sodium</p> <p style="text-align: right;">Cat. No.: HY-141172A</p> <p>TCO-PEG2-Sulfo-NHS ester sodium is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>TCO-PEG24-acid</p> <p style="text-align: right;">Cat. No.: HY-141163</p> <p>TCO-PEG24-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p> 
<p>TCO-PEG24-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141171</p> <p>TCO-PEG24-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p> 	<p>TCO-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-140015</p> <p>TCO-PEG3-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p> 
<p>TCO-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-133476</p> <p>TCO-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>TCO-PEG3-amide-C3-triethoxysilane</p> <p style="text-align: right;">Cat. No.: HY-141185</p> <p>TCO-PEG3-amide-C3-triethoxysilane is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p> 











<p>TCO-PEG3-amine</p> <p style="text-align: right;">Cat. No.: HY-141178</p>	<p>TCO-PEG3-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133477</p>
<p>TCO-PEG3-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>TCO-PEG3-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141166</p>	<p>TCO-PEG3-oxyamine</p> <p style="text-align: right;">Cat. No.: HY-133474</p>
<p>TCO-PEG3-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>	<p>TCO-PEG3-oxyamine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>TCO-PEG3-TCO</p> <p style="text-align: right;">Cat. No.: HY-141187</p>	<p>TCO-PEG36-acid</p> <p style="text-align: right;">Cat. No.: HY-141164</p>
<p>TCO-PEG3-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG36-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-141159</p>	<p>TCO-PEG4-amine</p> <p style="text-align: right;">Cat. No.: HY-141179</p>
<p>TCO-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG4-biotin</p> <p style="text-align: right;">Cat. No.: HY-141183</p>	<p>TCO-PEG4-DBCO</p> <p style="text-align: right;">Cat. No.: HY-140310</p>
<p>TCO-PEG4-biotin is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p>	<p>TCO-PEG4-DBCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG4-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>


<p>TCO-PEG4-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141167</p>	<p>TCO-PEG4-TCO</p> <p style="text-align: right;">Cat. No.: HY-141188</p>
<p>TCO-PEG4-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG4-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: right;"></p> <p>Purity: 99.58% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG4-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG5-maleimide</p> <p style="text-align: right;">Cat. No.: HY-133475</p>	<p>TCO-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-141160</p>
<p>TCO-PEG5-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG6-amine</p> <p style="text-align: right;">Cat. No.: HY-141180</p>	<p>TCO-PEG6-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141168</p>
<p>TCO-PEG6-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG6-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-141161</p>	<p>TCO-PEG8-amine</p> <p style="text-align: right;">Cat. No.: HY-141181</p>
<p>TCO-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TCO-PEG8-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TCO-PEG8-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-141169</p>	<p>TCO-PEG8-TCO</p> <p style="text-align: right;">Cat. No.: HY-141189</p>
<p>TCO-PEG8-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>TCO-PEG8-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>











<p>TCO-PEG8-TFP ester</p> <p>Cat. No.: HY-141173</p>	<p>TCO-PEG9-maleimide</p> <p>Cat. No.: HY-141184</p>
<p>TCO-PEG8-TFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>TCO-PEG9-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>TCO-PNB ester</p> <p>Cat. No.: HY-141175</p>	<p>tert-Butyl 11-aminoundecanoate</p> <p>Cat. No.: HY-130715</p>
<p>TCO-PNB ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 100 mg</p>
<p>Tetra(cyanoethoxymethyl) methane</p> <p>Cat. No.: HY-124531</p>	<p>Tetraethyl butane-1,4-diylbis(phosphonate)</p> <p>Cat. No.: HY-140003</p>
<p>Tetra(cyanoethoxymethyl) methane is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tetraethyl butane-1,4-diylbis(phosphonate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tetraethyl butane-1,4-diylbis(phosphoramidate)</p> <p>Cat. No.: HY-141324</p>	<p>Tetraethyl decane-1,10-diylbis(phosphonate)</p> <p>Cat. No.: HY-140325</p>
<p>Tetraethyl butane-1,4-diylbis(phosphoramidate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tetraethyl decane-1,10-diylbis(phosphonate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tetraethyl heptane-1,7-diylbis(phosphonate)</p> <p>Cat. No.: HY-140323</p>	<p>Tetraethyl octane-1,8-diylbis(phosphonate)</p> <p>Cat. No.: HY-140324</p>
<p>Tetraethyl heptane-1,7-diylbis(phosphonate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Tetraethyl octane-1,8-diylbis(phosphonate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>











<p>Tetraethylene glycol (PROTAC Linker 18)</p> <p style="text-align: right;">Cat. No.: HY-W018745</p>	<p>Tetraethylene glycol monohexadecyl ether</p> <p style="text-align: right;">Cat. No.: HY-W096096</p>
<p>Tetraethylene glycol (PROTAC Linker 18) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 g</p>	<p>Tetraethylene glycol monohexadecyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tetraethylene glycol monomethyl ether</p> <p style="text-align: right;">Cat. No.: HY-W018365</p>	<p>Tetraethylene glycol monotosylate (Tos-PEG4)</p> <p style="text-align: right;">Cat. No.: HY-41541</p>
<p>Tetraethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 99.35% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 250 mg, 500 mg</p>	<p>Tetraethylene glycol monotosylate is a cleavable and acylhydrazone-based ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tetraethylene glycol monotosylate also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tetraethylene glycol-d8 (PROTAC Linker 18-d8)</p> <p style="text-align: right;">Cat. No.: HY-W018745S</p>	<p>Tetrahydropyranyldiethyleneglycol (THP-PEG2-OH)</p> <p style="text-align: right;">Cat. No.: HY-126916</p>
<p>Tetraethylene glycol-d8 (PROTAC Linker 18-d8) is the deuterium labeled Tetraethylene glycol. Tetraethylene glycol (PROTAC Linker 18) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tetrahydropyranyldiethyleneglycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tetrazine-Ph-acid</p> <p style="text-align: right;">Cat. No.: HY-124480</p>	<p>Tetrazine-Ph-NHCO-C3-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-133479</p>
<p>Tetrazine-Ph-acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 99.65% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Tetrazine-Ph-NHCO-C3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 98.01% Clinical Data: Size: 5 mg, 10 mg, 25 mg</p>
<p>Tetrazine-Ph-NHCO-PEG3-alcohol</p> <p style="text-align: right;">Cat. No.: HY-133460</p>	<p>Tetrazine-Ph-NHCO-PEG4-alkyne</p> <p style="text-align: right;">Cat. No.: HY-133464</p>
<p>Tetrazine-Ph-NHCO-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Tetrazine-Ph-NHCO-PEG4-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>





<p>Tetrazine-Ph-NHCO-PEG4-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-133462</p> <p>Tetrazine-Ph-NHCO-PEG4-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Tetrazine-Ph-NHCO-PEG6-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-133461</p> <p>Tetrazine-Ph-NHCO-PEG6-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tetrazine-Ph-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-126908</p> <p>Tetrazine-Ph-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>	<p>Tetrazine-Ph-PEG4-Ph-aldehyde</p> <p style="text-align: right;">Cat. No.: HY-133465</p> <p>Tetrazine-Ph-PEG4-Ph-aldehyde is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tetrazine-Ph-PEG5-NHS ester</p> <p style="text-align: right;">Cat. No.: HY-130551</p> <p>Tetrazine-Ph-PEG5-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tetrazine-Ph-PEG5-Ph-tetrazine</p> <p style="text-align: right;">Cat. No.: HY-133463</p> <p>Tetrazine-Ph-PEG5-Ph-tetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>TFP-PEG3-TFP</p> <p style="text-align: right;">Cat. No.: HY-W096112</p> <p>TFP-PEG3-TFP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TGN-020</p> <p style="text-align: right;">Cat. No.: HY-W008574</p> <p>TGN-020 is a selective Aquaporin 4 (AQP4) inhibitor with an IC_{50} of 3.1 μM. TGN-020 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats.</p>  <p>Purity: 98.03% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 10 mg, 50 mg, 100 mg</p>
<p>Thalidomide-O-amido-PEG4-azide</p> <p style="text-align: right;">Cat. No.: HY-141011</p> <p>Thalidomide-O-amido-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG4-propargyl</p> <p style="text-align: right;">Cat. No.: HY-141013</p> <p>Thalidomide-O-amido-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thiol-C10-amide-PEG8</p> <p>Cat. No.: HY-138533</p>	<p>Thiol-C2-PEG2-OH</p> <p>Cat. No.: HY-135085</p>
<p>Thiol-C10-amide-PEG8 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-C2-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-C9-PEG4</p> <p>Cat. No.: HY-138527</p>	<p>Thiol-C9-PEG4-acid</p> <p>Cat. No.: HY-138526</p>
<p>Thiol-C9-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-C9-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-C9-PEG5</p> <p>Cat. No.: HY-138529</p>	<p>Thiol-C9-PEG5-acid</p> <p>Cat. No.: HY-138528</p>
<p>Thiol-C9-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-C9-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-C9-PEG7</p> <p>Cat. No.: HY-138517</p>	<p>Thiol-PEG-CH2COOH (MW 2000)</p> <p>Cat. No.: HY-140728</p>
<p>Thiol-C9-PEG7 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG-CH2COOH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 2000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-PEG-CH2COOH (MW 3400)</p> <p>Cat. No.: HY-140729</p>	<p>Thiol-PEG-CH2COOH (MW 5000)</p> <p>Cat. No.: HY-140730</p>
<p>Thiol-PEG-CH2COOH (MW 3400) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 3400</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG-CH2COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>MW 5000</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 100 mg, 250 mg</p>











<p>Thiol-PEG-COOH (MW 5000)</p> <p style="text-align: right;">Cat. No.: HY-138310</p>	<p>Thiol-PEG10-alcohol (HS-PEG10-OH)</p> <p style="text-align: right;">Cat. No.: HY-133295</p>
<p>Thiol-PEG-COOH (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  <p>MW 5000</p> </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG10-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Thiol-PEG12-acid</p> <p style="text-align: right;">Cat. No.: HY-141326</p>	<p>Thiol-PEG12-alcohol (HS-PEG12-OH)</p> <p style="text-align: right;">Cat. No.: HY-133297</p>
<p>Thiol-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Thiol-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-PEG2-acid</p> <p style="text-align: right;">Cat. No.: HY-138524</p>	<p>Thiol-PEG2-t-butyl ester</p> <p style="text-align: right;">Cat. No.: HY-132100</p>
<p>Thiol-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG2-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-PEG3-acetic acid</p> <p style="text-align: right;">Cat. No.: HY-W190729</p>	<p>Thiol-PEG3-acid</p> <p style="text-align: right;">Cat. No.: HY-140018</p>
<p>Thiol-PEG3-acetic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG3-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: ≥95.0% Clinical Data: Size: 50 mg, 100 mg, 500 mg</p>
<p>Thiol-PEG3-Boc (Thiol-PEG3-t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-141327</p>	<p>Thiol-PEG3-NHBoc</p> <p style="text-align: right;">Cat. No.: HY-138759</p>
<p>Thiol-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG3-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <div style="text-align: center;">  </div> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thiol-PEG3-phosphonic acid</p> <p style="text-align: right;">Cat. No.: HY-141318</p> <p>Thiol-PEG3-phosphonic acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Thiol-PEG3-phosphonic acid ethyl ester</p> <p style="text-align: right;">Cat. No.: HY-141319</p> <p>Thiol-PEG3-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Thiol-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130213</p> <p>Thiol-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG4-alcohol (HS-PEG4-OH)</p> <p style="text-align: right;">Cat. No.: HY-133292</p> <p>Thiol-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Thiol-PEG4-amide-NH2</p> <p style="text-align: right;">Cat. No.: HY-138530</p> <p>Thiol-PEG4-amide-NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG4-Boc (Thiol-PEG4-t-butyl ester)</p> <p style="text-align: right;">Cat. No.: HY-141328</p> <p>Thiol-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thiol-PEG5-acid (HS-PEG5-CH2CH2COOH)</p> <p style="text-align: right;">Cat. No.: HY-133290</p> <p>Thiol-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Thiol-PEG5-alcohol (HS-PEG5-OH)</p> <p style="text-align: right;">Cat. No.: HY-133293</p> <p>Thiol-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Thiol-PEG6-acid</p> <p style="text-align: right;">Cat. No.: HY-133291</p> <p>Thiol-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Thiol-PEG6-alcohol (HS-PEG6-OH)</p> <p style="text-align: right;">Cat. No.: HY-130580</p> <p>Thiol-PEG6-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thiol-PEG8-acid</p> <p style="text-align: right;">Cat. No.: HY-130542</p> <p>Thiol-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thiol-PEG8-alcohol (HS-PEG8-OH)</p> <p style="text-align: right;">Cat. No.: HY-133294</p> <p>Thiol-PEG8-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: ≥98.0% Clinical Data: Size: 100 mg</p>
<p>Thiol-PEG9-alcohol (HS-PEG9-OH)</p> <p style="text-align: right;">Cat. No.: HY-133296</p> <p>Thiol-PEG9-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-C1-PEG5</p> <p style="text-align: right;">Cat. No.: HY-138403</p> <p>THP-C1-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-C4-PEG4</p> <p style="text-align: right;">Cat. No.: HY-138465</p> <p>THP-C4-PEG4 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-CH3-ethyl propionate</p> <p style="text-align: right;">Cat. No.: HY-138534</p> <p>THP-CH3-ethyl propionate is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG1-alcohol</p> <p style="text-align: right;">Cat. No.: HY-W038771</p> <p>THP-PEG1-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG1-Boc</p> <p style="text-align: right;">Cat. No.: HY-138368</p> <p>THP-PEG1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG1-THP</p> <p style="text-align: right;">Cat. No.: HY-138531</p> <p>THP-PEG1-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG10-Boc</p> <p style="text-align: right;">Cat. No.: HY-138347</p> <p>THP-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>THP-PEG10-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-138316</p>	<p>THP-PEG10-OH</p> <p style="text-align: right;">Cat. No.: HY-138413</p>
<p>THP-PEG10-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG10-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG10-THP</p> <p style="text-align: right;">Cat. No.: HY-134747</p>	<p>THP-PEG11-OH</p> <p style="text-align: right;">Cat. No.: HY-141227</p>
<p>THP-PEG10-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG11-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG11-THP</p> <p style="text-align: right;">Cat. No.: HY-132014</p>	<p>THP-PEG12-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132104</p>
<p>THP-PEG11-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG12-THP</p> <p style="text-align: right;">Cat. No.: HY-134699</p>	<p>THP-PEG13-Boc</p> <p style="text-align: right;">Cat. No.: HY-138478</p>
<p>THP-PEG12-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG13-OH</p> <p style="text-align: right;">Cat. No.: HY-138389</p>	<p>THP-PEG16-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132058</p>
<p>THP-PEG13-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>THP-PEG16-THP</p> <p style="text-align: right;">Cat. No.: HY-132077</p>	<p>THP-PEG2-Mal</p> <p style="text-align: right;">Cat. No.: HY-138404</p>
<p>THP-PEG16-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG2-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG2-methyl propionate</p> <p style="text-align: right;">Cat. No.: HY-138348</p>	<p>THP-PEG24-THP</p> <p style="text-align: right;">Cat. No.: HY-138329</p>
<p>THP-PEG2-methyl propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG24-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG3-OH</p> <p style="text-align: right;">Cat. No.: HY-130216</p>	<p>THP-PEG4-Boc</p> <p style="text-align: right;">Cat. No.: HY-138352</p>
<p>THP-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG4-C1-OH</p> <p style="text-align: right;">Cat. No.: HY-134675</p>	<p>THP-PEG4-OH</p> <p style="text-align: right;">Cat. No.: HY-130230</p>
<p>THP-PEG4-C1-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG4-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG4-Pyrrolidine(N-Boc)-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-130820</p>	<p>THP-PEG4-Pyrrolidine(N-Me)-CH2OH</p> <p style="text-align: right;">Cat. No.: HY-130821</p>
<p>THP-PEG4-Pyrrolidine(N-Boc)-CH2OH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degradar-1 (HY-129523).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>THP-PEG4-Pyrrolidine(N-Me)-CH2OH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degradar-1 (HY-129523).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>


<p>THP-PEG5-OH</p> <p style="text-align: right;">Cat. No.: HY-126917</p>	<p>THP-PEG6-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-138349</p>
<p>THP-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG6-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG6-OH</p> <p style="text-align: right;">Cat. No.: HY-126918</p>	<p>THP-PEG7-alcohol</p> <p style="text-align: right;">Cat. No.: HY-132068</p>
<p>THP-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. THP-PEG6-OH is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG7-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG8-Boc</p> <p style="text-align: right;">Cat. No.: HY-138340</p>	<p>THP-PEG8-OH</p> <p style="text-align: right;">Cat. No.: HY-126919</p>
<p>THP-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG8-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG8-THP</p> <p style="text-align: right;">Cat. No.: HY-132072</p>	<p>THP-PEG8-Tos</p> <p style="text-align: right;">Cat. No.: HY-141228</p>
<p>THP-PEG8-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG8-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>THP-PEG9-OH</p> <p style="text-align: right;">Cat. No.: HY-138483</p>	<p>THP-PEG9-THP</p> <p style="text-align: right;">Cat. No.: HY-134698</p>
<p>THP-PEG9-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>THP-PEG9-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

TLR4-IN-C34-C2-amide-C6-OH

Cat. No.: HY-145245

TLR4-IN-C34-C2-amide-C6-OH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.

Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg, 500 mg




TLR4-IN-C34-C2-COOH

Cat. No.: HY-W092043

TLR4-IN-C34-C2-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.

Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg, 500 mg, 1 g




Tos-aminoxy-Boc-PEG4-Tos

Cat. No.: HY-140380

Tos-aminoxy-Boc-PEG4-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg




Tos-O-C4-NH-Boc

Cat. No.: HY-132004

Tos-O-C4-NH-Boc is an alkyl ether-based PROTAC linker can be used in the synthesis of PROTACs, such as BSI-03-204 (HY-136250).

Purity: 96.31%
Clinical Data: No Development Reported
Size: 500 mg




Tos-PEG1-CH2-Boc

Cat. No.: HY-130158

Tos-PEG1-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg




Tos-PEG1-O-CH2COOH (PROTAC Linker 28)

Cat. No.: HY-125844

Tos-PEG1-O-CH2COOH (PROTAC Linker 28) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg




Tos-PEG12-Tos

Cat. No.: HY-140371

Tos-PEG12-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg




Tos-PEG13-Boc

Cat. No.: HY-140365

Tos-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg



Tos-PEG14-OH

Cat. No.: HY-134713

Tos-PEG14-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg




Tos-PEG2-Boc

Cat. No.: HY-130534










Tos-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg




<p>Tos-PEG2-C2-Boc</p> <p style="text-align: right;">Cat. No.: HY-133069</p>	<p>Tos-PEG2-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-130532</p>
<p>Tos-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG2-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG2-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130415</p>	<p>Tos-PEG2-NH-Boc</p> <p style="text-align: right;">Cat. No.: HY-135798</p>
<p>Tos-PEG2-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG2-NH-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.23% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg</p>
<p>Tos-PEG2-NH2 (PROTAC Linker 27)</p> <p style="text-align: right;">Cat. No.: HY-125842</p>	<p>Tos-PEG2-O-Propargyl</p> <p style="text-align: right;">Cat. No.: HY-130162</p>
<p>Tos-PEG2-NH2 (PROTAC Linker 27) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>Tos-PEG2-O-Propargyl is a PEG-based PROTAC linker can be used in the synthesis of Thalidomide-O-PEG2-propargyl (HY-126458).</p>  <p>Purity: 98.47% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Tos-PEG2-OH</p> <p style="text-align: right;">Cat. No.: HY-W090623</p>	<p>Tos-PEG2-THP</p> <p style="text-align: right;">Cat. No.: HY-132020</p>
<p>Tos-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG2-THP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG20-Tos</p> <p style="text-align: right;">Cat. No.: HY-140372</p>	<p>Tos-PEG21-Tos</p> <p style="text-align: right;">Cat. No.: HY-140373</p>
<p>Tos-PEG20-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Tos-PEG21-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>

<p>Tos-PEG3</p> <p style="text-align: right;">Cat. No.: HY-23408</p>	<p>Tos-PEG3-C2-methyl ester</p> <p style="text-align: right;">Cat. No.: HY-140375</p>
<p>Tos-PEG3 is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Tos-PEG3 (structure 1) can be used for the synthesis of 3'-aminoxy oligonucleotides solid supports.</p> <p style="text-align: center;"></p> <p>Purity: 97.39% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>	<p>Tos-PEG3-C2-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tos-PEG3-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130674</p>	<p>Tos-PEG3-CH2COOtBu</p> <p style="text-align: right;">Cat. No.: HY-45018</p>
<p>Tos-PEG3-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG3-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg</p>
<p>Tos-PEG3-NH-Boc (PROTAC Linker 9)</p> <p style="text-align: right;">Cat. No.: HY-128805</p>	<p>Tos-PEG3-O-C1-CH3COO (PROTAC Linker 6)</p> <p style="text-align: right;">Cat. No.: HY-128802</p>
<p>Tos-PEG3-NH-Boc (PROTAC Linker 9) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: 99.66% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg, 500 mg</p>	<p>Tos-PEG3-O-C1-CH3COO (PROTAC Linker 6) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG4-acid</p> <p style="text-align: right;">Cat. No.: HY-130417</p>	<p>Tos-PEG4-CH2-Boc</p> <p style="text-align: right;">Cat. No.: HY-42620</p>
<p>Tos-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG4-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 250 mg, 1 g</p>
<p>Tos-PEG4-CH2COOH</p> <p style="text-align: right;">Cat. No.: HY-130473</p>	<p>Tos-PEG4-NH-Boc (PROTAC Linker 7)</p> <p style="text-align: right;">Cat. No.: HY-128803</p>
<p>Tos-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG4-NH-Boc (PROTAC Linker 7) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) Cat. No.: HY-130422</p>	<p>Tos-PEG4-THP Cat. No.: HY-130819</p>
<p>Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) can be used in the synthesis of a series of PROTACs, such as BI-3663 (HY-111546).</p>  <p>Purity: 97.44% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Tos-PEG4-THP is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degradar-1 (HY-129523).</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg</p>
<p>Tos-PEG5-Boc Cat. No.: HY-130523</p>	<p>Tos-PEG5-C2-Boc Cat. No.: HY-133070</p>
<p>Tos-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG5-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG5-CH2COOtBu Cat. No.: HY-140366</p>	<p>Tos-PEG6-C2-Boc Cat. No.: HY-133071</p>
<p>Tos-PEG5-CH2COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG6-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG6-CH2-Boc Cat. No.: HY-130526</p>	<p>Tos-PEG6-OH Cat. No.: HY-140356</p>
<p>Tos-PEG6-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tos-PEG7-OH Cat. No.: HY-117028</p>	<p>Tos-PEG8-Tos Cat. No.: HY-140369</p>
<p>Tos-PEG7-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tos-PEG8-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

Tos-PEG9 Cat. No.: HY-140357


Tos-PEG9 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tos-PEG9-Boc Cat. No.: HY-125534


Tos-PEG9-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tos-PEG9-Tos Cat. No.: HY-140370


Tos-PEG9-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG2-OH Cat. No.: HY-114995


Tr-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Tr-PEG2-OH is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG4-OH Cat. No.: HY-126883


Tr-PEG4-OH is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG5-OH Cat. No.: HY-120845


Tr-PEG5-OH is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG8-OH Cat. No.: HY-130165


Tr-PEG8-OH is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tri(Amino-PEG3-amide)-amine Cat. No.: HY-140249


Tri(Amino-PEG3-amide)-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Tri(Amino-PEG3-amide)-amine TFA Cat. No.: HY-140249A


Tri(Amino-PEG3-amide)-amine TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tri(Amino-PEG4-amide)-amine Cat. No.: HY-140250

Tri(Amino-PEG4-amide)-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: ≥95.0%
Clinical Data:
Size: 100 mg, 250 mg

<p>Tri(Amino-PEG4-amide)-amine TFA</p> <p style="text-align: right;">Cat. No.: HY-140250A</p>	<p>Tri(Amino-PEG5-amide)-amine</p> <p style="text-align: right;">Cat. No.: HY-140251</p>
<p>Tri(Amino-PEG4-amide)-amine TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Tri(Amino-PEG5-amide)-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>
<p>Tri(Mal-PEG2-amide)-amine</p> <p style="text-align: right;">Cat. No.: HY-141008</p>	<p>Tri(t-butoxycarbonylethoxymethyl) ethanol</p> <p style="text-align: right;">Cat. No.: HY-113924</p>
<p>Tri(Mal-PEG2-amide)-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Tri(t-butoxycarbonylethoxymethyl) ethanol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH</p> <p style="text-align: right;">Cat. No.: HY-145255</p>	<p>Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH</p> <p style="text-align: right;">Cat. No.: HY-145253</p>
<p>Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Tri-(PEG1-C2-acid)</p> <p style="text-align: right;">Cat. No.: HY-140541</p>	<p>Triethylene glycol (PROTAC Linker 25)</p> <p style="text-align: right;">Cat. No.: HY-W017440</p>
<p>Tri-(PEG1-C2-acid) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: Size: 1 mg, 5 mg</p>	<p>Triethylene glycol (PROTAC Linker 25) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.88% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg</p>
<p>Triethylene glycol bis(p-toluenesulfonate) (Bis-Tos-PEG3)</p> <p style="text-align: right;">Cat. No.: HY-W013731</p>	<p>Triethylene glycol monobenzyl ether</p> <p style="text-align: right;">Cat. No.: HY-W044459</p>
<p>Triethylene glycol bis(p-toluenesulfonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.42% Clinical Data: No Development Reported Size: 500 mg</p>	<p>Triethylene glycol monobenzyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.</p>  <p>Purity: 99.25% Clinical Data: No Development Reported Size: 100 mg</p>

Triethylene glycol monodecyl ether

Cat. No.: HY-W190971

Triethylene glycol monodecyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triethylene glycol monododecyl ether

Cat. No.: HY-W142506

Triethylene glycol monododecyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

Cat. No.: HY-21577

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is also a PEG/Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg

Trityl-PEG10-azide

Cat. No.: HY-140861

Trityl-PEG10-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Trityl-PEG8-azide

Cat. No.: HY-140860

Trityl-PEG8-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trt-PEG4-C2-acid hydrate

Cat. No.: HY-W096111A

Trt-PEG4-C2-acid (hydrate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UV Cleavable Biotin-PEG2-Azide

Cat. No.: HY-140920

UV Cleavable Biotin-PEG2-Azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: ≥95.0%
Clinical Data:
Size: 25 mg, 100 mg

VES-POFP

Cat. No.: HY-134751

VES-POFP is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WSPC Biotin-PEG3-DBCO

Cat. No.: HY-140137

WSPC Biotin-PEG3-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[10-(Diethoxy-phosphoryl)-decyl]-phosphonic acid

Cat. No.: HY-140327

[10-(Diethoxy-phosphoryl)-decyl]-phosphonic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α -Lipoic acid-NHS

(DL- α -Lipoic acid-NHS)

Cat. No.: HY-141336

α -Lipoic acid-NHS is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%


Clinical Data:

Size: 1 mg, 5 mg

β -Estradiol-6-one 6-(O-carboxymethyloxime)

Cat. No.: HY-133407

β -Estradiol-6-one 6-(O-carboxymethyloxime) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

PROTAC-Linker Conjugates for PAC

PROTAC-Linker for PROTAC-antibody Conjugates


PROTAC-linker Conjugate for PAC comprises an antibody conjugated via a linker to a PROTAC. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding group ("E3LB"), a linker ("L2") and a protein binding group ("PB"). To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis. While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A "linker" (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D).

PROTAC-Linker Conjugates for PAC

PAC

Cat. No.: HY-112100

PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ER α) degrader compared to PROTAC (without Ab).




Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC BRD4 degrader for PAC-1

Cat. No.: HY-129938

PROTAC BRD4 degrader for PAC-1 (compound 5), a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 and disulfide-containing linker.




Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC BRD4 Degrader-5-CO-PEG3-N3

Cat. No.: HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader GNE-987 and PEG-based linker.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

PROTACs











PROTAC (PROteolysis-TARgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.

PROTACs Inhibitors, Agonists, Antagonists, Modulators & Chemicals

<p>(S)-GNE-987</p> <p>Cat. No.: HY-129937</p> <p>(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>A1874</p> <p>Cat. No.: HY-114305</p> <p>A1874 is a nutlin-based (MDM2 ligand) and BRD4-degrading PROTAC with a DC₅₀ of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.</p>  <p>Purity: 99.28% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>ACBI1</p> <p>Cat. No.: HY-128359</p> <p>ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC₅₀s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.</p>  <p>Purity: 98.21% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>AGB1</p> <p>Cat. No.: HY-145227</p> <p>AGB1 is a fast, highly selective, and potent bump-and-hole (B&H)-PROTAC degrader for BromoTag. AGB1 exhibits degradation for Ab:Brd4^{BD2 L387A} and Ab: BromoTag-Brd2 with pDC₅₀s of 7.8 and 7.9. AGB1 exhibits binary affinity to VHL (K_d=125 nM).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>ARCC-4</p> <p>Cat. No.: HY-130492</p> <p>ARCC-4 is a low-nanomolar Androgen Receptor (AR) degrader based on PROTAC, with a DC₅₀ of 5nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide.</p>  <p>Purity: 99.54% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>ARD-2128</p> <p>Cat. No.: HY-132292</p> <p>ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity.</p>  <p>Purity: 99.04% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>ARD-2585</p> <p>Cat. No.: HY-139436</p> <p>ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor.</p>  <p>Purity: 99.48% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>ARD-266</p> <p>Cat. No.: HY-133020</p> <p>ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.</p>  <p>Purity: 99.67% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>ARD-61</p> <p>Cat. No.: HY-139659</p> <p>ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>ARV-471</p> <p>Cat. No.: HY-138642</p> <p>ARV-471 is an oral estrogen receptor PROTAC protein degrader for breast cancer. ARV-471 is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex.</p>  <p>Purity: 99.60% Clinical Data: Phase 2 Size: 5 mg, 10 mg, 25 mg</p>











<p>ARV-771</p> <p style="text-align: right;">Cat. No.: HY-100972</p>	<p>ARV-825</p> <p style="text-align: right;">Cat. No.: HY-16954</p>
<p>ARV-771 is a potent BET PROTAC based on E3 ligase von Hippel-Lindau with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.</p>  <p>Purity: 99.02% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>ARV-825 is a PROTAC connected by ligands for Cereblon and BRD4. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.</p>  <p>Purity: 99.32% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>
<p>AT6</p> <p style="text-align: right;">Cat. No.: HY-112375</p>	<p>AU-15330</p> <p style="text-align: right;">Cat. No.: HY-145388</p>
<p>AT6 is a PROTAC AT1 analogue, which is a PROTAC connected by ligands for von Hippel-Lindau and BRD4 with highly selectivity to bromodomain (Brd4).</p>  <p>Purity: 98.74% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg</p>	<p>AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide.</p>  <p>Purity: 99.57% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Azido-PEG2-VHL</p> <p style="text-align: right;">Cat. No.: HY-145715</p>	<p>BETd-246</p> <p style="text-align: right;">Cat. No.: HY-115568</p>
<p>Azido-PEG2-VHL is a multikinase degrader which can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity.</p>  <p>Purity: 98.04% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>BETd-260 (ZBC 260)</p> <p style="text-align: right;">Cat. No.: HY-101519</p>	<p>BI-3663</p> <p style="text-align: right;">Cat. No.: HY-111546</p>
<p>BETd-260 (ZBC 260) is a PROTAC connected by ligands for Cereblon and BET, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line. BETd-260 potently suppresses cell viability and robustly induces apoptosis in hepatocellular carcinoma (HCC) cells.</p>  <p>Purity: 99.01% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>BI-3663 is a highly selective PTK2/FAK PROTAC (DC_{50}=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC_{50} of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker.</p>  <p>Purity: 98.14% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>BRD4 degrader AT1</p> <p style="text-align: right;">Cat. No.: HY-111433</p>	<p>BSJ-03-123</p> <p style="text-align: right;">Cat. No.: HY-111556</p>
<p>BRD4 degrader AT1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4 as a highly selective Brd4 degrader, with a K_d of 44 nM for Brd4^{BD2} in cells.</p>  <p>Purity: 98.90% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>BSJ-03-123 is a PROTAC connected by ligands for Cereblon and CDK as a potent and novel CDK6-selective small-molecule degrader.</p>  <p>Purity: 99.45% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>

<p>BSJ-03-204</p> <p style="text-align: right;">Cat. No.: HY-136250</p>	<p>BSJ-04-132</p> <p style="text-align: right;">Cat. No.: HY-136252</p>
<p>BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC_{50}s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively.</p>  <p>Purity: 98.34% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>BSJ-04-132 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC_{50}s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively.</p>  <p>Purity: 98.08% Clinical Data: No Development Reported Size: 5 mg</p>
<p>BSJ-4-116</p> <p style="text-align: right;">Cat. No.: HY-139039</p>	<p>CC-885-CH2-PEG1-NH-CH3</p> <p style="text-align: right;">Cat. No.: HY-145449</p>
<p>BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC_{50} of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).</p>  <p>Purity: 99.62% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>CC-885-CH2-PEG1-NH-CH3 is a neoDegradator that can be used in the synthesis of Antibody neoDegradator Conjugate (AnDC).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CCT367766</p> <p style="text-align: right;">Cat. No.: HY-122653</p>	<p>CFT-2718</p> <p style="text-align: right;">Cat. No.: HY-132941</p>
<p>CCT367766 is a potent and the third generation heterobifunctional and Cereblon-based pirin targeting protein degradation probe (PDP, or PROTAC), depletes pirin protein expression at low concentration.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CFT-2718 is a new BRD4-targeting degrader (PROTAC) with enhanced catalytic activity and in vivo properties.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CMP98</p> <p style="text-align: right;">Cat. No.: HY-136257</p>	<p>CP-10</p> <p style="text-align: right;">Cat. No.: HY-125835</p>
<p>CMP98, a PROTAC, is unable to induce degradation of VHL. CMP98 can be used as a negative control compound for CM11. CMP98 consists of two Hippel-Lindau ligands on their active domain.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p>	<p>CP-10 is a PROTAC connected by ligands for Cereblon and CDK, with highly selective, specific, and remarkable CDK6 degradation (DC_{50}=2.1 nM).</p>  <p>Purity: 98.03% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p>
<p>CP5V</p> <p style="text-align: right;">Cat. No.: HY-130257</p>	<p>CRBN-6-5-5-VHL</p> <p style="text-align: right;">Cat. No.: HY-136262</p>
<p>CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation.</p>  <p>Purity: 98.06% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>CRBN-6-5-5-VHL is a potent and selective von Hippel-Lindau-based cereblon (CRBN) degrader with a DC_{50} value of 1.5 nM. CRBN-6-5-5-VHL has almost no effect on the degradation of the neo-substrates IKZF1 and IKZF3.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DB-0646</p> <p style="text-align: right;">Cat. No.: HY-137343</p>	<p>dBET1</p> <p style="text-align: right;">Cat. No.: HY-101838</p>
<p>DB-0646, a PROTAC, is a multi-kinase degrader.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>dBET1 is a PROTAC connected by ligands for Cereblon and BRD4 with an EC_{50} of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker.</p> <p style="text-align: center;"></p> <p>Purity: 99.24% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>dBET23</p> <p style="text-align: right;">Cat. No.: HY-123911</p>	<p>dBET57</p> <p style="text-align: right;">Cat. No.: HY-123844</p>
<p>dBET23 is a highly effective and selective PROTAC BRD4 degrader with a $DC_{50/5h}$ of ~ 50 nM for BRD4_{BD1} protein.</p> <p style="text-align: center;"></p> <p>Purity: 99.33% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>dBET57 is a potent and selective degrader of BRD4_{BD1} based on the PROTAC technology. dBET57 mediates recruitment to the CRL4^{Cereblon E3} ubiquitin ligase, with a $DC_{50/5h}$ of 500 nM for BRD4_{BD1}, and is inactive on BRD4_{BD2}.</p> <p style="text-align: center;"></p> <p>Purity: 99.66% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>dBET6</p> <p style="text-align: right;">Cat. No.: HY-112588</p>	<p>dCBP-1</p> <p style="text-align: right;">Cat. No.: HY-134582</p>
<p>dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC_{50} of 14 nM, and has antitumor activity.</p> <p style="text-align: center;"></p> <p>Purity: 99.73% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression.</p> <p style="text-align: center;"></p> <p>Purity: 99.52% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>dFKBP-1</p> <p style="text-align: right;">Cat. No.: HY-103634</p>	<p>di-Ellipticine-RIBOTAC</p> <p style="text-align: right;">Cat. No.: HY-141878</p>
<p>dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of FKBP12, the Thalidomide based Cereblon ligand and a linker.</p> <p style="text-align: center;"></p> <p>Purity: 98.84% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>di-Ellipticine-RIBOTAC is a dual-function small molecule that reduces c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo amyotrophic lateral sclerosis (ALS) models.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>dMCL1-2</p> <p style="text-align: right;">Cat. No.: HY-128360</p>	<p>Dovitinib-RIBOTAC</p> <p style="text-align: right;">Cat. No.: HY-139682</p>
<p>dMCL1-2 is a potent and selective PROTAC of myeloid cell leukemia 1 (MCL1) (Bcl-2 family member) based on Cereblon, which binds to MCL1 with a K_D of 30 nM. dMCL1-2 activates the cellular apoptosis machinery by degradation of MCL1.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Dovitinib RIBOTAC is a targeted RNA degrader that cleaves pre-miR-21 with enhanced potency and selectivity.</p> <p style="text-align: center;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>DP-C-4</p> <p style="text-align: right;">Cat. No.: HY-141481</p>	<p>dTAGV-1 TFA</p> <p style="text-align: right;">Cat. No.: HY-145514</p>
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP.</p>  <p>Purity: 99.72% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12^{F36V} fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12^{F36V}-Nluc in vivo.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>dTRIM24</p> <p style="text-align: right;">Cat. No.: HY-111519</p>	<p>ERD-308</p> <p style="text-align: right;">Cat. No.: HY-128600</p>
<p>dTRIM24 is a selective bifunctional degrader of TRIM24 based on PROTAC, consists of ligands for von Hippel-Lindau and TRIM24.</p>  <p>Purity: 99.69% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment.</p>  <p>Purity: 99.05% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>FAK PROTAC B5</p> <p style="text-align: right;">Cat. No.: HY-143458</p>	<p>FKBP12 PROTAC dTAG-13 (dTAG-13)</p> <p style="text-align: right;">Cat. No.: HY-114421</p>
<p>FAK PROTAC B5 (Compound B5) is a FAK PROTAC degrader with an IC₅₀ value of 14.9 nM. FAK PROTAC B5 presents strong FAK degradation activity, antiproliferative activity, outstanding plasma stability and moderate membrane permeability. FAK PROTAC B5 inhibits cell migration and invasion.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12^{F36V} with expression of FKBP12F36V in-frame with a protein of interest.</p>  <p>Purity: 99.52% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>FKBP12 PROTAC dTAG-7 (dTAG-7)</p> <p style="text-align: right;">Cat. No.: HY-123941</p>	<p>FKBP12 PROTAC RC32 (RC32)</p> <p style="text-align: right;">Cat. No.: HY-130835</p>
<p>FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12^{F36V} with expression of FKBP12^{F36V} in-frame with a protein of interest.</p>  <p>Purity: 99.88% Clinical Data: No Development Reported Size: 5 mg</p>	<p>FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984).</p>  <p>Purity: 95.23% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Folate-MS432</p> <p style="text-align: right;">Cat. No.: HY-115873</p>	<p>Gefitinib-based PROTAC 3</p> <p style="text-align: right;">Cat. No.: HY-123921</p>
<p>Folate-MS432, a PROTAC, is capable of degrading MEKs in a folate receptor-dependent manner in cancer cells.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC₅₀s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutation) cells, respectively.</p>  <p>Purity: 99.98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>


<p>GMB-475</p> <p style="text-align: right;">Cat. No.: HY-125834</p> <p>GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.</p> <p>Purity: 99.20% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p> 	<p>GNE-987</p> <p style="text-align: right;">Cat. No.: HY-129937A</p> <p>GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. GNE-987 exhibits picomolar cell BRD4 degradation activity ($DC_{50}=0.03$ nM for EOL-1 AML cell line).</p> <p>Purity: 98.90% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 
<p>GSK215</p> <p style="text-align: right;">Cat. No.: HY-132296</p> <p>GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>HDAC6 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-132998</p> <p>HDAC6 degrader-1 is a PROTAC that comprises a selective HDAC6 inhibitor Nexturastat A (Nex A) as the HDAC6 binder, a linker and a ligand for recruiting E3 ligase.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Homo-PROTAC cereblon degrader 1</p> <p style="text-align: right;">Cat. No.: HY-111594</p> <p>Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient Cereblon (CRBN) degrader with only minimal effects on IKZF1 and IKZF3.</p> <p>Purity: 99.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 	<p>Homo-PROTAC pVHL30 degrader 1</p> <p style="text-align: right;">Cat. No.: HY-111593</p> <p>Homo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC, consists of two ligands of von Hippel-Lindau.</p> <p>Purity: 99.83% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>INY-03-041</p> <p style="text-align: right;">Cat. No.: HY-133120</p> <p>INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor GDC-0068 conjugated to Lenalidomide (Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC_{50}s of 2.0 nM, 6.8 nM and 3.5 nM, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>JB170</p> <p style="text-align: right;">Cat. No.: HY-141512</p> <p>JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader ($DC_{50}=28$ nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A ($EC_{50}=193$ nM) over AURORA-B ($EC_{50}=1.4$ μM).</p> <p>Purity: 98.40% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>JH-XI-10-02</p> <p style="text-align: right;">Cat. No.: HY-111518</p> <p>JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC_{50} of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.</p> <p>Purity: 98.18% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg</p> 	<p>JPS014</p> <p style="text-align: right;">Cat. No.: HY-145815</p> <p>JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 

<p>JPS016</p> <p style="text-align: right;">Cat. No.: HY-145816</p>	<p>JPS035</p> <p style="text-align: right;">Cat. No.: HY-145818</p>
<p>JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>JPS036</p> <p style="text-align: right;">Cat. No.: HY-145819</p>	<p>KB02-JQ1</p> <p style="text-align: right;">Cat. No.: HY-129917</p>
<p>JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems.</p>  <p>Purity: 98.29% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>KB02-SLF</p> <p style="text-align: right;">Cat. No.: HY-129610</p>	<p>LC-2</p> <p style="text-align: right;">Cat. No.: HY-137516</p>
<p>KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems.</p>  <p>Purity: 99.25% Clinical Data: No Development Reported Size: 1 mg</p>	<p>LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC₅₀s between 0.25 and 0.76 μM.</p>  <p>Purity: ≥95.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg</p>
<p>MC-VC-PABC-amide-PEG1-CH2-CC-885</p> <p style="text-align: right;">Cat. No.: HY-145448</p>	<p>MD-222</p> <p style="text-align: right;">Cat. No.: HY-134823</p>
<p>MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>MD-222 is the first-in-class highly potent PROTAC degrader of MDM2. MD-222 consists of ligands for Cereblon and MDM2. MD-222 induces rapid degradation of the MDM2 protein and activation of wild-type p53 in cells. MD-222 has anticancer effects.</p>  <p>Purity: 99.28% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>MD-224</p> <p style="text-align: right;">Cat. No.: HY-114312</p>	<p>MG-277</p> <p style="text-align: right;">Cat. No.: HY-130122</p>
<p>MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 consists of ligands for Cereblon and MDM2.</p>  <p>Purity: 99.74% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor based on Cereblon E3 ligand, GSPT1, with a DC₅₀ of 1.3 nM.</p>  <p>Purity: 98.94% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>

MI-389

Cat. No.: HY-136688

MI-389 is a PROTAC translation termination factor **GSPT1** degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4^{CRBN} E3 ligase.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS170

Cat. No.: HY-145282

MS170 is a potent and selective **PROTAC AKT** degrader. MS170 depletes cellular total AKT (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MS21

Cat. No.: HY-141807

MS21, a novel degrader of **AKT**, selectively inhibits the growth of PI3K/PTEN pathway-mutant cancers with wild-type KRAS and BRAF.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS33

Cat. No.: HY-141797

MS33 is a potent **WDR5** degrader, with K_ds of 870 nM and 120 nM for **VCB** and **WDR5**, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS4077

Cat. No.: HY-112156

MS4077 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 37 nM for binding affinity to ALK.




Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MS4078

Cat. No.: HY-112155

MS4078 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 19 nM for binding affinity to ALK.




Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MS432

Cat. No.: HY-130602

MS432 is a first-in-class and highly selective PD0325901-based **von Hippel-Lindau**-recruiting **PROTAC** degrader for **MEK1** and **MEK2**. MS432 displays good plasma exposure in mice, exhibiting DC₅₀ values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS4322

Cat. No.: HY-141877

MS4322 is a first-in-class **PRMT5** degrader and a valuable chemical tool (**PROTAC**) for exploring the **PRMT5** functions in health and disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS5033

Cat. No.: HY-143882

MS5033 is a potent **PROTAC**-based **AKT (protein kinase B)** degrader, with a DC₅₀ of 430 nM in PC3 cells.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



MS67

Cat. No.: HY-141796

MS67 is a potent and selective **WD40 repeat domain protein 5 (WDR5)** degrader with a K_d of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

<p>MS83</p> <p style="text-align: right;">Cat. No.: HY-139620</p>	<p>MS98</p> <p style="text-align: right;">Cat. No.: HY-145281</p>
<p>MS83 is a proof-of-concept PROTAC by linking the KEAP1 ligand to a BRD4/3/2 binder.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total AKT (T-AKT) with the DC₅₀ value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with K_ds of 4 nM, 140 nM, and 8.1 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MT-802</p> <p style="text-align: right;">Cat. No.: HY-122562</p>	<p>MZ 1</p> <p style="text-align: right;">Cat. No.: HY-107425</p>
<p>MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC₅₀ of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).</p>  <p>Purity: 98.55% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. K_ds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively.</p>  <p>Purity: 99.43% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 50 mg</p>
<p>MZP-54</p> <p style="text-align: right;">Cat. No.: HY-112376</p>	<p>MZP-55</p> <p style="text-align: right;">Cat. No.: HY-112377</p>
<p>MZP-54 is a PROTAC connected by ligands for von Hippel-Lindau and BRD3/4, with a K_d of 4 nM for Brd4^{BD2}.</p>  <p>Purity: 98.16% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>MZP-55 is a PROTAC connected by ligands for von Hippel-Lindau and BRD3/4, with a K_d of 8 nM for Brd4^{BD2}.</p>  <p>Purity: 99.13% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>NJH-2-056</p> <p style="text-align: right;">Cat. No.: HY-143344</p>	<p>OARV-771</p> <p style="text-align: right;">Cat. No.: HY-145264</p>
<p>NJH-2-056 is a deubiquitinase-targeting chimera (DUBTAC) linking the OTUB1 recruiter EN523 to the CFTR chaperone lumacaftor. NJH-2-056 can be used for cystic fibrosis research.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>OARV-771 is a VHL-based BET degrader (PROTAC) with improved cell permeability. OARV-771 shows DC₅₀s of 6, 1, and 4 nM for Brd4, Brd2 and Brd3, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PhosTAC7</p> <p style="text-align: right;">Cat. No.: HY-145232</p>	<p>Pomalidomide-C5-Dovitinib</p> <p style="text-align: right;">Cat. No.: HY-139996</p>
<p>Similar to PROTACs in their ability to induce ternary complexes, PhosTAC7 focuses on recruiting a Ser/Thr phosphatase to a phosphosubstrate to mediate its dephosphorylation.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>PROTAC AR Degradar-4</p> <p style="text-align: right;">Cat. No.: HY-111848</p>	<p>PROTAC AR Degradar-4 TFA</p> <p style="text-align: right;">Cat. No.: HY-111848A</p>
<p>PROTAC AR Degradar-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degradar-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC AR Degradar-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degradar-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).</p> <p>Purity: ≥98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p>
<p>PROTAC AR-V7 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-145479</p>	<p>PROTAC Axl Degradar 1</p> <p style="text-align: right;">Cat. No.: HY-144624</p>
<p>PROTAC AR-V7 degrader-1 (Compound 6) is a potent, orally bioavailable and selective AR-V7 degrader with the DC_{50} of 0.32 μM by recruiting VHL E3 ligase to Androgen receptor (AR) DNA binding domain (DBD) binder.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC Axl Degradar 1 is a potent and selective PROTAC Axl degrader with an IC_{50} of 0.92 μM. PROTAC Axl Degradar 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degradar 1 induces mehuosis.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC Axl Degradar 2</p> <p style="text-align: right;">Cat. No.: HY-144627</p>	<p>PROTAC B-Raf degrader 1</p> <p style="text-align: right;">Cat. No.: HY-111758</p>
<p>PROTAC Axl Degradar 2 is a potent and selective PROTAC Axl degrader with an IC_{50} of 1.61 μM. PROTAC Axl Degradar 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degradar 2 induces mehuosis.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity.</p> <p>Purity: 99.18%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p>
<p>PROTAC Bcl-xL degrader-1</p> <p style="text-align: right;">Cat. No.: HY-131188</p>	<p>PROTAC Bcl-xL degrader-2</p> <p style="text-align: right;">Cat. No.: HY-139309</p>
<p>PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an IAP E3 ligases binding group.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC Bcl-xL degrader-2 is a potent Bcl-xL (Bcl-2 family member) degrader based on von Hippel-Lindau ligand, with an IC_{50} of 0.6 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p>
<p>PROTAC Bcl-xL degrader-3</p> <p style="text-align: right;">Cat. No.: HY-132997</p>	<p>PROTAC Bcl2 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-125876</p>
<p>PROTAC Bcl-xL degrader-3 is a potent PROTAC Bcl-xL degrader (WO2020163823A2, compound 44).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC_{50}, 4.94 μM; DC_{50}, 3.0 μM) and Mcl-1 (IC_{50}, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to...</p> <p>Purity: 98.78%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p>

<p>PROTAC BET Degrader-1</p> <p style="text-align: right;">Cat. No.: HY-103633</p> <p>PROTAC BET Degrader-1 is a PROTAC connected by ligands for Cereblon and BET, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.</p>  <p>Purity: 98.30% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>PROTAC BET Degrader-10</p> <p style="text-align: right;">Cat. No.: HY-112718</p> <p>PROTAC BET Degrader-10 is a potent BET protein BRD4 degrader extracted from patent WO2017007612A1, example 37, connected by ligands for Cereblon and BRD4, with a DC_{50} of 49 nM.</p>  <p>Purity: 98.89% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>PROTAC BET degrader-2</p> <p style="text-align: right;">Cat. No.: HY-114228</p> <p>PROTAC BET degrader-2 is a PROTAC connected by ligands for Cereblon and BET with an IC_{50} value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.</p>  <p>Purity: 98.21% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>PROTAC BET degrader-3</p> <p style="text-align: right;">Cat. No.: HY-114229</p> <p>PROTAC BET Degrader-3 is a PROTAC connected by ligands for von Hippel-Lindau and BET.</p>  <p>Purity: 98.64% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>PROTAC BRD2/BRD4 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-130612</p> <p>PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-1</p> <p style="text-align: right;">Cat. No.: HY-133131</p> <p>PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC_{50} of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC BRD4 Degrader-10</p> <p style="text-align: right;">Cat. No.: HY-138633</p> <p>PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 1.3 nM and 18 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-11</p> <p style="text-align: right;">Cat. No.: HY-138634</p> <p>PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.23 nM and 0.38 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC BRD4 Degrader-12</p> <p style="text-align: right;">Cat. No.: HY-138635</p> <p>PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.39 nM and 0.24 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-13</p> <p style="text-align: right;">Cat. No.: HY-138636</p> <p>PROTAC BRD4 Degrader-13 (compound 9d) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-13 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.025 nM and 6.0 nM, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>PROTAC BRD4 Degrader-14</p> <p style="text-align: right;">Cat. No.: HY-138637</p>	<p>PROTAC BRD4 Degrader-15</p> <p style="text-align: right;">Cat. No.: HY-139294</p>
<p>PROTAC BRD4 Degrader-14 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC_{50}s of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-14 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC_{50}s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC BRD4 Degrader-2</p> <p style="text-align: right;">Cat. No.: HY-133136</p>	<p>PROTAC BRD4 Degrader-3</p> <p style="text-align: right;">Cat. No.: HY-135558</p>
<p>PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC_{50} of 14.2 nM against BRD4 BD1.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-3 (compound 1004.1) is an efficacious PROTAC connected by ligands for von Hippel-Lindau and BRD4.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC BRD4 Degrader-5</p> <p style="text-align: right;">Cat. No.: HY-133737</p>	<p>PROTAC BRD4 Degrader-7</p> <p style="text-align: right;">Cat. No.: HY-136857</p>
<p>PROTAC BRD4 Degrader-5 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-5 can potent degrade BRD4 in HER2 positive and negative breast cancer cell lines.</p> <p>Purity: 99.51%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p>	<p>PROTAC BRD4 Degrader-7 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC_{50}s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC BRD4 Degrader-8</p> <p style="text-align: right;">Cat. No.: HY-138555</p>	<p>PROTAC BRD4 Degrader-9</p> <p style="text-align: right;">Cat. No.: HY-138632</p>
<p>PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC_{50}s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.</p> <p>Purity: 98.06%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.86 nM and 7.6 nM, respectively.</p> <p>Purity: 98.23%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p>
<p>PROTAC BRD9 Degrader-1</p> <p style="text-align: right;">Cat. No.: HY-103632</p>	<p>PROTAC BRD9 Degrader-2</p> <p style="text-align: right;">Cat. No.: HY-145395</p>
<p>PROTAC BRD9 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD9 (IC_{50}=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology.</p> <p>Purity: 98.30%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p>	<p>PROTAC BRD9 Degrader-2 is a BRD9 bifunctional degrader for treating cancer.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

<p>PROTAC BRD9 Degradar-3</p> <p style="text-align: right;">Cat. No.: HY-145400</p>	<p>PROTAC BRD9 Degradar-4</p> <p style="text-align: right;">Cat. No.: HY-145403</p>
<p>PROTAC BRD9 Degradar-3 is a BRD9 bifunctional degrader for treating cancer.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC BRD9 Degradar-4 is a BRD9 bifunctional degrader for treating cancer.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC BRD9 Degradar-5</p> <p style="text-align: right;">Cat. No.: HY-145947</p>	<p>PROTAC CBP/P300 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-138536</p>
<p>PROTAC BRD9 Degradar-5 is a PROTAC for targeted degradation of BRD9.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC CBP/P300 Degradar-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degradar-1 potently inhibited cell viability of multiple cancer cell lines.</p>  <p>Purity: 99.18% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>PROTAC CDK2/9 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-130709</p>	<p>PROTAC CDK9 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-103628</p>
<p>PROTAC CDK2/9 Degradar-1 (Compound F3) is a potent dual degrader for CDK2 ($DC_{50}=62$ nM) and CDK9 ($DC_{50}=33$ nM). PROTAC CDK2/9 Degradar-1 suppresses prostate cancer PC-3 cell proliferation ($IC_{50}=0.12$ μM) by effectively blocking the cell cycle in S and G2/M phases.</p>  <p>Purity: 99.85% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>PROTAC CDK9 Degradar-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective CDK9 degrader.</p>  <p>Purity: 98.34% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg</p>
<p>PROTAC CDK9 degrader-2</p> <p style="text-align: right;">Cat. No.: HY-112811</p>	<p>PROTAC CDK9 degrader-4</p> <p style="text-align: right;">Cat. No.: HY-115728</p>
<p>PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC_{50} of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC CDK9 degrader-4 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC CRABP-II Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-111840</p>	<p>PROTAC CRABP-II Degradar-2</p> <p style="text-align: right;">Cat. No.: HY-111841</p>
<p>PROTAC CRABP-II Degradar-1 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC CRABP-II Degradar-2 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>PROTAC CRABP-II Degradar-3</p> <p style="text-align: right;">Cat. No.: HY-111842</p> <p>PROTAC CRABP-II Degradar-3 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC CRBN Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-128845</p> <p>PROTAC CRBN Degradar-1 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Lindau (VHL) binding group. PROTAC CRBN Degradar-1 is an cereblon (CRBN) degrader.</p>  <p>Purity: 99.34% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>PROTAC EED degrader-1</p> <p style="text-align: right;">Cat. No.: HY-130614</p> <p>PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_b of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC_{50}=8.17) targeting the EED subunit.</p>  <p>Purity: 99.56% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>PROTAC EED degrader-2</p> <p style="text-align: right;">Cat. No.: HY-130615</p> <p>PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_b of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC_{50}=8.11) targeting the EED subunit.</p>  <p>Purity: 98.64% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>PROTAC EGFR degrader 2</p> <p style="text-align: right;">Cat. No.: HY-144304</p> <p>PROTAC EGFR degrader 2 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC_{50} of 4.0 nM and good EGFR degradation activity with DC_{50} of 36.51 nM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC EGFR degrader 3</p> <p style="text-align: right;">Cat. No.: HY-144605</p> <p>PROTAC EGFR degrader 3 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectivity. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC ER Degradar-10</p> <p style="text-align: right;">Cat. No.: HY-145073</p> <p>PROTAC ER Degradar-10 is a potent PROTAC ER degrader and can be used for cancer research. PROTAC ER Degradar-10 is extracted from patent WO2021133886, example 36.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC ER Degradar-2</p> <p style="text-align: right;">Cat. No.: HY-128528</p> <p>PROTAC ER Degradar-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC ER Degradar-3</p> <p style="text-align: right;">Cat. No.: HY-128527</p> <p>PROTAC ER Degradar-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC ER Degradar-4</p> <p style="text-align: right;">Cat. No.: HY-135309</p> <p>PROTAC ER Degradar-4 is a von Hippel-Lindau-based PROTAC estrogen receptor (ER) degrader, binding to ER with an IC_{50} of 0.8 nM. PROTAC ER Degradar-4 induces ER degradation in MCF-7 cells with an IC_{50} of 0.3 nM.</p>  <p>Purity: 98.05% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>

<p>PROTAC ERRα Degradere-1</p> <p style="text-align: right;">Cat. No.: HY-128838</p> <p>PROTAC ERRα Degradere-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRα) binding group. PROTAC ERRα Degradere-1 is an PROTAC estrogen-related receptor alpha (ERRα) degrader.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>PROTAC ERRα Degradere-2</p> <p style="text-align: right;">Cat. No.: HY-128839</p> <p>PROTAC ERRα Degradere-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRα) binding group. PROTAC ERRα Degradere-2 is an estrogen-related receptor alpha (ERRα) degrader.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC ERRα Degradere-3</p> <p style="text-align: right;">Cat. No.: HY-139185</p> <p>PROTAC ERRα Degradere-3 is a potent and selective ERRα degrader based on von Hippel-Lindau ligand. PROTAC ERRα Degradere-3 is capable of specifically degrading ERRα protein by >80% at a concentration of 30 nM. PROTAC ERRα Degradere-3 is inactive against ERRβ and ERRγ proteins.</p> <p>Purity: 98.82% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>PROTAC ERα Degradere-1</p> <p style="text-align: right;">Cat. No.: HY-112098</p> <p>PROTAC ERα Degradere-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degradere-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degradere-1 is an estrogen receptor-alpha (ERα) degrader.</p> <p>Purity: 99.59% Clinical Data: No Development Reported Size: 2 mg, 5 mg, 10 mg</p> 
<p>PROTAC ERα Degradere-2</p> <p style="text-align: right;">Cat. No.: HY-111846</p> <p>PROTAC ERα Degradere-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degradere-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.</p> <p>Purity: 98.88% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>PROTAC ERα Y537S degrader-1</p> <p style="text-align: right;">Cat. No.: HY-145071</p> <p>PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC FAK degrader 1</p> <p style="text-align: right;">Cat. No.: HY-119932</p> <p>PROTAC FAK degrader 1 is a selective and potent von Hippel-Lindau-based focal adhesion kinase (FAK) degrader with an IC₅₀ of 6.5 nM, DC₅₀ of 3 nM.</p> <p>Purity: 99.87% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 	<p>PROTAC FKBP Degradere-3</p> <p style="text-align: right;">Cat. No.: HY-135345</p> <p>PROTAC FKBP Degradere-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and a von Hippel-Lindau binding group. PROTAC FKBP Degradere-3 is a potent FKBP degrader.</p> <p>Purity: 98.73% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 
<p>PROTAC FLT-3 degrader 1</p> <p style="text-align: right;">Cat. No.: HY-114323</p> <p>PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC₅₀ 0.6 nM. Anti-proliferative activity; apoptosis induction.</p> <p>Purity: 98.70% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 	<p>PROTAC HSP90 degrader BP3</p> <p style="text-align: right;">Cat. No.: HY-115997</p> <p>PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 



<p>PROTAC IDO1 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-131911</p>	<p>PROTAC IRAK3 degrade-1</p> <p style="text-align: right;">Cat. No.: HY-142662</p>
<p>PROTAC IDO1 Degradar-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC_{50}=2.84 μM).</p> <p>Purity: 98.17%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>PROTAC IRAK3 degrade-1 is a potent and selective degrader of IRAK3 (IC_{50} = 5 nM).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC IRAK4 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-129966</p>	<p>PROTAC IRAK4 degrader-3</p> <p style="text-align: right;">Cat. No.: HY-135382A</p>
<p>PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1. Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively.</p> <p>Purity: 99.55%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC IRAK4 degrader-4</p> <p style="text-align: right;">Cat. No.: HY-139315</p>	<p>PROTAC IRAK4 degrader-5</p> <p style="text-align: right;">Cat. No.: HY-139316</p>
<p>PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>PROTAC IRAK4 degrader-6</p> <p style="text-align: right;">Cat. No.: HY-139317</p>	<p>PROTAC K-Ras Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-129523</p>
<p>PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>PROTAC K-Ras Degradar-1 (Compound 518) is potent K-Ras degrader based on Cereblon E3 ligand, exhibits \geq70% degradation efficacy in SW1573 cells.</p> <p>Purity: 98.06%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p>
<p>PROTAC KRAS G12C degrader-1</p> <p style="text-align: right;">Cat. No.: HY-139186</p>	<p>PROTAC Mcl1 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-125877</p>
<p>PROTAC KRAS G12C degrader-1 is a Cereblon-based KRAS^{G12C} degrader, with an IC_{50} of 414 nM for CRBN. PROTAC KRAS G12C degrader-1 induces CRBN/KRAS^{G12C} dimerization and degrades GFP- KRAS^{G12C} in reporter cells.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on Cereblon ligand, is a potently and selectively Mcl-1 (Bcl-2 family member) inhibitor with an IC_{50} of 0.78 μM.</p> <p>Purity: 98.13%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p>

<p>PROTAC MDM2 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-128840</p> <p>PROTAC MDM2 Degradar-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degradar-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.</p> <p>Purity: 98.39% Clinical Data: No Development Reported Size: 10 mg, 25 mg</p> 	<p>PROTAC MDM2 Degradar-2</p> <p style="text-align: right;">Cat. No.: HY-128841</p> <p>PROTAC MDM2 Degradar-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degradar-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.</p> <p>Purity: 98.50% Clinical Data: No Development Reported Size: 10 mg, 25 mg</p> 
<p>PROTAC MDM2 Degradar-3</p> <p style="text-align: right;">Cat. No.: HY-128842</p> <p>PROTAC MDM2 Degradar-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degradar-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.</p> <p>Purity: 98.69% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 	<p>PROTAC MDM2 Degradar-4</p> <p style="text-align: right;">Cat. No.: HY-128843</p> <p>PROTAC MDM2 Degradar-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degradar-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC PARP1 degrader</p> <p style="text-align: right;">Cat. No.: HY-114324</p> <p>PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC₅₀ of 6.12 μM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>PROTAC PD-1/PD-L1 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-131183</p> <p>PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.</p> <p>Purity: 98.35% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>PROTAC RAR Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-111844</p> <p>PROTAC RAR Degradar-1 comprises a IAP ligand binding group, a linker and a RAR ligand binding group. PROTAC RAR Degradar-1 is an RAR degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells.</p> <p>Purity: 95.02% Clinical Data: No Development Reported Size: 1 mg</p> 	<p>PROTAC RIPK degrader-2</p> <p style="text-align: right;">Cat. No.: HY-111866</p> <p>PROTAC RIPK degrader-2 is a nonpeptidic PROTAC based on von Hippel-Lindau ligand which potently targets serine-threonine kinase RIPK2 and has highly selective for RIPK2 degradation.</p> <p>Purity: 99.05% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p> 
<p>PROTAC RIPK degrader-6</p> <p style="text-align: right;">Cat. No.: HY-111870</p> <p>PROTAC RIPK degrader-6 (example 1) is a Cereblon-based PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder.</p> <p>Purity: 99.32% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p> 	<p>PROTAC SGK3 degrader-1 (SGK3-PROTAC1)</p> <p style="text-align: right;">Cat. No.: HY-125878</p> <p>PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent SGK3 degrader based on von Hippel-Lindau ligand.</p> <p>Purity: 99.32% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 

<p>PROTAC Sirt2 Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-103636</p>	<p>PROTAC SOS1 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-145737</p>
<p>PROTAC Sirt2 Degradar-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase.</p> <p>Purity: 98.50% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 	<p>PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 agonist with an DC_{50} of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC SOS1 degrader-2</p> <p style="text-align: right;">Cat. No.: HY-144657</p>	<p>PROTAC TTK degrader-1</p> <p style="text-align: right;">Cat. No.: HY-143904</p>
<p>PROTAC SOS1 degrader-2 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-2 decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. PROTAC SOS1 degrader-2 significantly inhibits the tumor growth in vivo.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC_{50} values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC TTK degrader-2</p> <p style="text-align: right;">Cat. No.: HY-143905</p>	<p>PROTAC VEGFR-2 degrader-1</p> <p style="text-align: right;">Cat. No.: HY-146368</p>
<p>PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC_{50} values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>The compound is a new angiogenesis inhibitor, which can be used to normalize abnormal blood vessels and effectively deliver drugs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PROTAC-O4I2</p> <p style="text-align: right;">Cat. No.: HY-141881</p>	<p>PROTAC Hemagglutinin Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-147654</p>
<p>PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC_{50} value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells.</p> <p>Purity: 98.00% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>PROTAC Hemagglutinin Degradar-1 (Compound V3) is a potent PROTAC influenza hemagglutinin (HA) degrader with a median degradation concentration of 1.44 μM. PROTAC Hemagglutinin Degradar-1 shows broad-spectrum anti-influenza virus activity.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>PZ703b</p> <p style="text-align: right;">Cat. No.: HY-115718</p>	<p>QCA570</p> <p style="text-align: right;">Cat. No.: HY-112609</p>
<p>PZ703b is a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>QCA570 is a PROTAC connected by ligands for Cereblon and BET, with an IC_{50} of 10 nM for BRD4 BD1 Protein.</p> <p>Purity: 99.69% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 

<p>RIP2 Kinase Inhibitor 4</p> <p style="text-align: right;">Cat. No.: HY-136010</p> <p>RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC₅₀ of 8) and inhibits the release of related TNF-α.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SB1-G-187</p> <p style="text-align: right;">Cat. No.: HY-137342</p> <p>SB1-G-187, a PROTAC, is a multi-kinase degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SD-36</p> <p style="text-align: right;">Cat. No.: HY-129602</p> <p>SD-36 is a potent and efficacious STAT3 PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC₅₀=10 nM).</p>  <p>Purity: 99.46% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>SHP2 protein degrader-1</p> <p style="text-align: right;">Cat. No.: HY-145159</p> <p>SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for researching SHP2 related diseases.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SHP2 protein degrader-2</p> <p style="text-align: right;">Cat. No.: HY-145703</p> <p>SHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SHP2-D26</p> <p style="text-align: right;">Cat. No.: HY-145162</p> <p>SHP2-D26 is a first, potent and effective SHP2 degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SIAIS117</p> <p style="text-align: right;">Cat. No.: HY-146022</p> <p>SIAIS117 is a potent Brigatinib-PROTAC degrader. SIAIS117 is a ALK PROTAC based on Brigatinib and VHL-1 conjugation. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SIAIS178</p> <p style="text-align: right;">Cat. No.: HY-128756</p> <p>SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC₅₀ of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.</p>  <p>Purity: 99.48% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>SIM1</p> <p style="text-align: right;">Cat. No.: HY-141438</p> <p>SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all BET family members, with preference for BRD2 degradation (IC₅₀=1.1 nM; K_d=186 nM). SIM1 shows sustained anti-cancer activity.</p>  <p>Purity: 99.72% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>SJ10542</p> <p style="text-align: right;">Cat. No.: HY-145696</p> <p>SJ10542 is a potent and selective JAK2/3 directing phenyl glutarimide (PG)-PROTAC with DC_{50s} of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>


<p>SJ995973</p> <p style="text-align: right;">Cat. No.: HY-145125</p>	<p>SJF620</p> <p style="text-align: right;">Cat. No.: HY-133137</p>
<p>SJ995973 (PROTAC) is a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SJF620 is a PROTAC connected by ligands for Cereblon and Btk with a DC₅₀ of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.</p>  <p>Purity: 99.27% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>
<p>SJF620 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-133137A</p>	<p>SJFα</p> <p style="text-align: right;">Cat. No.: HY-114404</p>
<p>SJF620 hydrochloride is a PROTAC connected by ligands for Cereblon and Btk with a DC₅₀ of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.</p>  <p>Purity: 99.28% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>SJFα is a 13-atom linker PROTAC based on von Hippel-Lindau ligand. SJFα degrades p38α with a DC₅₀ of 7.16nM, but is far less effective at degrading p38δ (DC₅₀=299nM) and does not degrade the other p38 isoforms (β and γ) at concentrations up to 2.5μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SJFδ</p> <p style="text-align: right;">Cat. No.: HY-114405</p>	<p>SK-575</p> <p style="text-align: right;">Cat. No.: HY-139156</p>
<p>SJFδ is a 10-atom linker PROTAC based on von Hippel-Lindau ligand. SJFδ degrades p38δ with a DC₅₀ of 46.17nM, but does not degrade p38α, p38β, or p38γ.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p>	<p>SK-575 is a highly potent and specific proteolysis-targeting chimera (PROTAC) degrader of PARP1. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SR-1114</p> <p style="text-align: right;">Cat. No.: HY-115881</p>	<p>TD-165</p> <p style="text-align: right;">Cat. No.: HY-130714</p>
<p>SR-1114 is a first-in-class PROTAC ENL degrader. SR-1114 elicits rapid, CRBN-dependent degradation of ENL with DC₅₀s of 150 nM, 311 nM, and 1.65 μM in MV4;11, MOLM-13, and OCI/AML-2 cells, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TD-165 is a PROTAC-based cereblon (CRBN) degrader. TD-165 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.</p>  <p>Purity: 98.01% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>TD-428</p> <p style="text-align: right;">Cat. No.: HY-114407</p>	<p>TD-802</p> <p style="text-align: right;">Cat. No.: HY-146397</p>
<p>TD-428 is a PROTAC connected by ligands for Cereblon and BRD4. TD-428 is a highly specific BRD4 degrader with a DC₅₀ of 0.32 nM. TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>THAL-SNS-032</p> <p style="text-align: right;">Cat. No.: HY-123937</p>	<p>Thalidomide-NH-CBP/p300 ligand 2</p> <p style="text-align: right;">Cat. No.: HY-139707</p>
<p>THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).</p> <p style="text-align: right;"></p> <p>Purity: 99.16% Clinical Data: No Development Reported Size: 5 mg</p>	<p>Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440).</p> <p style="text-align: right;"></p> <p>Purity: 99.85% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>TL12-186</p> <p style="text-align: right;">Cat. No.: HY-130665</p>	<p>TL13-112</p> <p style="text-align: right;">Cat. No.: HY-123919</p>
<p>TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM).</p> <p style="text-align: right;"></p> <p>Purity: 98.05% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg</p>	<p>TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.14 nM.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>TL13-12</p> <p style="text-align: right;">Cat. No.: HY-122582</p>	<p>UNC6852</p> <p style="text-align: right;">Cat. No.: HY-130708</p>
<p>TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.69 nM.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>UNC6852 is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a von Hippel-Lindau ligand, with an IC₅₀ of 247 nM for EED.</p> <p style="text-align: right;"></p> <p>Purity: 98.68% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>VZ185</p> <p style="text-align: right;">Cat. No.: HY-114322</p>	<p>XY-06-007</p> <p style="text-align: right;">Cat. No.: HY-145226</p>
<p>VZ185 is a potent, fast, and selective von Hippel-Lindau based dual degrader probe of BRD9 and BRD7 with DC₅₀s of 4.5 and 1.8 nM, respectively. VZ185 is cytotoxic in EOL-1 and A-402 cells, with EC₅₀s of 3 nM and 40 nM, respectively.</p> <p style="text-align: right;"></p> <p>Purity: 98.34% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>XY-06-007 is a selective and potent bump-and-hole (B&H)-PROTAC BRD4_{BD1}L94V degrader. XY-06-007 shows a DC_{50, 6 h} of 10 nM against BRD4_{BD1}L94V with no degradation of off-targets. XY-06-007 demonstrates suitable pharmacokinetics for in vivo studies.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>XY028-133</p> <p style="text-align: right;">Cat. No.: HY-129180</p>	<p>XY028-140</p> <p style="text-align: right;">Cat. No.: HY-138946</p>
<p>XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK.</p> <p style="text-align: right;"></p> <p>Purity: 98.03% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells.</p> <p style="text-align: right;"></p> <p>Purity: 98.28% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>

XZ739

Cat. No.: HY-133557

XZ739, a **Cereblon**-dependent PROTAC **BCL-XL** (**Bcl-2** family member) degrader with a DC_{50} value of 2.5 nM in MOLT-4 cells after 16 h treatment. XZ739 also induces cell death through caspase-mediated apoptosis.




Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YF135

Cat. No.: HY-144323

YF135 is an efficient and reversible-covalent **KRAS^{G12C}** PROTAC. YF135 is designed and synthesized by tethering KRAS G12C inhibitor 48 (compound 6d) as the ligand, and basing on the scaffold of MRTX849 linkage VHL ligand.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZXH-3-26

Cat. No.: HY-122826

ZXH-3-26 is a PROTAC connected by ligands for **Cereblon** and **BRD4** with a $DC_{50/5h}$ of 5 nM. The $DC_{50/5h}$ refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM.




Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ZXH-4-130

Cat. No.: HY-132857

ZXH-4-130 is a highly potent and selective degrader of **CRBN**. ZXH-4-130 is a **CRBN-VHL** compound (hetero-PROTAC).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZXH-4-130 TFA

Cat. No.: HY-132857A

ZXH-4-130 TFA is a highly potent and selective degrader of **CRBN**. ZXH-4-130 is a **CRBN-VHL** compound (hetero-PROTAC). ZXH-4-130 TFA induces ~80% **CRBN** degradation at 10 nM in MM1.S cells.




Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZXH-4-137

Cat. No.: HY-132862

ZXH-4-137 is a potent and selective **CRBN** degrader (PROTAC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

 β -NF-JQ1

Cat. No.: HY-130256

β -NF-JQ1 is a PROTAC that recruits **Aryl Hydrocarbon Receptor E3** ligase to target proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

PROTACs

PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins








SNIPERs











IAP-dependent Protein Eraser, Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers








Specific and Non-genetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers (SNIPER), a class of small-molecule degraders, is designed to induce IAP-mediated ubiquitylation and proteasomal degradation of target proteins.

SNIPERs recruit IAP family of RING-type E3 ligases-cIAP1, cIAP2, and XIAP. The SNIPER chemical structure consists of selective IAP antagonist (i.e., Bestatin, MV1, and LCL161), PEG linker and peptide- or small-molecule-based protein of interest (POI)-specific component. Unlike the chimeric molecules that recruit von Hippel-Lindau and cereblon ubiquitin ligases, SNIPERs induce simultaneous degradation of IAPs such as cIAP1 and XIAP along with the target proteins.

SNIPERs Inhibitors

<p>Biotin-BS</p> <p style="text-align: right;">Cat. No.: HY-111879</p> <p>Biotin-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and biotin, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BzNH-BS</p> <p style="text-align: right;">Cat. No.: HY-111878</p> <p>BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC AR Degradar-4</p> <p style="text-align: right;">Cat. No.: HY-111848</p> <p>PROTAC AR Degradar-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degradar-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC AR Degradar-4 TFA</p> <p style="text-align: right;">Cat. No.: HY-111848A</p> <p>PROTAC AR Degradar-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degradar-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).</p>  <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 5 mg</p>
<p>PROTAC CRABP-II Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-111840</p> <p>PROTAC CRABP-II Degradar-1 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC CRABP-II Degradar-2</p> <p style="text-align: right;">Cat. No.: HY-111841</p> <p>PROTAC CRABP-II Degradar-2 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>PROTAC CRABP-II Degradar-3</p> <p style="text-align: right;">Cat. No.: HY-111842</p> <p>PROTAC CRABP-II Degradar-3 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>PROTAC ERα Degradar-2</p> <p style="text-align: right;">Cat. No.: HY-111846</p> <p>PROTAC ERα Degradar-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degradar-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.</p>  <p>Purity: 98.88% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>PROTAC RAR Degradar-1</p> <p style="text-align: right;">Cat. No.: HY-111844</p> <p>PROTAC RAR Degradar-1 comprises a IAP ligand binding group, a linker and a RAR ligand binding group. PROTAC RAR Degradar-1 is an RAR degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells.</p>  <p>Purity: 95.02% Clinical Data: No Development Reported Size: 1 mg</p>	<p>SNIPER(ABL)-013</p> <p style="text-align: right;">Cat. No.: HY-111860</p> <p>SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 20 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>SNIPER(ABL)-015</p> <p style="text-align: right;">Cat. No.: HY-111854</p>	<p>SNIPER(ABL)-019</p> <p style="text-align: right;">Cat. No.: HY-111873</p>
<p>SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 5 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 0.3 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(ABL)-020</p> <p style="text-align: right;">Cat. No.: HY-111872</p>	<p>SNIPER(ABL)-024</p> <p style="text-align: right;">Cat. No.: HY-111861</p>
<p>SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.</p>  <p>Purity: 99.44% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p>	<p>SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 5 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(ABL)-033</p> <p style="text-align: right;">Cat. No.: HY-111871</p>	<p>SNIPER(ABL)-039</p> <p style="text-align: right;">Cat. No.: HY-111874</p>
<p>SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 0.3 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 nM. IC₅₀s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(ABL)-044</p> <p style="text-align: right;">Cat. No.: HY-111862</p>	<p>SNIPER(ABL)-047</p> <p style="text-align: right;">Cat. No.: HY-111863</p>
<p>SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 2 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(ABL)-049</p> <p style="text-align: right;">Cat. No.: HY-111851</p>	<p>SNIPER(ABL)-050</p> <p style="text-align: right;">Cat. No.: HY-111858</p>
<p>SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 100 μM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>SNIPER(ABL)-058</p> <p style="text-align: right;">Cat. No.: HY-111859</p>	<p>SNIPER(BRD)-1</p> <p style="text-align: right;">Cat. No.: HY-111875</p>
<p>SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 μM.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a BET inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of BRD4 via the ubiquitin-proteasome pathway.</p> <p style="text-align: right;"></p> <p>Purity: 98.40% Clinical Data: No Development Reported Size: 1 mg</p>
<p>SNIPER(ER)-110</p> <p style="text-align: right;">Cat. No.: HY-122825</p>	<p>SNIPER(ER)-87</p> <p style="text-align: right;">Cat. No.: HY-129619</p>
<p>SNIPER(ER)-110 consists of a IAP ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC₅₀s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC₅₀=0.097 μM).</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(TACC3)-1</p> <p style="text-align: right;">Cat. No.: HY-111876</p>	<p>SNIPER(TACC3)-11</p> <p style="text-align: right;">Cat. No.: HY-145895</p>
<p>SNIPER(TACC3)-1 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway based on IAP ligand. SNIPER(TACC3)-1 induces cancer cell death.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SNIPER(TACC3)-11 is a potent FGFR3-TACC3 degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>SNIPER(TACC3)-2</p> <p style="text-align: right;">Cat. No.: HY-111877</p>	
<p>SNIPER(TACC3)-2 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway based on IAP ligand. SNIPER(TACC3)-2 induces cancer cell death.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Target Protein Ligand-Linker Conjugates

Target Protein Ligand-Linker Conjugate incorporates a ligand for the target protein and a linker. When binding to an E3 ligase ligand, the conjugate will be a PROTAC with ability to induce ubiquitylation and subsequent degradation the protein of interest.

Target proteins are usually proteins whose overexpression or accumulation may play important roles in the progress of diseases. Numbers of PROTACs have been developed to degrade kinases, transcription factors, epigenetic tools and E3 ligase themselves.

The optimal lengths of the PROTAC linkers are reported varying from 12-carbon to over 20-carbon, and the commonly used linkers in the development of PROTACs are PEGs, Alkyl-Chain and Alkyl/ether.


Target Protein Ligand-Linker Conjugates Chemicals

<p>BMS-1166-N-piperidine-CO-N-piperazine</p> <p>Cat. No.: HY-131386</p>	<p>BRD4 ligand-Linker Conjugate 1</p> <p>Cat. No.: HY-132943</p>
<p>BMS-1166-N-piperidine-CO-N-piperazine incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker.</p> <p>BMS-1166-N-piperidine-CO-N-piperazine can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>BRD4 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Desmorpholinyl Quizartinib-PEG2-COOH</p> <p>Cat. No.: HY-131230</p>	<p>Dual PARP EGFR ligand for PROTAC</p> <p>Cat. No.: HY-141486</p>
<p>Desmorpholinyl Quizartinib-PEG2-COOH incorporates a ligand for FLT-3, and a PEG-based PROTAC linker.</p> <p>Desmorpholinyl Quizartinib-PEG2-COOH can be used in the synthesis of PROTAC FLT-3 degrader 1 (HY-114323).</p> <p>Purity: 95.09%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 250 mg</p>	<p>Dual PARP EGFR ligand for PROTAC incorporates a ligand for PARP and EGFR, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>ERRα Ligand-Linker Conjugates 1</p> <p>Cat. No.: HY-130499</p>	<p>FAK ligand-Linker Conjugate 1</p> <p>Cat. No.: HY-44148</p>
<p>ERRα Ligand-Linker Conjugates 1 incorporates a ligand for estrogen-related receptor alpha (ERRα), and a PROTAC linker, which recruit E3 ligases MDM2. ERRα Ligand-Linker Conjugates 1 can be used in the synthesis of a series of PROTACs, such as PROTAC ERRalpha Degradar-1 (HY-128838).</p> <p>Purity: 96.70%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p>	<p>FAK ligand-Linker Conjugate 1 incorporates a ligand for FAK, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). FAK ligand-Linker Conjugate 1 can be extensively used for PROTAC-mediated protein degradation.</p> <p>Purity: 98.28%</p> <p>Clinical Data:</p> <p>Size: 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg</p>
<p>K-Ras ligand-Linker Conjugate 1</p> <p>Cat. No.: HY-129775</p>	<p>K-Ras ligand-Linker Conjugate 2</p> <p>Cat. No.: HY-129776</p>
<p>K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>K-Ras ligand-Linker Conjugate 3</p> <p>Cat. No.: HY-130707</p>	<p>K-Ras ligand-Linker Conjugate 4</p> <p>Cat. No.: HY-130822</p>
<p>K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg</p>	<p>K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).</p> <p>Purity: 95.06%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg</p>

K-Ras ligand-Linker Conjugate 5

Cat. No.: HY-130823

K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).




Purity: 96.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

K-Ras ligand-Linker Conjugate 6

Cat. No.: HY-130991

K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP).




Purity: 95.18%
Clinical Data: No Development Reported
Size: 100 mg

MRTX849 ethoxypropanoic acid

Cat. No.: HY-139403

MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2 (HY-137516).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg